Identification and characterisation of gene regulation by the POU4F3 (BRN-3C) transcription factor in the inner ear by Tornari, C.
 
IDENTIFICATION AND CHARACTERISATION 
OF GENE REGULATION BY THE POU4F3 
(BRN-3C) TRANSCRIPTION FACTOR IN THE 
INNER EAR 
Chrysostomos Tornari 
Submitted for the degree of PhD 
University College London  
2009 
Declaration    2
     
DECLARATION 
I, Chrysostomos Tornari, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been indicated in 
the thesis. Where work has been conducted by other members of our laboratory, this has 
been indicated by their initials or an appropriate reference: 
 
SD  Dr Sally Dawson 
ET  Dr Emily Towers 
VG  Dr Valentina Gburcik Lazovic 
JK  Mr John Kelly 
  
Abstract    3 
ABSTRACT 
Hair  cells  are  the  mechanosensory  cells  of  the  inner  ear  whose  loss  causes  irreversible 
hearing loss in mammals. POU4F3, a POU domain transcription factor, is only expressed 
in hair cells in the inner ear and is essential for hair cell terminal maturation in mice. In 
humans, it is essential for hair cell survival as all three identified families with a POU4F3 
mutation show autosomal dominant adult onset progressive hearing loss. The pathways by 
which POU4F3 has this effect are unknown as little is known about its target genes (only 
four  such  genes  are  known:  Bdnf,  Ntf3,  Gfi1  and  Lhx3).  Therefore,  identification  of 
unknown POU4F3 target genes would aid the understanding of hair cell maturation and 
survival. 
 
Prior to starting my doctoral work, a subtractive hybridization was carried out in an inner 
ear cell line (UB/OC 2) which was manipulated to either over  or under express POU4F3 to 
identify  unknown  POU4F3  target  genes.  The  clones  produced  by  this  screen  were  first 
matched to their corresponding gene; the presence of these genes in POU4F3 expressing 
UB/OC 2  cells  was  then  confirmed  by  western  blot  and/or  reverse  transcriptase  PCR. 
Where possible, expression was also confirmed in cochlear hair cells by immunofluorescence 
microscopy. 
 
Subsequently,  the  interaction  of  POU4F3  with  these  genes  was  characterised. 
Bioinformatics  software  was  used  to  identify  putative  POU4F3  recognition  elements  in 
target  gene  promoters,  and  these  sequences  were  then  synthesised  and  used  in  a  DNA 
binding  assay  (EMSA)  to  assess  POU4F3  binding.  The  ability  of  POU4F3  to  regulate 
putative gene promoters was also tested using luciferase assays. 
 
By these methods, one gene (Nr2f2) was shown to be a direct target of POU4F3 in vitro and 
two other genes were shown to be likely POU4F3 targets. The identification of these genes 
improves  our  understanding  of  the  mechanism  of  POU4F3  function  and  further 
investigation of these networks may yield therapies for deafness caused by hair cell loss.  
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1   
GENERAL INTRODUCTION 
Being able to perceive, interpret and appreciate sound is an important part of human life. 
Our sense of hearing is essential to our ability to respond to changes in our environment, 
communicate  with  others  and  appreciate  music.  Though  the  loss  of  this  ability  can  be 
compensated  for  through  various  means  (sign  languages,  hearing  dogs,  appliances  with 
visual alerts etc.), such methods are often only used by people who lose their hearing early 
in life (RNID 2009). For the increasing number of people who have to manage hearing loss 
later in life, the adjustment can pose a very different and difficult challenge (Van Laer et al. 
2007). Across the age range, hearing loss can have a wide personal and social effect. In 
children, it has been shown to adversely affect confidence, behaviour and acceptance by 
peers (Moeller 2007), whilst quality of life is reported to be significantly affected in older 
people with age related hearing loss (ARHL) (Howarth et al. 2006). 
 
Worldwide, approximately 278 million people have a moderate to profound hearing loss in 
both  ears  (World  Health  Organization  2006).  Though  more  is  being  done  to  identify 
children with hearing loss and reduce risk factors for hearing loss at all ages, ARHL  – 
which affects approximately 40% of people by age 65 – will become an increasing problem 
due to our ageing society (Ohlemiller 2004). Furthermore, greater voluntary noise exposure 
– e.g. due to increased use of personal music players – is predicted to contribute to the 
incidence of noise related hearing loss despite reductions in occupational noise exposure 
(Daniel 2007). Therefore, research into the anatomically and molecularly complex systems 
that  underlie  hearing  is  required  to  improve  our  understanding  of  this  process  and  to 
identify new strategies by which to prevent and treat hearing loss. 
 
This thesis addresses the lack of knowledge regarding gene regulatory networks in hair 
cells,  the  primary  sensory  cells  of  the  inner  ear.  The  POU4F3  transcription  factor  is 
uniquely  expressed  in  these  mechanosensory  cells  in  the  inner  ear  (Erkman  et  al. 
1996;Xiang  et  al.  1998)  where  it  has  been  shown  to  be  essential  for  their  terminal 
differentiation in mice (Xiang et al. 1998) and for their survival in humans (Collin et al. 
2008;Vahava et al. 1998). However, the mechanism of its function is poorly understood. 
Therefore, we attempted to identify POU4F3 target genes to explain how this transcription  
1 General introduction    15 
factor generates and maintains the hair cell phenotype and, thereby, identify proteins that 
are involved in the terminal differentiation and survival of hair cells. 
1.1  Normal hearing and balance 
Sound  is  mechanical  energy  travelling  through  a  medium  in  a  longitudinal  wave  at 
frequencies audible to humans (i.e. in the range of approximately 20Hz to 20kHz) (Kingsley 
1999b). Prior to its transduction into electrical energy by the ear, it undergoes multiple 
complex  steps  of  modification  in  order  to  optimise  the  useful  information  that  can  be 
extracted from the original signal. 
 
The first step in this modification occurs prior to sound reaching the ear. The torso, neck 
and head give a modest boost to sound below 1kHz (less than 5dB) (Ballachanda 1997). The 
head is also an important factor in the determination of sound localization on the horizontal 
axis as the difference in sound pressure and timing between ears is influenced by head size 
and shape (Pickles 1988). 
1.1.1  The outer ear 
The ear itself is divided into three sections: the outer, middle and inner ear. Sound first 
arrives at the outer ear which, in turn, is divided into the pinna and the ear canal (see 
Figure 1.1). These structures do not simply pass sound into the skull unmodified. They are 
designed  to  gather  sound,  aid  in  its  localization  and  boost  its  pressure  in  the  speech 
frequencies. 
 
The first two of these functions are carried out by the pinna (also called the auricle). Due to 
its larger surface area, more sound arrives here than would arrive at the ear canal alone 
and  the  folds  of  the  pinna  direct  this  additional  sound  into  the  ear  canal.  As  well  as 
directing the sound, the pinna modifies sounds that do not enter the ear canal directly in 
order to aid in localization. Sound therefore takes two paths to the ear canal: the direct 
path (into the ear canal) and the reflected path (via the pinna). Sound from the reflected 
path  undergoes  spectral  modification  that  is  variable  depending  on  its  horizontal  and 
vertical localization i.e. the location of a sound source determines which part of the pinna 
the sound arrives at first which determines its spectral modification. This modified sound 
combines with sound from the direct path, and the signature of the combined signal allows 
identification  of  the  sound’s  location  following  transduction  and  neural  processing 
(Middlebrooks et al. 1991). This processing takes place in the brainstem where the timing, 
phase, pressure and spectral differences between sounds arriving at each ear are compared. 
This large area of hearing research is beyond the scope of this thesis and is not discussed 
further.  Though  the  pinna  is  essential  for  vertical  localization,  its  role  in  horizontal 
localization is not essential and its most important role in this task is in distinguishing 
front/back ambiguity (Pickles 1988).  
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Figure 1.1. Gross anatomy of the ear. 
The ear is divided into the outer ear, middle ear and inner ear. The outer ear comprises the 
pinna  and  external  auditory  meatus  and  is  divided  from  the  middle  ear  by  the  tympanic 
membrane. The middle ear transmits movement of the tympanic membrane to the inner ear via 
the three ossicles: the malleus, the incus and the stapes. The movements of the stapes are 
transduced to electrical energy in the hair cells of the cochlea and transmitted to the brain via 
the cochlear division of the vestibulocochlear nerve. The remaining sensory organs of the inner 
ear transduce head acceleration and position information which is passed to the higher brain 
centres via the vestibular portion of the vestibulocochlear nerve (adapted from Kelley 2006). 
 
 
The  final  role  of  the  external  ear  –  amplification  of  speech  frequencies  –  is  primarily 
performed  by  the  ear  canal.  This  canal  starts  in  the  pinna  and  ends  at  the  tympanic 
membrane (also called the eardrum) i.e. it is a cylinder that is closed at one end (see Figure 
1.1). The length of such a cylinder is ¼λ of its resonant frequency and, as the adult ear 
canal  is  approximately  25mm  long,  its  resonant  frequency  is  approximately  3.4kHz. 
Frequencies  at  and  around  this  frequency  are  therefore  amplified  and  the  ear  canal 
provides most of the 15 to 20dB amplification that is applied to sounds from 1.5 to 7.0kHz 
(see Ballachanda 1997 for review). The range of this amplification and the fundamental 
frequency of the canal therefore lie within the important frequency range for speech (250Hz 
to 4kHz) (Sataloff et al. 1993). 
1.1.2  The middle ear 
The middle ear translates vibration of the tympanic membrane into vibration of the liquid 
that fills the cochlea. It not only passes sound from the outer ear to the inner ear but also 
matches the impedance from air to liquid – to optimise the efficiency of energy transfer – 
and alters the spectral response of the incoming sound to enhance important frequencies 
(Pickles 1988). Encased in the temporal bone, it is a space that contains small bones, nerves 
and  muscles  that  either  aid  in  the  above  functions  or,  in  the  case  of  the  facial  and 
glossopharyngeal nerves, pass through the middle ear (Dean et al. 1996).  
Picture removed for copyright purposes  
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Sound  that  has  passed  through  the  ear  canal  reaches  the  tympanic  membrane,  which 
separates  the outer and middle ear. This  sound causes variation in pressure in the ear 
canal,  creating  a  pressure  difference  between  the  outer  ear  and  the  middle  ear  (which 
contains air at atmospheric pressure). High pressure on the lateral tympanic membrane – 
caused by compression of air particles during a sound wave – causes it to move medially i.e. 
towards the middle ear. Conversely, rarefactions create low pressure, causing the tympanic 
membrane to move laterally, towards its resting position. The maintenance of atmospheric 
pressure in the middle ear is necessary for this to occur and it is achieved by the connection 
of the middle ear to the pharynx via the Eustachian tube which, though closed at rest, is 
easily opened by pharyngeal muscle movements (see Figure 1.1) (Vander et al. 2001). 
 
The functions of the middle ear are primarily achieved by the ossicles – the smallest bones 
in the human body – without which only a small proportion of sound that is transmitted by 
the tympanic membrane would reach the inner ear (Kurokawa et al. 1995). In each middle 
ear, there are three ossicles. The first of this chain is the malleus (hammer) which has a 
long arm that is attached to the tympanic membrane, a neck, and a head which articulates 
with the second ossicle, the incus (anvil), via a synovial joint. The incus is also divisible into 
three parts: the head, which is attached to the malleus; the short process which connects 
this bone to the posterior wall of the middle ear; and the long process which articulates, via 
another synovial joint, to the stapes (stirrup). This final ossicle is divided into the head, 
which  articulates  with  the  incus,  followed  by  two  processes  which  join  the  head  to  the 
footplate. It is the footplate that delivers the vibration of the ossicles to the cochlea via an 
opening in the bony capsule of the inner ear called the oval window (fenestra vestibuli). In 
reptiles,  the  tympanic  membrane  is  joined  directly  to  the  oval  window  by  the  stapes. 
However,  bones  from  the  reptilian  jaw  evolved  to  form  the  malleus  and  incus  which 
improve the impedance matching and spectral response of the middle ear, allowing more 
accuracy in hearing (Clack et al. 2004).  
 
The middle ear transfer function 
Impedance matching by the middle ear is achieved as follows: 
  
1)  A  greater  pressure  is  applied  at  the  oval  window  than  at  the  tympanic 
membrane because the surface area of the footplate of the stapes is smaller than 
that of the tympanic membrane (see Equation 1.1). 
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Equation 1.1. Pressure-area relationship between tympanic membrane and oval window. 
TympM = tympanic membrane, OW = oval window, P = pressure, A = area. 
 
OW OW TympM TympM A P A P × = ×  
 
2)  The lever action of the middle ear bones modify the movement of the stapes, 
increasing  its  force  and  decreasing  its  velocity  to  provide  a  small  benefit  in 
impedance matching. 
3)  The conical shape of the tympanic membrane allows it to buckle so that the 
malleus moves less than the surface of the membrane providing another small 
benefit to the impedance match (Pickles 1988).  
 
These factors contribute to what is known as the transfer function of the middle ear which 
increases the pressure at the footplate of the stapes whilst decreasing velocity. Differences 
in  the  efficiency  of  this  function  at  different  frequencies  are  the  result  of  the  physical 
properties of the middle ear which optimise transmission of the most important frequencies. 
In humans, the greatest pressure gain peaks near 0.9kHz (26.6dB) with fairly flat gain at 
low  frequencies  and  steadily  falls  off  above  0.9kHz  to  zero  pressure  gain  at  7.0kHz. 
Therefore, the middle ear can be described as a bandpass filter as it transmits sounds at 
different frequencies with differing efficiency (Kurokawa et al. 1995). Consequently, middle 
ear  dysfunction,  e.g.  due  to  abnormal  bone  remodelling  in  the  middle  ear  (otosclerosis), 
causes hearing loss as sound is no longer efficiently transmitted to the cochlea (Cureoglu et 
al. 2009). 
 
Middle ear muscles 
Ossicular function is determined both by the constant effect of their anatomy and also by 
the variable effect of two muscles – tensor tympani and stapedius – which attach to the 
malleus  and  stapes  respectively  to  control  their  stiffness.  Contraction  of  these  muscles 
influences both the amount and spectrum of sound that is transmitted from the outer ear to 
the inner ear. The tensor tympani arises from a bony canal in the middle ear wall and 
attaches to the long arm of the malleus. Similarly, the stapedius muscle arises from a bony 
canal and  attaches  to the neck of the stapes (Moore et al. 1999). Tensor tympani has a 
modest function, contracting in response to high intensity sound and in response to head 
and  pharyngeal  muscle  movement  and  causing  almost  no  attenuation  in  sound 
transmission  (Kingsley  1999b).  The  stapedius  muscle  has  a  larger  effect,  causing  an 
approximately 10dB attenuation in response to the sound of more than approximately 70dB 
or muscle movements (Kingsley 1999b;Sataloff et al. 1993). The combined effect of these 
muscles protect the inner ear from damage by sustained sound of high intensity. However, 
the latency of this reaction renders it insufficient to protect the inner ear from sudden loud 
noises (Vander et al. 2001).  
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1.1.3  The anatomy and function of the inner ear 
The inner ear is responsible for the detection of sound, head acceleration and head position. 
Encased in the petrosal  temporal bone – the hardest bone in the human body – it is a 
liquid filled  cavity  (the  bony  labyrinth)  with  extremely  complex  anatomy  that  can  be 
divided into the bulla, three semicircular canals (with their associated ampullae) and the 
cochlea. The bony labyrinth contains the membranous labyrinth and its six sensory organs 
that convert sensory information to action potentials via their sensory epithelia (see Table 
1.1).  The  ampullae  of  the  semicircular  canals  house  their  respective  cristae,  the  bulla 
contains the utricle and saccule (each of which contains a sensory macula) and the cochlea 
houses  the  cochlear  duct,  within  which  the  organ  of  Corti  transduces  sound.  Action 
potentials generated by the sensory hair cells in  these epithelia travel through afferent 
neurons  in  the  vestibulocochlear  nerve  to  the  brain  where  the  signal  is  processed  and 
perceived (Vander et al. 2001). 
 
Table 1.1. Sensory organs of the inner ear. 
(adapted from Kingsley 1999b). 
Organ  Sensory Epithelium  Function 
Cochlea  Organ of Corti  Sound transduction 
Saccule  Saccular macula 
Linear vertical head acceleration 
and orientation 
Utricle  Utricular macula 
Linear horizontal head acceleration 
and orientation 
Superior 
semicircular canal 
Superior crista ampullaris  
Head rotation around rostro caudal 
axis 
Posterior 
semicircular canal 
Posterior crista ampullaris 
Head rotation around horizontal 
axis  
Horizontal 
semicircular canal 
Horizontal crista ampullaris  Head rotation around vertical axis 
 
Cochlear anatomy 
Sound is delivered to the inner ear either by the movements of the footplate of the stapes in 
the oval window due to sound that has passed through the outer and middle ear, or by 
conduction through bone. The cochlea extracts frequency and amplitude information from 
this sound and passes this information to higher centres via the vestibulocochlear nerve. 
Both cellular and acellular cochlear components are required for this process. 
 
The  cochlea  –  which  is,  perhaps,  the  most  anatomically  complex  sensory  organ  –  is 
composed of three liquid filled spaces which spiral around a central bony projection called 
the modiolus for little under 2.75 turns in humans to give the organ its characteristic shape  
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(Kingsley 1999b). These three spaces are named the scala vestibuli, scala media and scala 
tympani. The superior edge of the scala vestibuli and the inferior edge of the scala tympani 
are bordered by the bony labyrinth. The scala vestibuli starts near the oval window and 
coils up the cochlea on top of the other two compartments to the apex of the cochlea where 
it is continuous with the scala tympani at an opening called the helicotrema. The scala 
tympani then coils down the cochlea to end at a membrane called the secondary tympanic 
membrane that covers the round window of the bony labyrinth. The scala  tympani and 
scala vestibuli are filled with extracellular fluid known as perilymph – a sodium rich liquid 
with similar composition to cerebro spinal fluid that is continuous with the cerebro spinal 
fluid via the cochlear duct (see Figure 1.2a) (Kingsley 1999b).  
 
Sandwiched in between these two compartments lies the roughly triangular scala media. 
This is separated from the scala vestibuli at its superior border by the Reissner’s membrane, 
which  is  composed  of  mesothelial  cells  superiorly  and  epithelial  cells  inferiorly  with  a 
basement membrane in between these two layers (see Figure 1.2b). The epithelial cells are 
connected by tight junctions and adherens junctions to maintain fluid separation between 
the scala media and scala vestibuli (Slepecky 1996;Wangemann et al. 1996). The lateral 
border is formed by the lateral wall which comprises the stria vascularis and spiral limbus; 
regions important in setting up and maintaining potassium concentration of the liquid that 
fills the scala media, the endolymph. This liquid also fills the remainder of the membranous 
labyrinth via the ductus reuniens.  On the inner aspect of the inferior border of the scala 
media lies the organ of Corti and associated support cells. This is the sensory epithelium of 
the cochlea that contains the hair cells – the sensory transductory cells of the cochlea. Hair 
cells are organised into one row of inner hair cells (IHCs) and – in humans – three to four 
rows of outer hair cells (OHCs). The IHCs are the ‘true’ sensory cells of the inner ear and 
are mainly innervated by afferent neurons that transmit transduced signals to the brain. 
OHCs,  on  the  other  hand,  have  a  mainly  efferent  innervation  and  act  to  sensitize  and 
modulate IHC function (see below). The nerve fibres travel medially to the spiral lamina, 
through the habenula perforata and into Rosenthal’s canal in the modiolus where their cell 
bodies form the spiral ganglion. Axons of both bipolar and pseudounipolar neurons continue 
from here to the vestibulocochlear nerve (Kingsley 1999b).  Pillar cells separate IHCs from 
OHCs, forming the perilymph filled tunnel of Corti and, along with the other supporting 
cells of the organ of Corti (Deiters and Hensen cells) contribute to a reticular lamina at the 
surface of the sensory epithelium. The remaining cells of the floor of the scala media (inner 
sulcus  cells,  inner  phalangeal  cells,  Claudius  cells  and  Boettcher  cells)  have  less  well 
characterised  function  and  are  involved  in  processes  such  as  ion  transport  rather  than 
mechanical support. The organ of Corti and the cells that populate the distance between the 
Hensen  cells  and  lateral  wall  lie  on  the  basilar  membrane  (BM)  which  is  a  specialised 
basement membrane that is mainly composed of homogeneous ground substance with fibres 
embedded in its matrix (see Figure 1.2b) (Slepecky 1996).   
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Morphologically  the  BM  forms  the  inferior  border  of  the  scala  media.  However,  liquid 
separation between the scala media and scala tympani is achieved by the reticular lamina 
which connects hair cell and support cell apices across the sensory epithelium, maintaining 
cell apices in the potassium rich endolymph and cell bodies in the sodium rich perilymph 
(Slepecky 1996). The  location of this boundary is  important because the differential ion 
concentrations across the reticular lamina set up an electrical potential (the endocochlear 
potential)  of  +80mV  (Wangemann  2006).  This  potential  difference,  combined  with  basal 
conductances in hair cells, establishes the hair cell resting membrane potential which is 
required for transduction (see Figure 1.2c) (Housley et al. 2006;Kros 1996).  
 
Highly organised finger like projections called stereocilia arise from the hair cell apices into 
the endolymph of the scala media towards a structure called the tectorial membrane (TM) 
which overlies the organ of Corti and arises from a bony prominence of the modiolus called 
the spiral lamina. The TM is composed of gel like connective tissue and the tips of the OHC 
stereocilia  are  known  to  be  embedded  in  this  matrix.  There  is  still  some  debate  as  to 
whether IHC stereocilia are also embedded in the TM, though it is widely agreed that they 
are not and that a groove in the TM that overlies the IHC stereocilia (Hensen’s stripe) 
interacts with the inner hair cell stereocilia indirectly (Raphael et al. 2003). The mass and 
movement of the TM are required for normal hair cell mechano electrical transduction (see 
below) and mutations in the genes that encode TM proteins are known to cause deafness 
(see Richardson et al. 2008 for review).  
 
Cochlear function 
Early inner ear physiologists attempted to discover what function different parts of the 
cochlea played in converting sound – which was itself poorly understood – into hearing. 
Helmholtz  theorised  that  the  BM  acts  as  a  string  of  resonators  tuned  to  different 
frequencies that conduct a Fourier analysis of incoming sounds. Georg von Békésy provided 
empirical evidence to support this by showing that the cadaveric BM vibrates in different 
places for different pure tones depending on frequency and that movement of one part of 
the  BM  causes  movement  in  other  parts  i.e.  the  BM  is  not  a  string  of  independent 
resonators. Importantly, he observed that the basal BM resonates to high frequencies at its 
thin, narrow base and low frequencies at its thick, wide apex (Patuzzi 1996). This ability to 
separate sounds into their component frequencies underlies the tonotopy of the inner ear: 
the observation that different frequencies are represented at different locations on the BM 
and, consequently, that different hair cells correspond to specific frequencies. 
 
In this model, sound that is delivered to the scala vestibuli by movement of the footplate of 
the stapes causes a pressure difference between the scala vestibuli and scala tympani. This 
pressure  difference  causes  movement  of  the  BM.  The  movement  in  a  given  region  is 
dependent on the resonant frequency of that region and, therefore, only certain parts of the  
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BM resonate in response to a given frequency with the amplitude of the movement being 
proportional  to  the  amplitude  of  the  incoming  sound.  When  the  organ  of  Corti  moves 
upwards, towards the TM, hair cell stereocilia are bent in the direction of the longest row, 
causing a  mechanoelectrical transduction (MET) channel to be opened and allowing the 
non selective influx of sufficiently small positively charged ions – primarily potassium due 
to the high endolymphatic potassium concentration – causing transduction currents within 
the cells. Conversely, when the BM is pushed downwards, hair cell stereocilia are  bent 
towards the shortest row, causing MET channels to close and reducing the likelihood of 
transduction currents in the cell (Hudspeth 2000). Transduction currents are transmitted 
to afferent neurons by the release of neurotransmitters from the hair cell base and these 
signals are then received and processed by higher brain centres (Kingsley 1999b). 
 
However, the observed frequency selectivity of the cadaveric BM described by von Békésy is 
not  sufficient  to  explain  the  observed  frequency  selectivity  of  the  human  ear.  Applying 
concepts from radio engineering to this problem, Gold used a mathematical model to show 
that the input of an appropriate amount of energy to the BM would counteract the viscous 
damping  by  the  liquid  in  the  cochlea  and  would  sharpen  its  frequency  tuning  to  better 
explain observed frequency selectivity (Gold 1948). Gold was not able to identify the site of 
the required sensation and feedback of signal, though it has since been found that this 
function is carried out by OHCs. The required sharpening of the BM response is achieved 
by the opposite process of mechanoelectrical transduction: electromechanical transduction. 
In this process, OHCs, having converted kinetic energy into depolarising electrical energy 
(in the form of a transduction current) convert the electrical energy back into mechanical 
energy by the ‘motor protein’ called prestin (Slc26a5) that causes the OHCs to contract 
(Zheng et al. 2002). The energy provided by this movement is sufficient to overcome much of 
the viscous damping of BM movement by the cochlear liquids and allows sharpening of the 
frequency  response  of  the  BM  to  allow  more  frequency specific  activation  of  IHCs, 
accounting for the observed frequency selectivity of hearing (Gold 1948;Robles et al. 2001). 
Furthermore, loss of prestin function due to its mutation, such as that seen in two human 
families, results in a recessive non syndromic hearing loss (Liu et al. 2003). 
 
Though  the  precise  biomechanical  mechanism  through  which  OHC  electromechanical 
transduction sharpens frequency selection is still being debated, the effect of BM movement 
induced by cellular movement in the inner ear has been exploited for diagnostic purposes. 
The sound created by this BM movement is detectable in the ear canal and is known as an 
otoacoustic emission (OAE), as predicted by Gold and proven by Kemp in his 1978 paper 
which first identified evoked OAEs (Kemp 1978). OAEs now serve as a clinical measure of 
cochlear function that does not require the cooperation of the subject. This method is now 
widely  used  to  detect  hearing  loss  e.g.  in  the  UK  National  Health  Service’s  neonatal 
hearing screening programme (MRC Hearing & Communication Group 2008).  
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Vestibular anatomy and function 
As  for  cochlear  hair  cells,  vestibular  hair  cells  in  all  five  vestibular  sensory  epithelia 
transduce sound by the movement of stereocilia that lead to transduction currents. The 
differences  in  vestibular  stimuli  transduced  by  the  different  epithelia  are  due  to  the 
location and overlying structures of each sensory epithelium (see Figure 1.3). 
 
The saccule and utricle transduce the same type of stimuli as they have the same overlying 
otoconia  which  provide  the  necessary  mass  for  the  underlying  hair  cells  to  respond  to 
gravity. When the head is moved, the inertia of the heavy otoconia causes them to slide 
back over the underlying sensory epithelium. This causes displacement of the stereocilia 
which  results  in  depolarisation  or  hyperpolarisation  of  the  hair  cells  depending  on  the 
direction  of  the  displacement.  Though  both  the  saccule  and  utricle  interpret  linear 
acceleration and head position, the differences in the direction of travel sensed is dependent 
on  the  placement  of  the  epithelium  i.e.  the  saccular  macula  lies  in  the  vertical  plane 
whereas the utricular macula is horizontal (see Figure 1.3a&b) (Kingsley 1999b). 
 
Similarly,  the  three  cristae  of  each  inner  ear  transduce  rotational  acceleration  by  the 
movement of endolymph against a gelatinous matrix (the cupula) which overlies the hair 
cells in the  sensory epithelia.  The relative movement of the cupula  against the sensory 
epithelium  causes  displacement  of  the  hair  cell  stereocilia,  resulting  in  transduction 
currents.  The  type  of  rotation  detected  by  the  different  cristae  is  dependent  on  the 
orientation  of  the  semicircular  canal  to  which  it  is  attached  (see  Figure  1.3c).  Higher 
centres compare contralateral inputs and integrate the signals from the different cristae to 
determine the net rotation of the head in three dimensions. Signals from the vestibular 
organs are also integrated with ocular cues in brainstem nuclei to maintain balance. As in 
the cochlea, vestibular epithelia are connected to their higher brain centres by both afferent 
and efferent neurons which travel in the vestibulocochlear nerve (Kingsley 1999b).  
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1.2  Inner ear development 
With the advent of molecular biological techniques that are sufficiently sensitive to allow 
the study of inner ear development, there has been an explosion in the understanding of 
this process in the last decade (Kelley et al. 2005). From a patch of thickened ectoderm 
through to the elaborate structure of the labyrinth, many signalling networks have been 
shown to be involved in inner ear morphogenesis. These signals direct a combination of 
proliferation, differentiation, growth, migration and programmed cell death which result in 
the formation of the mature inner ear (Bok et al. 2007).  
 
In brief, the inner ear is formed as follows: a patch of thickened ectoderm called the otic 
placode is formed on the anterolateral surface of the embryo and invaginates to form the 
otic cup. The cup then deepens and the surface epithelium begins to close off its roof. Once 
the cup has pinched off from the surface of the embryo, it is known as the otocyst (also 
known as otic cyst / otic vesicle). The otocyst undergoes a series of complex remodelling 
processes which lead to the mature anatomy of the labyrinth. This section describes the 
above processes in the order in which they occur and the signalling mechanisms on which 
they are known to rely. 
1.2.1  Early inner ear morphogenesis 
The first sign of inner ear development is the thickening of the surface ectoderm adjacent to 
the developing hindbrain to form the otic placode. Though it is known that cells from a wide 
area converge to form this structure, little is known of the mechanisms by which this is 
achieved.  Therefore,  much  work  is  being  done  to  identify  the  important  factors  in  this 
process from the bewildering array of signalling molecules – primarily of the FGF family – 
that are likely to be involved (Groves 2005) and recent work is beginning to unravel this 
extremely complicated signalling network (Zelarayan et al. 2007). 
  
Subsequently, the cup invaginates and a large number of apoptotic cells are detectable at 
its  edges.  As  the  cup  begins  to  close  off  from  the  surface  epithelium,  the  diminishing 
opening between the developing otic cup and the surface becomes known as the otic pore. 
Apoptotic cells continue to line this pore and are thought to be required to break down its 
lumen,  the  obliteration  of  which  results  in  the  otic  cup  pinching  off  from  the  surface 
ectoderm.  The  developing  inner  ear  is  now  known  as  the  otocyst,  which  is  a  roughly 
spherical space that is lined by a pseudo stratified epithelium (Kelley 2007;Leon et al. 2004).   
 
Throughout  otic  cup  and  otocyst  development,  specific  proteins  demarcate  different 
functional domains which are anatomically indistinguishable. These protein domains define 
the axes of the developing labyrinth and some proteins are required to establish the axes 
whilst  others  are  expressed  as  a  result  of  axis  specification.  The  three  axes  that  are  
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established by this process are the anteroposterior axis, dorsoventral axis and mediolateral 
axis (see Figure 1.4a) (Bok et al. 2007). 
 
Protein  expression  at  this  stage  and  beyond  is  better  understood  than  that  of  placode 
induction. The anteroposterior axis is the first to be established and is first identifiable in 
the invaginating otic cup though cells in the anterior and posterior domains are unlikely to 
have become committed to their fate until the cup is half closed. The signals responsible for 
the establishment of this axis are unknown; it was thought that signals from the hindbrain 
were responsible though recent experiments in the chick have cast doubt on this hypothesis. 
The axis itself, however, is quite clear with multiple genes being selectively expressed in 
the  anterior  region  (Fgf10,  Lfng,  Delta1,  Ngn1  and  NeuroD)  from  which  neuroblasts 
delaminate soon after otic cup closure to form the cochleovestibular ganglion (CVG, initially 
known as the statoacoustic ganglion (Fritzsch et al. 1998)) (Bok et al. 2007;Kelley 2006). 
These neuroblasts migrate into the mesenchymal space ventromedial to the otocyst. They 
subsequently return axons to innervate the sensory epithelia that develop near to where 
they were generated (Abello et al. 2007). The expression of a different group of genes (Tbx1, 
Otx1, Otx2 and Goosecoid) becomes detectable in the posterior otic cup at the same time as 
the known anterior markers. Tbx1 – which is among the best studied of these markers – is 
thought to be responsible for maintaining the posterior domain by preventing anteriorly 
expressed genes from extending their expression into more posterior regions (see section 
1.2.2 for Tbx1 function in the developing sensory epithelium) (Bok et al. 2007;Mansour et al. 
2005).  Consistent  with  a  role  in  limiting  the  anterior  neurosensory  fate,  Tbx1  deletion 
results in a 1.83 fold increase in the size of the CVG (Raft et al. 2004). 
 
Like the anteroposterior axis, markers of the dorsoventral axis are identifiable at the otic 
cup stage though the cells in these domains are thought to commit to their fate later than 
those in the anteroposterior axis. It has been shown that the dorsoventral axis is required 
for the specification of the cochlea and saccule from the ventral otocyst (pars inferior), and 
of the semicircular canals and utricle from the dorsal otocyst (pars superior) (Bok et al. 
2007;Leon  et  al.  2004).  Unlike  the  anteroposterior  and  mediolateral  axes,  the  inductive 
signals for the dorsoventral axis are known. The developing hindbrain secretes Wnt factors 
that  induce  the  dorsal  otic  markers  (Dlx5,  Dlx6,  Hmx2,  Hmx3  and  Gbx2)  and  sonic 
hedgehog  (Shh)/Gli  signals  that  define  the  ventral  domain  (marked  by  Lfng,  Ngn1, 
NeuroD1,  Sox2  and  Six1).  Furthermore,  Shh  signalling  restricts  Wnt  expression  to  the 
dorsal  region  though  it  is  unknown  how  Shh  signalling  is  regulated.  Other  ventrally 
expressed proteins (Six1 and Eya1) have also been shown to be involved in this process as 
Wnt  and  Shh  knockout  animals  do  not  completely  lose  their  dorsoventral  patterning. 
However, it is unclear how these signals are regulated and, as their function does not fully 
explain the observed morphogenesis, it is thought that at least one other hindbrain signal is 
required for ventral patterning (Bok et al. 2007;Mansour et al. 2005).  
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The final axis to become identifiable – though it is likely to be specified much earlier than it 
becomes visible – is the mediolateral axis. Current evidence suggests that medial domain 
identity  is  acquired  due  to  Wnt  and  Fgf  signals  from  the  hindbrain  and  that  the 
specification of the lateral domain is also guided by signals from the hindbrain. However, 
the  latter  process  is  poorly  understood  and  the  roles  of  midline  structures  (i.e.  the 
notochord  and  floorplate)  require  further  characterisation,  as  does  the  role  of  hedgehog 
signalling (Whitfield et al. 2007). 
 
Shortly  after  its  appearance,  and  following  the  establishment  of  its  axes,  the  otocyst  is 
largely capable of completing its development independent of signals from its surrounding 
mesenchyme  (approximately  E11.5  in  mice)  (Fritzsch  et  al.  1998).  From  this  point  on, 
cellular  proliferation,  differentiation  and  survival  –  both  in  the  otocyst  and  CVG  –  are 
essential for otocyst growth and development. These processes are initially dependent on 
insulin related growth factor signalling that is balanced by apoptotic hotspots (Leon et al. 
2004). 
1.2.2  Late inner ear and sensory epithelial development 
The first structures to emerge from the ellipsoid otocyst are the endolymphatic and cochlear 
ducts. The endolymphatic duct arises from the dorsomedial aspect of the otocyst (Kelley 
2006;Rinkwitz et al. 2001) and a group of apoptotic cells are visible at the junction of the 
developing endolymphatic duct with the otocyst; this process may aid duct formation by 
limiting  epithelial  proliferation  (Fekete  et  al.  1997;Leon  et  al.  2004).  Similarly  –  both 
temporally and morphologically – the cochlear duct extends from the ventral otocyst and an 
apoptotic  hotspot  is  visible  on  the  ventromedial  otocyst.  This  spot  is  located  where  the 
cochlear duct joins the saccule and persists for much of cochlear duct extension where it 
may direct differentiation between these two regions (see Figure 1.4c) (Leon et al. 2004). As 
these structures extend, the prosensory regions of the developing otic vesicle (regions that 
will give rise to the three cristae, utricular macula, saccular macula and organ of Corti) 
become  identifiable  as  thickened  epithelial  plaques  containing  nascent  CVG  neurites 
(Kelley 2006).  
 
Prosensory domain development 
Initially, two prosensory domains are identifiable: a posterior spot that goes on to form the 
posterior crista and the anteroventral stripe that forms the rest of the sensory epithelia (see 
Figure 1.4d) (Bok et al. 2007). It is currently unclear whether the posterior region separates 
from  the  remainder  of  the  developing  prosensory  domain  or  if  the  two  regions  arise 
separately (Kelley 2006). These prosensory regions are marked by SRY box containing gene 
2 (Sox2) which is expressed in both of the initial prosensory domains and, in mice, has been   
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shown to be required for the normal development of the sensory epithelia (Dabdoub et al. 
2008;Kiernan et al. 2005b).  
 
The earliest  known network that is involved in  the specification of  these  regions is  the 
Notch signalling network. Experiments in chicks, zebrafish and mice have shown that the 
Notch receptor (Notch1) is expressed early in development, before the development of the 
otic placode. Its expression is maintained throughout the remaining development of the 
otocyst and inner ear and its function is thought to be in the regulation of the size of the 
initial  sensory  patch  through  regulation  of  the  placement  of  sensory/non sensory 
boundaries.  However,  it  is  not  thought  to  be  required  for  sensory  patch  specification 
(Daudet et al. 2007;Kelley 2006). 
 
Consistent with a role for Notch receptors in prosensory domain patterning, the Notch 
related genes lunatic fringe (Lfng) and jagged 1 (Jag1) are expressed in patterns consistent 
with  the  development  of  the  prosensory  domain.  LFNG  is  a  modulator  of  Notch 
glycosylation (Panin et al. 2002) that is expressed in the anteroventral prosensory domain; 
the region that gives rise to the utricular macula, saccular macula and organ of Corti. In 
non mammalian vertebrates, the modification of Notch glycosylation by LFNG has been 
shown to inhibit the sensitivity of Notch 1 to one of its ligands: serrate. The mammalian 
homologue of serrate is Jag1, which is expressed in a pattern that abuts the prosensory 
domain  during  its  specification.  Though  it  has  been  suggested  that  Jag1  and  Notch 
signalling are involved in the specification of sensory patches, experiments in chick and 
zebrafish seem to contradict this hypothesis. However, redundancy in mammalian Notch 
signalling may explain the conflicting data in this field. Therefore, elucidating the role of 
each of the above genes in prosensory specification and development is likely to determine 
which factors are necessary for prosensory domain specification (Daudet et al. 2007;Kelley 
2006). 
 
Another gene that is implicated in prosensory domain development is Tbx1 As previously 
mentioned Tbx1 is expressed posteroventrally and is responsible for restricting neuroblast 
development  from  the  anterior  (CVG forming)  domain  (Bok  et  al.  2007).  It  is  therefore 
protective of the cells of the posterior domain which overlaps with the prosensory domain 
from which the non neuronal sensory cells arise (Bok et al. 2007;Kelley 2006). Consistent 
with this model, over expression of Tbx1 leads to an enlarged sensory epithelium and Tbx1 
mutation  in  humans  results  in  a  syndrome  which  includes  sensorineural  hearing  loss 
amongst its signs (Di George syndrome) (Bok et al. 2007;Kelley 2006).  
 
Tbx1 expression overlaps with that of bone morphogenetic protein 4 (Bmp4) – a member of 
the  transforming  growth  factor  beta  superfamily  –  in  the  posteroventral  region  of  the 
otocyst. Though expression of Bmp4 is initially diffuse and located in the posteroventral otic  
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cup,  its  expression  is  later  refined  to  the  nascent  cristae  i.e.  the  non Lfng expressing 
prosensory regions (see Figure 1.4d) (Cole et al. 2000;Pujades et al. 2006). As for Notch, 
BMP4  signalling  was  thought  to  be  involved  in  specification  of  prosensory  patches  and 
experiments designed to test this hypothesis yielded unclear results. However, a consistent 
theme has emerged from these experiments suggesting that BMP4 is involved in cellular 
patterning  of  the  developing  sensory  domains;  consequently,  manipulation  of  BMP4 
signalling results in abnormal hair cell numbers in a chick model (Pujades et al. 2006). 
 
A number of other markers, e.g. Islet1, prospero related homeobox 1 (Prox1) and fibroblast 
growth  factor  16  (Fgf16),  have  also  been  shown  to  be  expressed  in  patterns  that  are 
consistent with that of  the developing prosensory region and their function is currently 
being studied (Bermingham McDonogh et al. 2006;Radde Gallwitz et al. 2004;Wright et al. 
2003). The characterisation of these factors, along with the factors described above, has 
significantly  improved  our  understanding  of  prosensory  domain  establishment  and 
development. This is allowing a shift in focus in this research area from the identification of 
regional markers to the full understanding of the mechanisms of prosensory specification 
and development. 
 
Semicircular canal development 
The  semicircular  canals  are  required  for  delivering  rotational  acceleration  forces  to  the 
cristae for transduction. These canals develop alongside their respective cristae though they 
arise from the dorsolateral otocyst rather than the posterior or anteroventral otocyst from 
which  the  cristae  originate  (Rinkwitz  et  al.  2001).  The  nascent  semicircular  canals 
evaginate from the otocyst to form the anterior and posterior canal genesis zones prior to 
that of the lateral semicircular canal. In higher vertebrates, the epithelia of the opposing 
walls of the pouch come into contact during pouch extension to form a ‘fusion plate’ at the 
centre  of  the  pouch.  Apoptotic  cells  appear  within  these  fusion  plates  at  the  time  of 
epithelial contact which  occurs in  the order of semicircular canal development (anterior 
first, then posterior and, finally, lateral). The clearance of epithelial cells from the centre of 
the canal that results from these apoptotic foci gives rise to the anatomy of the mature 
semicircular canal. Consequently, inhibition of apoptosis leads to defects in the clearing of 
the centres of the semicircular canals in chick experiments (Fekete et al. 1997). Alongside 
central clearing, each canal develops an ampulla at one end that houses its respective crista 
(i.e. the anterior end of the anterior canal, the posterior end of the posterior canal and the 
anterior end of the lateral canal) (see Figure 1.4c & d) (Bok et al. 2007;Leon et al. 2004). 
 
Utricle and saccule formation 
As  the  Lfng expressing  region  of  the  anteroventral  prosensory  domain  develops,  it 
eventually segregates into the utricular macula, saccular macula and organ of Corti. The 
first  of  these  three  to  separate  is  the  utricular  macula,  which  is  known  to  become  
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independent  of  the  anteroventral  stripe  by  E12  in  the  mouse.  The  Ngn1  and  Notch 
pathways are then thought to regulate the maturation of this epithelium by guiding cell 
fate determination i.e. differentiating hair cells, support cells and neural cells. The saccular 
macula separates from the anteroventral stripe in a similar manner to the utricular macula 
at E13. As with the utricular macula, members of the Ngn1 and Notch signalling pathways 
are thought to be involved in guiding its terminal development (see Figure 1.4d) (Bok et al. 
2007). 
 
The processes before and after separation of these epithelia are being elucidated and little 
is known about the process by which these epithelia become distinct from the anteroventral 
stripe and each other. A number of genes (Hmx2, Hmx3, Otx1, and Otx2) are thought to be 
active  in  influencing  this  process  from  the  non sensory  tissues  that  surround  the 
prosensory domain and only one protein, GATA3, is known to be differentially expressed 
between the utricle and saccule at this stage (Bok et al. 2007;Karis et al. 2001). Also, a 
conserved region of apoptotic cells is consistently observed at the junction of the cochlea 
and saccule in a site that goes on to form the ductus reuniens (the duct that joins the scala 
media  to  the  saccule)  which  is  likely  to  be  required  for  the  separation  of  these  organs 
(Fekete et al. 1997;Leon et al. 2004;Nishikori et al. 1999).  
 
As prosensory development proceeds, additional apoptotic hotspots are observed within and 
around the sensory epithelia and within the CVG (including the cristae and organ of Corti). 
These are thought to be required to allow axons that have been extended from the CVG to 
penetrate  the  sensory  epithelium  and  contact  sensory  cells,  as  well  as  aiding  in  CVG 
maturation (Bok et al. 2007;Fekete et al. 1997;Leon et al. 2004). 
 
Cochlear extension and maturation 
As  the  cochlear  duct  extends  from  the  otocyst,  it  begins  to  take  on  its  mature  (coiled) 
appearance at around E12 in the mouse (Kelley 2007).  The prosensory domain continues to 
be marked by SOX2 and LFNG whilst a non sensory stripe of BMP4 expression becomes 
visible  on  the  opposite  wall  of  the  extending  cochlear  duct  after  prosensory  plaque 
specification (see Figure 1.4) (Bok et al. 2007).  
 
Between E12 and E14, cells in the nascent organ of Corti exit the cell cycle in an apical to 
basal wave and, from this point on, there is minimal cell proliferation and apoptosis in this 
developing sensory epithelium (Jones et al. 2007;Ruben 1967). The cochlear duct continues 
to transform after this terminal mitosis in a basal to apical direction and does not complete 
its coiling until approximately E19 P0 (see Figure 1.4d) (Jones et al. 2007;Kelley 2007). 
This elongation process changes the cochlear duct from a short, thick structure (the dorsal 
cochlear floor is four to six cells deep when the cochlear duct first appears) to a much longer  
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and thinner structure that is only two cell layers deep in the mature organ of Corti (see 
Figure 1.5) (Kelley 2007).  
 
The  proposed  model  by  which  cochlear  growth  is  achieved  in  the  absence  of  cellular 
proliferation is known as convergent extension. This model is based on the process by which 
many axial structures develop across phyla (Zajac et al. 2000) and by which the body axis is 
elongated in vertebrate gastrulation and neurulation (Jenny et al. 2006). In this model, 
cells  in  the  developing  epithelium  elongate  and  subsequently  intercalate  as  they  move 
towards the lumen of the cochlear duct, causing growth along the basal apical axis. As cells 
no  longer  proliferate  at  this  stage,  the  cochlear  duct  epithelium  becomes  thinner  as 
epithelial cells intercalate and as the cochlear duct elongates (Jones et al. 2007;Wang et al. 
2005). This cochlear extension occurs at the same time as the organisation of planar cell 
polarity (PCP) in the nascent organ of Corti (see section 1.3.3). 
 
Once the inner ear has completed its morphogenesis, the elaborate structures that have 
been  created  become  encased  in  bone  (the  otic  capsule).  Correct  formation  of  the  otic 
capsule  is  dependent  on  signaling  between  the  epithelium  of  the  cochlear  duct  and  the 
surrounding  mesenchyme  e.g.  the  Shh Tbx1 Pou3f4  axis  in  the  periotic  mesenchyme  is 
required for normal duct patterning (Bok et al. 2007;Rinkwitz et al. 2001). Once the capsule 
ossifies around the membranous labyrinth, there is no further growth in the inner ear – a 
fact that is exploited in paediatric cochlear implantation, as implants do not need to be 
changed as children grow. 
1.2.3  Summary of inner ear development 
A  large  number  of  dynamically  expressed  factors  are  now  known  to  be  required  to 
transform the flat otic placode into the complicated three dimensional labyrinth. The high 
resolution  that  is  being  achieved  in  the  identification  and  characterisation  of  expressed 
factors in this process is aiding in the emerging understanding of the precise contribution of 
each of these factors. Apart from explaining the causes of a number of human deafnesses – 
e.g.  X linked  deafness  seen  in  DFN3  (Pou3f4  mutation)  (de  Kok  et  al.  1995)  –  these 
processes precede or coincide with hair cell development (see next section) and, therefore, 
signalling networks involved in morphogenesis may influence future therapies to prevent or 
reverse hearing loss.  
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1.3  Hair cells 
There are four different types of hair cell in the mammalian inner ear. Inner hair cells 
(IHCs) and outer hair cells (OHCs) of the cochlea are required for auditory transduction 
whilst Type I and Type II vestibular hair cells are found in the remaining inner ear sensory 
epithelia and are required for balance sensation (Kingsley 1999b;Kingsley 1999a). These 
functions depend on the specialised anatomy and physiology of the sensory epithelia and 
require  functional  hair  cells.  Consequently,  hair  cell  loss  causes  loss  of  hearing  and 
vestibular function that is irreversible in mammals, where hair cells do not regenerate. 
1.3.1  Hair cell and support cell specification 
Cochlear hair cells arise from a group of mitotically quiescent cells of the prosensory patch 
in the elongating cochlear duct. In many neuronal systems, excessive progenitor cells are 
produced  and  subsequently  eliminated  to  produce  mature  patterning.  However,  the 
cochlear prosensory domain does not follow this model as it appears to have the required 
number of cells for full development at the time of terminal mitosis as supported by the 
lack of apoptosis in this region (Kelley 2007).  Therefore, the timing of the terminal mitosis 
requires precise control to ensure correct development. Though the signals that control the 
timing of terminal mitosis are unknown, one of the first identifiable effectors of this timing 
mechanism is the cyclin kinase inhibitor p27Kip1 (Kelley 2007).  
 
Most progenitor cells in the nascent organ of Corti of the mouse cochlear duct have long 
been  known  to  exit  the  cell  cycle  between  E13  and  E14  beginning  in  the  apex  and 
progressing to the base (Ruben 1967). This wave of terminal mitosis creates an apical to 
basal  line  of  mitotically  quiescent  cells  along  the  middle  of  the  developing  sensory 
epithelium that encompasses the  full thickness of the epithelium and is called the zone of 
non proliferation (ZNP) (Chen et al. 1999;Chen et al. 2002). Consistent with its known role 
in cell cycle regulation, p27Kip1 expression begins abruptly at the cochlear apex at E12 and 
extends  basally,  to  become  strongly  expressed  throughout  the  ZNP  by  E14  (Chen  et  al. 
1999). The temporal and spatial correlation of p27Kip1 expression with mitotic quiescence, as 
shown by BrdU studies, provides evidence for its requirement in preventing mitosis in this 
region (see Figure 1.5a) (Chen et al. 2002). Results from p27Kip1 knockout mice support this 
result as they show a delay in terminal mitosis that is associated with supernumerary hair 
cells and severe hearing loss (Chen et al. 1999;Lowenheim et al. 1999). 
 
Though mitosing cells are identifiable in the organ of Corti of  p27Kip1 knockout mice as late 
as postnatal day six (the latest date investigated) (Chen et al. 1999), both hair cells and 
support cells are able to stop mitosing and differentiate. This indicates that another factor 
or  other  factors  are  involved  in  halting  mitosis  in  the  developing  organ  of  Corti  and 
retinoblastoma  (Rb)  has  been  shown  to  be  one  such  factor.  
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Rb is upregulated at E15.5 in basal hair cells (i.e. during early hair cell differentiation) and 
its  expression  extends  from  the  base  to  the  apex  following  the  wave  of  hair  cell 
differentiation (see section 1.3.2). It is subsequently expressed throughout the ZNP, and is 
weakly expressed in other cochlear cells (Liu et al. 2008;Mantela et al. 2005;Sage et al. 
2005). Current evidence shows that Rb protein is required for the maintenance of mitotic 
quiescence in the organ of Corti and in the terminal maturation of outer hair cells through 
an unknown mechanism (Mantela et al. 2005;Sage et al. 2005;Sage et al. 2006). Given its 
role in prevention of proliferation, Rb inhibition is thought to be a potential strategy for 
hair cell regeneration as hair cells re enter the cell cycle when Rb is inhibited. However, the 
hair cells produced by this method subsequently die by apoptosis. Therefore, further work 
on short term inhibition of Rb function is required to clarify whether hair cells can be made 
to minimally mitose without proceeding to apoptosis or oncogenesis (Sage et al. 2006). 
 
Following the induction of mitotic quiescence in the ZNP by p27Kip1 and Rb, it is thought 
that the cyclin kinase inhibitors p19Ink4d and p21Cip1 are required to prevent hair cells re 
entering  the  cell  cycle.  Codeletion  of  these  factors  results  in  a  sudden  loss  of  cell  cycle 
control at P3 (in mice) and inappropriate S phase entry of hair cells with the production of 
supernumerary hair cells. This dysregulation leads to p53 mediated apoptosis of mitosing 
hair cells resulting in a phenotype similar to that of Rb knockout mice and supporting the 
hypothesis  that  maintenance  of  hair  cells  in  the  postmitotic  state  is  dependent  on  a 
network of interacting cyclin kinase inhibitors (Laine et al. 2007). 
  
At the time that the ZNP is established, it is thought that its constituent cells have equal 
potential to become hair cells or support cells and that only cells of the ZNP contribute to 
the  organ  of  Corti  (Kelley  2007).  Within  the  ZNP  hair  cells  and  support  cells  are  born 
simultaneously, suggesting that they share a common lineage, with viral tracing studies in 
the chick confirming that hair cells and support cells share a common progenitor (Fekete et 
al. 1998). Though it is thought that IHCs are the first cells to become identifiable in the 
maturing organ of Corti, recent work in developing rats has cast doubt on this as high 
resolution  electron  microscopy  techniques  have  revealed  cells  whose  morphology  is 
consistent with that of inner pillar cells prior to IHC detection (Thelen et al. 2009). 
 
If inner pillar cells are indeed the first cells to differentiate following terminal mitosis in 
the ZNP, IHCs are the next cell type to become identifiable, followed by the OHCs and 
support cells (see Figure 1.5b) (Thelen et al. 2009). The IHCs are located on the modiolar 
side of the border between the greater and lesser epithelial ridges where inner pillar cells 
develop. The earliest marker of hair cells is the basic helix loop helix (bHLH) transcription 
factor Atoh1 (formerly known as Math1) which marks a column of nascent inner hair cells 
that span the distance from the BM to the lumen of the cochlear duct (see Figure 1.5c) 
(Chen et al. 2002).  Many conflicting results  are available regarding when Atoh1 is first  
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detectable, though it is accepted that this transcription factor is initially expressed basally 
in a diffuse group of cells at E12.5 and later refined to be expressed more specifically in 
nascent HCs once they have adopted their fate (see Figure 1.5a) (Kelley 2007). However, it 
has not been proven whether all of the cells of the Atoh1 positive column become hair cells 
or if only the luminal cells adopt the hair cell fate and it is therefore unclear whether all 
Atoh1 positive  cells  at  this  stage  are  committed  to  the  hair  cell  fate  (Chen  et  al. 
2002;Goodyear et al. 2006).  
 
Atoh1 is thought to be initially maintained at low levels by the HLH proteins Ids1, Ids2 and 
Ids3  until,  through  an  unknown  mechanism,  Atoh1  expression  is  able  to  rise  above  a 
threshold in nascent hair cells. This allows it to regulate its target genes and may allow it 
to positively autoregulate. Two of the genes that are upregulated in Atoh1 expressing cells 
are  the  Notch  ligands  Jag2  and  Delta-like  1  (Dll1).  These  factors  mediate  a  process  of 
lateral inhibition by acting on the Notch1 receptor of adjacent cells, thereby initiating the 
expression  of  Notch  target  genes  in  these  cells  (Hes1  and  Hes5),  causing  them  to 
differentiate as support cells (Kelley 2007;Kiernan et al. 2005a). Consistent with this model, 
dysregulation of Notch signalling – e.g. by deletion of the Nr2f1 nuclear receptor – disrupts 
normal patterning of the sensory epithelial mosaic (Kelley 2007;Tang et al. 2006) and alters 
the expression of the prosensory marker Sox2, which is downregulated in Atoh1 expressing 
cells through an unknown mechanism. However, Sox2 expression is maintained in support 
cells – most likely due to Notch mediated upregulation – where it is able to induce the 
homeodomain transcription factor Prox1 to suppress the hair cell fate, thereby preventing 
overproduction of inner hair cells (Dabdoub et al. 2008;Kelley 2007). 
1.3.2  Hair cell differentiation 
Soon after the onset of Atoh1 expression, a number of hair cell specific proteins become 
identifiable. The cells that express these markers subsequently develop morphologically, 
acquiring the specialised structures required for MET and electromechanical transduction 
(in OHCs), and gaining functional maturity. Hair cell differentiation proceeds in a basal to 
apical direction (Lim et al. 1985). 
 
One  of  the  first  known  steps  in  hair  cell  differentiation  is  the  downregulation  of  the 
connexin genes that leads to a loss of gap junctions. In chick studies, this downregulation 
has been shown to precede morphological changes in hair cells and occurs with a decoupling 
of developing hair cells from much of the basal extracellular matrix so that only the most 
basilar of the column of nascent hair cells has contact with the underlying extracellular 
matrix (similar to the developing mouse organ of Corti) (Bryant et al. 2005;Chen et al. 2002).  
 
Unlike gap junctions, tight junctions and adherens junctions are retained by developing 
hair cells (Bryant et al. 2005). At the hair cell apices, tight junctions become more complex  
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as development proceeds with adherens junctions developing beneath them. These apical 
junctions become mature as the endocochlear potential is generated at P6 in mice. They 
also define the junction between apical and lateral membranes in the hair cells and this 
distinction  is  thought  to  allow  trafficking  of  different  proteins  to  these  different  sites 
(Bryant et al. 2005).  
 
Almost immediately after hair cell specification and onset of Atoh1 expression, hair cells 
begin  to  express  an  array  of  marker  genes.  These  include  the  calcium binding  proteins 
calmodulin, calretinin and parvalbumin; the unconventional myosins VI, VIIa and XVa (see 
section  1.3.3);  and  the  POU domain  transcription  factor,  POU4F3  (see  section  1.5.3) 
(Bryant et al. 2005;Xiang et al. 1998). Calretinin and parvalbumin are also expressed in 
sensory ganglion neurons making them less specific markers for early differentiating hair 
cells (Xiang et al. 1998). In contrast to this, other factors are downregulated as hair cells 
differentiate, e.g. the gap junctions and GATA3, the latter of which is first downregulated 
in hair cells and subsequently downregulated in support cells (Rivolta et al. 1998b). 
 
As well as the signalling proteins described, retinoic acid signalling is known to be involved 
in  hair  cell  development.  In  the  embryonic  organ  of  Corti,  it  is  known  to  promote 
differentiation of epithelial cells to hair cells and accompanying support cells. It normally 
acts through hetero dimers of its receptors (Goodyear et al. 2006) of which retinoic acid 
receptor  (RAR)  α,  retinoid  X  receptor  (RXR)  α  and  RXRβ  are  expressed  by  E13  in  the 
cochlear epithelium, becoming more strongly expressed as hair cells develop (though RAR α 
expression  is  rapidly  suppressed  between    E17  and  P3)  (Raz  et al.  1999).  Treatment  of 
cochlear cultures with a retinoic acid antagonist causes changes in the expression of Pou4f3 
and myosin VIIa but does not affect myosin VI expression, suggesting that retinoic acid 
signalling  is  not  required  for  hair  cell  specification  but  is  responsible  for  hair  cell 
maturation. The fact that not all markers are eliminated when retinoic acid signalling is 
suppressed suggests that there is more than one differentiation pathway at work in nascent 
hair cells (Raz et al. 1999). 
1.3.3  Morphological maturation of hair cells 
As described in section 1.1.3, hair cells display highly specialised apical structures called 
stereocilia  that  are  grouped  together  to  form  a  hair  bundle  that  is  required  for 
mechanoelectrical  transduction  (MET).  Stereocilia  are  identifiable  early  in  hair  cell 
differentiation with scanning electron microscopy studies in the developing mouse showing 
that they are first observable at E12.5 in the utricle and E13.5 in the cristae and saccule 
(Bryant  et  al.  2005;Goodyear  et  al.  2006).  In  the  cochlea  they  have  been  tentatively  
identified at E15 by transmission electron microscopy (E18 in rat as shown by scanning 
electron microscopy) (Bryant et al. 2005;Goodyear et al. 2006;Siemens et al. 2004;Zine et al. 
1996).   
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A  striking  feature  of  the  mature  organ  of  Corti  is  the  high  regularity  and  identical 
orientation of its cells and cellular organelles including hair bundles. This regularity arises 
because  cells  must  be  correctly  oriented  in  the  organ  of  Corti  if  they  are  to  respond 
appropriately  to  movements  of  the  BM.  A  similarly  strict  regulation  of  orientation  is 
exhibited in the vestibular sensory epithelia (Kelly et al. 2007). At the hair cell apices, this 
process of polarisation can be seen in the development of the hair bundles. 
 
Around the time that they are born, hair cells have polygonal apices with many microvilli 
and  a  kinocilium  (a  true  cilium)  at  the  centre  (Zine  et  al.  1996).    Lateralisation  of  the 
kinocilium  is  one  of  the  earliest  events  in  hair  bundle  development,  and  this  initiates 
asymmetry in the hair cell apex. The bundle develops centrally in a circular shape but is 
refined  to  its  adult  shape  as  development  proceeds.  Mature  OHC  hair  bundles  are  W 
shaped and IHC hair bundles are characteristically straight or slightly curved (see Figure 
1.6a) (Kelly et al. 2007). Consistent with the wave of hair cell differentiation, stereocilia 
first appear in the basal region of the cochlea and are later detectable apically (Zine et al. 
1996).  As  they  grow,  they  undergo  extensive  remodelling  to  achieve  their  mature 
morphology e.g. tapering at the base and repositioning on the apex. The regular rows of 
both IHC and OHC hair bundles mature to form a ‘staircase’ pattern in which adjacent 
rows of stereocilia increase in height in the modiolar to striolar direction  (Bryant et al. 
2005;Goodyear  et  al.  2006).  The  staircase  arrangement  of  stereocilia  becomes  more 
apparent throughout the P0 P4 age range and, by P4 P6, hair bundles attain their adult 
shape (Lelli et al. 2009;Nishida et al. 1998); the kinocilia are also lost at P6 (Lelli et al. 
2009). By the time of functional hair cell maturation (P10 12), apical hair cell stereocilia are 
longer than those in the base due to their faster growth rate and due to shortening of basal 
hair cell stereocilia (see Figure 1.6b) (Bryant et al. 2005;Goodyear et al. 2006;Lelli et al. 
2009).  
 
Though the kinocilium is initially moved in the same direction in all hair cells, apical cell 
polarity  is  not  as  strictly  aligned  as  it  will  become  as  the  organ  of  Corti  matures.  A 
microfilament network that runs parallel  to the apical membrane – which is associated 
between  hair  cells  and  support  cells  through  adherens  junctions  –  may  be  involved  in 
signalling  this  polarization  and  striated  rootlets  parallel  to  the  hair  cell  apices  may  be 
involved  in  positioning  the  kinocilia.  Though  the  orientation  of  the  bundles  is  slightly 
variable early in hair bundle development (e.g. at E17 in the mouse cochlea), by P10, there 
is very little difference in bundle orientation between hair cells (Goodyear et al. 2006). This 
orientation process is thought to be mediated by a group of genes that control similar cell 
polarity processes in Drosophila development (Celsr1, Vangl2, Frizzled and members of the 
Wnt signalling pathway) (Kelly et al. 2007).  
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Figure 1.6. Stereocilial links and structure. 
a) Scanning electron micrograph of the mid-basal guinea pig organ of Corti showing mature 
stereocilial morphology. Red arrow, IHCs; blue arrows, OHCs; asterisk, tunnel of Corti; green 
arrows, neurons (adapted from Lenoir 1999). b) electron micrographs of the five different types 
of link seen in the hair bundle (centre) (taken from Figure 1 in Nayak et al. 2007). c) a recent 
model of MET at the stereocilial apex. In this model, stereocilial movement in the excitatory 
direction  puts  tension  on  the  tip-links  (composed  of  CDH23  apically  and  PCD15  basally), 
physically  opening  the  MET  channel  (mc),  thus  allowing  small  cations  to  enter.  The  upper 
portion of the tip-link is attached by a harmonin isoform and the tip-link is maintained at optimum 
tensions by a process of adaptation that requires MYO1C (taken from Figure 7 in Grillet et al. 
2009). 
 
 
The stereocilia – which more closely resemble enlarged microvilli than true cilia like the 
kinocilium – are known to be composed of a large number of proteins. Cytoskeletal core 
proteins  Actin,  Fimbrin,  and  Espin  form  much  of  the  stereocilial  structure  whilst  the 
unconventional  hair  cell  myosins  are  required  for  correct  stereocilial  development  and 
function. In mice, a myosin VI mutation leads  to a circling  and deaf phenotype (Snell’s 
waltzer); a myosin VIIa mutation causes vestibular dysfunction and deafness (Shaker1); 
and a myosin XVa mutation causes deafness and circling behaviour (Shaker2) (Goodyear et 
al.  2006;Liang  et al.  1998).  Though  the  precise  functions  of  these  molecular  motors  are 
unknown,  the  above  mutations  are  known  to  cause  auditory  and  vestibular  defects  by 
disruption of the hair bundle (Bryant et al. 2005;Goodyear et al. 2006). 
 
As the stereocilia mature, links between them become apparent. These links have been best 
characterised in the chick basilar papilla where, from hair bundle apex to base,  tip links, 
horizontal top connectors, shaft connectors and ankle links have been identified (Bryant et 
al. 2005;Goodyear et al. 2006). If the kinocilium is still present (i.e. before P6 in the mouse 
cochlea), then there are also abundant kinocilial links present which join the kinocilium to 
the immediately adjacent stereocilia in the tallest row of the hair bundle (see Figure 1.6b) 
(Nayak et al. 2007). The tip links grow radially between the stereocilia and are later refined 
a)  b) 
c) 
Picture removed for copyright 
purposes 
Picture removed for copyright 
purposes 
Picture removed for copyright purposes  
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to remove extraneous links, leaving only those that are in line with the direction of hair 
bundle displacement (Waguespack et al. 2007).  These are thought to be  involved in the 
gating of the MET channel (see section 1.3.4) and are formed by an asymmetric complex of 
the cell adhesion molecules cadherin 23 and protocadherin 15 (Kazmierczak et al. 2007). A 
large  and  heterogeneous  group  of  mutations  in  these  genes  are  known  to  cause  deaf 
blindness in humans (Reiners et al. 2006) but only cause inner ear dysfunction in Ames 
Waltzer mice due to abnormal stereocilial development; the difference between mice and 
humans most likely being due to functional redundancy between different isoforms of these 
cadherins in mice (Ahmed et al. 2008). The remaining links are thought to play a purely 
structural role in co ordinating hair bundles so that they move as a functional unit, though 
their precise roles are uncharacterised (Bryant et al. 2005). Furthermore, the function of an 
increasing  array  of  cell  membrane  proteins  (Integrins  and  Ptprq),  PDZ binding  domain 
proteins (Harmonin b, Whirlin and Sans) and downstream target genes of PCP genes and 
integrins  (Rho GTPases)  are  being  characterised  in  developing  hair  cells  (Bryant  et  al. 
2005;Goodyear  et  al.  2006)  where  they  are  also  thought  to  be  involved  in  hair  bundle 
maturation and function. 
 
As well as the array of proteins described above, microRNAs have also been implicated in 
normal  hair  cell  development.  These  molecules  bind  to  target  mRNA  and  repress  its 
translation to produce subtle changes in protein expression (Weston et al. 2009). miR 96, 
which is expressed from a primary transcript that also encodes miR 182 and miR 183, has 
been shown to be required for normal hair cell development. Mutation in the seed region of 
this microRNA (the part of the molecule that interacts with target mRNAs) causes hair 
bundle deformity in heterozygous mice and very few recognisable hair cells in four to six 
week  old  homozygotes.  Heterozygotes  consequently  display  highly  raised  hearing 
thresholds and homozygotes have no detectable hearing at  4 weeks of  age (Lewis et al. 
2009). Furthermore, miR 96 mutation in humans causes a progressive autosomal dominant 
hearing loss (Mencia et al. 2009). These effects are thought to be due to the dysregulation of 
translation of 96 transcripts identified by microarray analysis (particularly Slc26a5, Ocm, 
Gfi1, Ptprq and Pitpnm1 which are involved in hair cell development and function) (Lewis 
et al. 2009). 
 
At the hair cell apices, stereocilial roots insert into a dense body of cytoskeletal proteins 
called the cuticular plate. This structure contains α actin, spectrin, tropomyosin, myosin Ie 
and myosin VI and is first identifiable at E14 15 in the mouse cochlea using an antibody 
that recognises one of its unidentified components i.e. before stereocilia become detectable. 
During its generation, many uncoated vesicles are present in the apical hair cell cytoplasm, 
and coated pits suggest extensive endocytotic activity and high membrane turnover at the 
apical membrane. As this subsides, the cuticular plate thickens and joins the hair cell apex 
and neck by the formation of a junctional complex (Forge et al. 1993; Nishida et al. 1998).   
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1.3.4  Functional maturation of hair cells 
To perform their specialised functions properly, hair cells require a hair bundle with MET 
channels; ion channels in the basolateral membrane (for K+ and Ca2+) with fast enough 
kinetics  to  produce  sufficiently  sensitive  receptor  potentials;  and  adequately  developed 
synapses for the informative release of neurotransmitter. Mice start to hear at about P10 
12, at which point all of the above factors are in place. Electromechanical transduction is 
also in place in OHCs at this stage (see below) (Kros 1996;Marcotti et al. 1999;Meyer et al. 
2009). The development and mature function of these processes is described in this section. 
 
Mechanoelectrical transduction 
When hair cell stereocilial bundles are deflected away from the modiolus, it is thought that 
tip links  are  stretched  due  to  the  relative  rotational  movement  of  stereocilia  in 
neighbouring  rows.  The  tension  generated  in  the  tip links  is  transmitted  to  the  as yet 
unidentified MET channel by an unknown coupling mechanism causing the influx of small 
cations from the endolymph that results in hair cell depolarisation (Xu et al. 2009). These 
tip links are maintained  at optimal tension by an adaptation process (Holt et al. 2000). 
Gradually, more aspects of these processes are being identified and their development is 
being characterised (see Figure 1.6c). 
 
Morphologically, the transduction apparatus can be divided into the upper tip link density 
(UTLD), the tip link, the lower tip link density (LTLD) and the MET channel. It is thought 
that the MET channel is located at the tips of the stereocilia though it is uncertain whether 
it is located on taller or shorter stereocilia (though it is unlikely to be present at both ends 
of the tip link) (Fettiplace et al. 2006). The most recent model at the time of writing places 
the  MET  channel  at  the  top  of  the  shorter  stereocilia  in  the  LTLD  where  force  is 
transmitted to it by the lower (PCD15) portion of the tip link via an unknown mechanism 
(Grillet et al. 2009). The upper part of the tip link is composed of CDH23 and this part 
inserts into the UTLD. A protein called harmonin has recently been shown to form part of 
the  UTLD  and  it  is  thought  that  harmonin  couples  CHD23  to  the  F actin  in  the  taller 
stereocilium (see Figure 1.6c) (Grillet et al. 2009). Though harmonin a and/or b is known to 
be  primarily  expressed  at  the  UTLD  in  adult  mice,  different  isoforms  of  harmonin  are 
expressed  in  different  parts  of  the  stereocilia  and  at  different  levels  throughout 
development (Boeda et al. 2002;Grillet et al. 2009). 
 
The MET channel is known to be expressed as early as E18.5 in mice as its transducer 
current (IT) develops in the basal cochlea at this date. It is thought that this early MET 
channel expression (well before the onset of hearing) might be required to regulate hair 
bundle maturation and to facilitate spontaneous action potentials that are generated by 
developing hair cells (Kros 1996). Though the MET channel current is identifiable from  
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E18.5 (in inner hair cells), cochlear IHCs and OHCs do not become mechanosensitive until 
between  P0  and  P2  (Lelli  et al.  2009).  These  hair  cells  are  identifiable  in  the  basal  P0 
cochlea with the developmental gradient of mechanotransduction moving from base to apex 
to encompass all cochlear hair cells at P7 as demonstrated by FM1 43 staining (a styryl dye 
that permeates the open MET channel (Gale et al. 2001)) (Lelli et al. 2009). Functional, but 
closed, MET channels have been identified at earlier dates in these regions by deflecting 
hair bundles and measuring evoked currents. By this method, >80% of OHCs in the mid 
apical and apical turns are identified as being mechanosensitive at P2. Furthermore, there 
is a systematic increase in the amplitude of maximal transduction currents (between P0 
and P2 in the base and between P2 and P6 in the apex) with similar maturation of the 
operating range (stabilising at P2 3 basally and P5 6 apically) and adaptation (stabilising 
at P4 basally and P6 apically) (Lelli et al. 2009). It is thought that harmonin is required for 
maturation  of  these  MET  transducer  currents  as  the  currents  produced  by  mature 
harmonin  mutant  cochlear  hair  cells  resemble  those  of  immature  wild  type  hair  cells 
(Grillet et al. 2009). 
 
Hair cell ion channels, currents, innervation and synaptic maturation 
A full discussion of the variety of currents that are seen in developing and mature hair cells 
(including the MET current) is beyond the scope of this work. However, these currents will 
be  briefly  discussed  along  with  synaptic  maturation  due  to  the  requirement  of  these 
processes for normal hair cell development.  
 
Following specification, the IHC has a resting potential of approximately  50mV due to the 
IK,emb current. This resting potential becomes more negative by E16.5 due to the additional 
K+ current, IK1. At this stage, Ca2+ and Na+ currents with fast activation kinetics become 
identifiable and IHCs are therefore likely to be able to release synaptic vesicles by this 
point (Housley et al. 2006). All of these currents rapidly increase in size in the base by 
E17.5 (E18.5 in the apex) where ICa is necessary for calcium action potentials and INa and 
IK1 modulate the frequency and shape of these action potentials which are quite small and 
slow (Goodyear et al. 2006;Kros 1996).  
 
These action potentials are spontaneous and are thought to be important for the correct 
maturation of synaptic connections i.e. they are necessary for the development and survival 
of neural connections as well as the development and survival of IHCs themselves. Afferent 
neurons begin to form synapses with IHCs at about E18 when, in the basal cochlea, the 
MET transducer current (IT)  is also present (though probably not yet mechanosensitive) 
(Goodyear et al. 2006;Housley et al. 2006;Kros 1996;Lelli et al. 2009). Therefore, as well as 
potentially regulating hair bundle maturation, IT might be required with ICa to facilitate 
spontaneous action potentials (Goodyear et al. 2006;Kros 1996). 
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Spontaneous  action  potentials,  both  due  to  intrinsically  generated  Ca2+  spikes  and 
purinergic  signalling,  continue  into  the  second  postnatal  week  by  which  time  in  vitro 
studies  have  shown  that  large  changes  are  completed  in  hair  cell  innervation  and  ion 
channel expression (Housley et al. 2006;Tritsch et al. 2007). From P3 to P10, temporary 
efferent synaptic connections are formed with the IHCs that are thought to inhibit afferent 
firing via the ISK2 current, thereby setting up rhythmic firing patterns in immature afferent 
neurons that are required for coding functional hair cell output. Also in the early postnatal 
period, the delayed rectifier K+ current IK,neo develops (P0), efferent synapses at the OHCs 
express  SK2  currents  and  OHCs  become  electromotile  (from  about  P8)  (Goodyear  et  al. 
2006;Kros 1996). 
 
Final maturation of IHCs occurs towards the end of the second postnatal week when there 
is a sudden expression – at the onset of hearing – of the fast, non inactivating outward K+ 
current IK,f which allows IHCs to respond to hair bundle movement with the fast, graded 
receptor  potentials  required  for  appropriately  detailed  encoding  of  sound  intensity.  A 
potassium current (IK(Ca)) is also found and thought to regulate neurotransmitter release. 
Finally, IK,f (IBK), a KCNQ4 current (IK,n) and IK,s are expressed. IK,f and IK,n take over from 
IK1  in  setting  the  resting  potential  in  the  mature  IHC  and  IK,s  (a  delayed rectifier  K+ 
current  with  slow  action  kinetics)  may  contribute  to  the  adaptation  of  IHC  receptor 
potentials to long duration tone bursts (Goodyear et al. 2006;Kros 1996). 
 
Once signals are transmitted from the MET channel to the remainder of the IHC, the signal 
has  to  be  transmitted  to  the  nervous  system.  This  is  accomplished  by  release  of  the 
excitatory amino acid neurotransmitter glutamate from IHCs that acts on AMPA receptors 
on postsynaptic afferent neurons. Glutamate release is dependent on maturation of IHC 
presynaptic function and, to facilitate this, there is an increase in ICa and synaptic vesicle 
exocytosis in the first postnatal week. Though ICa subsequently declines, exocytosis remains 
constant  and  these  changes  are  accompanied  by  a  large scale  remodelling  of  the 
presynaptic IHC that is associated with the development of plates of presynaptic ‘ribbons’ 
around the onset of hearing. These changes are thought to be essential for precise control of 
neurotransmitter  release  (reviewed  in  Kros  1996;Meyer  et  al.  2009).  In  mice,  ribbon 
synapses have been shown to be tuned so that their morphology at mature IHCs is similar 
throughout  the  cochlea  but  with  a  tonotopic  variation  in  synaptic  density  (Meyer  et  al. 
2009). 
 
Effect of thyroid hormone signalling on inner ear development 
The thyroid hormone receptors TRα1 and TRα2 (encoded by Thra) are expressed in most of 
the sensory epithelia of the inner ear whereas TRβ1 and TRβ2 (encoded by Thrb) are only 
expressed in the cochlear epithelium in both the greater epithelial ridge (GER) and lesser 
epithelial ridge (LER). Induced hypothyroidism influences the activity of the T3 responsive  
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thyroid hormone receptors (TRα1, TRβ1 and TRβ2) and causes a delay in organ of Corti 
development  with  additional  defects  in  TM  development.  Furthermore,  knockout  of  all 
thyroid receptors leads to defects and delay in hair cell functional maturation as measured 
by the disruption of normal hair cell ion currents (Goodyear et al. 2006). 
 
Outer hair cell mechanoelectrical transduction 
The  lateral  membranes  of  IHCs  and  OHCs  appear  similar  at  birth.  However,  the  OHC 
lateral membrane becomes specialised by P8 (when OHCs become electromotile) i.e. prior to 
the onset of hearing at P10 12 in mice (P15 in the rat) (Bryant et al. 2005;Goodyear et al. 
2006;Jensen Smith et al. 2007;Kros 1996).  The support cells disconnect from the lateral 
membrane, leaving a liquid filled gap, and endoplasmic cisternae develop parallel to the 
OHC  lateral  membrane  where  prestin  (Slc26a5),  Glut 5,  actin  and  Ca2+ ATPase  become 
localised. The organisation of these proteins and the cisternae continues to develop in a 
time frame consistent with functional maturation of OHCs (as measured by OAEs) and, 
therefore, the onset of electromotility at P8 in mouse OHCs  (Bryant et al. 2005;Marcotti et 
al. 1999). 
 
Following the described processes of prosensory domain specification, hair cell specification 
and  differentiation,  mature  hair  cells  are  able  to  detect  subatomic  deflections  of  hair 
bundles (Dallos 1992). This ability underlies the exquisite sensitivity of human hearing and 
small perturbations of the above processes – including genetic mutations – are sufficient to 
abolish the function of this sensitive system.  
1 General introduction    46 
1.4  Abnormal hearing 
1.4.1  Epidemiology and classification of hearing loss 
278 million people worldwide are estimated to have a moderate to profound hearing loss in 
both ears (World Health Organization 2006) which can arise from damage at any level of 
the  auditory  pathway  from  the  outer  ear  to  higher  brain  centres.  Hearing  loss  often 
presents in childhood and 68 million people are thought to have hearing loss that originated 
in childhood with about 62 million of this population aged less than 15 years. This is due to 
an estimated neonatal incidence of about 720 000 cases per year worldwide which doubles 
by age 9 in developed countries such as the UK (Fortnum et al. 2001;Olusanya et al. 2007).  
 
According  to  current  measures,  two  thirds  of  the  burden  of  hearing  loss  is  borne  by 
developing countries. However, it has been argued that the World Health Organization’s 
thresholds  for  disabling  hearing  loss  are  set  too  high  and,  therefore,  do  not  take  into 
account less severe hearing losses that can be disabling in noisy environments. Therefore 
the number of people in both the developed and developing world that are living with a 
disabling  hearing  loss  is  likely  to  be  higher  than  the  above  figure  (Olusanya  et  al. 
2007;Smith et al. 2006). 
 
Traditionally, hearing loss is described as being either conductive, sensorineural or mixed 
in origin. Conductive hearing loss is hearing loss due to abnormality of the outer or middle 
ear  that  causes  reduced  sound  conduction  to  sensory  hair  cells  of  the  inner  ear  and 
sensorineural  hearing  loss  (SNHL)  refers  to  damage  to  the  cochlea,  sensory  neurons  or 
higher auditory centres (Bull et al. 2007) (see Table 1.2). 
 
SNHL is the most common sensory deficit in more developed societies and, based on years 
of healthy life lost, adult onset hearing loss from all causes is the third largest cause of 
disability  after  depressive  disorders  and  unintentional  injuries  (Olusanya  et  al.  2007). 
However, some authors argue that permanent childhood hearing impairment is likely to 
cause a greater loss of healthy life if properly accounted for (Olusanya et al. 2007). 
 
Due to differences in healthcare, living conditions and culture, the causes of hearing loss 
vary greatly between developed and developing countries. The largest causes of hearing loss 
in developing countries (infection and medication) now account for only a small amount of 
hearing loss in the developed world where genetic deafness and age related hearing loss 
(ARHL) are responsible for most hearing loss (see Olusanya et al. 2007 for review). The 
problem of ARHL – which is growing due to the ageing population in developed countries 
such as the UK – is further complicated by increasing rates of dual sensory loss as vision 
impairment is also associated with age (Heine et al. 2002). In recent studies, ARHL has  
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been shown to have a prevalence of 29 43% in men and 17 20% in women of 60 69 years of 
age (Agrawal et al. 2008;Gopinath et al. 2009). 
 
Table 1.2. Classification of hearing loss. 
Causes of hearing loss categorised by location of lesion and in approximate order of incidence 
in the developed world (adapted from Bull et al. 2007). 
Conductive  Sensorineural 
Wax  Age related hearing loss (ARHL) 
Otitis media  Noise induced hearing loss (NIHL) 
Barotrauma  Genetic (Congenital, early  or late onset) 
Otosclerosis  Drug  / Poison induced (including solvents) 
Injury of tympanic membrane  Menière’s disease 
Traumatic ossicular dislocation  Late otosclerosis 
Congenital ear canal atresia  Inner ear infections and meningitis 
Middle ear agenesis  Hypoxia 
Middle ear tumours  Jaundice 
  Vestibular Schwannoma 
  Head Injury 
  CNS disease 
  Metabolic 
1.4.2  Testing and characterisation of hearing loss 
Worldwide, there is a trend towards early detection of childhood hearing impairment. The 
importance of early identification and characterisation of hearing loss in achieving better 
outcomes  in  auditory  habilitation  has  been  established,  especially  regarding  childhood 
development; late (>1 year) detection and management of hearing impairment is associated 
with substantial developmental deficits in communication and cognition (Olusanya et al. 
2007). Adequate assessment of adult hearing loss is, likewise, important in determining the 
cause and, therefore, the appropriate treatment for hearing loss. 
 
Simple clinical tests can be used to identify and categorise hearing loss. The tuning fork 
tests  devised  by  Weber  (to  identify  unilateral  hearing  loss)  and  Rinne  (to  differentiate 
conductive and sensorineural hearing losses) still form part of hearing examination though 
they provide little information on the frequency distribution of hearing losses (Ludman et al. 
1998). Audiometric tests can also perform the function of identifying hearing loss and aid in 
the differentiation between conductive and sensorineural hearing loss. However, they serve 
the further purpose of characterising the frequency distribution and quantifying hearing 
loss which makes it possible to track  its progression (Ludman et al.  1998;Prosser et al. 
2007).  Finally,  imaging  techniques  such  as  MRI  and  CT  are  employed  to  identify  gross 
anatomical causes of hearing loss (Phelps 1998). 
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Focussing  on  SNHL,  commonly  available  quantitative  tests  are  pure  tone  audiometry, 
speech audiometry, auditory brainstem responses (ABRs) and otoacoustic emissions. In the 
first two tests, a subject’s ability to detect sounds of differing frequency and intensity is 
tested. Pure tone audiometry presents sinusoidal waveforms for this task whereas speech 
audiometry uses speech sounds. Subjects report their ability to detect a pure tone or repeat 
speech  sounds  to  the  examiner  as  appropriate.  This  results  in  the  production  of  an 
audiogram  whereby  the  lowest  intensity  at  which  sound  of  a  given  frequency  can  be 
detected  is  plotted  relative  to  the  expected  threshold  for  a  number  of  frequencies  (see 
Figure 1.10b for an example) (Ludman et al. 1998;Prosser et al. 2007). Of the two tests, 
speech audiometry is thought to be more relevant to communication and is therefore more 
useful  in  monitoring  the  results  of  rehabilitative  interventions  (Prosser  et  al.  2007). 
However,  both  pure  tone  and  speech  audiometry  are  restricted  by  the  requirement  of 
communication  from  the  subject.  Though  most  adults  and  children  aged  five  years  and 
above  can  undergo  pure  tone  audiometry,  younger  children  require  special  conditioning 
procedures and it is difficult and time consuming to test these children (Prosser et al. 2007). 
 
Such co operation is not required for ABRs and OAEs. ABRs measure the response of the 
auditory brainstem to auditory stimuli by detecting action potentials at six to seven points 
between the cochlear nerve and subthalamic nuclei. This test looks for neural abnormalities 
and is able to localise auditory brainstem deficits as well as detecting cochlear hearing loss. 
OAEs,  on  the  other  hand,  look  solely  at  OHC  function.  Different  stimuli  are  used  to 
measure the cochlear response at different frequencies and intensities (Ludman et al. 1998) 
to  identify  cochlear  causes  of  hearing  loss.  Given  the  ease  with  which  OAEs  can  be 
measured (usually in 3 5 minutes per subject), they have become the screening method of 
choice  for  the  UK  NHS  neonatal  hearing  screening  programme  (MRC  Hearing  & 
Communication Group 2008). 
 
The above tests, allied with more specialised tests and a battery of vestibular function tests, 
currently aid in the assessment and management of patients with hearing loss (Ludman et 
al. 1998;Omahoney et al. 1998;Prosser et al. 2007). Once an audiogram is obtained, the 
severity of hearing loss can be quantified, and the type of hearing loss can be categorised 
(i.e. low frequency, middle frequency, high frequency or flat).  
 
The above tests currently aid in  tailoring treatment for hearing loss (see  section 1.4.6), 
though  they  are  likely  to  play  a  greater  diagnostic  role  as  the  audiogram  phenotype  of 
different  hearing  losses  becomes  better characterised,  as  the  temporal  progression  of 
different  hearing  losses  are  better  understood  and  as  the  audiogram histological 
relationship  of  hair  cell mediated  and  non hair  cell mediated  hearing  loss  is  elucidated 
(Prosser et al. 2007). Perhaps most importantly, future improvement in the sensitivity of 
these assessment tools may guide genetic investigations for hearing loss in order to identify  
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which of the hundreds of chromosomal loci that cause hearing loss are at fault in a given 
patient with a suspected genetic cause of hearing loss (see sections 1.4.4 and 1.5.4) (Prosser 
et al. 2007). 
1.4.3  Sensorineural hearing loss (SNHL) 
SNHL can be caused by a diverse group of factors that either cause direct damage to the 
organ  of  Corti  (e.g.  infection  and  trauma)  or  cause  hair  cell  dysfunction  through  other 
mechanisms which can underlie the differences in onset of different hearing losses (e.g. 
genetic  hearing  loss  and  aminoglycoside  antibiotics)  (see  Table  1.3).  Fortunately,  in  the 
developed world, the incidence of hearing loss due to preventable causes has been greatly 
reduced.  This  change  is  due  to  improvements  in  prenatal  and  perinatal  care  (including 
maternal vaccination against rubella), careful use of aminoglycoside antibiotics (see section 
1.4.6),  appropriate  treatment  of  infection,  reduced  exposure  to  solvents  and  genetic 
counselling (Olusanya et al. 2007).  
 
Unfortunately, although NIHL caused by occupational exposure to noise is thought to be on 
the  decline,  NIHL  from  other  causes  seems  set  to  rise.  This  is  thought  to  be  due  to 
increased voluntary exposure to high intensity noise though personal music players and 
loud concerts as well as the failure to implement a variety of lifestyle factors (of various 
levels  of  evidence)  which  can  be  preventative,  i.e.  using  hearing  protection,  smoking 
cessation,  increasing  exercise,  improving  nutrition  and  reducing  other  risk  factors  for 
diabetes or heart disease. (Daniel 2007). 
 
Table 1.3. Types and onset of SNHL. 
The  different  types  of  SNHL  categorised  by  onset    (data  from  Bull  et  al.  2007;Daniel 
2007;Howarth et al. 2006;Olusanya et al. 2007;Smith et al. 2005). 
Onset  Prenatal  Perinatal  Postnatal  Early-onset  Late-onset 
Genetic / Chromosomal 
Infectious 
Drugs (e.g. Aminoglycoside antibiotics) / Poisons (e.g. solvents) 
     Noise 
   Trauma 
     
Birth 
Asphyxia 
  
  
Neonatal 
Jaundice 
   
      Prematurity   
  
Low 
Birthweight 
  
Type 
      Age  
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1.4.4  Genetic causes of hearing loss 
Many of the critical factors for physiological hearing have been identified as their mutation 
results in hearing loss (in both humans and mouse models) (Robin et al. 2005;Van Camp & 
Smith  2008).  Less  than  15  years  ago,  few  genetic  causes  of  hearing  loss  were  known. 
However, since the advent of new molecular biological experimental techniques, mutations 
at over  100 loci have been shown to  be responsible for hereditary hearing loss and the 
majority  of  the  mutations  at  these  loci  cause  SNHL  (Prosser  et  al.  2007;Robin  et  al. 
2005;Van Camp & Smith 2008). Though mutations causing hearing loss eventually result 
in similar pathology (i.e. hair cell loss and organ of Corti degeneration), the factors which 
they affect are active in a range of sites as shown in Figure 1.7 (Friedman et al. 2007); this 
diversity of function and localization is representative of the complexity of the inner ear. 
The  level  of  disability  caused  by  these  hereditary  hearing  losses  is  dependent  on  the 
severity (mild, moderate or profound) and time of onset (typically described as congenital, 
prelingual,  postlingual  or  adult)  of  hearing  loss,  though  these  factors  can  vary  greatly 
(summarised in Table 1.4). 
 
More than half of neonates with SNHL have hereditary hearing loss. Of this number, 30% 
are syndromic (most commonly due to SLC26A4 mutation that causes Pendred’s syndrome) 
and approximately 50% are attributed to non syndromic gap junction mutation (GJB2 and 
GJB6),  with  the  remainder  being  attributable  to  other  non syndromic  causes,  such  as 
POU4F3 mutation (Robin et al. 2005;Smith et al. 2005) (see Table 1.4 and sections 1.5.3 
and  1.5.4  ).  Consequently,  clinical  investigation  of  suspected  hereditary  hearing  loss  is 
usually restricted to GJB2 and SLC26A4 analysis (Prosser et al. 2007). 
 
Such hearing losses can be inherited by a number of different modes (autosomal dominant, 
autosomal recessive, X linked or mitochondrial). Furthermore, both the mode of inheritance  
and type of hearing loss caused by different mutations in the same gene can vary greatly 
(see Table 1.4). This is illustrated by GJB2 mutation that can result in either autosomal 
recessive  nonsyndromic  hearing  loss  or  autosomal  dominant  syndromic  hearing  loss 
depending  on  the  mutation  present.  Looking  more  closely  at  these  GJB2  mutant 
phenotypes,  the  time  of  onset  of  hearing  loss  is  also  highly  variable,  causing  either 
prelingual  or  postlingual  deafness,  which  will  result  in  a  large  difference  in  language 
acquisition in affected individuals (see Table 1.4). 
 
Although the largest cause of hearing loss (GJB2 mutation) does not cause hearing loss by 
a direct effect on hair cells (mature hair cells do not express gap junctions), a large amount 
of genetic deafness is due to hair cell loss (Smith et al. 2005;Van Camp & Smith 2008). This 
is either due to mutation of genes that are selectively expressed in hair cells (as in Figure 
1.7d,e & f) or by hair cell death secondary to other cochlear disorders (Friedman et al. 2007).  
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Attempts are currently underway to identify more genes that are required for normal inner 
ear function through large forward genetics (phenotype driven) mutagenesis programs. In 
such programs, random mutations are generated in mice (e.g. by ENU mutagenesis) and 
the progeny are tested for hearing loss, initially with a simple test (e.g. response to a click) 
and later by more detailed investigation (e.g. ABR hearing testing) (Acevedo Arozena et al. 
2008). It is hoped that these new mutant mice will give us a better understanding of the 
mechanisms of hearing and deafness. 
 
Figure 1.7. Cochlear expression of factors involved in hereditary hearing loss. 
Schematic of factors required for normal hearing which are expressed in different parts of the 
cochlea and whose mutation results in SNHL: a) cochlear section (RM, Reissner’s membrane); 
b) tectorial membrane; c) stria vascularis; d) hair cell and support cells; e) hair cell apex and hair 
bundle links; f) stereocilium (taken from Friedman et al. 2007). 
 
 
Though  there  is  a  strong  focus  on  the  identification  of  mutations  that  cause  SNHL  in 
animal  models,  this  sometimes  overlooks  the  complex  interaction  between  genetic  and 
environmental factors  that confound human SNHL study. As environmental factors can 
greatly influence hearing loss, it is difficult to identify genetic factors that can underlie 
sensitivity to these environmental causes of hearing loss, making it hard to attribute the 
correct share of causality to each factor. An example of this is the mitochondrial mutation 
Picture removed for copyright purposes  
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(A1555G)  that  underlies  a  non syndromic  hearing  loss  and  increased  sensitivity  to 
aminoglycoside  ototoxicity  (Zhang  et  al.  2005).  However,  using  novel  resources,  genetic 
modifiers  of  susceptibility  to  late onset  hearing  loss  are  being  identified.  Using  a  large 
sample of patients with hearing loss, Friedman et al. were recently able to identify GRM7 
(a gene that encodes a type of metabotropic glutamate receptor), the mutation of which is 
thought to underlie susceptibility to ARHL (Friedman et al. 2009b). Furthermore, using a 
different approach (i.e. candidate gene SNPs and the HapMap project), van Laer et al. were 
able to identify a gene that is associated with ARHL (GRHL2) due to a mutation in an 
intronic region that is likely to affect its regulation and, therefore, expression (Van Laer et 
al. 2008). 
 
Given that more deafness causing genes are now known, it has been suggested that genetic 
testing is likely to become a more integral part of the evaluation of hearing impairment, 
particularly in children. This is important for prognosis in terms of disease progression and 
response to treatment, as well as being valuable for genetic counselling of parents. It is also 
an appealing prospect for healthcare services as it can be cheaper than the battery of tests 
that many patients are subjected to, assuming that a mutation is found (Robin et al. 2005). 
However, given the considerable heterogeneity in the genetic causes of hearing loss, the 
poor genotype phenotype correlation seen for most forms of deafness (see Table 1.4), and 
the  number  of  environmental  factors  that  can  greatly  affect  phenotype,  the  challenges 
facing the design and implementation of such diagnostic tests are considerable.  
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1.4.5   Hair cell death 
Hair cell loss in humans leads to permanent SNHL and loss of vestibular function because 
there is no hair cell regeneration in the mammalian cochlea and little regeneration in the 
vestibular epithelia (Matsui et al. 2005). As well as gene mutation, noise, medications (such 
as aminoglycoside antibiotics and the cytotoxic agent cisplatin), age and other factors can 
also cause hearing loss via hair cell death (Holley 2005).  
 
Although  the  mechanisms  that  trigger  hair  cell  death  have  not  been  elucidated,  the 
signalling pathways involved in this process are becoming increasingly well characterised. 
For  example,  apoptosis  (type  1  programmed  cell  death),  necrosis  and  necrosis like 
programmed cell death (type 2 programmed cell death) have all been implicated in hair cell 
loss due to noise and cochlear implantation trauma (Eshraghi et al. 2006). In noise induced 
hearing loss (NIHL), basal cochlear OHCs have been shown to be the most susceptible to 
damage as these are the first hair cells to be lost following noise exposure (Henderson et al. 
2006). This may be due to reactive oxygen species (ROS) and toxic free radicals that are 
known  to  be  produced  in  the  stria  vascularis  and  later  appear  in  OHCs.  ROS  are  also 
associated with aminoglycoside induced hair cell loss, cisplatin induced hair cell loss and, 
along with reactive nitrogen species, hair cell loss in pneumococcal labyrinthitis (secondary 
to  meningitis)  (Cheng  et  al.  2005;Klein  et  al.  2008;Matsui  et  al.  2004a;Rizzi  et  al. 
2007;Rybak et al. 2007). However, it is not understood whether ROS cause cochlear damage 
or if they are the products of dying cells (Henderson et al. 2006). In NIHL, hair cell death 
occurs via a mixture of necrosis and apoptosis in the initial phase which later progresses 
due to apoptosis alone (Henderson et al. 2006). Hair cell death is thought to be triggered by 
JNK  and  c jun  activation  which  leads  to  Bax  translocation  to  the  mitochondria  and 
cytochrome c release with associated caspase activation (Cheng et al. 2005). 
 
The mechanism of hair cell death due to aminoglycoside antibiotics is thought to share the 
same  upstream  component  as  NIHL  (Cheng  et  al.  2005).  Approximately  4  hours  after 
neomycin application, the intracellular Ca2+ concentration undergoes a sustained increase 
which is temporally linked to phosphorylation of JNKs (and, subsequently, c Jun) which, in 
turn, leads to apoptosis (Cheng et al. 2005;Gale et al. 2004;Matsui et al. 2004b). Though 
cisplatin induced  apoptosis  acts  through  the  same  end effectors  as  aminoglycosides  and 
produces a similar pattern of hair cell loss, it does not seem to be controlled by the JNK / 
MAPK pathway, suggesting the presence of more than one apoptotic trigger in hair cells 
(Cheng et al. 2005). One such trigger may be p53, which is upregulated in hair cells in 
response to cisplatin treatment suggesting that it is an upstream regulator of cisplatin 
induced hair cell death (Cheng et al. 2005;Rybak et al. 2007).  
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The deeper insight into hair cell death that has been gained in recent years has clarified 
the disease mechanisms of many different types of hearing loss. This knowledge is now 
being turned into potential preventative measures against hearing loss (see section 1.4.7). 
1.4.6  Current SNHL management strategies 
Though a variety of medical and surgical interventions are available for the treatment of 
conductive hearing losses, there is still only a limited range of treatment options for SNHL 
(Kulkarni et al. 2008). However, for many causes of SNHL, effective preventative measures 
can be taken from the governmental to the personal level (see Table 1.5). 
 
Table 1.5. Global prevention strategies for SNHL. 
(based on Daniel 2007;Fransen et al. 2008;Olusanya et al. 2007).  
Cause  Interventions 
ARHL 
Risk  factor  reduction  e.g.  smoking  cessation  and  weight  loss  for 
overweight individuals 
 
NIHL 
Public  health  education  to  avoid  exposure  to  excessive  noise. 
Legislation to reduce noise exposure 
 
Genetic 
Genetic counselling and avoidance of consanguineous marriages  
 
Drug  / Poison 
induced (including 
solvents) 
Medical and public health education to avoid exposure to ototoxic 
drugs and solvents 
 
Infection 
Immunisation,  improved  obstetric  and  neonatal  care  and  prompt 
treatment 
 
Hypoxia 
Improved obstetric and neonatal care 
 
Jaundice 
Improved obstetric and neonatal care 
 
 
SNHL  has  fallen  in  developed  countries  due  to  the  implementation  of  some  of  these 
prevention strategies, especially improvements in neonatal care and vaccination. However, 
children in less developed countries have not benefited from these advances as they cannot 
access  this  care  and  rates  of  both  acquired  and  genetic  hearing  loss  (often  due  to 
consanguinity)  are  higher.  Vaccination,  better  healthcare  and  genetic  counselling  is 
required  to  overcome  these  problems  and,  more  importantly,  prevent  serious  and 
potentially fatal infections (Smith et al. 2005). 
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Due to the irreplaceable nature of hair cells, however, such measures provide no benefit 
once SNHL is established. Therefore, treatment focuses on the development of management 
strategies such as lip reading and signing along with amplification of incoming sounds to 
optimise input to remaining hair cells. Amplification is currently possible through three 
strategies: increasing the volume of sound reaching the inner ear, electrical stimulation of 
the cochlea and electrical stimulation of the brainstem (Kulkarni et al. 2008). 
 
Amplification of sound to the inner ear is achieved through wearable hearing aids, bone 
anchored hearing aids and middle ear implants. These interventions are aimed at patients 
with mild to severe hearing loss and rely on residual hearing to detect incoming sound. An 
increasing array of devices are becoming available for this and more digital hearing aids 
are  being  produced  as  these  devices  are  able  to  perform  signal  processing  to  optimise 
signals in different auditory environments (Kulkarni et al. 2008). 
 
Direct electrical stimulation of the cochlea in the form of cochlear implants has become 
increasingly refined over the last two decades and has greatly improved the treatment of 
severe to profound hearing loss that was previously treated by high powered hearing aids 
(Ramsden et al. 2007). Cochlear implants work through an array of electrodes (usually 22) 
that  are  inserted  into  the  scala  tympani  of  the  affected  cochlea  and  present  incoming 
sounds  (received  by  an  external  microphone  and transmitted  transdermally  to  a  speech 
processor) to the spiral ganglion cells and surviving dendrites by direct, tonotpic electrical 
stimulation (Kulkarni et al. 2008;Ramsden et al. 2007). Though originally used in adults, 
there has been a rapid move to early implantation because of improved neonatal hearing 
screening. Though it is unclear what the effect of early implantation will be, it is thought 
that  the  improvement  in  hearing  provided  by  cochlear  implants  will  cause  hearing 
impaired children’s development to more closely match that of their peers and that this will 
not adversely affect family relationships (Moeller 2007;Smith et al. 2005). Unfortunately, 
due  to  their  cost,  cochlear  implantation  only  remains  a  viable  therapeutic  option  for 
patients in developed countries (Tarabichi et al. 2008). 
 
The  most  recent  intervention  for  the  treatment  of  SNHL  is  the  implantation  of  the 
electrode  arrays  that  either  stimulate  the  surface  of  the  brainstem  or  use  penetrating 
electrodes to stimulate brainstem nuclei. Such implants are used when the normal neural 
pathway from the cochlea is absent and, though they do not provide the same performance 
as  cochlear  implants,  they  aid  in  patients’  ability  to  lip read  and  recognise  sentences 
(Kulkarni et al. 2008;Ramsden et al. 2007). 
1.4.7  Future strategies in hearing loss 
Future strategies will focus on reducing the incidence of hearing loss and on the creation of 
new treatments for SNHL. The former task will rely, for the most part, on making existing  
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preventative  strategies  more  widely  available  whilst  the  latter  is  the  focus  of  a  large 
amount of scientific research. 
 
Prevention and treatment of hearing loss in the developing world 
Given  that  the  largest  cause  of  acquired  SNHL  in  the  developing  world  is  infection, 
increased  vaccination  against  rubella,  haemophilus  influenzae  and  streptococcus 
pneumoniae – most likely through the World Health Organization’s global programme for 
vaccines – has the potential to greatly reduce the burden of hearing loss in these countries 
(Smith et al. 2005). 
 
However, existing therapies for infection can also cause SNHL, particularly aminoglycoside 
antibiotics. Though these effective bactericidal drugs are the mainstay for the treatment of 
serious  (usually  gram negative)  infections  due  to  their  affordability  and  efficacy,  the 
morbidity caused by aminoglycoside induced SNHL is significant, particularly in China. As 
cheap  alternatives  for  these  antibiotics  are  not  available,  pharmaceutical  hair  cell 
protection  by  aspirin  co administration  is  being  investigated.  This  strategy  appears 
promising and the use of aspirin with other ototoxic drugs, such as cisplatin, is also being 
studied. However, it is uncertain whether the gastric side effects of aspirin will outweigh 
any benefit and whether hair cell protection comes at the cost of drug efficacy (Rizzi et al. 
2007;Rybak et al. 2007). 
 
Other prominent causes of hearing loss in industrialised developing countries are noise and 
solvents. In developed countries, legislation to reduce exposure to noise and solvents in the 
workplace  has  shown  a  marked  reduction  in  occupational  hearing  loss  and  the 
implementation of similar laws in developing countries is likely to have a similar effect 
(Tarabichi  et  al.  2008).  Finally,  increased  provision  of  existing  SNHL  treatments  in 
developing  countries  through  global  health  strategies  will  provide  benefit  to  a  large 
population, the main impediment being cost. 
 
New therapies for SNHL 
Much work is going into identifying new methods to prevent hair cell loss and regenerate 
lost hair cells. As well as using existing drugs to protect hair cells from programmed cell 
death following an insult, new molecules are being trialled for their protective properties. 
For example, inhibitors of the JNK pathway, such as D JNKI 1, have shown promise in 
protecting hair cells against damage due to noise and cochlear implant insertion in animal 
models (Eshraghi et al. 2006). Similarly, infusion of caspase inhibitors has shown promise 
in protecting against cisplatin ototoxicity (Rybak et al. 2007). Finally, antioxidants and free 
radical scavengers, which are presumed to work by reducing ROS in the cochlea following 
an insult such as cisplatin administration, have also shown promise in the prevention of 
SNHL in animal models. These molecules are thought to assist endogenous otoprotective  
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mechanisms and free radical scavengers to protect hair cells against damage from noise, 
drugs and age (Darrat et al. 2007;Rybak et al. 2007). 
 
Though these strategies provide hope for a great reduction in hearing loss in the future, 
they cannot provide any benefit to those who already have SNHL due to hair cell loss. As 
avians and lower vertebrates are able to regenerate their hair cells following trauma such 
as  aminoglycoside administration or noise (unlike mammals), there has  been a drive to 
understand the mechanisms that mediate regeneration with a view to manipulating these 
pathways in mammalian support cells to induce hair cell regeneration (Cotanche 2008). 
Following hair cell loss in the chick basilar papilla (the chicken equivalent of the cochlea), 
hair cells are regenerated by two distinct pathways: transdifferentiation and proliferation. 
Initially transdifferentiation predominates. In this process, support cells upregulate genes 
involved in hair cell development and become hair cells. Later, support cells re enter the 
cell cycle and mitose to form either two new hair cells, one hair cell and one support cell or, 
later, two support cells (Cotanche 2008;Matsui et al. 2005). Though the understanding of 
this process is progressing, the signals that initiate transdifferentiation and proliferation in 
the chick basilar papilla have yet to be identified and, therefore, it has not been possible to 
determine  whether  these  signals  can  induce  regeneration  in  the  mammalian  cochlea 
(Cotanche 2008). Furthermore, attempts to induce support cell differentiation using growth 
factors (e.g. FGF, IGF, BDNF, EGF and TGF) have had only limited success (Matsui et al. 
2004a). 
 
Therefore,  current  efforts  to  induce  hair  cell  regeneration  are  focusing  on  more  recent 
techniques  such  as  gene  therapy  and  transplantation  (e.g.  of  stem  cells).  Gene  therapy 
relies on the manipulation of gene expression in cochlear cells to correct genetic hearing 
loss,  prevent  hair  cell  loss  or  replace  lost  hair  cells  from  residual  cochlear  cells.  The 
correction  of  genetic  hearing  loss  would  most  likely  require  an  understanding  of  the 
mechanism of hair cell loss and, potentially, the creation of a specific therapy for each form 
of genetic deafness. Otoprotection would require the upregulation of protective genes such 
as Ntf3 and Bdnf (which enhance spiral ganglion cell survival) and antioxidant enzymes 
such as Mn superoxide dismutase (Kesser et al. 2008;Pfister et al. 2007). Finally, strategies 
for regeneration, without knowledge of factors that trigger regeneration in avian and other 
systems, rely on upregulation of factors involved in hair cell specification such as ATOH1 
(Cotanche 2008;Kesser et al. 2008;Pfister et al. 2007). 
 
As well as there being limited knowledge of which factors to target, gene therapy faces 
challenges in terms of routes of application and gene transfer vectors. Much progress has 
been made in solving these problems in recent years. Many routes have been tested for the 
delivery of reagents to the inner ear (e.g. diffusion through the round window and injection 
at different sites), with detectable expression of transgenes being identified using many of  
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these techniques. However, the trauma caused by some of these delivery techniques may 
mean that they are not viable routes for the treatment of human hearing loss. Different 
gene transfer methods have also been intensely investigated, with adenovirus and adeno 
associated virus showing the most promise. Furthermore, recent experiments have shown 
that  adenoviral  vectors  are  capable  of  transfecting  human  vestibular  epithelia  in  vitro. 
However, initially promising in vivo results in non primate laboratory animals have shown 
that  there  are  still  many  obstacles  to  overcome  in  this  field.  For  example,  Atoh1 
overexpression by a viral transfection strategy is capable of inducing hair cell regeneration 
in  the  deafened  cochlea  (Izumikawa  et  al.  2005),  however,  trauma  during  delivery, 
cytotoxicity  of  transfection,  misplacement  of  regenerated  hair  cells  and  degeneration  of 
regenerated hair cells mean that such therapy still appears far from clinical applicability 
(Edge et al. 2008;Izumikawa et al. 2005). 
 
The final novel and promising method proposed for the regeneration of hair cells is centred 
around the transplantation of stem cells to the cochlea. This method has both the potential 
to replace hair cells and to reform the cochlear microarchitecture which is eventually lost 
when hair cells die. Ideally, cells for transplantation would come from the patient in order 
to  avoid  host versus graft  disease  and  the  need  for  immunosuppression.  However, 
xenografting  (e.g.  using  porcine  cells)  or  allografting  (e.g.  with  stem  cells  derived  from 
human  foetal  tissue)  currently  seem  more  realistic  strategies  as  cells  are  more  readily 
available for these purposes. The challenges faced in this field are similar to those in gene 
therapy (e.g. potential oncogenesis). Furthermore, the triggers that can induce full hair cell 
differentiation have yet to be identified and the targeting of stem cell delivery to desired 
sites is currently impossible (Chen et al. 2007;Rivolta 2007;Ulfendahl 2007). 
 
Though much work remains to be done in order for the above methods to benefit SNHL 
patients, they remain viable strategies. Recent advances in retinal regeneration aid in the 
proof of many principals of sensory epithelial regeneration and lessons learned from this, 
and similar systems should aid the advancement of hair cell regeneration whilst protecting 
against some of the pitfalls of regenerative therapy (Enzmann et al. 2009).  
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1.5  Transcription  factors  and  regulation  of  gene 
expression by POU4F3 
The ability of cells to selectively express different genes from an identical genome underlies 
the large differences in cell type seen in individual organisms and allows cells to respond to 
external signals at the transcriptional level. This ability is primarily achieved through the 
interaction  of  gene  regulatory  proteins  with  DNA  binding  sites  and  non DNA  binding 
cofactors  (Alberts  et  al.  2002).  Both  gene  regulatory  proteins  and  non DNA  binding 
cofactors  are  known  as  transcription  factors  as  they  both  influence  the  rate  of  gene 
transcription though this term is usually used with reference to gene regulatory proteins 
and  will  be  used  as  such  with  non DNA  binding  proteins  referred  to  as  cofactors, 
coactivators or corepressors as appropriate. 
 
In some cases, the relationship between the binding of transcription factors to DNA binding 
sites and the initiation of transcription is simple, acting as an on/off switch. However, this 
is rarely the case in eukaryotic gene promoters, which are DNA regions that are responsible 
for the control of transcription of a given gene. Promoters act as processors; integrating 
multiple inputs from regulatory transcription factors to determine the level of expression of 
the gene they control (Alberts et al. 2002). They can be present at a number of locations, 
though they are usually located 5’ to the transcriptional start site (TSS) of the gene they 
control. Such promoters are classically composed of a core promoter (the minimum part of 
the promoter that is required for transcriptional initiation), proximal promoter and a distal 
promoter. These different regions contain binding sites that are recognised and bound by 
different transcription factors, which recognise them due to their sequence. Such binding 
sites  vary  in  length  though  they  are  usually  less  than  20bp  long  (Alberts  et  al. 
2002;Heintzman et al. 2007). 
 
Epigenetic regulatory mechanisms also influence whether a transcription factor is able to 
bind  the  DNA.  Various  forms  of  DNA  methylation  prevent  transcription  factor  binding 
whilst modification of chromatin packing, e.g. due to the modification of histones, can also 
inhibit or favour transcription factor binding (Alberts et al. 2002;Heintzman et al. 2007). 
1.5.1  Transcription factor structure and function 
Transcription  factors  typically  contain  a  DNA  binding  domain  and  protein protein 
interaction  domains  through  which  they  mediate  the  regulation  of  their  target  genes. 
Through different forms of DNA binding domain, transcription factors are able to recognise 
diverse binding sites, usually by binding the major groove of the double helix and reading 
the outside of the nucleotides in this groove. As well as the individual code of the bases, the 
overall geometry of the helix can be recognised and other features of the DNA, e.g. the 
energy required to bend it, can also influence TF binding (Alberts et al. 2002).  
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Figure 1.8. Interaction of transcription factors to initiate transcription. 
The  assembly  of  the  RNApol  II  preinitiation  complex  on  eukaryotic  promoters.  Transcription 
factors act on distal enhancers to increase the probability of assembly of the RNApol II complex 
on the core promoter via their interaction with general transcription factors (Krishnamurthy et al. 
2009). 
 
A number of different structures have evolved in order for transcription factors  to bind 
DNA.  These  are  the  helix turn  helix,  zinc  finger,  leucine  zipper  and  helix loop helix 
domains. One of the most commonly occurring of these is the helix turn helix domain in 
which there are typically two alpha helices joined by a short amino acid chain (the turn). It 
is usually the helix nearer the C terminal which binds DNA in the major groove (Alberts et 
al. 2002). 
 
Once bound to the DNA, transcription factors can upregulate target gene transcription by 
recruiting cofactors to aid in the assembly of the RNA polymerase II (RNApol II) complex 
(e.g.  coactivators  and  general  transcription  factors  that  form  part  of  the  RNApol  II 
preinitiation  complex).  Transcription  factors  can  also  repress  the  transcription  of  target 
genes. In its most simple form, gene transcription can be downregulated by the binding of a 
transcription factor to a region that causes the binding site of an upregulatory transcription 
factor  to  become  blocked.  However,  transcriptional  repression  is  often  more  complicated 
and requires the recruitment of corepressors which downregulate target gene transcription 
by modifying chromatin or inhibiting RNApol II formation. The complexes formed between 
transcription factors, cofactors and transcriptional protein complexes are extremely large 
and, due to the ability of DNA to be remodelled to bring distant regions into close contact, 
enhancer elements can be located far from the core promoter that they influence (Figure 
1.8) (Alberts et al. 2002;Krishnamurthy et al. 2009). 
Picture removed for copyright purposes  
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Typically, a group of transcription factors, acting proximal to the TSS, will be responsible 
for basal gene expression with this transcriptional control being modulated by numerous 
other transcription factors, acting distally. The effect of distally acting transcription factors 
may  be  weaker  and  these  factors  might  only  be  expressed  in  special  circumstances  e.g. 
during oxidative stress (Heintzman et al. 2007). 
1.5.2  The POU family 
The POU family is named after the first members of the class to be identified: Pit-1, Oct-1 
and Oct-2 (mammalian); and Unc-86 (C. elegans) (Verrijzer et al. 1993). These transcription 
factors are members of the larger homeodomain family that is defined by the presence of a 
characteristic  60  amino  acid  helix turn helix  DNA binding  domain  –  the  homeodomain 
(Scott et al. 1989). The homeodomain contained in POU transcription factors is called the 
POU homeodomain  (POUH)  and  comprises  three  alpha  helices  of  which  the  second  and 
third form a helix turn helix motif, and the third contacts the major groove (Verrijzer et al. 
1993). 
 
The POUH is preceded by another DNA binding domain that is 74 82 amino acids long and, 
as it is unique to POU factors, is called the POU specific (POUS) domain (Verrijzer et al. 
1993). The POUS, which comprises four alpha helices, contacts the DNA with an extended 
form of the helix turn helix motif formed between helices two and three with helix three 
making contact with the major groove (Assa Munt 1993). These two domains are joined by 
a  linker  that  is  poorly conserved  between  family  members  and  the  three  components 
described  (POUS,  linker  and  POUH)  together  form  a  region  named  the  POU domain 
(Verrijzer et al. 1993). It is thought that the complicated structure of this bipartite DNA 
binding  domain  allows  for  fine  control  of  DNA  binding  at  binding  sites  in  target  gene 
promoters – typically octamers – which are asymmetrical due to the structure of the POU 
domain  (Alberts  et  al.  2002;Aurora  et  al.  1992;Verrijzer  et  al.  1993).  In  support  of  this 
explanation, it has been shown that all three components of the POU domain contribute to 
the sequence specificity of DNA binding (Aurora et al. 1992;Verrijzer et al. 1993). 
 
Though POU family members tend to exist as monomers in solution, they have been shown 
to bind DNA both as monomers and dimers. Dimerisation, where it occurs, is thought to 
take place on the DNA, i.e. once a monomer has bound to a DNA binding site in a target 
gene promoter, and such interactions are mediated through the POU domain (Andersen et 
al. 2001;Aurora et al. 1992;Verrijzer et al. 1993). Once bound, POU family transcription 
factors are able to either upregulate or downregulate target genes. The type of regulation at 
a  particular  site  is  dependent  on  coregulators  which  interact  with  N   and  C terminally 
located  transactivation  domains  in  the  POU  protein  as  well  as  interacting  with  the 
homeodomain (Andersen et al. 2001).  
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The functional role of these transcription factors has since been investigated and they have 
been shown to be important in a variety of developmental and homeostatic functions. The 
main action of POU domain transcription factors is seen in neural cells of various kinds e.g. 
pituitary, neocortical and retinal with particular attention being given to their actions in 
embryonic development (He et al. 1989;Robertson 1988;Veenstra et al. 1997). In these cells, 
they regulate terminal cell proliferation, differentiation, migration and survival (Table 1.6) 
(Andersen et al. 2001). 
 
Table 1.6. Functions of the original POU family genes. 
(Andersen et al. 2001;McGhee et al. 1997;Robertson 1988). 
Organism 
Transcription 
Factor 
Localization  Function 
Pit 1  Pituitary Cells 
GH,  PRL,  TSHβ,  GHRHR  and 
other pituitary marker activation 
Oct 1  Ubiquitous  
Activates  small  nuclear  RNA 
(snRNA) and histone H2B genes 
Mammalian 
Oct 2 
B Lymphocytes, 
glia & neurons 
Activates immunoglobulin genes 
C. elegans  Unc 86  Neuroblast Cells  Fate specification of neural cells 
 
A large array of POU family genes have now been identified and divided into subfamilies 
(POU1 to POU6) based on their homology in the POU domain (Andersen et al. 2001;He et al. 
1989;Verrijzer et al. 1993). The POU4 family (POU4F) is one of these subfamilies and the 
first member of this group to be identified was Pou4f1 (also known as Brn 3a and Brn 3.0) 
which is involved in gene regulation in sensory neurons and is required for differentiation 
and survival of certain sensory and autonomic neurons (Andersen et al. 2001;He et al. 1989). 
Pou4f2  (also  known  as  Brn 3b  and  Brn 3.2)  was  identified  soon  after  and  shown  to  be 
expressed in the central nervous system and retina (Lillycrop et al. 1992;Xiang et al. 1993). 
Finally, Pou4f3 (also known as Brn 3c or Brn 3.1) was identified from a cDNA library and 
localised to mouse chromosome 18 (Gerrero et al. 1993;Ninkina et al. 1993;Xia et al. 1993). 
The POU4F factors are highly conserved and the human POU4F proteins share 98% amino 
acid similarity to their corresponding murine genes (Xiang et al. 1995). 
 
Pou4f3  was  found  to  have  limited  expression  in  the  rat  central  and  peripheral  nervous 
system beginning at around E13. By adulthood, its expression had reduced to undetectable 
levels in the mouse brain (Gerrero et al. 1993;Ninkina et al. 1993;Theil et al. 1993). In the 
spinal cord, it was inferred that POU4F3 was present in mechanosensitive sensory neurons 
due to labelling of cells in lamina 4/5 of rat spinal cord by in situ hybridization (the authors 
could not identify exactly which cell types had been stained). It was also present in the 
trigeminal and dorsal root ganglia (Erkman et al. 1996;Ninkina et al. 1993). Finally, it was 
found  to  be  expressed  in  retinal  ganglion  cells  and  in  the  inner  ear  (Erkman  et  al. 
1996;Xiang et al. 1995). Though the role of Pou4f3 in the nervous system and retina has 
received little attention, its expression pattern in the inner ear has prompted much work.  
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POU4F3 was shown to be uniquely expressed in hair cells of the inner ear, beginning in the 
basal cochlea and extending to include all the hair cells of both the cochlear and vestibular 
sensory epithelia (see Figure 1.9a) (Erkman et al. 1996;Raz et al. 1999;Xiang et al. 1997). 
The  onset  of  this  expression,  in  mice,  was  found  to  be  as  early  as  E12.5  in  postmitotic 
nascent hair cells (Xiang et al. 1998) and no other POU4F members are expressed in hair 
cells (Erkman et al. 1996;Ryan 1997). Two knockout mice, one spontaneous Pou4f3 mutant 
mouse and three human families with POU4F3 mutations have since revealed that Pou4f3 
is required for the terminal maturation and survival of hair cells (sections 1.5.3 and 1.5.4 
respectively)  (Collin  et  al.  2008;de  Heer  et  al.  2009;Erkman  et  al.  1996;Hertzano  et  al. 
2004;Vahava et al. 1998;Xiang et al. 1998;Xiang et al. 1997). 
1.5.3  The role of Pou4f3 in hair cell development in rodents 
The expression of POU4F3 in the inner ears of mice and rats has been investigated from 
embryonic to adult ages. Its expression begins at E12.5 in the otic vesicle, soon after Atoh1 
and before the hair cell specific myosins VI and VIIa at E13.5. It is accepted to be restricted 
to postmitotic cells. However, interpretation of results showing this and similar results for 
other  proteins  is  complicated  by  a  lack  of  consistency  and  information  in  reporting  the 
region of the developing inner ear analysed (e.g. Chen et al. 2002;Xiang et al. 1998). 
 
In the developing cochlea, Pou4f3 expression begins in the base (see Figure 1.9a) (Erkman 
et al. 1996;Raz et al. 1999) and extends to include all hair cells of the inner ear by birth, 
following the wave of hair cell differentiation. Once present, POU4F3 expression is thought 
to be maintained at a high level in the hair cells of the inner ear throughout adulthood, 
though  direct  evidence  of  this  is  lacking  (Erkman  et  al.  1996;Raz  et  al.  1999;Ryan 
1997;Xiang et al. 1998;Xiang et al.  1997).  There has been no report of  a  basal to apical 
gradient of POU4F3 expression in the late postnatal or adult organ of Corti. 
 
The role of Pou4f3 in hair cell development and maintenance has been clarified by three 
Pou4f3 mutant mice (a fourth mouse was created to investigate the role of Pou4f3 in retinal 
ganglion cell axon outgrowth and is therefore beyond the scope of this thesis (Wang et al. 
2002)).  Erkman et al. produced the first reported Pou4f3 knockout mouse by creating a null 
mutation at the gene locus which removed the entire protein coding region. Heterozygous 
animals  were  normal,  but  homozygous  knockout  mice  (Pou4f3-/-)  had  severe  deficits  in 
balance, coordination and autonomic response to vestibular stimuli, with hyperactivity (by 
5 6) weeks and complete deafness (Erkman et al. 1996;Murakami et al. 2002). This was 
shown to be due to a lack of differentiated hair cells in the early postnatal period and was 
followed  by  deterioration  of  the  morphology  of  the  organ  of  Corti  and  spiral  ganglion 
neurons (Erkman et al. 1996).  
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A knockout mouse was also created by Xiang et al. in which all of exon one and most of exon 
two of the Pou4f3 gene were deleted by homologous recombination. Again, heterozygous 
mice showed a normal phenotype. Knockout mice, however, showed circling behaviour with 
reduced  weight  and  fertility  when  compared  to  wild  type  mice.  The  deficits  seen  were 
thought to be due to the increased energy expenditure that arises due to circling behaviour. 
These knockout mice were also completely deaf and showed a marked balance deficit (Xiang 
et al. 1997). Histological investigation again revealed that the deafness and balance deficits 
seen are caused by a severe loss of hair cells (see Figure 1.9b). Though mature hair cells are 
not seen, nascent hair cells are produced in the developing organ of Corti of knockout mice 
(see Figure 1.9c). However, these cells (which express the hair cell markers myosin VI and 
VIIa, calretinin and parvalbumin) never develop mature hair cell morphology and undergo 
apoptosis in the late embryonic and early postnatal inner ear resulting in near complete 
loss by P5, supporting a role for POU4F3 in hair cell survival (Xiang et al. 2003;Xiang et al. 
1998;Xiang et al. 1997). At P7/8, only 1% of nascent hair cells remain in the cochlea and 
20% remain in the vestibular sensory epithelia (Xiang et al. 2003). These results support 
the  suggestion  of  Raz  et  al.  that  more  than  one  pathway  may  be  involved  in  hair  cell 
differentiation (Raz et al. 1999).  
 
The final Pou4f3 mutant mouse to be reported is the dreidel mouse (Hertzano et al. 2004). 
This  mouse  has  a  spontaneous  dinucleotide  deletion  in  the  Pou4f3  coding  sequence, 
upstream of the POU domain (reported as c.388_389delTG). This mutation was predicted to 
result in a truncated, non functional protein. Dreidel homozygous mice display a similar 
phenotype  to  other  Pou4f3  mutant  mice  with  vertical  head  tossing,  circling  and  hyper 
reactivity  combined  with  a  hearing  loss  (ABR  threshold  >100dB  SPL).  As  in  the  other 
mouse mutants, the phenotype observed is a result of hair cell degeneration and, though 
hair cell loss in dreidel homozygous mice is severe, it appears less severe than that of the 
other two Pou4f3 knockout mice whose inner ear morphology has been reported (Erkman et 
al. 1996;Hertzano et al. 2004;Xiang et al. 1998;Xiang et al. 1997). 
 
As well as hair cell degeneration, neuronal loss has been noted in the inner ears of Pou4f3 
knockout mice. The spiral ganglia of Pou4f3-/- mice show minimal neuronal loss at E17.5 
and appear normal up to P0. From P1 4 onwards, however, there is a clear reduction in the 
number  of  spiral  ganglion  neurons  and,  by  P14,  most  spiral  ganglion  and  vestibular 
ganglion  neurons  have  degenerated  with  synapses  on  type  I  hair  cells  being  markedly 
reduced  (Erkman  et  al.  1996;Xiang  et  al.  2003;Xiang  et  al.  1997).  In  fact,  vestibular 
ganglion  neuron  degeneration  appears  to  begin  earlier  than  spiral  ganglion  neuron 
degeneration  with  a  significant  reduction  in  vestibular  ganglion  size  by  E16.5.  The 
deterioration of spiral and vestibular ganglia was shown to be due to an increased rate of 
apoptosis  in  the  late  embryonic  and  early  postnatal  periods  (Xiang  et  al.  1998).  In  the 
cochlea, there is a consequent disruption in both afferent and efferent innervation with  
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particular disruption in the outer hair cell region. By six months, very little innervation 
remains in the inner ear apart from in the cochlear apex where it appears that some fibres 
can remain despite the lack of mature hair cells (see Figure 1.9d) (Xiang et al. 2003). 
 
As support cells and neurons do not express Pou4f3, it is most likely that their deterioration 
is secondary to a lack of trophic support from mature hair cells (Erkman et al. 1996;Xiang 
et al. 2003;Xiang et al. 1998;Xiang et al. 1997). However, the pattern of neuronal loss in 
Pou4f3-/- mice does not match that of any single neurotrophic factor knockout mouse (Xiang 
et  al.  2003).  Nonetheless,  POU4F3  has  been  shown  to  upregulate  the  expression  of  the 
neurotrophic factors brain derived neurotrophic factor (Bdnf) and neurotrophin 3 (Ntf3 also 
known as NT 3 ) and it is possible that the combined reduction of expression of these two 
factors contributes to the phenotype seen (Clough et al. 2004;Xiang et al. 2003) (See section 
1.5.5). 
1.5.4  The role of POU4F3 in hair cell maintenance 
Given that Pou4f3 was found to be expressed in adult rodent hair cells, it was suggested 
that it might play a role in maintaining hair cells and promoting their survival (Ryan 1997). 
Furthermore, given that POU4F3 is able to upregulate the neurotrophins BDNF and NT 3 
(Clough et al. 2004), it may be required for the maintenance of innervation of hair cells or 
for the trophic support of neighbouring cells. 
 
Evidence for such a role has been provided by three human families. In these families, 
individuals  who  are  heterozygous  for  one  of  three  disease causing  POU4F3  mutations 
display a late onset, dominant and progressive non syndromic hearing loss (DFNA15) (see 
Figure 1.10a) (Collin et al. 2008;Vahava et al. 1998). The first family to be identified was an 
Israeli Jewish family (family H) in which hearing loss begins the ages of 18 and 30 years 
and progresses to a moderate to severe hearing loss by age 50 with complete penetrance in 
affected individuals by the age of 40. Following linkage analysis, precise identification of 
the genomic location of Pou4f3 and sequencing, the investigators identified an eight base 
pair deletion in the protein coding region. This deletion causes a frameshift that was shown 
(in vitro) to cause a truncation of the resulting protein due to a premature stop codon. Prior 
to the stop codon, four amino acid residues are also mutated (Collin et al. 2008;Vahava et al. 
1998). 
 
A detailed audiological evaluation of members of family H revealed bilateral, sensorineural 
and  progressive  deafness  with  variable  audiogram  configuration  (see  Figure  1.10b). 
Furthermore,  OAE  testing  of  affected  individuals  confirmed  OHC  dysfunction  and  ABR 
testing revealed a normal central auditory pathway, supporting the hypothesis that hearing 
loss  in  this  family  is  due  to  hair  cell  loss  and  that  POU4F3  is  required  for  hair  cell 
maintenance (Frydman et al. 2000).  
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Figure 1.10. DFNA15 caused by POU4F3 mutation. 
POU4F3 mutation has been shown to be the cause of DFNA15 in three human families. The 
mode of inheritance has been shown to be autosomal dominant (a) (taken from Figure 1 in 
Pauw et al. 2008). Though audiograms in affected individuals are not sufficiently characteristic 
to  aid  diagnosis,  affected  individuals  typically  demonstrate  flat  or  gently  downsloping  
audiograms (b) (taken from Figure 1 in Vahava et al. 1998). 
 
 
For  a  decade,  family  H  was  the  only  known  family  with  hearing  loss  due  to  POU4F3 
mutation.  However,  two  Dutch  families  have  recently  been  identified  to  have  missense 
POU4F3 mutations which, like in family H, result in non syndromic autosomal dominant 
hearing  impairment.  In  the  first  of  these  two  families  (family  W05 549),  investigators 
identified  c.865C>T  which  is  predicted  to  result  in  L289F  (where  1  is  the  initiator 
methionine) (Collin et al. 2008). Hearing loss in family W05 549 is self reported to begin 
from childhood to the age of 60 years (mean age of onset was 35 years) with most patients 
exhibiting an early adult to midlife onset. Again, the mutation was fully penetrant with 
most individuals showing flat or gently downsloping audiogram configurations (however, 
other configurations were also observed). These audiograms were comparable to those seen 
for family H (see Figure 1.10b), though the rate of progression and severity of hearing loss 
a) 
b) 
Picture removed for copyright purposes 
Picture removed for copyright purposes  
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at different ages was shown to vary between family H and family W05 549 (Pauw 2008). 
Interestingly, the authors comment that speech recognition in family W05 059 is relatively 
preserved compared to audiogram severity. This may be due to loss of OHCs with relatively 
preserved  IHC  function as  is  the  case  for  other  deafnesses,  which  show  preservation  of 
speech  recognition  scores  compared  to  pure tone  audiometry  (Pauw  et  al.  2008). 
Furthermore,  nearly  all  members  of  this  family  (28  of  the  30  living  family  W05 059 
members) display vestibular deficits. These deficits are highly variable and do not correlate 
to  gender,  tinnitus  or  degree  of  hearing  impairment.  Vestibular  involvement  cannot  be 
excluded from family H as it was not tested (van Drunen et al. 2009). 
 
Most recently, the audiometric and vestibular characterisation of a family with a c.668T>C 
mutation in the POU4F3 POUS domain, resulting in L223P, has been carried out (Collin et 
al. 2008;de Heer et al. 2009). This family again displays an autosomal dominant late onset 
hearing loss with onset most often in early adulthood and with a flat or gently downsloping 
audiogram. Good speech recognition scores were again reported (though these results were 
not subjected to statistical analysis) (de Heer et al. 2009) and the phenotype of this family 
was  reported  to  be  milder  than  that  of  the  other  two  families  reported  (de  Heer  et  al. 
2009;Frydman  et  al.  2000;Pauw  et  al.  2008).  This  is  likely  to  correlate  with  milder 
impairment  of  L223P  mutant  POU4F3  function  compared  to  L289F  as  reported  in 
molecular  studies  of  the  DNA  binding  and  transactivation  capability  of  these  mutants 
(Collin et al. 2008). 
 
One of the challenges faced by clinicians in this field is the identification of the cause of 
hearing  loss  in  their  patients.  As  more  therapies  become  available,  this  will  become 
increasingly important. Unfortunately, according to the evidence above, there is no clear 
phenotype genotype correlation for DFNA15. Though many patients display flat or gently 
downsloping  audiograms  with  good  speech  recognition  scores  relative  to  pure  tone 
audiometry  scores,  there  are  also  affected  individuals  with  very  different  results  and 
vestibular dysfunction appears to vary greatly depending on the disease causing mutation 
(Collin et al. 2008;de Heer et al. 2009;Frydman et al. 2000;Pauw et al. 2008;Vahava et al. 
1998;van Drunen et al. 2009). It is possible that this variation is due to confounding factors, 
however,  no  such  factors  have  yet  been  identified,  making  the  future  identification  of 
affected individuals and families difficult. As Collin et al. suggest, the recent identification 
of  the  two  Dutch  families  with  POU4F3  mutations  may  reflect  a  higher  prevalence  of 
DFNA15 than previously thought. Therefore, they suggest routine screening of the small 
POU4F3 gene as part of a battery of diagnostic tests for deafness in certain populations 
appears  reasonable  (Collin  et  al.  2008).  However,  a  more  comprehensive  study  of  the 
prevalence  of  DFNA15  in  different  populations  would  be  required  before  the  cost 
effectiveness of such a strategy could be determined. 
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As well as the genotypes and phenotypes of DFNA15 patients, the likely mechanisms of the 
three disease causing POU4F3 mutations have also been investigated. All three mutations 
are predicted to cause amino acid substitution or peptide truncation in the POU domain of 
POU4F3 (Collin et al. 2008;Vahava et al. 1998). In family H, the four residue mutation and 
truncation is found in the POUH (at the end of the first of three alpha helices that form this 
subdomain), as is the L289F mutation of family W05 059 (which is in the third alpha helix) 
(Collin et al. 2008;Vahava et al. 1998;Weiss et al. 2003). L223P, on the other hand, causes 
its substitution in the POUS (adjacent to the start of the third of four alpha helices in this 
subdomain)  (Collin  et  al.  2008).  The  effect  of  these  mutations  on  DNA  binding, 
transactivation  and  nuclear  localization  have  since  been  investigated.  As  expected  for 
mutations  in  the  POU  domain,  all  three  mutations  cause  deficits  in  DNA  binding  and 
transactivation with L223P appearing to cause the smallest deficit (Collin et al. 2008;Weiss 
et  al.  2003).  Weiss  et  al.  investigated  the  effect  of  the  original  mutation  on  protein 
localization and identified one bipartite nuclear localization signal (NLS) which is disrupted 
in  the  truncated  protein  and  one  monopartite  NLS.  Protein  localization  has  since  been 
investigated  for  L223P  and  L289F.  Though  neither  of  these  mutations  are  predicted  to 
affect  either  NLS  (as  the  eight  base pair  deletion  in  family  H  does),  they  both  cause 
transfected  cells  to  show  a  degree  of  cytoplasmic  POU4F3  expression  (Collin  et  al. 
2008;Vahava et al. 1998;Weiss et al. 2003), suggesting that they may interfere with the 
known NLSs or that they disrupt/interfere with unknown NLSs in POU4F3. 
 
Given the impediments to obtaining and manipulating human inner ear tissue (see section 
1.6.1), alternative methods have been used  to try to elucidate the mechanism  by which 
POU4F3  heterozygosity  causes  hearing  loss.  Four  hypotheses  may  explain  deafness  in 
human heterozygous individuals with a mutation in the POU domain of POU4F3. The first 
of these is a dominant negative effect whereby mutant POU4F3 dimerises with wild type 
POU4F3 or other proteins to inhibit or otherwise alter their function; the second is that the 
mutation causes a gain of function which results in mutant POU4F3 binding to new DNA 
sequences; the third is that mutant POU4F3 might somehow trigger cell death; and the 
fourth is haploinsufficiency. 
 
Following the identification of family H, Pou4f3+/- mice (Erkman et al. 1996) were aged to 
24  months  in  order  to  identify  which  of  the  above  mechanisms  might  explain  DFNA15 
(Keithley et al. 1999). However, these mice did not show a greater ARHL than wild type 
controls. Given that the mouse strain used may not be a suitable model for investigating 
this form of hearing loss – one of the strains of the mixed background mouse used displays 
ARHL due to hair cell loss which may mask Pou4f3 related hearing loss despite wild type 
controls (Spongr et al. 1997), and many humans with POU4F3 mutations do not display 
hearing  loss  until  mid life  (Vahava  et  al.  1998)  –  in  vitro  models  have  provided  more 
evidence of the mechanisms through which POU4F3 mutations cause hearing loss. Firstly,  
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in vitro experiments show that a dominant negative effect is unlikely to underlie DFNA15. 
Without  binding  to  DNA,  the  N terminal  domain  of  POU4F3  does  not  appear  to  bind 
cofactors and, if POU4F3 is capable of dimerisation, this is likely to be through the POU 
domain which is mutated in all three identified DFNA15 causing mutations (Collin et al. 
2008;Sud et al. 2005;Vahava et al. 1998). Furthermore, mutant POU4F3 does not interfere 
with wild type POU4F3 transactivation in vitro (Weiss et al. 2003). The second hypothesis 
described (gain of function) is also unlikely to be correct as it is unlikely that the three 
different mutations identified could all cause such a similar gain of function (Collin et al. 
2008;Vahava et al. 1998). Thirdly, Weiss et al. proposed that cytoplasmic accumulation of 
mutant POU4F3 may lead to hair cell death, though a potential mechanism by which this 
might  occur  has  not  been  suggested  (Weiss  et  al.  2003).  Therefore,  the  most  probable 
explanation of deafness due to POU4F3 mutation currently appears to be haploinsufficiency, 
though it is difficult to prove this mechanism as Pou4f3+/- mice do not appear to be an 
appropriate model for DFNA15 (Keithley et al. 1999). 
 
In summary, the three human families identified with mutations in the POU4F3 coding 
sequence causing DFNA15 have suggested that POU4F3 mutation causing deafness may 
not be as rare as first thought (Collin et al. 2008;Vahava et al. 1998). Furthermore, they 
support a life long role for POU4F3 in maintaining hair cells and promoting their survival. 
Therefore, a greater understanding of the mechanism of POU4F3 function can not only 
provide  potential  strategies  for  prevention  of  DFNA15,  but  can  also  identify  hair  cell 
survival mechanisms which could be manipulated to prevent acquired hearing loss. 
1.5.5  POU4F3 regulation, structure and function 
The function of POU4F3 in hair cell development and maintenance is dependent on its 
regulation, structure and transcriptional environment. Regulation of Pou4f3 is important 
for  highly  cell specific  expression  whilst  its  structure  and  environment  dictate  its 
subcellular  localization,  DNA  binding  capability  and  target  gene  regulation.  Pou4f3  has 
been localized to chromosome 18 in the mouse (Xia et al. 1993) and rat and chromosome five 
in humans (Xiang et al. 1995). It is composed of two exons, with a similar structure to 
Pou4f1, and gives rise to only one transcript, which produces a 37kDa protein (Gerrero et al. 
1993;Xiang et al. 1995). This is in contrast to its two family members, each of which has 
been shown to produce a long and short transcript with different functions (Theil et al. 
1995;Theil et al. 1993). 
 
Little is known of the factors that regulate Pou4f3 in order to produce hair cell specific 
expression in the inner ear. In an in vivo preparation of the chicken retina, the products of 
a number of genes have been associated with increased cBrn3c (Chicken Pou4f3) expression 
(Cath5 (Chicken Ath5), Math5 (Mouse Ath5 / Atoh7), Pou4f1, Pou4f2 and Pou4f3) though a 
direct mechanism of cBrn3c of upregulation has not been shown for these genes (Liu et al.  
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2001). Similarly, in cochlear cultures, POU4F3 expression has been shown to be dependent 
on retinoic acid signalling, without evidence for the mechanism of regulation, which may be 
indirect  (Raz  et  al.  1999).  Conversely,  an  NFAT C/EBP  composite  element  is  able  to 
regulate a recognition element in the POU4F3 promoter (Yang et al. 2003) and an analysis 
of sequence variants at the POU4F3 locus identified an SP family binding cis regulatory 
element in the POU4F3 5’ flanking region which may affect its regulation in vitro (Nolan et 
al. 2007). However, the significance of these relationships have not been studied in vivo. 
Further characterisation of these interactions is likely to help clarify the requirement of 
POU4F3 for hair cell survival and may identify polymorphisms associated with late onset 
hearing loss, particularly presbyacusis (Nolan et al. 2007).  
 
The POU4F3 protein can be separated into two main domains. The first domain is the N 
terminal  activation  domain,  which  encompasses  the  POU IV  box  –  a  region  of  high 
homology  between  POU4F  members  (Gerrero  et  al.  1993).  Similar  to  the  N terminal  of 
POU4F1  (Budhram Mahadeo  et  al.  1995;Theil  et  al.  1993),  this  N terminal  domain  is 
involved in transactivation and appears to function following binding of POU4F3 to DNA, 
presumably through protein protein interactions (Smith et al. 1998;Sud et al. 2005). The 
second domain in POU4F3 is the POU domain described above (see section 1.5.2) which is 
present  in  POU4F3  in  its  normal  POUS linker POUH  conformation  (see  Figure  1.11) 
(Gerrero et al. 1993;Ninkina et al. 1993). 
 
The POU domain is highly conserved between POU4F members, showing approximately 
95%  sequence  similarity  with  the  greatest  number  of  mismatches  present  in  the  linker 
region (see Figure 1.11a). The third helix of the POUH (i.e. the helix that makes contact 
with  the  major  groove  (Verrijzer  et  al.  1993))  is  fully  conserved  between  mammalian 
POU4F  members  (Xiang  et  al.  1995).  It  was  therefore  predicted  that  POU4F  members 
compete  for  the  same  DNA  sequences  when  coexpressed  (Xiang  et al.  1995)  and  this  is 
supported by experiments which show that POU4F3 can upregulate POU4F1 target genes 
(Budhram Mahadeo  et  al.  1995;Smith  et  al.  1998).  However,  this  is  not  the  case  in  the 
organ of Corti as only POU4F3 is expressed in hair cells and, though POU4F DNA binding 
sites have been shown to be similar, there are subtle differences in sequence specificity 
between POU4F members (see Figure 1.11c) (Gruber et al. 1997;Xiang et al. 1995).   
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Although transactivation by POU factors, including POU4F1, can be mediated through the 
POU domain (Andersen et al. 2001;Budhram Mahadeo et al. 1995), the isolated POU4F3 
POU domain was not able to mediate transactivation when tested in an inner ear cell line 
(Sud et al. 2005) in contrast to its ability to upregulate a herpes simplex virus promoter in 
neuronal cells (ND7) (Liu et al. 2000). It was also thought that POU4F members, unlike 
other POU factors, were unable to dimerise through their POU domain (Andersen et al. 
2001;Gruber  et  al.  1997),  however,  POU4F  members  are  likely  to  form  dimers  on 
appropriate recognition elements as demonstrated by the dimerisation of the POU4F1 POU 
domain on a Brn 2 (POU3F2) consensus oligonucleotide; though they may also function as 
monomers (Rhee et al. 1998). No structural data are available for POU4F members and it is 
therefore  unknown  whether  the  POUS  and  POUH  bind  opposite  DNA  strands  like  Oct1 
(Klemm et al. 1994) or the same strand, like Pit 1 (Jacobson et al. 1997). 
 
As POU4F3 is only likely to affect target gene transcription when bound to DNA (Sud et al. 
2005), its regulatory function is dependent on the presence of POU4F3 binding sites  in 
target gene promoters. Furthermore, as shown by experiments with POU4F1 and POU4F2, 
the structure of the promoter, including the context and spacing of binding sites, can have 
an effect on transcriptional regulation (Dawson et al. 1996;Morris et al. 1996). Though no 
consensus sequence has been independently derived for POU4F3, consensus sequences for 
both POU4F2 (Xiang et al. 1995) and POU4F1 (Gruber et al. 1997) have been determined 
(see Figure 1.11c) and shown to be similar to those of Brn 2 (POU3F2) and Brn 5 (POU6F1) 
(Rhee et al. 1998). POU4F3 has been shown to have affinity for similar binding sites to its 
family members (Xiang et al. 1995), however, the affinity and transcriptional activity of 
POU4F3 at these sites has not been reported (binding affinity being a strong predictor of 
transcriptional  activation  for  POU4F1  (Trieu  et  al.  1999)).  Given  the  large  amount  of 
genomic sequence currently available (in stark contrast to the time that the above work 
was published), a greater understanding of POU4F3 affinity for these sites and the factors 
that determine its transcriptional function once bound will greatly aid in the identification 
and characterisation of POU4F3 target genes. However, targets discovered in silico may be 
biased to the existing consensus sequences. Therefore, unbiased identification of POU4F3 
binding sites, e.g. by random oligonucleotide selection or chromatin immunoprecipitation, 
will greatly aid the accuracy of such experiments, as will feed back on the transcriptional 
effect of POU4F3 at predicted binding sites. 
 
Though  POU4F3  is  known  to  be  a  transcription  factor,  few  of  its  targets  have  been 
identified. Initially its regulatory function was investigated for known targets of POU4F1 
in  neuronal  cells.  POU4F3  was  able  to  transactivate  a  number  of  POU4F1  target  gene 
promoters  (SNAP 25,  α internexin,  synapsin  three  neurofilament  subunits)  (Budhram 
Mahadeo et al. 1995;Morris et al. 1996;Smith et al. 1998). It was also shown to be capable of 
repressing  one  promoter  (the  α3  nicotinic  acetylcholine  receptor  subunit  gene  promoter)  
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(Milton et al. 1996). However, the relevance of these interactions to hair cells is unclear as 
POU4F3 is able to regulate different promoters in different cell types (e.g. neuronal versus 
non neuronal)  (Clough  et  al.  2004;Smith  et  al.  1998;Sud  et  al.  2005).  Though  it  was 
suggested  that  differences  in  regulation  are  due  to  the  POU4F3  N terminal  activation 
domain only being active in neuronal cells (Smith et al. 1998), contradictory results were 
obtained using a more sensitive assay system (Sud et al. 2005). Furthermore, regulation by 
POU4F3, like regulation by other POU4F members, is likely to be influenced by the context 
of its binding sites (Budhram Mahadeo et al. 1995;Dawson et al. 1996). 
 
Since  the  demonstration  of  the  requirement  for  POU4F3  in  hair  cell  development  and 
survival (Erkman et al. 1996;Vahava et al. 1998;Xiang et al. 1998;Xiang et al. 1997), the 
identification of POU4F3 target genes has focused on these cells. To date, the only proven 
directly  upregulated  targets  of  POU4F3  are  the  neurotrophins  BDNF  and  NT 3,  as 
demonstrated by DNAse footprinting, EMSA and luciferase assay (Clough et al. 2004) and, 
for BDNF, supported by microarray results in POU4F3 mutant mice (Hertzano et al. 2007). 
These genes are known to be required for maintenance of normal hair cell innervation by 
providing trophic support to neurons, and a role for POU4F3 in their expression in vivo is 
supported  by  the  reduced  expression  of  BDNF  in  immature  hair  cells  in  Pou4f3-/-  mice 
(NT 3 expression does not appear to be markedly reduced) (Xiang et al. 2003). However, it 
is likely that BDNF expression in the developing inner ear is also influenced by additional 
factors, e.g. miR15a (Friedman et al. 2009a), as its expression does not closely match that of 
POU4F3 (Hertzano et al. 2007). 
 
In  addition  to  the  above  targets  Gfi  and  Lhx3  are  strongly  associated  with  POU4F3 
expression. Calbindin2 may also be associated with POU4F3 expression though very little 
evidence  exists  for  this  possible  interaction  (Hertzano  et  al.  2004;Hertzano  et  al.  2007). 
Both Gfi1 and Lhx3 were identified based on the microarray comparison of cDNAs present 
in  wild  type  and  Pou4f3ddl/ddl  (homozygous  dreidel  mutant)  whole  inner  ears  and  the 
expression of both genes seems to mirror that of Pou4f3, though Lhx3 expression declines 
postnatally despite increased Pou4f3 transcription (Hertzano et al. 2007). Subsequent RNA 
in situ hybridization and immunohistochemistry has revealed that both genes have hair 
cell specific expression patterns in the inner ear. Though Lhx knockout does not affect hair 
cell development (Hertzano et al. 2007), Gfi1 knockout results in OHC loss, which proceeds 
to total disruption of the organ of Corti by P14, demonstrating an important role for this 
presumed target of POU4F3 in hair cell development and maintenance (Wallis et al. 2003). 
However,  the  mechanism  by  which  POU4F3  may  upregulate  these  genes  has  not  been 
reported, and there is, therefore, a lack of evidence to support direct regulation of Gfi1 or 
Lhx3 expression by POU4F3. 
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In  summary,  POU4F3  expression  in  the  inner  ear  is  essential  for  hair  cell  terminal 
differentiation and survival (Erkman et al. 1996;Xiang et al. 1998;Xiang et al. 1997) and 
little is known of the target genes through which it is able to generate and maintain the 
mature hair cell phenotype. In order to understand the mechanism of POU4F3 function, 
unknown  targets  must  be  identified  and  characterised.  Furthermore,  the  mechanism 
through which POU4F3 regulates these genes is likely to be important in the identification 
of  strategies  to  prevent  hair  cell  loss  in  patients  with  POU4F3  mutations  as  well  as 
identifying  new  strategies  in  preventing  hair  cell  loss  in  the  general  population  due 
acquired hearing loss. However, such investigations face unique challenges posed by the 
complicated biology of the inner ear. 
1.6  Investigation of inner ear biology 
1.6.1  Difficulties of analysing inner ear biology 
The  inner  ear  is  one  of  the  most  inaccessible  organs  in  the  mammalian  body  and  the 
irreplaceable hair cells are surrounded by a complex and delicate microarchitecture that 
necessitates removal of the whole inner ear in order to use them for molecular biological 
investigation. As mammalian hair cells are mitotically quiescent and cannot be cultured, 
experiments rely on hair cells obtained from inner ears of laboratory animals; commonly 
mouse, rat or guinea pig. Many inner ears would be required to provide enough tissue for 
biochemical  analyses  given  the  low  number  of  hair  cells  available  per  inner  ear  
(approximately  20  000  depending  on  species  (Slepecky  1996))  and  many  research 
techniques  require  the  separation  of  hair  cells  from  other  cell  types  in  order  to  yield 
meaningful results. Though the latter has been attempted with success (e.g. Zheng et al. 
2000)  in  studies  similar  to  the  present  one  (see  section  3.1),  such  techniques  present 
differing  challenges  which  could  interfere  with  the  identification  of  transcription  factor 
target  genes.  The  traditional  techniques  of  enzymatic ,  microdissection   and  trituration 
based hair cell isolation (see references in He et al. 2000) can cause damage to hair cells 
which  may  alter  gene  expression  (this  may  be  due  to  direct  effects  of  enzymes,  or 
mechanical damage). The main limitation, however, is the length of time required between 
sacrificing the animal and using the cells (e.g. the trypsinisation step in He et al. 2000 
alone takes 15 minutes) which can affect gene expression. The more recent technique of 
laser  capture  microdissection  for  the  isolation  of  inner  ear  hair  cells  (Anderson  et  al. 
2007;Cristobal et al. 2004;Cristobal et al. 2005;Gao et al. 2007;Wu et al. 2008) circumvents 
the above problems and allows a reduction in the time between animal sacrifice and cell 
fixation by intracardial PFA infusion (Wu et al. 2008). However, as stated by De Preter et al. 
(De Preter et al. 2003), only small amounts of nucleic acids are obtained by LCM and the 
required staining protocols are not beneficial for RNA quality.  
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1.6.2  Utility of cell lines in inner ear research 
Cell lines provide a method with which to circumvent many of the problems outlined above. 
Many cells can be rapidly generated and their contents are rapidly accessible for use in 
molecular biological experimentation.  However, according to the desired application,  the 
cell line used can be of pivotal importance and cell lines are often not suitable for the study 
of protein function as they do not express required proteins or are not in their required 
niche.  
 
In investigating transcriptional regulation, the choice of cell type is particularly important 
given that the transcriptional environment can vary greatly and is a major determinant of 
cell phenotype. For example, POU4F3 is able to upregulate the SNAP 25 promoter in a 
neuronal cell line (ND7), but not in non neuronal and inner ear sensory epithelial cell lines 
(BHK, UB/OC 1 and UB/OC 2) (Smith et al. 1998;Sud et al. 2005). Conversely, it is able to 
upregulate Bdnf and Ntf3 promoters in UB/OC and BHK cell lines but not in ND7 cells 
(Clough et al. 2004). As these differences are likely to be due to differences present in the 
native tissue that these cells were derived from, the use of an inner ear cell line is likely to 
yield  more  physiologically  relevant  results  in  investigations  of  inner  ear  transcriptional 
regulation than other cell types (see section 3.1). However, as cultured cells do not precisely 
represent the cells of interest, it is possible that artefactual interactions will be discovered 
in these cells. Therefore, regulatory relationships identified in cell lines require supporting 
evidence from native tissue, where possible, to confirm and strengthen evidence for any 
interactions discovered. 
1.7  Project aims 
Hair  cell  loss  due  to  different  causes  remains  the  principal  cause  of  deafness.  In  turn, 
deafness is the most common sensory disability in the western world (Olusanya et al. 2007). 
Therefore,  a  method  to  replace  hair  cells,  or  prevent  their  loss,  would  benefit  a  large 
population. Unfortunately, no such methods exist and we remain reliant on prostheses such 
as hearing aids and cochlear implants to  ameliorate hearing without improving and, in 
some cases, further damaging residual hearing (Kulkarni et al. 2008). 
 
Though an increasing number of proteins are being shown to be expressed in hair cells, 
signalling networks within these cells remain poorly characterised and, until recently, very 
difficult to investigate. A greater understanding of these networks could potentially aid in a 
variety of therapeutic measures e.g. gene therapy, drug therapy, stem cell programming 
and growth factor therapy. 
 
In  my  project,  I  took  the  POU4F3  transcription  factor  as  a  start point  from  which  to 
investigate  the  networks  that  it  is  likely  to  control  given  its  essential  role  in  hair  cell 
differentiation and survival (Collin et al. 2008;Erkman et al. 1996;Vahava et al. 1998;Xiang  
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et  al.  1998;Xiang  et  al.  1997).  I  investigated  a  pool  of  potential  POU4F3  target  genes, 
previously generated in our laboratory by a subtractive hybridization screen in UB/OC 2 
cells,  in  order  to  determine  whether  these  genes  alter  their  expression  in  response  to 
POU4F3 and whether they are directly regulated by POU4F3. I also aimed to investigate 
the physiological significance of any regulatory relationships in vivo by determining the 
expression patterns of selected newly identified POU4F3 target genes. Particular priority 
was given to genes that might be important in hair cell survival and might therefore be 
useful in preventing hair cell loss or promoting hair cell regeneration.  
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2   
MATERIALS AND METHODS 
NB  All water used is type III purified water unless otherwise stated. 
All chemicals were supplied by BDH, Invitrogen, Promega or Sigma-Aldrich unless  
otherwise stated. 
Restriction endonucleases were purchased from Promega unless otherwise stated.  
Where work has been carried out by other members of the laboratory, it is made clear  
in the text 
2.1  Safety 
2.1.1  Unsealed radioactive sources 
All  procedures  using  unsealed  radioactive  sources  were  conducted  according  to  local 
regulations. Where possible, radioactive sources were used in a room designated for work 
with radioactive reagents and appropriate monitoring and personal dosimetry was carried 
out. 
2.1.2  Genetically modified bacteria 
Bacteria were manipulated and disposed of according to local regulations. 
2.1.3  General 
All procedures were carried out according to UCL safety regulations. 
2.2  General equipment 
 
Eppendorf 
Centrifuges:  5417C,  5417R,  5804R, 
MiniSpin;  Concentrator:  5301;  Thermal 
cyclers:  Mastercycler  gradient, 
Mastercycler personal 
 
Jenway 
6305 UV/Vis Spectrophotometer  
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Luckham 
R100 rotatest shaker 
Millipore 
Elix  and  Milli Q®  water  purification 
system 
Nanodrop
® 
ND 1000 spectrophotometer 
New Brunswick Scientific 
C2 incubator shaker 
 
Sorvall 
RC 5C plus centrifuge 
Stuart Scientific 
STR6 platform shaker 
Techne 
Dri Block® DB 2D heat block 
UVP 
3UV™  Transilluminator;  GelDoc it 
imaging system 
2.3  Stock solutions 
Luria-Bertani broth (LB) 
•  1%  Tryptone  
  (DUCHEFA) 
•  0.5%  Yeast extract  
  (DUCHEFA) 
•  0.17M  NaCl 
LB-Agar 
•  98.5%  LB 
•  1.5%  Micro Agar  
  (DUCHEFA) 
 
PBS pH 7.4 at 25°C (Sigma-
Aldrich) 
•  0.01M  phosphate buffer 
•  0.0027M  potassium  
  chloride 
•  0.137M  sodium chloride 
50x TAE 
•  2M  Tris 
•  1M  Glacial acetic  
  acid 
•  50mM  EDTA pH 8.0 
2.4  BLAST  analysis  of  subtractive  hybridization 
clones  
cDNA clones that had been produced by the subtractive hybridization screen were sent for 
sequencing  by  members  of  the  laboratory.  The  sequences  generated  from  this  analysis 
contained  adaptor  sequences  that  had  been  used  to  amplify  and  clone  differentially 
expressed transcripts from the  subtractive hybridization screen into the pGEM T® Easy 
vector. The sequences of these adaptors were therefore aligned with the sequenced data 
from  the  subtractive  hybridization  clones  using  the  ‘pairwise  alignment’  function  of  the 
BioEdit software package (a modified Smith Waterman alignment algorithm) or manually 
and  then  deleted  from  the  sequence  data  if  present  (Hall  2007;Hall  1999).  This  edited 
sequence data was copied to a text file and annotated in FASTA format for each gene. In 
order to identify genes corresponding to the cDNA sequences, these files were used to query 
the Ensembl mouse cDNA database by nucleotide nucleotide BLASTN analysis using the 
WU BLAST 2.0 software package through the Ensembl website (Ensembl 2008a;Gish 2004). 
The algorithm for near exact matches was used to identify genes that corresponded to the  
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cDNA sequences in order to minimise type 2 error. If significant alignments were found for 
a given sequence, the most significantly aligned gene was taken to be the corresponding 
gene  for  that  sequence.  Sequences  that  had  no  significant  matches  (p  <  0.05)  were  re 
analysed  using  mouse  genomic  database  and  discarded  if  no  significant  matches  were 
identified. Subsequent analysis of these matches is described in section 3.2. 
2.5  Cell culture 
2.5.1  Equipment for cell culture 
ALC 
PK10 centrifuge 
Binder 
WTC tissue culture incubator 
 
 
Kendro 
Heraeus  HeraSafe  KS  safety  cabinet; 
Heraeus  HeraCell  150  tissue  culture 
incubator 
Nikon 
Eclipse  TS100  microscope
2.5.2  University of Bristol organ of Corti-1 (UB/OC-1) and UB/OC-2 cells 
UB/OC 1 and UB/OC 2 cells — developmental inner ear sensory epithelial cell lines — were 
cultured in Eagle minimum essential medium supplemented with L Glutamine, 10% heat 
inactivated  foetal  bovine  serum  and  50U/ml  γ interferon  in  a  33ºC  incubator  with  5% 
carbon dioxide (Rivolta et al. 1998a). Cells were passaged by trypsinisation with 1% trypsin 
in  5mM  HEPES buffered  Hanks’  balanced  salt  solution  followed  by  centrifugation  at 
1000rpm for 3 minutes, resuspension in culture medium (described above) and seeding at 
approximately 1 2 x 105 cells per 75cm2 flask. 
2.5.3  Baby hamster kidney -21 (BHK-21) cells 
BHK 21 cells were cultured in Dulbecco’s modified Eagle medium supplemented with 10% 
heat inactivated foetal bovine serum in a 37ºC incubator with 5% carbon dioxide. Cells were 
seeded and passaged as for UB/OC 1 &  2 cells. 
2.5.4  ND7 cells 
ND7 cells — a sensory neuronal / neuroblastoma hybrid cell line (Wood et al. 1990) — were 
cultured in L glutamine containing L 15 media supplemented with 10% heat inactivated 
foetal  bovine  serum,  0.32%  sodium  bicarbonate,  0.25%  glucose  and  0.85%  penicillin 
streptomycin. Cells were incubated at 37ºC, 5% carbon dioxide, seeded at approximately 1 2 
x 105 cells per 75cm2 flask and passaged by mechanical dissociation.  
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2.6  General DNA manipulation 
2.6.1  Plasmid DNA purification 
Where plasmid DNA has been used, it has been purified using the MiniPrep kit (Qiagen) 
spin method or the MidiPrep kit (Qiagen) spin method: 
MiniPrep  
Bacteria (typically XL1 Blue cells (Stratagene) or JM109 cells (Promega)) were cultured in 
2ml  LB  containing  1x  ampicillin  (100 g/ml)  for  8  hours  or  in  5ml  LB  +  1x  ampicillin 
(100 g/ml) for 16 hours. 1.5ml of broth was centrifuged in a 1.5ml microcentrifuge tube at 
3000rpm for 2 minutes at 4°C. The bacterial pellet was resuspended and DNA was purified 
according to the manufacturer’s instructions. Typically, the column (used to bind and wash 
the DNA) was dried on a heat block for two minutes at 50°C following the final ethanol 
(‘Buffer PE’) wash and DNA was eluted in 50 l water. 
 
MidiPrep 
Bacteria (typically XL1 Blue (Stratagene) or JM109 (Promega) cells) were cultured in 50ml 
LB  containing  1x  ampicillin  (100 g/ml)  for  16  hours.  The  full  culture  was  typically 
centrifuged at 4000rpm for 20 minutes at 4°C and the pellet was processed according to the 
manufacturer’s protocol apart from the second centrifugation step which was replaced by 
the filtration of the supernatant from the first centrifugation step through a cloth filter. 
DNA was typically resuspended in 200 l water and its concentration was determined as 
explained in section 2.11.4 or using a Nanodrop® ND 1000 spectrophotometer. 
2.6.2  Digestion of DNA by restriction endonucleases 
Typically, 1 g plasmid DNA was digested with 10 units of restriction endonuclease with the 
appropriate buffer at 1x concentration in a final volume of 30 l made up with water. 1 hour 
at 37°C was sufficient to ensure complete digestion. 
2.6.3  Agarose gel electrophoresis 
Typically,  0.5 1 g  DNA  was  electrophoresed  on  a  1 1.5%  agarose  gel  containing  0.01% 
ethidium bromide at approximately 80mA for 45 minutes. The gel was then visualised and 
electrophoresed further if necessary. Exposure to the ultra violet light of the visualiser was 
minimised if the integrity of the DNA sequence needed to be maintained as the UV light is 
mutagenic.  
2.6.4  Extraction of DNA from agarose gel 
DNA for extraction was electrophoresed in a low melting point agarose gel of appropriate 
percentage  (typically  1%).  The  required  band  was  cut  out  using  a  scalpel  under  UV 
illumination and the DNA from the band was extracted using the MinElute kit (Qiagen)  
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(for bands of >70bp  and <4kb) or using the Gel Extraction kit (Qiagen) according to the 
manufacturer’s instructions. 
2.6.5  DNA ligations 
DNA ligation was carried out either by the TA method or using T4 DNA ligase. 
TA method 
PCR amplicons which had been amplified using a polymerase that leaves un paired adenine 
residues at the 3’ ends (typically GoTaq (Promega)) were ligated into the pDrive cloning 
vector  according  to  the  manufacturer’s  instructions  (PCR  Cloning  kit  (Qiagen)).  The 
ligation typically proceeded for 3 hours at room temperature or 16 hours at 16°C. 
T4 DNA ligase method 
The following mixture was typically used for DNA ligations for both blunt  and sticky ended 
inserts though blunt ended ligations were usually attempted at more than one vector:insert 
ratio: 
•  1 l  T4 DNA ligase (Promega) 
•  1 l  Linearised Vector 
•  3 l  Insert 
•  5 l   2x T4 DNA ligase buffer (Promega) 
Ligations were typically incubated for 16 hours at 16°C. 
2.6.6  Transformation of competent bacteria 
Chemically competent XL1 Blue (Stratagene) bacteria of transformation efficiency of >1 x 
105  cfu/ g  DNA/100 l  competent  cells  (for  subcloning  applications)  or  >1  x  105  cfu/ g 
DNA/100 l (for transformation of purified circular DNA) were thawed on ice and aliquoted 
into  1.5mL  microcentrifuge  tubes  on  ice.  To  each  aliquot,  no  more  than  5 l  of  ligation 
mixture was added (typically the maximum amount was used). The reaction was incubated 
on ice for a minimum of 45 minutes followed by a two minute heat shock at 42°C. 500 l LB  
was then added and the cells were incubated for 30 minutes in a shaking incubator at 230 
rotations per minute prior to being spread onto LB Agar plates and incubated upside down 
at 37°C for 16 hours in an oven. Colonies were picked either the following morning (for 
MiniPreps from 2mL cultures) or stored at 4°C and picked in the evening (for MiniPreps 
from  5mL  cultures  or  MidiPreps  from  50mL  cultures)  using  a  1 200 l  pipette  tip  and 
incubated for 8 or 16 hours respectively prior to DNA purification.  
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2.7  Reverse  Transcriptase  Polymerase  Chain 
Reaction (RT-PCR) 
2.7.1  Equipment for RT-PCR agarose gel electrophoresis 
Jencons 
Mini Plus horizontal electrophoresis unit 
2.7.2  RT-PCR primer oligonucleotide design. 
 
Table 2.1. PCR primer oligonucleotide design parameters. 
Parameter  Range 
Length  20 35bp 
GC content  40 60% 
Terminal nucleotide  C or G 
Salt adjusted melting temperature (Tm)  >60ºC 
Single nucleotide repetitions  <3bp at 3’ end of oligonucleotide 
Hairpins  None with Oligocalc 
Complementarity  None with Oligocalc 
Self annnealing  None with Oligocalc 
Primer Dimers  <5bp match between primers 
Amplicon length  >800bp, <1.5kb 
Exon specificity  cDNA specific 
BLAST results against appropriate genome 
Ensured that Tm of non specific interaction was at 
least 5ºC below that of the specific reaction 
 
Primers were designed to be as sequence specific as possible whilst maintaining optimal 
melting temperatures for PCR to minimise non specific amplification (Table 2.1). This was 
done by ensuring that primers were of optimum length and GC content (for optimal melting 
temperature), checking for secondary structure potential within primer pairs and, finally, 
checking that the sequences to which the primers were designed were genomically unique.  
Furthermore,  where  possible,  primer  pairs  were  designed  to  differing  exons  in  order 
differentiate – by size – between sequences amplified from cDNA and those amplified due 
to genomic DNA contamination. The amplicon was designed to be large enough to easily 
size separate  by  agarose  gel  electrophoresis  though  small  enough  to  not  exceed  the 
optimum range for the GoTaq polymerase (Promega) that was used. Furthermore, where 
possible,  primers  were  designed  to  amplify  target  gene  exons  whose  transcription  in 
UB/OC 2 cells had been suggested by the results of the subtractive hybridization screen 
and  subsequent  BLAST  analysis  (for  full  details  of  individual  primer  sequences  and 
properties, see Appendix).  
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2.7.3  RNA extraction and reverse transcription from UB/OC-2 cells 
The RNeasy Mini kit (Qiagen) was used to extract RNA from a 75cm2 tissue culture flask of 
approximately 90% confluent UB/OC 2 cells. The RNA was then reverse transcribed into 
cDNA using the Omniscript RT kit (Qiagen) according to the manufacturer’s instructions. 
2.7.4  PCR design and parameters 
The following recipe was used for each reaction: 
•  13.875 l  water 
•  5 l  GoTaq Green Master Mix, 2X 
•  2 l  25mM MgCl2 
•  1 l  dNTPs (5mM each) 
•  1 l  sense primer 
•  1 l  antisense primer 
•  1 l  UB/OC 2 cell reverse transcribed cDNA (diluted to approx. 5ng/ l) 
•  0.125 l  GoTaq polymerase 
The above samples were used in PCR with the following thermal cycler program: 
1.  95°C  1 minute 
2.  95°C  30 seconds 
3.  64°C  30 seconds 
4.  72°C  1 minute 20 seconds 
5.  REPEAT STEPS 2 TO 4 FOR 34 CYCLES 
6.  72°C  10 minutes 
Samples were then electrophoresed on a 1.5% agarose gel and visualised (see section 2.6.3). 
2.8  Western blotting 
2.8.1  Equipment for western blotting 
Bio-Rad 
Protean IIxI cell for PAGE 
2.8.2  Reagents for whole cell protein extraction and western blotting 
Lysis buffer 
•  50mM  Tris HCl pH 7.9 
•  50mM  KCl 
•  1mM  EDTA 
•  2mM   DTT 
•  1 tablet/10ml  cOmplete mini 
protease inhibitor cocktail (Roche) 
•   25%  glycerol 
Lysis buffer was filter sterilised prior to 
use. 
10x TBS 
•  1.5M  NaCl 
•  0.2M  Tris (24.2g Tris) 
TBS-T 
•  1x   TBS 
•  0.1%  Tween  
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1L 10x SDS PAGE Gel Running 
Buffer 
•  144.2g  Glycine 
•  100ml  10% SDS 
•  30.3g  Tris 
1L 10x Western Blotting Buffer 
•  144g  Glycine 
•  30.3g  Tris 
 
 
 
1x Western Blotting Buffer 
•  10%  10x Blotting  
  Buffer 
•  30%  methanol 
•  60%  H20 
1x SDS Gel Loading Buffer 
•  50mM  Tris HCl pH6.8 
•  2%  SDS 
•  10%  glycerol 
•  0.1%  bromophenol  
  blue 
•  100mM  DTT 
2.8.3  Gels for western blotting 
Western resolving gel 
•  10%   acrylamide /  
  bis acrylamide (37.5:1) 
•  375mM   Tris pH8.8 
•  0.1%   SDS 
•  0.1%   ammonium persulfate 
•  0.04%   TEMED 
 
Western stacking gel 
•  5%  acrylamide /  
  bis acrylamide (37.5:1) 
•  0.125M  Tris pH6.8 
•  0.1%  SDS 
•  0.1%  ammonium  
  persulfate  
•  0.1%  TEMED 
2.8.4  Whole cell protein extraction 
UB/OC 1, UB/OC 2, ND7, BHK and HeLa cells (the latter of which were cultured by ET) 
were  grown  in  4 6  175cm2  tissue  culture  flasks  until  approximately  90%  confluent  — 
generating 8 12 x 106 cells respectively. The growth media were then replaced with 12ml 
PBS and cells were harvested using a cell scraper. The PBS, containing the dissociated cells, 
was pooled to a 50ml Falcon tube and centrifuged at 1000rpm at 4ºC for 5 minutes. The 
supernatant was removed from the tube and the pellet was resuspended in 50 l lysis buffer 
per 106 cells. Lysis was carried out using a 100 l homogeniser and the lysate was pelleted 
by  centrifugation  at  14000rpm  at  4ºC  for  10  minutes.  The  protein  concentration  was 
estimated  by  measurement  of  the  optical  density  of  the  solution  at  A280  and  A260  by 
spectrophotometry and using the values obtained in Equation 2.1:  
 
Equation 2.1. Protein Concentration. 
)) Density(A   Optical     (0.76   -   )) Density(A   Optical     (1.55   ) g/ ( ion  Concentrat Protein  260 280 × × = l µ µ
 
 
100 g  aliquots  were  then  snap  frozen  with  liquid  nitrogen.  Tubes  were  stored  at  
 80ºC.  
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2.8.5  SDS PAGE of protein 
A 10% polyacrylamide western resolving gel was poured in a Protean IIxI cell for PAGE 
(Bio Rad), overlaid with water saturated isobutanol and allowed to set. The isobutanol was 
then removed with paper towel. A 5% western stacking gel was poured, an appropriately 
sized  well  comb  was  inserted  and  the  gel  was  allowed  to  set.  Once  set,  the  comb  was 
removed and the wells were rinsed with 1x SDS PAGE gel running buffer. Protein samples 
were made up to 20 l in SDS gel loading buffer (to a final concentration of 1x SDS gel 
loading buffer), denatured by heating to 95ºC for 2 minutes and loaded into the wells; 15 l 
of Rainbow™ coloured molecular weight marker (Amersham Biosciences) was run alongside 
the protein extract for later sizing. The gel was run at 25mA/gel until the dye front entered 
the resolving gel, the current was then turned up to 35mA/gel until the molecular weight 
marker of relevant weight had been adequately resolved. 
2.8.6  Western blotting 
An  Immobilon P  (PVDF)  transfer  membrane  (Millipore)  which  had  been  cut  to  the 
dimensions  of  the  gel  was  equilibrated  in  100%  methanol  for  15  seconds,  followed  by 
equilibration in water for 2 minutes and then 1x blotting buffer for 5 minutes. The glass 
plates of the gel assembly were carefully separated and the stacking gel was trimmed from 
the resolving gel. The gel was then transferred onto a dry piece of Whatmann 3MM paper 
and  a  sandwich  was  assembled  comprising,  from  bottom  to  top:  back  plate  of  western 
blotting  tray;  sponge;  Whatmann  3MM  paper  sheet;  gel  (Whatmann 3MM  paper side 
down); equilibrated PVDF membrane; two more pieces of Whatmann 3MM paper; upper 
sponge; upper plate of western blotting tray. The blot was run at 215mA for 3 4 hours in a 
Trans blot™ cell (Bio Rad). The sandwich was then separated and the membrane carefully 
removed  and  inspected  to  ensure  adequate  transfer  of  the  molecular  marker.  The 
membrane was dried by immersion in 100% methanol for 10 seconds followed by air drying 
at  room  temperature  for  15  minutes  or  until  thoroughly  dry.  It  was  then  cut  into 
appropriate size strips and either stored at  20ºC or immediately used for immunodetection. 
2.8.7  Ponceau S staining of PVDF membranes 
In order to visualise lanes on a blotted membrane to assist in cutting the membrane into 
strips prior to immunodetection, the protein on the membranes was stained by 5 minute 
incubation  with  Ponceau  S  solution  (Sigma Aldrich)  at  room  temperature  under  gentle 
agitation. Once the strips had been cut, staining  was reversed with water washes until 
protein bands were no longer visible in order to facilitate immunodetection. 
2.8.8  Immunolabelling of proteins on Immobilon P membranes 
Membranes were either used directly after blotting or removed from storage at  20ºC and 
allowed  to  warm  to  room  temperature  prior  to  manipulation.  Blocking  of  non specific 
antigenicity was conducted by incubation of the membrane for 1 hour at room temperature  
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in TBS T containing 10% Marvel. Following a 5 minute wash in TBS T, the membrane was 
incubated  for  1  hour  in  a  solution  of  1x  TBS T  and  5%  Marvel  which  contained  an 
appropriate dilution of primary antibody (1:1000 for anti NR2F2; 1:2000 for anti RBMS1; 
1:250 for anti ZRANB2). 
 
The  membrane  was  then  twice  rinsed  with  1x  TBS T  and  two  5  minute  incubations  in 
TBS T with 5% Marvel were carried out followed by incubation for 1 hour in a solution of 1x 
TBS T and 5% Marvel containing an appropriate dilution of a secondary HRP conjugated 
antibody raised against the IgG of the animal that the primary antibody  was raised in 
(1:5000 swine anti rabbit immunoglobulins for anti NR2F2 and anti RBMS1; 1:1000 goat 
anti mouse immunoglobulins for anti ZRANB2). Finally, one 15 minute and two 5 minute 
washes were carried out in TBS T. 
2.8.9  Detection of chemoluminescence 
The membrane was removed from the TBS T wash and any remaining TBS T was poured 
off.  5ml  Immobilon™  Western  chemiluminescent  HRP  substrate  was  added  to  the 
membrane for 5 minutes. The reagent mix was then poured off and any excess was drained 
onto paper towel. The blot was covered with plastic wrap, a piece of Hyperfilm™ ECL™ 
film was placed on top and was left to expose for 5 minutes in an X ray film cassette.  
2.8.10  Equalisation 
Equalisation of protein expression by comparison of detected bands with a housekeeping 
protein was not carried as this was not required in the present study i.e. the experiment 
was conducted to identify the presence or absence of protein expression in a given cell line, 
not to compare the levels of expression between cell lines. However, Ponceau staining of the 
PVDF membrane was carried out to ensure that sufficient protein had been transferred to 
the membrane for detection. Coomassie staining (a more sensitive assessment of protein 
loading) of identically loaded gels was also carried out. 
2.9  Immunofluorescence immunohistochemistry 
2.9.1  Equipment for immunofluorescence immunohistochemistry 
Carl Zeiss 
LSM 510 META inverted laser scanning confocal microscope and laser module. 
Leica 
Dissecting microscopes: MZ 125 & MZ 75 ;  CM1850 cryostat  
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2.9.2  Reagents for immunofluorescence on UB/OC-2 cells 
 
Blocking solution 
•  10%  Goat serum (Invitrogen) 
•  0.2%  Triton X solution (Sigma Aldrich) 
•  89.8%  PBS solution 
2.9.3  UB/OC-2 cell culture and immunohistochemistry 
UB/OC 2 cells were seeded at approximately 1 x 105 cells/ well in a six well plate which 
contained 0 or 1.5 thickness 13mm diameter uncoated glass coverslips (VWR). Cells were 
grown to approximately 80% confluency and fixed for 20 minutes in 4% PFA in PBS at room 
temperature. Three 5 minute PBS washes were carried out and coverslips were stored at 
4ºC  in  PBS.      Non specific  antibody  binding  was  prevented  by  the  addition  of  blocking 
solution to each coverslip for 1 hour at room temperature prior to the addition of optimally 
diluted primary antibody in blocking solution for a 1 hour incubation at room temperature 
(1:1000 for anti NR2F2; 1:500 2000 for anti RBMS1). The coverslips were then rinsed with 
PBS three times followed by the application of a 1 5 M DAPI, 1:200 (i.e. 1Unit/ml) Alexa 
633 conjugted phalloidin and 2 g/ml Alexa 488 conjugated goat anti rabbit IgG secondary 
antibody  mix  diluted  in  blocking  serum  which  was  incubated  for  2  hours  at  room 
temperature.  Slides were then rinsed with water three times and finally mounted on glass 
slides using Fluromount G solution (Southern Biotech). Cells were visualised using a Zeiss 
LSM 510 Meta microscope. 
2.9.4  Reagents for immunofluorescence on cryosections 
Blocking solution 
•  10%  Goat serum  
  (Invitrogen) 
•  0.1 0.5%  Triton X solution 
   (Sigma Aldrich) 
•  89.8%  PBS solution 
1% low gelling agarose gel 
•  1%  low gelling  
  agarose 
•  18%  sucrose 
•  0.05%  sodium azide 
•  80.95%  PBS 
2.9.5  Preparation of cryosections 
Tissue for cryosectioning (from Sprague Dawley rats or CBA/ca mice) was fixed in 4% PFA 
solution  (in  PBS)  for  1 2hours  at  room  temperature  or  overnight  at  4ºC.  Samples  were 
cryoprotected by incubation in 30% sucrose in PBS overnight at 4ºC. The tissue was then 
mounted in a 1% low gelling agarose gel which had been heated to 140ºC and allowed to 
cool to 37ºC. Once the agarose had set (typically by incubation at 4ºC overnight) a block was  
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cut from the agarose, attached to a cryostat chuck with OCT compound and rapidly frozen 
by immersion in liquid nitrogen prior to cryosectioning at  20 to  25 ºC. 
2.9.6  Blocking of non-specific antibody binding sites, immunolabelling 
and mounting 
Slides  were  allowed  to  equilibrate  to  room  temperature  and  the  sections  were  drawn 
around using a hydrophobic pen. Blocking solution with 0.1 0.5% Triton X was then added 
and incubated for 1 hour at room temperature. Slides were drained and optimally diluted 
primary antibody, diluted in blocking solution, was added to the slides (1:1000 for anti 
NR2F2 and 1:250/500 for anti ZRANB2) which were left to incubate overnight at 4ºC. The 
following  morning,  three  5  minute  washes  were  carried  out  with  PBS  and,  typically,  a 
solution of blocking solution, 2 g/ml secondary antibody (conjugated to Alexa 488 or 633) 
and 1Unit/ml phalloidin (conjugated to Alexa 488 or 633) was added for 2 hours at room 
temperature. Slides were again washed for three 5 minute washes with PBS prior to the 
addition of DAPI at 5 M (in PBS or blocking solution) for 20 minutes. Finally, the tissue 
was washed for three 5 minute periods in PBS and mounted in Fluromount G (Southern 
Biotech) under a 0 or 1.5 thickness 22mmx22mm or 22mmx50mm coverslip (VWR) which 
was sealed with nail varnish (Boots). Slides were visualised using a Zeiss LSM 510 Meta 
Microscope. 
 
2.10  Electrophoretic Mobility Shift Assay (EMSA) 
NB   The design of oligonucleotides used in EMSA analysis is described in section 3.5, 
4.8.1 and 5.5. 
2.10.1  Equipment for EMSA 
Bio-Rad 
Protean IIxI cell for PAGE (20cm glass plates, 3mm spacers) 
Epson 
Perfection 1650 scanner 
MSE 
Centaur 1 centrifuge 
Rietschle Thomas 
Welch Gel Master™ gel dryer vacuum system 
Scie-Plas 
Gel Dryer 
UMAX 
Astra 1200S scanner 
  
2 Materials and methods  92 
2.10.2  Reagents for EMSA 
Cytoplasmic Lysis Buffer 
•  10mM   HEPES pH7.6 
•  1mM   EDTA 
•  0.1mM  EGTA 
•  10mM   KCl 
•  1mM  DTT 
•  1mM  sodium  
  pyrophosphate 
•  1mg/ml  SP1 
•  1mM  vanidate 
Nuclear Lysis Buffer 
•  20mM   HEPES pH 7.6 
•  0.2mM  EDTA 
•  0.1mM  EGTA 
•  25%  Glycerol 
•  0.42M  NaCl2 
•  1mM  DTT 
•  1mM  sodium 
  pyrophosphate 
•  1mg/ml  SP1 
•  1mM  vanidate 
 
3µg/µl Poly(dI-dC)  
•  10Units poly(deoxyinosinic 
deoxycytidylic) acid sodium salt 
(15Units/mg) 
•  222.2 l   H2O 
10x Medium salt buffer 
•  0.5M  NaCl 
•  0.1M  Tris HCl pH7.5 
•  0.1M  MgCl2 
•  0.01M  DTT 
2x Parker buffer 
•  16%  Ficoll 
•  40mM  HEPES pH7.9 
•  100mM  KCl 
•  2mM  EDTA pH8.0 
•  1mM  DTT 
10x TBE 
•  0.89M  Tris borate 
•  20mM  EDTA pH 8.0 
2.10.3  In vitro protein translation 
cDNA for mouse Pou4f3 and Barhl1 was cloned into the pGEM® T Easy vector under the 
control of the T7 or SP6 promoter in our laboratory. Protein was synthesised according to 
the  manufacturer’s  instructions  using  either  the  TNT®T7  Coupled  Reticulocyte  Lysate 
System  (Promega)  or  the  TNT®SP6  Quick  Coupled  Transcription/Translation  System 
(Promega) using the provided SP6/T7 luciferase control DNA vector to synthesise luciferase 
protein which was used as a negative control in EMSA experiments.   
2.10.4  Nuclear protein extraction 
UB/OC 2 cells were grown in four 175cm2 tissue culture flasks to 90% confluency. The cells 
were washed once with PBS and placed on ice. 3ml of cytoplasmic lysis buffer was added to 
each flask and left to incubate on ice for 5 minutes prior to scraping of the cells with a cell 
scraper. The contents of each flask were then transferred to microcentrifuge tubes on ice 
(1ml per tube). 60 l of 10% NP 40 was added to the top side of each tube and the tubes 
were briefly vortexed and spun at 14000rpm at 4ºC for 30 seconds. The supernatant, which 
contains cytoplasmic proteins, was removed and stored at 4ºC. All traces of supernatant  
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were removed from the pellet and 60 l nuclear lysis buffer was added. The tube was flicked 
gently to dislodge the pellet and was then subjected to three freeze thaw cycles between an 
ethanol dry ice bath and a 37ºC water bath. The tubes were then centrifuged at 14000rpm 
at  4ºC  for  10  minutes.  The  supernatants  from  this  step  were  pooled,  their  protein 
concentration estimated as for whole cell protein extracts (Equation 2.1) and the protein 
aliquoted into 20 g aliquots and snap frozen in liquid nitrogen prior to storage at  80ºC. 
2.10.5  EMSA oligonucleotide  design and synthesis 
Double stranded oligonucleotides were designed as described in section 3.5 (general design) 
and synthesised by Operon Biotechnologies Inc.  
2.10.6   Probe preparation 
10 g of sense and antisense oligonucleotide were combined with 1x medium salt buffer in a 
total volume of 22.2 l. This mixture was heated to 95ºC for 10 minutes and left to slowly 
cool  to  room  temperature  to  anneal  the  single stranded  oligonucleotides  to  form  double 
stranded EMSA probe. Probe annealing was checked by electrophoresis of annealed probe 
alongside single stranded probe on a 3% Agarose gel. Following confirmation of annealing, 
probes were stored at  20ºC. 
2.10.7  Probe labelling 
Probes were diluted to 25ng/ l and 50ng of each probe was labelled in a standard T4 kinase 
reaction: 
 
•  50ng   probe 
•  2 l   10x Kinase buffer 
•  3 l   γ32P γ ATP (10 Ci/ l) (GE Healthcare) 
•  1 l   T4 Kinase (5 10U/ l) 
•  to 20 l  H2O    
 
The  reaction  was  incubated  at  37ºC  for  30  minutes.  80 l  H2O  was  then  added  and  the 
diluted reaction mixture was loaded onto a Sephadex G25 column and spun at 1500 rpm for 
2  minutes  to  separate  labelled  oligonucleotides  from  free  γ32P  γ ATP  (GE  Healthcare). 
Radiolabelled probes were stored at  20ºC.  
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2.10.8  Assay reaction  
Assay reactions were set up and incubated on ice for 10 minutes: 
 
•  10 l   2x Parker buffer 
•  3 g  polydI/dC 
•  2 4 l  UB/OC 2 Nuclear Protein Extract or in vitro translated protein 
•  0 1000ng  Non radiolabelled competition probe 
•  to 20 l  H2O    
 
1ng of labelled probe was then added to each tube and the tubes were incubated at room 
temperature for 15 30 minutes. 
2.10.9  Non-denaturing polyacrylamide gel electrophoresis 
A 4% polyacrylamide (29:1), 0.25x TBE gel was poured (dimensions: 200 x 200 x 3mm) and 
polymerisation  was  initiated  and  catalysed  by  0.05%  ammonium  persulfate  and  0.2% 
TEMED respectively. Once set, the wells were washed with 0.25x TBE and the gel was run 
in this buffer at 200 volts at 4ºC in the Protean IIxI cell until the current had fallen to 
below 30 mA per gel (typically 30 minutes). The samples were then loaded onto the gel and 
electrophoresed at 200 volts for 1 to 3 hours at 4ºC. 
2.10.10 Gel drying and autoradiography 
After electrophoresis, the gel was removed from its cast to a piece of Whatmann 3MM paper, 
covered with cling film (Terinex) and placed in a gel dryer at 80ºC under vacuum until dry 
(typically 1 2 hours). Autoradiography was carried out in an X ray film cassette with X ray 
film (SLS) that was exposed at  80ºC for between 1 hour to 5 days. Once exposed, the film 
was removed from the cassette in a dark room, developed and fixed using Kodak processing 
chemicals  for  autoradiography  films  (GBX  developer/replenisher  and  GBX 
fixer/replenisher) (Sigma Aldrich) according to the manufacturer’s instructions. Once dry, 
autoradiographs were scanned using an Epson or Umax scanner.   
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2.11  Cell transfection and reporter gene assay 
2.11.1  Equipment for luciferase assay 
Turner 
TD 20e luminometer 
2.11.2  Reagents for luciferase Assay 
10x HEPES-Buffered Saline (HBS) 
•  8.18%   NaCl (w/v) 
•  5.94%   HEPES (w/v) 
•  0.2%   Na2HPO4 (w/v) 
Filter sterilised with a 0.22 m filter and 
stored at 4ºC. 
2x HBS 
•  10ml   10x HBS 
•  40ml   water  
The solution was pH adjusted to 7.12 and 
filter  sterilized  with  a  0.22 m  filter.
2.11.3  Plasmid constructs for luciferase assay 
The  pGL3 basic NR2F2  4kb  promoter  (NR2F2p4kb)  luciferase  reporter  construct  was  
kindly  provided  by  Dr  M  Vasseur Cognet.  pGL 3 basic NR2F2  1.6kb  promoter 
(NR2F2p1.6kb)  was  kindly  provided  by  Dr  S  Tsai.  pGV Basic Rbms1  1.3kb  promoter 
(RBMS1p1.3kb)  luciferase  reporter  construct  was  kindly  provided  by  Dr  H  Ariga. 
pGL4.10[luc2]  was  purchased  from  Promega  UK  Ltd.  pSi Pou4f3  was  cloned  in  our  lab 
(Nolan et al. 2007). 
 
Figure 2.1. pDrive cloning vector. 
Schematic  diagram  of  the  pDrive  cloning  vector  which  was  used  in  order  to  clone  gene 
promoters which had been amplified from genomic DNA by PCR. Purified PCR product was 
ligated into the pDrive vector by TA ligation i.e. by ligation of the Adenine bases at the 3’ ends of 
the amplified promoter to the free uracil bases of the linearised pDrive vector. © Qiagen. 
Picture removed for copyright purposes  
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Figure 2.2. pGL4.10[luc2] vector. 
Schematic diagram of the pGL4.10[luc2] luciferase reporter vector which contains a synthetic 
luciferase gene that has been codon optimised for expression in mammalian cells. Promoters 
from  putative  POU4F3  target  genes  were  cloned  into  this  vector  for  investigation  of  their 
regulation by POU4F3. © Promega.  
 
 
pGL4.10-LUZP1p-2.8kb 
The pGL4.10[luc2] LUZP1 2.8kb promoter (LUZP1p2.8kb) luciferase reporter construct was 
produced  as  follows:  The  forward  primer  5’ TTCCAGTGTGGTCTTGAACTCCTGTGG 3’ 
and  reverse  primer  5’ GAGGATCCGGCGCTCCGCTC 3’  were  used  to  amplify  a  2.8kb 
fragment  of  the  LUZP1  promoter  from  mouse  genomic  DNA  (Promega)  with  GoTaq 
(Promega) and Pfu (Stratagene) polymerases which was inserted, by TA based ligation, into 
the  pDrive  cloning  vector  (Qiagen)  (see  Figure  2.1)  according  to  the  manufacturer’s 
instructions. The promoter orientation was checked by restriction digestion with XhoI and 
the  KpnI ΝheI  fragment  of  this  construct  was  inserted  into  the  KpnI NheI  site  of 
pGL4.10[luc2] (see Figure 2.2). Promoter integrity was checked by DNA sequencing. 
 
pGL4.10-Rbms1p-5.1kb 
This construct (abbreviated to RBMS1p5.1kb) was cloned by SD. The BsgI fragment of a 
plasmid containing 21kb of the RBMS1 5’ flanking region (kindly provided by Dr H Ariga) 
was incubated with the DNA polymerase large (Klenow) fragment (Promega) according to 
the manufacturer’s instructions to produce a blunt ended fragment. This was inserted into 
the  EcoRV  site  of  pGL4.10[luc2]  (see  Figure  2.2).  Correct  orientation  of  the  insert  in 
pGL4.10[luc2] was verified by digestion with PstI. 
 
pGV-B 
An  empty  pGV B  vector  (PicaGene)  was  created  by  excising  the  RBMS1  5’  flanking 
sequence  from  RBMS1p1.3kb  with  XbaI  and  HindIII.  The  sticky  ends  produced  were 
blunted by incubation with Klenow (as above) and re ligated to produce the final vector. 
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Figure 2.3. pGL4.23[luc2/minP] vector. 
Schematic of the pGL4.23[luc2/minP] luciferase reporter vector which contains the synthetic, 
codon-optimised  luc2  gene  as  well  as  a  minimal  TATA  promoter  downstream  of  POU4F3 
binding sites that were inserted into the EcoRV site of the vector. © Promega.  
 
 
pGL4.10-ZRANB2p-3.2kb 
The  pGL4.10[luc2]  3kb  Zranb2  5’  flanking  region  luciferase  reporter  construct 
(ZRANB2p3.2kb)  was  produced  as  follows:  The  forward  primer:  5’ 
GGTCCTTCACCCTCATGATAGCTCACTG 3’  and  reverse  primer  5’ 
CGTCACTGACTCGGAAATTCTTGGTCG 3’ were used to amplify a 3.2kb fragment of the 
LUZP1  promoter  from  mouse  genomic  DNA  (Promega)  with  long range  enzyme  mix 
(Qiagen) which was inserted, by TA based ligation, into the pDrive cloning vector (Qiagen) 
(see  Figure  2.1)  according  to  the  manufacturer’s  instructions;  the  orientation  of  the 
promoter was checked by restriction digestion with SacI and the KpnI XbaI fragment of 
this  construct  was  inserted  into  the  KpnI NheI  site  of  pGL4.10[luc2]  (see  Figure  2.2). 
Promoter integrity was checked by DNA sequencing. 
 
pGL4.23-NR2F2BS1-1,2,3&5x 
The  minimal  promoter  constructs  pGL4.23 NR2F2BS1 1x,  pGL4.23 NR2F2BS1 2x, 
pGL4.23 NR2F2BS1 3x  and  pGL4.23 NR2F2BS1 5x  were  constructed  by  blunt ended 
ligation  of  T4  kinase phosphorylated  EMSA  probe  NR2F2BS1  with  EcoRV linearised 
pGL4.23[luc2/minP] (see Figure 2.3). The number of repeats of NR2F2BS1 that had been 
incorporated  into  the  vector  were  assessed  by  NheI PvuII  restriction  digestion  and  size 
assessment by agarose gel electrophoresis. The “–nx” suffix of the construct name refers to 
the number of repeats of NR2F2BS1 contained in that construct. 
 
pGL4.23-NR2F2BS2-1-4x 
The  minimal  promoter  constructs  pGL4.23 NR2F2BS2 1x,  pGL4.23 NR2F2BS2 2x, 
pGL4.23 NR2F2BS2 3x  and  pGL4.23 NR2F2BS2 4x  were  constructed  as  for  pGL4.23 
NR2F2BS2 1,2,3&5 using NR2F2BS2 instead of NR2F2BS1  (see Figure 2.3). 
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Figure 2.4. pSi mammalian expression vector. 
The pSi expression vector, whose SV40  enhancer region induces constitutive expression of 
inserted DNA in mammalian cells, was used for the expression of proteins. © Promega.  
 
 
pSi-Dreidel 
pHM6 Dreidel, an expression construct for a 2bp missense mutated form of mouse POU4F3, 
was  kindly  provided  by  Prof.  Karen  Avraham.  For  compatibility  with  other  expression 
constructs used in luciferase assays, the dreidel coding sequence was cloned into the pSi 
expression  vector  by  insertion  of  the  EcoRV NotI  fragment  of  pHM6 Dreidel  into  the 
EcoRV NotI site of pSi. 
2.11.4  Purification of DNA from bacterial culture for transfection 
Bacteria were streaked out on an LB Agar ampicillin (100 g/ml) plate from glycerol stocks 
and incubated at 37ºC overnight. The following morning, single colonies were picked using 
a 200 l pipettor tip into 2ml  LB ampicillin (100 g/ml) and incubated at 37ºC at 220rpm in 
a shaking incubator for 8 hours. The culture was then decanted into 50ml of LB ampicillin 
(100 g/ml)  and  cultured  overnight.  The  next  morning,  bacteria  were  pelleted  by 
centrifugation at 4000rpm for 20 minutes at 4ºC, plasmid DNA was extracted using the 
MidiPrep  kit  (Qiagen)  and  resuspended  in  200 l  of  water.  The  DNA  concentration  was 
estimated  by  measuring  the  optical  density  of  the  resuspended  DNA  at  A260  using  a 
spectrophotometer and using the resultant value in Equation 2.2: 
 
Equation 2.2. DNA Concentration. 
 
1000
50)   Factor  Dilution  ) (A Density    (Optical
    ) / ( ion  concentrat DNA 
260 × ×
= l g µ µ  
 
DNA was diluted to desired concentrations in water and checked by diagnostic restriction 
enzyme digest followed by electrophoresis on an agarose gel of appropriate concentration. 
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2.11.5  Preparation of UB/OC-2, BHK and ND7 cells for transfection 
Cells were transfected based on a standard calcium precipitation protocol (e.g. Kingston et 
al. 2001). UB/OC 2, BHK or ND7 cells were plated at approximately 2 x 105 cells/well in a 
six well plate (BD Falcon). The next morning, the culture media were changed to DMEM + 
10%  FBS  and  the  cells  were  incubated  at  37ºC,  5%  CO2  for  at  least  one  hour  prior  to 
transfection. 
2.11.6  Preparation of precipitate 
400 l 2 x HBS was aliquoted into 1.5ml microcentrifuge tubes designated tubes B (one per 
condition  being  tested)  and  allowed  to  warm  to  room  temperature.  In  separate  tubes, 
designated tubes A, the following mixture was prepared (one per condition being tested): 
 
•  0.25M   CaCl2 
•  100 200 g/well  Luciferase reporter vector 
•  1 3 g/well   pSi / pSi Pou4f3 expression vector 
•  10ng/well  pRL null vector 
•  to 400 l  water  
 
The contents of each A tube were added to its corresponding B tube dropwise (total volume 
800 l). The precipitate was then allowed to form for 20 minutes at room temperature. 
2.11.7  Transfection 
Following precipitation, 200 l of precipitate was added to each well and mixed by pipetting 
up and down three times; experiments were conducted in triplicate. Following addition of 
precipitate,  ND7  cells  were  incubated  at  37ºC,  5%  CO2  for  a  minimum  of  6  hours  and 
UB/OC 2  or  BHK  cells  were  incubated  under  identical  conditions  for  a  minimum  of  16 
hours. After this incubation: The precipitate was removed from UB/OC 2 cells, the cells 
were shocked with DMEM + 15% glycerol for 2 minutes 30 seconds, washed with HBSS + 
10% FBS and then incubated in UB/OC 2 cell culture media; the precipitate was removed 
from BHK and ND7 cells and replaced with appropriate culture media.  All cell types were 
further incubated for a minimum of 24 hours prior to luciferase assay. 
2.11.8  Dual Luciferase assay and analysis 
Luciferase assays were carried out with the Dual Luciferase® kit (Promega) according to 
the manufacturer’s instructions, which were modified by the use of 50 l of LARII reagent 
instead of 100 l. Samples were assessed in a single point luminometer (Turner). A reporter 
construct was deemed to be regulated if significantly activated by pSi Pou4f3 compared to 
pSi, promoterless reporter construct, mutant POU4F3 expression construct or a mutant 
reporter construct (p<0.05) as determined by a two sample two tailed student’s t test i.e. 
Nr2f2 and Rbms1 reporter constructs, but not Luzp1 or Zranb2 reporter constructs.  
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2.12  Site-directed  mutagenesis  (SDM)  of  the  Nr2f2 
promoter 
NB  The mutagenesis for NR2F2BS2 from design of flanking primers and generation of 
the short insert through to the ligation of the long insert into the pDrive cloning 
vector was carried out by SD. 
2.12.1  Design  of  mutant  EMSA  probes  and  assessment  of  abolition  of 
POU4F3 binding 
Due to the highly gene specific nature of this mutagenesis, the design of oligonucleotides 
with  mutations  in  POU4F3  binding  sites  that  abolish  POU4F3  binding  is  described  in 
section 4.10.1. 
2.12.2  Attempted SDM of Nr2f2 promoter by QuikChange
® II XL kit 
The  QuikChange®  II  XL  kit  (Stratagene)  was  used  according  to  the  manufacturer’s 
instructions. The mutated EMSA oligonucleotide sequence was submitted with 40bp of its 
5’ and 3’ flanking sequence (from the Nr2f2 promoter) to the QuikChange® Primer Design 
Program (Stratagene 2006) in order to automatically generate SDM primers of appropriate 
physical properties. The results of this analysis are shown in Table 2.2. 
 
Table 2.2. Primers for attempted QuikChange
® II XL kit site-directed mutagenesis.  
Mutations of the wild type sequence are underlined. (F), forward primer; (R), reverse primer. 
SDM primer  
name 
5’ to 3’ sequence 
NM1Pri(F)  CCGCGCCCCCCTTTTTAGCCGATTTGATCACTTTGATTCTG 
NM1Pri(R)  CAGAATCAAAGTGATCAAATCGGCTAAAAAGGGGGGCGCGG 
NM2Pri(F)  GATAAAGTTGAGAGGAATTTATTTTAATTGCAGGGTAACAATGAGGTGAAGTCTGGTGTT 
NM2Pri(R)  AACACCAGACTTCACCTCATTGTTACCCTGCAATTAAAATAAATTCCTCTCAACTTTATC 
 
Though multiple attempts were made to mutate the Nr2f2 promoter by this protocol and 
despite optimisation, all attempts proved unsuccessful. 
2.12.3  Overview of NR2F2p4kb SDM by overlap extension PCR 
SDM by overlap extension PCR was carried out on the Nr2f2 promoter based on a method 
described by Horton (Horton 1993 and references therein) as this is a more robust means of 
mutagenesis  but  involves  more  subcloning  than  the  QuikChange®  method.  The  overlap 
extension method exploits the ability of PCR oligonucleotides of standard length (20 30bp) 
to bind DNA sequences with a 1 3bp mismatch (Ling et al. 1997). Such oligonucleotides are 
designed to both the sense and antisense sequence of the mutagenesis site and are each 
used  with  a  flanking  primer  in  PCR.  The  resulting  amplicons  (named  short  inserts) 
incorporate the mutagenesis primer sequence at the 5’ end and are designed to contain a 
restriction endonuclease recognition site 3’ to this which is required for later subcloning.  
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In the  second stage of the mutagenesis process,  the flanking primers used for both the 
sense and antisense mutagenesis are used in a PCR with the sense and antisense short 
inserts as template sequence. In initial cycles of the PCR, the overlapping region of the 
short inserts (which is equivalent to the mutagenesis primers used in the first PCR) primes 
polymerisation of a long amplicon (named the long insert) which comprises the two short 
inserts  joined  by  their  overlapping  region.  Therefore,  the  long  insert  contains  the 
mutagenesis  site  flanked  by  the  desired  restriction  endonuclease  recognition  sites.  In 
subsequent cycles of the PCR, the flanking primers prime amplification of the long insert. 
 
This long insert can then be ligated directly into the pDrive cloning vector by TA cloning 
(when an appropriate polymerase is used) for amplification and subsequent cloning into the 
wild type NR2F2p4kb vector in order to produce a reporter vector which incorporates the 
desired  mutations.  Alternatively,  the  long  insert  can  be  digested  by  the  appropriate 
restriction endonuclease for direct ligation (by T4 DNA ligase) into wild type NR2F2p4kb 
which has been similarly digested, phosphatased and purified. 
2.12.4  Reagents and methods used for the NR2F2p4kb SDM 
The mutant EMSA probes that had been used to verify abolition of POU4F3 binding by 
EMSA, and the SDM primers that had been used in the attempted QuikChange® SDM were 
used  to  introduce  the  desired  mutations  into  the  Nr2f2  promoter  (see  Figure  4.19  for 
schematic of the SDM process).  
 
This strategy minimises the length of amplicons required for the mutagenesis PCR and 
therefore makes the PCR conditions more favourable. This was particularly important due 
to the length and high GC content of the Nr2f2 promoter which were the most likely factors 
that caused the QuikChange® strategy to be unsuccessful. 
 
Mutagenesis PCR reactions 
Primers used for generation of the short fragments are shown in Table 2.3. The primers 
that  had  been  used  for  the  attempted  QuikChange®  mutagenesis  were  used  for  the 
mutation of NR2F2BS2 (Table 2.2 & Table 2.3) whilst  the mutant oligonucleotides that 
were used for EMSA analysis of mutations in NR2F2BS1 were used to mutate NR2F2BS1 
(Figure 4.17 & Table 2.3). These primers were used in a standard PCR reaction with a 
mixture of GoTaq (Promega) and Pfu (Roche) polymerases in a 2:1 ratio (see section 2.7.4) 
and the products of these reactions were electrophoresed on a low melting point agarose gel 
of  appropriate  concentration  (typically  1.5%).  The  band  of  correct  size  (see  Short  Insert 
Length, Table 2.3) was then excised and purified from the gel (see section 2.6.4 for DNA 
purification method).  
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Purified  short  insert  DNA  was  then  used  as  template  DNA  for  generation  of  the  long 
inserts. Flanking primers that had been used to generate the short inserts for each site 
were used to amplify the long insert i.e. N1ApaI5'P was used with MVCApaI3' to amplify 
the  long  insert  containing  NR2F2BS1mut  and  MVCER3’  was  used  with  MVCER5’  to 
amplify the long insert containing NR2F2BS2mut (Table 2.3). The same GoTaq (Promega) 
– Pfu (Roche) mix was used to amplify the long NR2F2BS2mut insert as was used in the 
short insert PCR whereas Herculase (Stratagene) polymerase was used for NR2F2BS1mut 
long  insert  amplification  as  this  insert  was  GC  rich.  The  NR2F2BS1mut  long  insert 
contained the potentially mutated POU4F3 binding site flanked by EcoRI restriction sites 
and  NR2F2BS2mut  long  insert  contained  the  mutated  POU4F3  binding  site  flanked  by 
ApaI  restriction  sites.  PCR  products  were  electrophoresed  on  a  1%  low  melting point 
agarose gel and the long insert was extracted from the gel (sections 2.6.3 and 2.6.4). 
2.12.5  Cloning of NR2F2BS2mut long insert into the NR2F2p4kb plasmid 
Purified  insert  was  ligated  into  the  pDrive  cloning  vector  (section  2.6.5,  TA  method). 
Colonies  incorporating  the  insert  (assessed  by  blue/white  selection)  were  cultured  and 
plasmid DNA was purified (Miniprep, section 2.6.1) and sequenced. NR2F2BS2mut pDrive 
clones containing the desired insert were digested with EcoRI and electrophoresed on a low 
melting point  agarose  gel.  DNA  was  extracted  from  the  gel  as  described  above.  The 
NR2F2p4kb  construct  (which  contains  4kb  of  Nr2f2  5’  flanking  region)  was  similarly 
digested,  electrophoresed  and  purified  prior  to  being  phosphatased  using  Calf  Alkaline 
Phosphatase (Promega) according to the manufacturer’s instructions. The  mutant  insert 
was  ligated  into  the  prepared  vector  using  T4  DNA  ligase  (section  2.6.5).  The  colonies 
produced were digested with the NheI and PstI restriction endonucleases and subjected to 
agarose gel electrophoresis (2.6.3) to determine insert orientation within the vector. Clones 
containing  the  insert  in  the  correct  orientation  were  subsequently  sequenced  to  verify 
incorporation of the mutant insert and this vector was named NR2F2p4kb BS2mut. 
2.12.6  Cloning  of  NR2F2BS1mut  long  insert  into  NR2F2p4kb  and 
NR2F2p4kb-BS2mut 
NR2F2BS1mut long insert was extracted from pDrive colonies as for NR2F2BS2mut except 
the ApaI restriction endonuclease was used instead of EcoRI. This insert was ligated into 
NR2F2p4kb  and  NR2F2p4kb BS2mut  which  had  been  prepared  as  NR2F2p4kb  was  in 
section  2.12.5  (with  ApaI  instead  of  EcoRI)  to  produce  NR2F2p4kb BS2mut  and 
NR2F2p4kb BS1&2mut. This ligation mixture was transformed and cultured as above and 
the  purified  plasmid  DNA  of  the  resultant  clones  was  digested  with  SacI  and 
electrophoresed in order to identify the orientation of the long insert. As well as selecting 
clones which incorporated the insert in the desired orientation, incorporation of the desired 
mutation was verified by allele specific hybridization. 
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2.13  Allele specific hybridization of plasmid DNA with 
EMSA oligonucleotides 
Prior  to  costly  sequencing  of  multiple  clones,  the  incorporation  of  the  desired  2bp 
NR2F2BS1  mutation  into  pDrive  or  NR2F2p4kb BS2mut  (to  make  NR2F2p4kb 
BS1&2mut) was verified by allele specific hybridization. 
2.13.1  Equipment used for allele specific hybridization 
Techne 
HB 1D hybridizer 
2.13.2  Reagents for allele specific hybridization 
Alkali denaturation buffer 
•  3.8M  NaCl 
•  0.5M  NaOH 
Hybridization solution 
•  30ml  20x SSPE 
•  5ml  SDS 
•  5ml  100x Denhardt’s  
  solution 
•  60ml  distilled water 
Wash buffer (3x SSPE, 0.1%SDS) 
•  15ml  20xSSPE 
•  100 l  SDS 
•  84.9ml  distilled water 
 
20x SSPE 
•  3M  NaCl 
•  0.2M  NaH2PO4 
•  20mM  EDTA 
The solution pH was corrected to 7.4 
Denhardt’s solution 
•  0.1%  Ficoll 
•  0.1%  Bovine serum  
  albumin 
•  0.1%  polyvinyl  
  pyrrolidone 
2.13.3  Preparation of membrane for hybridization 
Amersham Hybond™ N+ membrane (GE Healthcare) was cut to an approximate size of 
20cm x 10cm and boxes of approximately 1.5cm x 2.5cm were marked on the membrane in 
pencil. 1 2 l of Miniprep (Qiagen) DNA from potentially mutated clones was spotted onto 
individual cells of the membrane with NR2F2p4kb DNA included in one corner cell as a 
control for estimation of background radioactivity (see section 2.13.5). The DNA spotting 
pattern was duplicated on another membrane for each experiment and DNA was fixed to 
the  membrane  by  incubation  with  alkali  denaturation  buffer  for  20  minutes  at  room 
temperature. 
2.13.4  Pre-hybridization 
The duplicate membranes were placed in separate hybridization tubes (tube A and tube B), 
and briefly washed in wash buffer (3xSSPE, 0.1%SDS). They were then pre hybridized by 
replacement  of  the  denaturation  buffer  with  approximately  50ml  hybridization  solution  
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followed  by  incubation  at  58°C  (the  salt  adjusted  melting  temperature  of  the  wild  type 
NR2F2BS1 EMSA oligonucleotide minus two degrees) for 15 minutes.  
2.13.5  Hybridization and washing of membranes 
10 g of single stranded sense probes for NR2F2BS1 and NR2F2BS1mut (Figure 4.17) were 
radiolabelled as described in section 2.10.6 with the volume of the antisense strand omitted 
and the volume of 1x medium salt buffer reduced to 1.1 l accordingly. The entire volume of 
each labelled probe (11.1 l) was added to the hybridization solution in a hybridization tube: 
NR2F2BS1mut  was  added  to  tube  A  and  NR2F2BS1  to  tube  B.    Hybridizations  were 
incubated at 58°C for one hour. 
 
The  membranes  were  then  washed  for  15  minutes  periods  in  pre warmed  wash  buffer 
(3xSSPE, 0.1%SDS) at hybridization temperature and the radioactivity of the control cell 
(NR2F2p4kb) was estimated using a Geiger counter. Once the control cell had fallen to 
near background levels, excess wash buffer was removed from the membrane using paper 
towel. The membrane was covered in plastic wrap and autoradiographed at  80°C for 16 
hours with X ray film (SLS). Autoradiographs were developed, fixed and scanned as for 
EMSAs (section 2.10.10). 
2.14  Sequencing of NR2F2p4kbmut-BS1&2 clones 
Plasmids  were  sequenced  by  Geneservice  Ltd.  Chromatogram  and  sequence  files  were 
returned and the chromatogram was inspected to determine the signal to noise ration of the 
sequencing  reaction.  Sequence  was  aligned  against  sequenced  NR2F2p4kb  and  the 
Ensembl Nr2f2 5’ flanking region. This method was used to identify unintended mutations 
in clones from the NR2F2p4kb mutagenesis. 
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3   
CANDIDATE POU4F3 TARGET GENE 
IDENTIFICATION AND PRIORITISATION 
POU4F3 is a transcription factor that is essential to hair cell development and survival. 
Pou4f3  knockout  and  mutant  mice  have  demonstrated  that  it  is  required  for  hair  cell 
terminal maturation (Erkman et al. 1996;Hertzano et al. 2004;Xiang et al. 1998;Xiang et al. 
1997) and three human families with different POU4F3 mutations show that it is involved 
in the maintenance of hearing (Collin et al. 2008;Pauw et al. 2008;Vahava et al. 1998). As a 
transcription  factor,  POU4F3  produces  the  wild type  hair  cell  phenotype  by  binding  to 
specific  recognition  elements  in  the  promoter  regions  of  target  genes  and  recruiting  or 
blocking  other  transcription  factors  in  order  to  produce  a  positive  or  negative  effect  on 
target  gene  transcription.  The  phenotype  seen  in  Pou4f3  knockout  hair  cells  cannot 
therefore be explained directly by POU4F3 loss e.g. POU4F3 itself is not a component of the 
stereocilia and therefore cannot be structurally responsible for stereocilial deficits in Pou4f3 
mutant mice. Therefore, the transcriptomal effect produced by the up  or down regulation 
of target genes and their subsequent functions in hair cell development and maintenance 
must be responsible for the production of the hair cell phenotype. Hence, the phenotypes 
produced by Pou4f3 mutation in mice and humans are likely to be due to dysregulation of 
these target genes.  
 
In order to understand how Pou4f3 produces hair cell terminal differentiation and survival, 
the regulatory networks from Pou4f3 through to the hair cell phenotype would have to be 
traced. A full understanding of these pathways could provide strategies to reverse Pou4f3 
related  hearing  loss,  prevent  hair  cell  loss  from  other  causes  and  aid  in  hair  cell 
regeneration. 
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In this chapter I report the process by which the candidate target genes of POU4F3 were 
identified and the difficult – sometimes subjective – process by which a subset of these 
genes  were  prioritised  for  further  investigation.  Comparative  bioinformatic  analyses  of 
candidate target genes and preliminary experiments which were used to compare targets in 
this selection process are reported herein. Detailed bioinformatic investigation of prioritised 
candidate genes and characterisation of the regulation of individual genes by POU4F3 is 
reported in subsequent chapters (see chapters 4 & 5). 
3.1  Previous  work  in  the  identification  of  POU4F3 
target genes 
Prior to the start of my doctoral work, experiments were conducted in our laboratory to 
identify unknown POU4F3 target genes at the transcriptional level using a genetic screen. 
Historically,  hair  cell  genetic  networks  have  been  difficult  to  investigate  by  traditional 
molecular biological methods. This difficulty arises because of challenges in obtaining tissue 
of  appropriate  type  and  sufficient  quantity  and  purity  to  employ  such  techniques  (see 
section 1.6.1 for further detail). 
 
In  addition  to  the  known  difficulties  of  analysing  genetic  pathways  in  the  inner  ear, 
analysis of the transcriptional effect of POU4F3 by the common strategy of comparing wild 
type to mutant tissue could be confounded by secondary abnormalities and deterioration of 
nascent hair cells in Pou4f3 mutants. For example, apoptotic genes that are upregulated in 
cell death in Pou4f3 mutant mice (Xiang et al. 1998) would be more likely to be identified by 
a  genetic  screen  even  if  these  genes  aren’t  directly  regulated  by  POU4F3.  Although 
investigators  have  attempted  to  identify  POU4F3  target  genes  by  comparing  gene 
expression in wild type and dreidel Pou4f3 mutant whole E16.5 cochleas by microarray 
analysis (Hertzano et al. 2004;Hertzano et al. 2007), the level of apoptosis in the inner ears 
of  Pou4f3  mutant  mice  at  this  age  has  not  been  reliably  assessed  (Xiang  et  al.  1998). 
Therefore,  though  the  expression  of  two  genes  (Gfi1  and  Lhx3)  has  been  shown  to  be 
affected by the dreidel Pou4f3 mutation by this method (Hertzano et al. 2004;Hertzano et al. 
2007), the mechanism by which POU4F3 might regulate these genes is currently unknown. 
Hence, these genes may be dysregulated due to hair cell death rather than the direct effects 
of POU4F3 loss. 
 
Identification  of  target  genes  by  conducting  a  genetic  screen  in  vitro  in  cell  lines 
circumvents the difficulties in obtaining sufficient tissue of sufficient quality and minimises 
confounding by abnormal and apoptosing cells. However, a problem posed by cell lines is 
that  the  transcriptional  environment  in  which  the  screen  is  conducted  is  potentially 
different from that in the developing inner ear. As POU4F3 expression is initiated as early 
as E12.5 in the inner ear (Xiang et al. 1998), the UB/OC 2 cell line – which  is derived from 
E13 immortomouse sensory epithelium and constitutively expresses POU4F3, myosin VI  
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and myosin VIIa – was selected for use in the screen as it is likely to provide as suitable a 
transcriptional environment as possible compared to other cell lines (Rivolta et al. 1998a). 
3.1.1  Methods for identification of differential gene regulation 
At the time that the subtractive hybridization screen was carried out, many methods were 
available  to  identify  mRNAs  that  are  differentially  expressed  between  two  sources 
(summarised  in  Munir  et  al.  2004).  Broadly,  these  techniques  can  be  categorised  as 
differential display, subtractive hybridization and microarray. A subtractive hybridization 
method was chosen as it is unbiased in its identification of transcripts – unlike non tiling 
cDNA microarrays (reviewed in Mockler et al. 2005) – it is able to identify lowly expressed 
transcripts – unlike differential display (Ledakis et al. 1998) – and it was cost effective. 
Furthermore, at the time of the analysis no microarray chip was available that was tailored 
to the inner ear transcriptome. 
 
The major limitation of the subtractive hybridization screen is that it is biased towards 
reporting transcripts that display large differences in mRNA level though slight changes in 
the expression of some genes can have potent effects on phenotype and such changes are 
identifiable  using  oligonucleotide  microarrays.  It  consequently  also  leaves  out  the 
possibility  of  investigating  complex  and  subtle  multi gene  interactions  as  only  the  most 
differentially  expressed  of  the  directly  regulated  genes  in  a  network  may  be  identified. 
Despite its limitations, this method was appropriate for the identification of POU4F3 target 
genes. 
3.2  Subtractive hybridization in UB/OC-2 cells 
In our laboratory, the PCR Select™ cDNA Subtraction kit (Clontech) was used to identify 
POU4F3 target genes. UB/OC 2 cells were manipulated to over  or under express POU4F3 
by  stable  transfection  with  sense  Pou4f3  cDNA  or  anti sense  Pou4f3  N terminus  cDNA 
respectively. mRNA was extracted from the two cell populations and converted to cDNA 
which  was  then  separately  digested  to  produce  shorter,  blunt ended  cDNA  molecules  to 
which adaptor oligonucleotides were ligated. These samples were subjected to two rounds of 
hybridization  (to  enrich  differentially  expressed  transcripts)  and  two  rounds  of  PCR 
amplification (to amplify differentially expressed sequences and reduce background). The 
above  steps  were  carried  out  in  order  to  identify  both  upregulated  and  downregulated 
POU4F3 targets that were then subcloned into the pGEM T Easy vector (Promega). Virtual 
Northern analysis was carried out (with both upregulated and downregulated transcript 
pools) in order to confirm the expression pattern of individual clones to minimise the risk of 
false positives prior to sequencing of differentially expressed clones (Clontech Laboratories 
2008).  
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3.3  Follow-up  of  subtractive  hybridization  screen 
results 
As  with  other  methods  of  identification  of  differential  gene  expression,  subtractive 
hybridization screens present the problem of making sense of the substantial amount of 
data produced. Though not as statistically complicated as the interpretation of microarray 
data, subtractive hybridization screen results still require thorough verification and further 
investigation to confirm specific effects of manipulations on target genes. The differentially 
expressed transcripts produced by the screen were reduced in our laboratory to those that 
are most differentially expressed based on a series of virtual Northern blots.  
 
From  this  reduced  pool,  I  began  my  project  with  20  potentially  upregulated  and  one 
potentially downregulated transcript to investigate. These were provided in 26 sequencing 
files from 21 cDNA clones that had been generated in our laboratory from the subtractive 
hybridization screen. All bar one of the clones that I was allocated were from the ‘forward’ 
subtractive hybridization screen i.e. these potential targets of POU4F3 were upregulated in 
the presence of POU4F3 in the subtractive hybridization screen.  
3.3.1  Matching cDNA clones from the subtractive hybridization screen 
to mouse genes 
The  first  step  in  the  analysis  of  these  differentially  expressed  clones  was  to  identify  to 
which genes they correspond. As the primers used in sequencing these clones flanked the 
cloned sequence, adaptor oligonucleotides that were used in the subtractive hybridization 
prior to cloning of differentially expressed cDNAs into the pGEM T Easy vector (Promega) 
were  included  in  the  sequence  returned.  These  unwanted  sequences  were  identified  by 
alignment of the known adaptor sequence with the sequencing data and manually deleted 
to leave cDNA sequence alone. The trimmed sequences were then used to identify genes 
that correspond to the clones from the screen. Each trimmed sequence was individually 
submitted to the Ensembl nucleotide nucleotide BLASTN software through the Ensembl 
website  in  order  to  find  near exact  matches  (Ensembl  2008a;Gish  2004)  and  the  most 
significant match to a given clone was selected as the corresponding gene. If no statistically 
significant match was found (i.e. p value < 0.05), the clone was not followed up. 
 
The BLASTN analysis provides a low false positive rate (it is unlikely to incorrectly report 
non matching sequences as matches) however, certain regions of a query sequence will not 
be aligned with a homologous sequence if that sequence has characteristics that increase 
the risk of an alignment being due to chance e.g. highly repetitive regions. Therefore, for 
genes that were selected for further investigation, the trimmed clone sequence was aligned 
with  the  Ensembl  sequence  for  its  corresponding  gene  to  identify  whether  intervening 
regions were false negatives. This analysis also helped to identify which transcripts of a 
gene (if any) best matched the submitted cDNA sequence.  
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Of the 21 clones submitted, four did not produce any significant matches – this may have 
been due to factors such as sequencing error of the clone, short query sequence length, low 
sequence complexity or deficits in the Ensembl database. The remaining 17 clones matched 
14 genes in the mouse genome (see Table 3.1). 
3.3.2  Prioritising candidates for further study 
The  genes  identified  in  Table  3.1  –  referred  to  as  candidate  genes  –  perform  various 
functions, are of differing levels of characterisation and consequently had differing numbers 
of  experimental  reagents  available  (e.g.  antibody,  purified  protein  etc.).  Given  the  large 
amount  of  time  and  resources  required  to  investigate  each  interaction,  candidates  were 
prioritised for further study based on their known functions in other systems and their 
potential role in hair cell maturation and maintenance. Gene function data were required 
to inform this process and formulate hypotheses of candidate gene function which could 
guide future work.  
 
A rapid method of assessing the available information on the function of a gene product is 
to examine its Gene Ontology (GO) units. GO units are descriptions of the known functions 
of wild type gene products. These descriptions are drawn from structured vocabularies that 
classify  the  cellular  components  (i.e.  subcellular  localization),  molecular  functions  and 
biological processes in which gene products are involved. Furthermore, the type of evidence 
on which such functions are based can be identified as the GO database assigns an evidence 
code to each unit (Gene Ontology Consortium 2008). Therefore, candidate genes’ GO units 
were downloaded from the Ensembl genome browser and compared, with reference to the 
literature, to assist prioritisation of suitable candidates for further investigation. 
 
As mentioned in section 3.1.1, one of the benefits of the subtractive hybridization screen 
technique is its potential to identify novel and unknown genes. However – by definition – 
the  literature  on  such  genes  is  sparse  and  they  have  few  experimentally  verified  data. 
Therefore,  the  GO  units  for  these  genes  are  few  and  predominantly  computationally 
predicted (i.e. without experimental verification) making it difficult to hypothesise what 
their  functions  could  be  in  the  inner  ear  though  these  functions  could  be  interesting. 
Furthermore, there are often few experimental reagents available for the study of novel 
genes and generation of the required reagents is a lengthy and costly process. These factors 
make  such  genes  challenging  candidates  for  further  study  and  they  were  therefore  less 
likely  to  be  prioritised  for  further  investigation  when  found,  as  they  were  much  more 
difficult  to  pursue  immediately  despite  their  potential  novelty.  Candidate  genes  whose 
expression is known to be essential to the function of all mammalian cells were also less 
likely to be pursued as dysregulation of such genes in hair cells is unlikely to be due to a 
different mechanism than in other cells.   
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Based on these criteria, the genes identified were separated into two groups: 
 
•  Genes with known functions which could be relevant to hair cell terminal 
maturation and maintenance 
•  Genes with a potentially novel role in the inner ear 
 
Within these groups, genes were ranked according to their potential relevance to hair cell 
development and maintenance. Though GO units provide an indicator of this, the ranking 
was also based on scientific judgement of the literature and supporting evidence for those 
GO units as there is no quantitative method for the analysis of such a small sample of 
genes’ GO units i.e. it was not possible to analyse the GO units common to differentially 
expressed transcripts as the existing software requires much larger sample sizes to produce 
significant results. Candidate genes from each group which were judged to have the highest 
potential relevance to hair cell development and maintenance were then selected for further 
study. Only Slc16a1 was not included in this ranking as it was followed up by another 
member of the laboratory (ET) who had also identified it as a potential target of POU4F3 
from a different clone of the subtractive hybridization screen. The results of this analysis 
are presented in Table 3.2. 
 
Having  completed  this  analysis  of  the  known  functions  of  each  gene,  I  compared  the 
biological processes in which candidate genes are involved to identify whether they function 
in the same processes. This comparison did not identify a common theme in the functions of 
the  candidate  Pou4f3  target  genes  identified.  I  therefore  continued  to  investigate  high 
priority genes (Table 3.2) on an individual basis. 
 
Table 3.2. Categorisation of POU4F3 candidate target genes for follow up.  
NB: Slc16a1 is not included as it was investigated by ET. 
High priority 
due to 
existing evidence 
High priority 
due to 
potential novelty 
Low priority 
due to 
existing evidence 
Low priority 
due to 
lack of evidence 
Nr2f2  Luzp1  Actb  Amd1 
Metap2  Sertad2  Anxa5  BC010304 
Rbms1    Exosc9  Hnrnpa2b1 
Rcn1       
Zranb2       
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3.4  Reverse transcriptase PCR in UB/OC-2 cells 
Having narrowed down the list of candidate genes, the process of comparing, verifying and 
characterising POU4F3 candidate gene interactions began. As an initial verification, the 
correlation  of  candidate  gene  expression  with  POU4F3  expression  was  investigated.  All 
seven  of  the  high  priority  candidates  for  follow up  were  from  the  forward  subtractive 
hybridization screen (i.e. potentially upregulated targets of POU4F3), and may therefore be 
expressed in POU4F3 expressing cells. A sensitive, rapid and cost effective way of checking 
their transcription in such cells is by reverse transcriptase PCR (RT PCR), which identifies 
if the candidate gene is being transcribed by detection of mRNA signal. 
 
Ideally, hair cells would  be used to identify candidate gene expression as  these are the 
POU4F3 expressing cells of interest and therefore have the most relevant transcriptome. 
However, as for the subtractive hybridization, this was not practical due to difficulties in 
isolating sufficient hair cells to obtain RNA for reverse transcription and subsequent PCR. 
Therefore, in order to verify that the candidate genes are expressed in POU4F3 expressing 
cells, unmanipulated UB/OC 2 cells, which constitutively express POU4F3, were used as 
the source of RNA for reverse transcription. As previously explained (section 3.1), these 
cells provide a transcriptional environment that is more similar to that of the inner ear 
than many other cell lines (Rivolta et al. 1998a). 
 
The UB/OC 2 cDNA was used as the template for PCR reactions to detect candidate gene 
expression. Genomic DNA (gDNA) was digested using DNAse prior to reverse transcription 
of UB/OC 2 cell RNA to cDNA and any DNA fragments amplified from gDNA could be size 
separated from cDNA bands by agarose gel electrophoresis due to the exon specificity of the 
primers designed (see Appendix). Where possible, the primers were designed to amplify the 
exons  that  had  been  detected  in  the  subtractive  hybridization  screen  to  ensure 
identification  of  relevant  transcripts.  The  BLAST  analysis  described  in  section  3.3.1 
provided a guide as to which transcripts to design primers against. The exons identified by 
the BLAST analysis were likely to be at the known 3’ end of their gene as transcripts from 
the  subtractive  hybridization  were  amplified  using  a  poly  dT  primer  which  primes  the 
amplification of cDNA from the poly(A) tail of an RNA molecule. 
 
Figure 3.1 shows that bands were amplified for all seven of the genes investigated. Though 
non specific bands were present for three genes (Rbms1, Sertad2 and Zranb2), each gene 
yielded a band of predicted size without genomic DNA contamination (as determined by 
size). This result supports subtractive hybridization screen results and is compatible with 
the potential upregulation of these genes by POU4F3. 
  
3 Candidate Pou4f3 target gene identification and prioritisation  114 
 
Figure 3.1. Candidate gene mRNA in UB/OC-2 cells. 
UB/OC-2  cell  cDNA  was  used  as  a  template  in  PCR  reactions  with  exon-specific  primers 
against  candidate  genes  identified  in  the  subtractive  hybridization  screen  and  prioritised  for 
further study. The most intense band for each gene corresponded to the predicted amplicon 
length as measured by comparison to the molecular weight marker (see Appendix). NB, the 
specific production of the above bands from UB/OC-2 cDNA was confirmed by negative controls 
that did not include cDNA and showed no detectable DNA on agarose gel electrophoresis. 
 
 
3.5  Prediction  of  POU4F3  transcription  factor 
binding sites 
A bioinformatic analysis was carried out on the promoter regions of the seven candidate 
genes prioritised for further study (Table 3.2) to identify potential POU4F3 binding sites. 
The first step in this process is the identification of the promoter regions of candidate genes. 
3.5.1  Promoter identification and selection 
The Genomatix Gene2Promoter software was the promoter prediction program selected to 
identify candidate gene promoters. Many programs execute this task with varying success 
using different methods  (Bajic et al. 2004), however, the promoter prediction program on 
which  Gene2Promoter  is  based  (PromoterInspector)  provides  the  highest  sensitivity 
available (43%, i.e. 43% of positives can be expected to be true positives) (Scherf et al. 2000). 
This improvement is supplemented with oligo capping and comparative genomics to verify 
predictions (Bajic et al. 2004;Genomatix 2008;Scherf et al. 2000). 
 
In  this  analysis,  more  than  one  promoter  per  gene  was  predicted.  This  selection  was 
narrowed down to the most appropriate promoter prior to transcription factor binding site 
identification.  I  based  my  choice  of  promoter  on  the  RNA  transcript  to  which  it 
corresponded. The transcript is essential as the transcriptional start site (TSS) of a gene is 
a useful landmark in promoter prediction by this method (Bajic et al. 2004;Heintzman et al. 
2007).  Each  transcript  is  scored  by  Genomatix  based  on  the  completeness  of  its  5’ 
sequencing by the identification of the known sequence of the oligonucleotide that capped 
the 5’ end of the transcript. If a transcript has experimentally verified full 5’ sequencing, it 
is assigned a gold score; if the 5’ end of the transcript was confirmed by PromoterInspector 
1.6Kb  
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prediction,  its  score  is  silver  and  a  bronze  score  is  assigned  if  the  transcript  has  no 
confirmation  of  5’  completeness.  Only  promoters  with  gold  transcripts  were  further 
analysed. These Genomatix transcripts were compared to the Ensembl transcripts from the 
BLAST analysis and the promoter of the best matching transcript was chosen for further 
analysis.  Detailed  results  for  this  analysis  for  genes  that  were  followed up  further  are 
presented in chapters 4 & 5.  
3.5.2  Transcription factor binding site identification 
The Genomatix MatInspector and ModelInspector programs provided the largest number of 
publicly  available  matrices  for  transcription  factor  binding  sites  (including  the  POU4 
family)  to  assess  candidate  gene  promoters.  Therefore,  these  programs  were  used  to 
identify binding sites in candidate gene promoters.  
 
MatInspector  originally  did  this  by  matching  promoter  sequence  to  positional  weight 
matrices  for  transcription  factor  binding  sites  based  on  the  TRANSFAC  database  with 
positive  weighting  for  experimentally  verified  sites    (Quandt  et  al.  1995).  This  was 
improved for the version of the software used in this analysis. The weight matrix library 
was  generated  with  a  new  program  which  extended  the  original  algorithm;  multiple 
positional weight matrices for a transcription factor are grouped into families to reduce 
redundant matches and matrix thresholds were optimized for each matrix in the library on 
the basis of length and conservation (Cartharius et al. 2005). Unpublished experimental 
evidence in our laboratory suggest that this version of the MatInspector software has much 
greater accuracy in predicting transcription factor binding sites than its predecessors. 
 
Though the binding of a transcription factor like POU4F3 to a promoter is essential for its 
function, the existence of the binding site alone is not sufficient for regulation. Instead, the 
context of the binding site influences transcriptional regulation subsequent to transcription 
factor binding. The ModelInspector software takes this into account by adding contextual 
information (e.g. number of binding site repeats and structural DNA information such as 
hairpins)  to  predict  binding  modules  and  searches  a  pre defined  module  database  for  
regulatory  regions  with a  similar  signature  (Frech  &  Werner  1997).  These  modules  are 
therefore more likely to be functional than transcription factor binding sites identified in 
MatInspector and genes with such modules would be more promising candidates for further 
study than those with transcription factor binding sites alone.  
 
The  promoter  selected  for  each  gene  was  subjected  to  both  MatInspector  and 
ModelInspector analysis. ModelInspector modules were selected for further analysis along 
with the most significant MatInspector predictions. These results were collated (Table 3.3) 
and the predicted binding sites were compared between candidate genes in order to aid 
selection of candidate genes for further investigation (see section 3.7).   
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3.6  Candidate gene expression in the inner ear 
The  decision  to  continue  studying  a  gene  came  under  iterative  review  during  this 
investigation. One of the first of these iterations was the identification of the cellular and 
subcellular expression of candidate genes in the inner ear prior to conducting investigations 
into potential interactions between these genes’ promoters and POU4F3. The literature and 
a developmental gene expression database (the GENSAT database (Gong et al. 2003)) were 
searched to identify reported expression of  candidate genes in the inner ear. The GENSAT 
database is an online database of the neural expression profiles of a large number of genes. 
The  gene  expression  profile  is  made  visible  by  the  introduction  of  a  bacterial  artificial 
chromosome containing the Egfp gene in place of the gene of interest, the product of which 
is detectable by fluorescence or immunohistochemical methods (Gong et al. 2003). As well 
as the GENSAT database, the NCBI UniGene database was searched to identify whether 
target  gene  mRNA  transcripts  had  been  detected  in  the  inner  ear  (Boguski  et  al. 
1995;Wheeler et al. 2003). However, the GENSAT and UniGene analyses were found to be 
poor discriminators of candidate gene inner ear expression at  this stage – no inner ear 
expression  of  candidate  genes  was  found  in  GENSAT  and  the  UniGene  analysis  was 
positive for all candidate genes. Therefore, only the results of the literature search aided in 
the further refinement of candidate genes for investigation. 
3.6.1  Genes with identified cellular and subcellular inner ear expression 
profiles 
The analysis yielded inner ear expression data for Nr2f2 only (Tang et al. 2005). Tang et al. 
identified Nr2f2 mRNA expression at E8.75 and demonstrated the cellular and subcellular 
localization of NR2F2 protein at E15.5 (Tang et al. 2005). This evidence is further discussed 
in  section  4.5.2.  In  brief,  the  onset  of  NR2F2  expression  in  the  developing  inner  ear 
precedes that of POU4F3. However, at E15.5, NR2F2 was shown to be expressed in regions 
that were likely to include hair cells which are known to express POU4F3 (Tang et al. 2005; 
Xiang  et  al.  1998).  This  likely  temporospatial  colocalisation  made  NR2F2  a  very  strong 
candidate for further study and it was therefore selected for continued investigation.  
 
Expression data found in the above searches yielded two candidate genes – Rbms1 and 
Zranb2  –  that  are  ‘ubiquitously’  expressed  in  examined  tissues,  but  whose  cellular 
localization  within  those  tissues  is  largely  unknown  (Adams  et  al.  2000;Fujimoto  et  al. 
2000;Karginova et al. 1997;Nakano et al. 1998). Luzp1, by contrast, is expressed only in 
certain organs (Sun et al. 1996). The need to understand a gene’s cellular localization is 
highlighted by Nr2f2 which is known to be expressed in many tissues (e.g. Jonk et al. 1994) 
but shows marked cellular restriction within organs (e.g. Tang et al. 2005;Tripodi et al. 
2004).  
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3.6.2  Obtaining existing reagents for investigation of candidate genes 
With the exception of Nr2f2, none of these genes’ inner ear expression patterns had been 
characterised.  If  these  candidate  genes  are  upregulated  by  POU4F3,  they  would  be 
predicted to be expressed in hair cells. Furthermore, knowing the timing of the onset of 
changes  in  candidate  gene  expression  compared  with  that  of  POU4F3  could  clarify  the 
putative mechanism of regulation. Identification of expression of these genes in hair cells 
would  therefore  confirm  the  relevance  of  the  potential  interactions  identified  in  the 
subtractive hybridization screen to hair cell development and may provide further clues as 
to the role of POU4F3 candidate genes in hair cells. 
  
I  planned  to  investigate  cochlear  expression  using  antibodies  to  candidate  genes  for 
immunohistochemistry due to the relative rapidity and ease of this method compared to 
RNA in situ hybridization. A search of the literature and company websites was conducted 
to  identify  custom  made  and  commercial  antibodies  respectively.  This  search  identified 
antibodies for all candidate genes except Sertad2. The antibodies identified were verified 
for differing applications (i.e. not all had been used for immunohistochemistry which was 
their  primary  intended  use  in  this  study)  and  were  of  varying  specificities  (i.e.  some 
antibodies identified had cross reactivity to genes homologous to candidate genes). 
 
As  this  initial  screen  did  not  seek  to  perform  a  comprehensive  characterisation  of  gene 
expression or use an antibody intensive protocol, only a small amount of an antibody that 
was suitable for immunohistochemistry was required. Therefore, if no suitable commercial 
antibody was available, I identified and requested a small amount of custom made antibody 
from the laboratory that had made or commissioned it. If a suitable antibody was available 
commercially,  I  contacted  a  company  that  would  provide  a  sample  of  the  antibody  for 
assessment. 
 
By this method, I was able to obtain antibodies for RBMS1 (Takai et al. 1994) and ZRANB2 
(Abnova 2008a) for the identification of their inner ear expression. I was also able to obtain 
an anti NR2F2 antibody for further characterisation of NR2F2 expression (Tripodi et al. 
2004).  
3.7  Refinement  of  candidate  genes  for  further 
investigation 
At this stage of analysis, two genes had been chosen for early study. Nr2f2 was chosen 
because it encodes a well investigated transcription factor which is known to be involved in 
processes  relevant  to  hair  cell  development  and  maintenance  (see  chapter  4);  there  are 
many reagents available for its study; its transcription in UB/OC 2 cells was verified; and it 
is reported to be expressed in a region of the developing inner ear that gives rise to hair 
cells.  Furthermore,  a  promoter  module  for  Oct1  –  a  member  of  the  POU  family  which,  
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therefore, binds DNA in a similar way to POU4F3 (e.g. Li et al. 1993) – was identified in 
the Nr2f2 promoter as well as a high stringency predicted transcription factor binding site 
which provided potential sites for direct regulation of Nr2f2 by POU4F3.   
 
The  other  gene  selected  for  early  study  was  Zranb2.  This  is  a  ubiquitously  expressed 
(Adams et al. 2000;Nakano et al. 1998) regulator of alternative splicing (Adams et al. 2001) 
and  therefore,  despite  being  less  well  characterised  than  Nr2f2,  has  the  potential  to 
regulate  developmental  and  maintenance  pathways  in  the  inner  ear.  An  antibody  was 
obtained against ZRANB2, making it easy to rapidly verify its expression profile in the 
inner  ear,  provided  that  the  antibody  was  suitable  for  immunohistochemistry.  It  is 
transcribed in UB/OC 2 cells and, as for Nr2f2, one promoter module and one transcription 
factor binding site were identified in its 5’ flanking region making Zranb2 a good candidate 
gene for regulation by POU4F3. 
 
Rbms1 encodes a transcription factor which has been implicated in processes relevant to 
hair  cell  development  and  maintenance  (e.g.  cell  cycle  (c-myc) (Negishi  et al.  1994)  and 
apoptosis (mitochondrial) (Iida et al. 1997)). Like Nr2f2 and Zranb2, it was shown to be 
transcribed in UB/OC 2 cells by RT PCR. Furthermore, a BRNF module (i.e. a ‘Brn’ POU 
domain  factor  module  (see  Andersen  et  al.  2001))  was  initially  identified  in  the  mus 
musculus  Rbms1  gene  promoter  that  may  have  been  sufficient  for  POU4F3  regulation, 
though the promoter analysis was later redone for the human sequence for compatibility 
with reagents obtained (see section 5.5.2). Rbms1 was preferred for follow up given that we 
were able to obtain an  antibody that was potentially useful for future experiments and 
promoter reporter and expression constructs were available from collaborators.  
 
Metap2  was  not  prioritised  for  further  study  as  the  transcription  factor  binding  sites 
identified in its promoter were of lower quality and stringency than any other candidate 
gene being followed up at this stage. Although high stringency potential POU4F3 binding 
sites were identified in the Rcn1 and Sertad2 5’ flanking regions, I was unable to obtain an 
antibody  or  other  reagents  for  RCN1  and  SERTAD2  had  no  antibody  available. 
Furthermore, very little was known about the functions of either of these genes, making it 
difficult to assess their potential relevance to hair cell development and maintenance. As 
there was less reason to continue the investigation of these genes at this stage, they were 
not  prioritised  for  investigation.  However,  the  decision  to  continue  investigation  of 
prioritised  genes  came  under  iterative  review  throughout  this  study.  Therefore,  the 
literature and online databases of gene expression were monitored for Metap2, Rcn1 and 
Sertad2 throughout this investigation, with ongoing attempts being made to identify and 
obtain reagents for the investigation of these putative POU4F3 target genes. 
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The  final  gene  selected  for  follow up  was  Luzp1.  This  candidate  gene  had  predicted 
transcription factor binding sites of comparable quality to those of other genes selected for 
follow  up.  Its  known  expression  profile  is  amongst  the  most  restricted  of  the  candidate 
genes  and  it  is  likely  to  act  as  a  transcription  factor  (Lee  et  al.  2001;Sun  et  al.  1996). 
Therefore, like RBMS1, LUZP1 could potentially regulate a variety of processes in the inner 
ear. An antibody was available and I attempted (unsuccessfully) to obtain a sample of this 
whilst I continued to investigate this candidate gene. 
3.8  Summary 
Having identified candidate POU4F3 target genes from a subtractive hybridization carried 
out  in  our  laboratory,  a  small  number  of  candidate  genes  were  selected  for  further 
investigation based on measures that indicated the likelihood of POU4F3 regulation i.e. 
prediction of putative POU4F3 binding sites in predicted candidate gene promoters; the 
potential role of candidate genes in auditory hair cell maintenance and survival; and the 
reagents available for experimentation. 
 
The  expression  patterns  of  candidate  genes  in  the  inner  ear  and  the  upregulation  of 
candidate genes by POU4F3 suggested by the subtractive hybridization was subsequently 
tested to verify any interaction and to elucidate the mechanism by which POU4F3 might 
affect  target  gene  transcription.  Results  from  these  experiments  guided  the  ongoing 
prioritisation of genes and the allocation of resources for further investigation in order to 
allow greater focus on genes that were most likely to be involved in the guidance of hair cell 
terminal differentiation and survival that is mediated by POU4F3.  
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4   
CHARACTERISATION OF THE 
INTERACTION OF POU4F3 WITH THE 
NR2F2 PROMOTER 
All  candidate  genes  reported  herein  were  identified  as  putative  targets  of  the  POU4F3 
transcription  factor  from  a  subtractive  hybridization  screen  that  was  conducted  by 
members  of  our  laboratory.  This  screen  identified  mRNA  transcripts  that  were 
differentially expressed between cells that had been manipulated to either over  or under 
express Pou4f3. The transcripts were output from the subtractive hybridization screen in 
the  form  of  cDNA  sequences  that  had  been  cloned  into  the  pGEM T®  Easy  vector  and 
subsequently  sequenced.  In  order  to  identify  which  gene  in  the  mouse  genome  the 
transcripts had been produced from (i.e. which gene may be transcriptionally regulated by 
POU4F3), I used these sequencing files in BLAST analysis against the Ensembl mouse 
cDNA database. 
4.1  Identification  of  Nr2f2  as  a  potential  POU4F3 
target gene 
Nr2f2 was identified as  a potential target of POU4F3 from a clone (clone D8) that was 
produced from the forward (upregulated) subtractive hybridization screen as follows: The 
sequencing file for clone D8 was analysed to verify full sequencing of the cloned cDNA as a 
longer, higher quality sequence would provide higher quality matches on BLAST analysis. 
Sequencing  of  the  whole  insert  was  verified  by  identification  of  adaptor  oligonucleotide 
sequences at both the 5’ and 3’ ends of the sequence. These adaptors had been used to 
amplify  and  subsequently  clone  the  differentially  expressed  Nr2f2  cDNA  from  the 
subtractive  hybridization  screen  into  the  pGEM T®  Easy  vector  (Figure  4.1.a).  Adaptor 
oligonucleotide sequences were manually trimmed from the cDNA sequence prior to BLAST 
analysis and this analysis was conducted using the trimmed cDNA sequence against the 
annotated  genes  in  the  Ensembl  mouse  ‘gene  build’  database  (see  section  3.3.1)  i.e.  
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sequences that had been annotated as being transcribed from the mouse genome (Curwen 
et al. 2004).  
 
Five significant matches to the Nr2f2 sequence in the Ensembl database were identified by 
this  method  with  the  most  significant  match  being  343bp  long  and  of  100%  sequence 
identity to Nr2f2 (p = 8.6 x 10 273) (Figure 4.1.boxes 1&2, b). However, as an alternative 
transcript (NP_899084.2) was found to overlap with Nr2f2 in this region, a match of equal 
significance  to  the  Nr2f2  match  was  identified  to  this  transcript.  Therefore,  the  initial 
strategy of selecting the most significant match to a given clone as its corresponding gene 
(section 3.3.1) was not appropriate for clone D8. 
 
In order to verify the match of clone D8 to Nr2f2, the genomic locations of all significant 
matches (p < 0.05) that were produced by the BLAST analysis were checked. Though one of 
these matches was to the other member of the NR2F family (Nr2f1) (p = 3.3 x 10 25), this 
match was much shorter than the other significant matches (116bp, 87% sequence identity), 
less significant, and near the 3’ terminal of the transcript which is the most homologous to 
Nr2f2 (Tripodi et al. 2004). Therefore, this match to Nr2f1 was excluded as a match to clone 
D8. 
 
 
 
Figure 4.1. Clone D8 of the subtractive hybridization screen matches the Nr2f2 gene. 
(Legend on page 124) 
a) 
  GGGGNGGNNTTCNNNTCCCNNNNNNAAAAAGNGANNANCTTNCCCCGCGGCCGAGGTACAT
AGACACAGGACAATTAATAATTTGGAAAAAAATGACTTACNTTGTCCATTCTGCTAATTTTCT
CCCAATCTCCTTAAATGCACTTTTAGCAATATTTTTCAAAAATTTACCAAAAAGAAAAAAAGA
CTAATTTCCTTTTTATACAAAAATGATAAGTAGCAGGTTGTTCTGCCCAACACAGGAGTTGTTT
TCTTTCTTTTTTTTTAATGCATTCTGTAAAAGTTCATTTGGCAATCTCTCTCTTTCTCTCTCTCCT
TTTTGAAATTCACAGTCCATTAAATTCTTCCCCTCTCTTCTTTTTAGCAAACTTGTAACATCCTT
TCTTAACAGAAGGAAATTAAGCAAACAAAACCAGTCTTTTGCCTTTTCTTTCTCTGTTTCACTC
CCCCTTATTTTGATTGATTTATTTATTGAATTGCCATATATGGCCAGTTAAAACTGCTGCCGGA
CAGTAACATATCCCGGATGAGGGTTTCGATGGGGGTTTTACCTACCAAACGGACGAAAAACA
ATTGCTCTATGACTGAGGAGGAGACCGTGCGGAGGGAAGGGAGACGAAGCAAGAGCTTTCCG
AACCGTGTTGGCTGGTTGGGGTACCTGCCCGGGCGGCCGCTCGA 
b)  
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The  remaining  matches  were  found  to  be  in  the  same  genomic  region  as  the  most 
significant match (Figure 4.1.b, red boxes) and three matched Nr2f2 but not the overlapping 
transcript in that region (NP_899084.2). This suggested that Nr2f2 was the true match to 
clone D8. However, the BLAST analysis did not report the alignment of regions between 
matches; as discussed in section 3.3.1, the BLAST software used can fail to identify true 
homology  in  low  complexity  (i.e.  repetitive)  regions  as  these  regions  are  filtered  out  or 
masked  by  programs  included  in  the  WU BLAST  2  software  package  that  the  Ensembl 
BLAST tool uses (Gish 2004). Therefore, as a further verification of the match of Nr2f2 to 
clone D8, the trimmed clone D8 insert sequence was aligned with the last exon of Nr2f2 to 
identify whether the regions between BLAST matches also matched this sequence (Figure 
4.1.c.f&h). All significant BLAST matches to Nr2f2 were included in the alignment (Figure 
4.1.c.a e).  
 
This alignment showed that the whole of the clone D8 insert matched the Nr2f2 transcript 
in the Ensembl database with high sequence similarity (>99%). Furthermore, homologous 
regions not identified by BLAST analysis were shown to be of low complexity, as expected. 
This verified that the clone D8 sequence used in the BLAST analysis matched Nr2f2 and 
not NP_899084.2 as the alignment extended beyond the 3’ terminal of the latter transcript. 
Therefore, the clone D8 insert sequence that was reverse transcribed and cloned from an 
mRNA transcript in the subtractive hybridization screen unequivocally matches the Nr2f2 
transcript  in  the  Ensembl  database.  As  clone  D8  was  produced  from  the  forwards 
(upregulated)  POU4F3  subtractive  hybridization  screen,  the  above  match  to  Nr2f2 
indicates  that  POU4F3  upregulates  Nr2f2  in  UB/OC 2  cells.  Therefore,  POU4F3  may 
upregulate Nr2f2 expression in hair cells. 
4.2  Introduction to Nr2f2 
Nr2f2 was the first gene identified by the POU4F3 subtractive hybridization screen to be 
investigated.  It  is  a  well characterised  member  of  the  steroid/thyroid  hormone  nuclear 
receptor  superfamily  that  has  commonly  been  referred  to  as  apoAI  regulatory  protein 1 
(ARP 1) (Ladias et al. 1991), COUP TFII (Ritchie et al. 1990) and COUP TF2 (Wang et al. 
1991). In this document it is referred to as Nr2f2 as recommended by the Nuclear Receptors 
Nomenclature  Committee  in  order  to  place  it  in  a  systematic  framework  of  nuclear 
receptors based on its phylogeny (Nuclear Receptors Nomenclature Committee. 1999). 
4.3  Steroid/thyroid hormone nuclear receptors 
The steroid/thyroid hormone nuclear receptor superfamily is a large and well characterised 
group of nuclear receptor transcription factors that classically bind steroid/thyroid/vitamin 
derived  hormone  ligands  that  regulate  their  function.  The  binding  of  the  ligand  to  the 
nuclear receptor can take place outside the nucleus and induce translocation of the nuclear 
receptor  to  the  nucleus  (reviewed  in  Benoit  et  al.  2004;DeFranco  et  al.  1998)  or,  the  
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typically lipophilic ligand can be transported to the nucleus prior to binding to a nuclearly 
expressed receptor (e.g. reviewed in Kishimoto et al. 2006). Ligand binding classically acts 
to alter the transcriptional effect of nuclear receptors on their target genes. As the sources 
of ligands can be systemic, local or exogenous (including xenobiotic compounds), nuclear 
receptors are involved in both systemic/endocrine signalling (e.g. by steroid hormones) and 
local/paracrine regulation (e.g. by retinoids), thereby influencing processes from embryonic 
development to adult homeostasis (reviewed in Beato et al. 1995;Benoit et al. 2004;Weigel 
1996). 
4.3.1  Molecular function of steroid/thyroid hormone nuclear receptors 
For  classical  nuclear  receptors,  ligand  binding  induces  a  conformational  change  in  the 
receptor’s ligand binding domain (LBD) which, in turn, alters the binding of coactivators 
and corepressors, thus influencing target gene regulation (Beato et al. 1995;Weigel 1996). 
This transcriptional activity is mediated by the two ‘activation function’ (AF) helices of the 
nuclear receptor. AF 1 mediates ligand independent transcriptional activation whilst AF 2 
– which is part of the LBD – has ligand dependent function (Kishimoto et al. 2006;Noy 
2007;Weigel 1996). When not bound to ligand, the conformation of the AF 2 helix typically 
facilitates binding of corepressors to the LBD (e.g. HDAC); conversely, the binding of ligand 
to the LBD induces a conformational change in this protein region that allows binding of 
coactivators (e.g. HAT) (Gronemeyer et al. 2004;Kishimoto et al. 2006;Xu et al. 1999). 
 
Though  co factors  are  required  for  transcriptional  regulation  of  nuclear  receptor  target 
genes, their action is often secondary to DNA binding by the nuclear receptor. This DNA 
binding function is dependent on the DNA binding domain (DBD) of the protein, which 
recognises  specific  response  elements  in  target  gene  promoters.  The  canonical  hormone 
response element RGGTCA – in which R is a purine – is modified, extended and duplicated 
to yield specific response elements for different classes of nuclear receptor (Gronemeyer et 
al. 2004). DNA binding is further modulated by competition for binding sites with other 
nuclear  receptors  and  by  protein protein  interactions.  For  example,  homo   or  hetero 
dimerisation  of  nuclear  receptors  can  have  both  an  up  and  downregulatory  effect  on 
transcription and is sometimes required for DNA binding to palindromic hormone response 
element half sites in vivo (reviewed in Beato et al. 1995;Park et al. 2003). Other important 
protein protein  interactions  mediate  the  shuttling  of  nuclear  receptors  between  the 
cytoplasm and nucleus. For example, a 90kDa heat shock protein (hsp90) is associated with 
unliganded cytoplasmically expressed nuclear receptors in order to maintain cytoplasmic 
expression and dissociates from liganded nuclear receptor, allowing nuclear translocation 
(DeFranco  et  al.  1998).  Though  the  majority  of  nuclear  receptors  are  constitutively 
expressed in nuclei, most steroid hormone receptors which bind systemically acting ligands 
shuttle  between  the  cytoplasm  and  nucleus  and  this  translocation  is  dependent  on 
associated proteins (reviewed in Benoit et al. 2004;Kishimoto et al. 2006). Such proteins  
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might therefore be involved in the controlling the subcellular localization of NR2F2 which 
is  primarily  expressed  nuclearly,  though  it  has  been  reported  to  be  expressed 
cytoplasmically in the rat anterior pituitary gland (Raccurt et al. 2006). The final major 
area of nuclear receptor protein regulation is that of post translational modification. For 
example, phosphorylation, ubiquitination and  sumoylation of PPARγ (a nuclear receptor 
involved in development and metabolism) can all affect its function (Burgermeister et al. 
2007). Therefore, the regulation of nuclear receptor target genes can be controlled at the 
DNA level (at target gene promoter response elements), by protein protein interaction (by 
dimerisation/tetramerisation  and  nucleo cytoplasmic  shuttling)  and  by  post translational 
modification, resulting in complex regulation and function of these genes. 
4.3.2  Orphan nuclear receptors 
A  distinction  is  drawn  between  nuclear  receptors  based  on  their  ligand  binding 
characteristics. Nuclear receptors that display non classical ligand binding can be described 
as orphan or promiscuous. Promiscuous nuclear receptors, have affinity for multiple ligands 
e.g.  members  of  the  NR1  receptor  subfamily  are  activated  by  a  number  of  xenobiotic 
compounds (reviewed in Noy 2007). At the opposite end of the spectrum, orphan nuclear 
receptors are those that do or did not have identified ligands; naturally occurring ligands 
have  now  been  identified  for  more  than  half  of  the  human  nuclear  receptors  that  were 
originally termed ‘orphan’ (reviewed in Willson et al. 2002). 
 
Though ligands have now been identified for many ‘orphan’ nuclear receptors, it has been 
shown  that  a  number  of  the  remaining  orphan  receptors  are  unlikely  to  utilize  ligand 
signaling. This can be for one of two reasons. Firstly, the ligand binding pocket (LBP) of the 
receptor  can  be  occupied  by  a  tightly bound  cofactor  which  is  more  likely  to  act  as  an 
essential structural component rather than a signaling ligand (e.g. HNF4). Secondly, the 
LBP of the protein can be blocked by its own bulky amino acid  side chains though the 
receptor  can  still  regulate  transcription  as  the  AF 2  helix  is  folded  in  an  active 
conformation (e.g. Nurr1) (Benoit et al. 2004). 
 
NR2F2 was, until very recently, an orphan steroid/thyroid hormone nuclear receptor that 
had been categorised as such on the basis of its sequence similarity to Ear 3 (v erbA related 
human receptor 3, also known as COUP TFI or NR2F1), Ear 2 (NR2F6) and the Drosophila 
gene,  Seven up  (Ladias  et  al.  1991;Nuclear  Receptors  Nomenclature  Committee.  1999). 
Though  retinoid  acids  have  now  been  found  to  upregulate  NR2F2  activity  in  vitro,  the 
ligand for such regulation in vivo is unclear as no ligand that is able to bind NR2F2 at 
physiological concentrations had been identified (Kruse et al. 2008). Due to this delay in 
ligand identification, little is known about NR2F2’s endogenous ligand binding properties 
whereas its other biological functions are well investigated.   
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4.4  NR2F2 function and expression 
In development, NR2F2 is expressed in a wide range of tissues in a pattern that overlaps 
with,  but  is  distinct  from  that  of  its  family  member  NR2F1  (COUP TFI)  (reviewed  in 
Pereira et al. 2000). Its expression was first identified in whole organs by Northern blot (e.g. 
Ladias  et  al.  1991;Lutz  et  al.  1994),  and  its  localization  within  organs  has  since  been 
visualised in skin, brain, spinal cord, salivary gland, oesophagus, thyroid, lung, stomach, 
intestine, liver, pancreas, kidney, bladder, prostate, testis and ovary primarily by RNA in 
situ hybridization (Lutz et al. 1994;Pereira et al. 1995;Qiu et al. 1994a;Zhang et al. 2002). In 
development, NR2F factors are initially expressed in all three germ layers though their 
expression becomes more restricted as development progresses. Their level of expression is 
also  modulated  throughout  organogenesis  –  NR2F  factors  are  downregulated  as  organs 
complete  their  development  (Pereira  et  al.  1995).  More  recently,  knockout  and  protein 
expression studies have elucidated many of the suggested roles of NR2F2 and it has been 
found to be commonly involved in organogenesis. 
  
NR2F2’s well described expression and requirement in organ development is of particular 
relevance  to  the  present  study,  as  it  is  known  to  be  expressed  in  the  inner  ear  in 
development (see section 4.5.2). Its expression is seen in the otic placode at E8.75 (Tang et 
al. 2005) and subsequently follows a pattern that is comparable to that seen in other organs 
where it has been shown to be essential for normal patterning (see below). Furthermore, 
NR2F2  is  known  to  be  involved  in  sensory  organ  development  as  its  expression  in  the 
dorsal retina is thought to mediate dorsal ventral patterning of this sensory epithelium by 
interaction with retinoic acid signalling (McCaffery et al. 1999) – a signalling pathway that 
is also  important for inner ear development (reviewed in Romand et al. 2006).  
 
The most vital developmental function of NR2F2 – in terms of embryonic viability – is in 
cardiovascular development (Pereira et al. 1999). This was demonstrated by Nr2f2 mutant 
mice which were generated by disruption of most of exon 1 and the entire exon 2 of the 
three exon Nr2f2 gene. Two thirds of heterozygous Nr2f2 mutant mice generated by this 
method die before weaning and homozygous mutant mice show embryonic lethality at E10 
(Pereira  et al.  1999).  This  Nr2f2-/-  phenotype  is  thought  to  be  due  to  haemorrhage  and 
oedema in the brain and heart, which is due to defects in angiogenesis, heart development 
and capillary plexus formation associated with a reduction in Ang1 expression (a gene that 
is  also  involved  in  heart  and  vascular  development)  (Pereira  et  al.  1999).  Homozygous 
mutation of Nr2f2 also caused malformation of the cardinal veins (Pereira et al. 1999). This 
is  consistent  with  observations  from  a  subsequent  study  in  which  NR2F2  expression  in 
endothelial cells was ablated, showing that NR2F2 is required for specification of venous 
identity  and  is  associated  with  suppression  of  Notch  signalling  (You  et al.  2005a).  Like 
retinoic acid signalling, Notch signalling is required for inner ear development (Fekete et al. 
2002).  
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Neurally,  NR2F2  is  required  for  normal  central  nervous  system  development.  It  is 
expressed  in  the  murine  telencephalon  and  tectum  at  day  10.5  p.c.  and  later  shows 
expression in parts of all three brain compartments (forebrain, midbrain and hindbrain) 
(Qiu et al. 1994a) as is the case in chick development (reviewed in Qiu et al. 1994b). In late 
mouse  development,  NR2F2  shows  highly  organised,  stripe like  expression  in  the 
cerebellum (Yamamoto et al. 1999). Functionally, it has been shown to be important for the 
control of neurogenesis (Park et al. 2003), for the guidance of migrating neurons (Tripodi et 
al. 2004) and, with NR2F1, is important in the acquisition of gliogenic competency (the 
ability  to  differentiate  into  glial  cells)  (Naka  et  al.  2008).  Caudally,  NR2F2  has  been 
implicated in the development of spinal motor neurons by studies in the developing chick 
which showed its transient expression in the ventral spinal cord in a region where motor 
neurons  are  known  to  develop  (Lutz  et  al.  1994).  Furthermore,  it  is  expressed  in  the 
substancia gelatinosa of the spinal cord in the chick and mouse, a region known to give rise 
to sensory neurons. However, by 18.5 days p.c. NR2F2 is expressed in the whole of the 
mouse spinal cord, suggesting a differing maintenance role following cord development (Qiu 
et al. 1994a;Qiu et al. 1994b). 
 
These observations are consistent with NR2F2’s developmental theme of organ patterning 
and cell fate determination, a theme that is continued in other systems.  In the stomach, 
NR2F2  has  been  shown  to  be  important  for  radial  and  anteroposterior  patterning  by  a 
conditional knockout that showed defects consistent with a model of Nr2f2 regulation by 
Hedgehog signalling in this system (Takamoto et al. 2005b). Conditional Nr2f2 knockout 
mice also demonstrated that NR2F2 expression in the developing foregut is required for 
normal diaphragmatic development: homozygous conditional knockout mice had reduced 
survival  compared  to  heterozygous  littermates  due  to  lung  hypoplasia  secondary  to 
herniation by the liver and stomach through the diaphragm. This defect is consistent with a 
human form of congenital diaphragmatic hernia which is likely to be due to heterozygous 
Nr2f2 deletion (You et al. 2005b). 
 
More peripherally, NR2F2 has been implicated in limb and skeletal muscle development. 
Chimera  analysis  and  conditional  knockout  of  Nr2f2  in  embryos  showed  that  NR2F2  is 
required for normal limb bud outgrowth and myogenesis in the developing mouse (Lee et al. 
2004).  Finally,  NR2F2  is  predicted  to  be  required  for  lung,  liver  and  pancreatic 
organogenesis (Kimura et al. 2002;Zhang et al. 2002). Its role in the latter organ has been 
investigated  by  conditional  Nr2f2  knockout  in  pancreatic  beta cells  which  resulted  in 
glucose  intolerance  in  heterozygotes  and  embryonic  lethality  of  unknown  mechanism  in 
homozygotes  (Bardoux  et al.  2005).  This  metabolic  involvement  is  continued  postnatally 
(see below). 
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The above roles of NR2F2 in organogenesis illustrate that this nuclear receptor is essential 
for the normal development of a number of systems via differing processes i.e. cell fate 
determination, regulation of cell cycle and  maintenance of cell survival, as supported by 
data  from  species  other  than  mouse  and  chicken,  namely  Drosophila,  Xenopus  and  C. 
elegans.  Furthermore,  NR2F2  has  been  suggested  to  play  a  role  in  mesenchymal 
endothelial/epithelial  signalling  (reviewed  in  Pereira  et  al.  2000).  These  functions  are 
consistent with a potential role for NR2F2 in inner ear development. 
 
Though NR2F2 expression displays its greatest variability in development and is reduced 
on completion of organogenesis (Pereira et al. 2000), it is still widely expressed postnatally 
(see below). In the inner ear, POU4F3 is also expressed postnatally (Erkman et al. 1996). If 
Nr2f2  is,  indeed,  upregulated  by  POU4F3,  then  its  known  postnatal  functions  may  aid 
understanding of POU4F3 dependent postnatal maintenance of hair cell survival (Vahava 
et al. 1998). 
 
NR2F2  is  expressed  in  all  postnatal  adult  human  organs  examined  (primarily  in 
mesenchymal cells) and particular note was taken of its expression in the lung, kidney, 
gastrointestinal tract, liver, spleen and in the reproductive and endocrine systems (Suzuki 
et al. 2000). This study did not investigate the postnatal expression of NR2F2 in human 
neuronal  tissues  though,  in  the  mouse  brain,  NR2F2  was  found  to  be  predominantly 
expressed in the middle part of the brain, amygdaloid nucleus and arachnoid membranes 
with lower expression seen in regions neighbouring the hypothalamus and in the choroid 
plexus (da Silva et al. 1995). Subsequent study of NR2F2 in the rat showed that it is also 
expressed  in  the  pituitary,  where  it  was  found  to  be  primarily  expressed  in  lactotropes 
(prolactin producing  cells)  in  both  the  cytoplasm  and  the  nucleus.  This  study  also 
demonstrated that postnatal NR2F2 expression can be dynamic as both its cytoplasmic and 
nuclear expression was upregulated in pregnancy (Raccurt et al. 2006). 
 
Outside  the  brain,  NR2F2  has  been  implicated  in  menstruation  (Sato  et  al.  2003), 
steroidogenesis in the ovary (Murayama et al. 2008) and embryo implantation (Takamoto et 
al.  2005a).  Its  expression  varies  with  the  Hedgehog  family  genes  Indian  Hedgehog  and 
Desert Hedgehog (Katayama et al. 2006), probably due to regulation by Sonic Hedgehog 
(Shh), which has been shown to directly upregulate transcription at a response element in 
the Nr2f2 promoter (Krishnan et al. 1997) though a direct interaction has not been shown. 
As Shh signalling has been shown to be important in inner ear patterning, its interaction 
with Nr2f2 provides a potential avenue by which NR2F2 might be involved in inner ear 
development and function (reviewed in Bok et al. 2007). 
 
NR2F2 is also thought to play a role in mesenchymal epithelial signalling e.g. by mediating 
epithelial  oestrogen  receptor  expression  (Kurihara  et  al.  2007)  and  this  may  suggest  a  
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potential  role  for  NR2F2  in  hearing  maintenance,  a  function  in  which  the  oestrogen 
receptor  has  been  implicated  (Hultcrantz  et  al.  2006).  Therefore,  NR2F2  appears  to  be 
involved  at  multiple  levels  of  complex  biochemical  pathways,  though  its  in  vivo  roles 
require further characterisation. Much work would be required to elucidate whether NR2F2 
forms part of such signalling cascades in the inner ear and what effect this may have on 
hearing. Furthermore, many of these potential interactions have been identified through 
knockout studies. Though this allows us to see the endpoint of NR2F2 manipulation, it does 
not establish the mechanism of such interactions that can be elucidated through molecular 
studies. 
4.5  Initial selection of Nr2f2 as a candidate gene for 
investigation 
4.5.1  Analysis of known function and expression of NR2F2 
As many candidate genes were identified by the subtractive hybridization screen (Table 3.1), 
the  known  functions  of  these  genes  were  investigated  to  identify  those  with  greater 
potential  relevance  to  hair  cell  maintenance  and  development.  An  efficient  method  of 
identifying  gene  functions  and  quality  of  evidence  was  required  and  a  rapid  method  of 
assessing  the  available  information  on  the  function  of  a  protein  is  to  examine  its  Gene 
Ontology (GO) units, which are available in the Ensembl genome browser (see section 3.3.2).  
 
NR2F2 had 15 such units assigned to it at the time of this analysis (reproduced in Table 
4.1). Ten were based on experimental evidence and five were computationally predicted. 
This  was  the  largest  number  of  verifiable  GO  units  identified  for  any  candidate  gene 
reflecting both the level of characterisation of this gene and the breadth of functions it has 
been reported to have.  
 
The  GO  units  in  Table  4.1  correctly  identified  that  NR2F2  is  a  nuclear  receptor 
transcription factor with primarily nuclear expression and that it is involved in metabolism 
and developmental patterning i.e. the main features of NR2F2 that were known at the time 
of  the  analysis.  Based  on  this,  Nr2f2  was  selected  for  further  investigation.  This  was 
because its ability to act as a transcriptional regulator in development and direct organ 
patterning (particularly in neuronal systems) could place it at a pivotal point in the genetic 
pathways  of  hair  cell  development  and  inner  ear  patterning  (e.g.  Tripodi  et  al.  2004). 
Furthermore, though an endogenous ligand has not been identified, the high conservation 
of its ligand binding domain (LBD) and the ability of retinoids to modulate its function 
suggest that a ligand does exist (Kruse et al. 2008), and this potential for ligand regulated 
activity makes NR2F2 a potential drug target (Kruse et al. 2008).  
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Table 4.1. Nr2f2 GO units.  
IDA, inferred from direct assay; IEA, inferred from electronic annotation; TAS, traceable author 
statement; IMP, inferred from mutant phenotype. 
  GO ID  GO Term  Evidence Code 
Cellular 
component 
GO:0005634  Nucleus  TAS 
GO:0003700  Transcription factor activity  IEA 
GO:0003706 
Ligand regulated  transcription  factor 
activity 
TAS 
GO:0003707  Steroid hormone receptor activity  IEA 
GO:0003714  Transcription corepressor activity  TAS 
GO:0008270  Zinc ion binding  IEA 
Molecular 
function 
GO:0046872   Metal ion binding  IEA 
GO:0001764  Neuronal migration  IDA, IEA 
GO:0006350  Transcription  IEA 
GO:0006357 
Regulation of transcription from Pol II 
promoter 
TAS 
GO:0006629  Lipid metabolism  TAS 
GO:0007165  Signal transduction  TAS 
GO:0009952  Anterior/posterior pattern formation  IEA, IMP 
GO:0009956  Radial pattern specification  IEA, IMP 
Biological 
process 
GO:0030900  Forebrain development  IDA, IEA 
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4.5.2  Reported expression pattern of NR2F2 in the inner ear  
Following initial selection of candidate genes for further study, their known expression and 
function in the inner ear was investigated in order to help judge their potential relevance to 
hair cell development and survival. The literature and online databases of gene expression 
were  searched  to  determine  candidate  gene  expression  patterns.  Nr2f2  was  the  only 
prioritised  gene  from  the  pool  described  (see  Table  3.2)  with  histologically  verified 
expression in the inner ear. Its expression pattern was described in a single report where 
RNA in situ hybridization and immunohistochemistry were used to identify Nr2f2 mRNA 
and protein in the developing mouse cochlea (Tang et al. 2005). 
 
Nr2f2 expression has been detected as early as E8.75 in the otic placode by RNA in situ 
hybridization  (Tang  et  al.  2005).  It  is  expressed  in  the  ventral anterior  domain  and  its 
expression extends posteriorly by E9.75 to include the ventral posterior domain. Between 
E10 to E13.5 it was only detected in the distal tip of the extending cochlear duct floor. This 
changes by E15.5, a stage at which hair cells are maturing at the junction of the greater 
and lesser epithelial ridges (see Figure 1.5d). At this stage NR2F2 expression spanned the 
greater and lesser epithelial ridges and supero medial wall of the apical cochlear duct; it is 
more  restricted  to  the  lesser  epithelial  ridge  in  the  middle  turn  and  only  shows  faint 
expression in the lesser epithelial ridge basally (Tang et al. 2005). This expression in the 
organ  of  Corti  is  reported  to  reduce  to  undetectable  levels  postnatally,  as  examined  by 
immunohistochemistry (Tang et al. 2005). 
 
Expression  of  NR2F2  in  the  developing  sensory  epithelium  at  E15.5  in  the  mouse  is 
consistent with a potential role in hair cell development. Furthermore, its expression is 
likely  to  overlap  with  that  of  POU4F3,  supporting  a  possible  regulatory  relationship  in 
developing hair cells and making Nr2f2 a suitable gene for further investigation. However, 
a  lack  of  postnatal  NR2F2  expression  would  mean  that  it  is  not  involved  in  hair  cell 
survival. Given that the NR2F2 inner ear expression pattern is described in a single report 
and that the inability to detect its expression postnatally may be due to antibody sensitivity, 
I investigated NR2F2 expression at late developmental and early postnatal stages. In order 
to do this, an affinity purified anti NR2F2 rabbit polyclonal antibody was obtained from a 
collaborator (Dr Michelè Studer (Tripodi et al. 2004)). This antibody was different to the 
antibody  previously  used  to  investigate  the  NR2F2  expression  pattern  in  the  inner  ear 
though it was raised against the same region in NR2F2 (the N terminal of the protein that 
is most divergent from NR2F1). The specificity of the antibody had previously been checked 
by  our  collaborators  by  western  blotting  and  immunohistochemistry  with  immunogen 
blocking and was found to recognise NR2F2 without cross reactivity to NR2F1, though the 
data for this analysis were not shown in the reporting paper (Tripodi et al. 2004).  
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4.6  Verification  of  NR2F2  expression  in  UB/OC-2 
cells 
4.6.1  Immunoblot to examine NR2F2 expression in cell lines 
Prior to investigating NR2F2 expression in the inner ear, its expression in UB/OC 2 cells 
was assessed in order to test antibody specificity and verify translation of Nr2f2 mRNA 
detected in UB/OC 2 cells by RT PCR (see Figure 3.1). Protein expression was first assessed 
by  western  immunoblotting  to  assess  antibody  specificity  by  determining  the  molecular 
weight of any protein recognised. This method has the additional benefit of being able to 
identify any alternative NR2F2 isoforms that might be present in this inner ear cell line 
(though only one Nr2f2 transcript is known in the mouse (Ensembl 2008b)). Non POU4F3 
expressing  undifferentiated  UB/OC 1  cells  (derived  from  E13  immortomouse  sensory 
epithelium like UB/OC 2 cells (Rivolta et al. 1998a)) were included for comparison. 
 
Undifferentiated UB/OC 1 and UB/OC 2 whole cell protein extract was electrophoresed on 
a denaturing 10% polyacrylamide gel prior to electroblotting onto a PVDF membrane and 
immunodetection. The results of this analysis are shown in Figure 4.2. A strong band of 
approximately 50kDa and a weaker band of approximately 55kDa is seen for both UB/OC 1 
and UB/OC 2 protein extract. The predicted size of the NR2F2 protein is 46kDa and two 
antibody catalogues  show the protein size to be reported as 46kDa (Abcam) and 50kDa 
(Abnova). In these catalogues, both antibodies were tested against human NR2F2 (from 
HepG2 and 293T cells) which is identical in its peptide sequence to mouse NR2F2. The 
difference in sizing between the 50kDa band in Figure 4.2, the Abnova data and the Abcam 
data  may  be  due  to  differential  post translational  modification  of  the  protein,  but  its 
molecular weight is within the sensitivity range of the western immunoblot protocol. 
 
The less dense band of approximately 55kDa in Figure 4.2 appears similar to an extra band 
found  in  the  Abcam  western  immunoblot  and,  though  the  immunogen  is  unknown,  it 
probably represents a modified protein isoform rather than a non specific target of the anti 
NR2F2  antibody  used  as  it  has  been  identified  by  two  different  antibodies  (our 
collaborator’s and Abcam’s). It is unlikely to be the product of an alternative transcript as 
only one Nr2f2 transcript is known (Ensembl 2008b) and it is unlikely to represent cross 
reactivity to NR2F1 as any such band would be expected to be of slightly lower molecular 
weight (45kDa) (Raccurt et al. 2006). Furthermore, the antibody used was raised against a 
divergent NR2F region and has previously been reported not to recognise NR2F1 (Tripodi et 
al. 2004). As this experiment was carried out to determine antibody specificity rather than 
relative expression levels between cell types, equality of protein loading between lanes was 
not checked by equalisation with a housekeeping gene. Therefore, though the density of the 
55kDa  band  appears  different  in  UB/OC 1  and  UB/OC 2  cells,  it  is  not  possible  to 
determine if the antigen is differentially expressed between these two cell types.  
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Figure 4.2. Expression of NR2F2 in UB/OC-1 and UB/OC-2 cells. 
NR2F2 is detectable in UB/OC1 and UB/OC-2 cells as a strong band of 50kDa and a weaker 
band of 55kDa (arrows). According to two reports, the molecular weight of NR2F2 is 46kDa 
(Abcam 2008) or 50kDa (Abnova 2008b). A difference of 4kDa is not beyond the limits of error 
in such an experiment and this immunoblot is therefore consistent with both of these reports. 
 
 
This western immunoblot therefore shows that the antibody used is able to detect NR2F2 
which  is  expressed  in  UB/OC 1  and  UB/OC 2  cells.  Its  expression  in  UB/OC 1  cells  is 
consistent with its reported inner ear expression pattern where NR2F2 is expressed in the 
developing  sensory  epithelium  from  which  these  cells  are  derived  prior  to  the  onset  of 
POU4F3  expression  (Tang  et  al.  2005),  demonstrating  that  POU4F3  is  unlikely  to  be 
required for its expression. The  latter conclusion  is not  surprising given that NR2F2 is 
known  to  be  expressed  in  many  non POU4F3  expressing  cells  (e.g.  Tripodi  et al.  2004). 
These possibilities, coupled with  the reported work demonstrating the  sensitivity of  the 
antibody  (Tripodi  et  al.  2004)  demonstrate  that  it  specifically  recognises  NR2F2  and  is 
therefore suitable for the investigation of NR2F2 expression in the inner ear. 
4.6.2  Immunohistochemistry to detect NR2F2 in UB/OC-2 cells 
Having  shown  the  specificity  of  the  antibody  obtained  for  NR2F2,  it  was  used  for 
immunofluorescence immunohistochemistry in UB/OC 2 cells. This was done to identify if 
NR2F2 is expressed in all cells in the monolayer and whether its subcellular localization in 
these  cells  is  nuclear,  as  is  expected  –  it  has  only  been  found  to  be  expressed 
cytoplasmically in the rat pituitary gland (Raccurt et al. 2006). Though the suitability of the 
antibody for immunofluorescence microscopy had been previously demonstrated (Tripodi et 
al. 2004),  this experiment provided the opportunity to optimise the immunofluorescence 
protocol for later use in the study of rodent inner ear tissue which is harder to obtain and 
prepare. 
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Figure 4.3. NR2F2 expression in undifferentiated (proliferating) UB/OC-2 cells. 
NR2F2 is expressed in cell nuclei visualised by immunofluorescence microscopy (green, ii.b & 
ii.d). Anti-rabbit IgG alone (i.b) does not show any signal showing that staining in ii.b is specific 
to the anti-NR2F2 antibody. i.a & ii.a) DAPI, a fluorescent stain that binds to DNA and therefore 
labels cell nuclei; i.b) Alexa 488-conjugated anti-rabbit IgG; ii.b) anti-NR2F2 (primary antibody) 
and Alexa 488-conjugated anti-rabbit IgG (secondary antibody); i.c & ii.c) Alexa 633-conjugated 
Phalloidin, a toxin that binds to filamentous actin; i.d & ii.d) Merge. Images were taken using 
identical settings through a 20x objective. Arrowhead, mitosing or apoptosing cell. 
 
 
UB/OC 2 cells were grown to 80% confluence on glass coverslips, fixed and immunolabelled 
prior to visualisation by fluorescence microscopy with a Zeiss LSM 510 Meta microscope 
(see  Figure  4.3.ii).  The  non specific  (background)  labelling  pattern  of  the  secondary 
antibody used (Alexa 488 conjugated anti rabbit IgG) was also ascertained in these cells in 
order to verify its specificity and the efficacy of the blocking solution used by omission of 
anti NR2F2 antibody from these slides (Figure 4.3.i). 
 
Figure 4.3 shows that fluorescent signal is detected for NR2F2 in a pattern that overlaps 
with  that  of  DAPI  and  not  phalloidin  in  all  but  one  cell  (Figure  4.3.arrowhead).  These 
results  indicate  that  NR2F2’s  subcellular  localization  in  undifferentiated  (proliferating) 
UB/OC 2 cells is nuclear and that NR2F2 is expressed uniformly in UB/OC 2 cells. They 
also  confirm  that  the  antibody  used  is  suitable  for  immunohistochemistry  and  that  the 
antibody concentration and blocking solution used are appropriate for this application. I 
therefore proceeded to use the anti NR2F2 antibody at the dilution described to investigate 
NR2F2 expression in the rodent inner ear. 
 
 
 
 
 
 
i)  ii)  
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4.7  Immunohistochemistry  for  NR2F2  in  rat  and 
mouse inner ear tissue 
As previously described (see section 4.5.2), there is only one report of NR2F2 expression in 
the  inner  ear  which  showed  expression  in  the  developing  mouse  and  did  not  identify 
postnatal  NR2F2  expression  in  the  organ  of  Corti  (Tang  et  al.  2005).  I  therefore  re 
examined  its  expression  at  late  developmental  and  early  postnatal  stages  in  the  rat 
(sections 4.7.1 and 4.7.2) and mouse (section 4.7.3). Particular attention was paid to NR2F2 
expression  in  relation  to  POU4F3  expression  in  order  to  identify  any  correlation  in  the 
expression of the two genes that might indicate whether POU4F3 could modulate Nr2f2 
activation in the inner ear. However, the known expression of NR2F2 in cells that do not 
express  POU4F3  (e.g.  Figure  4.2)  suggests  that  such  a  modulation  may  be  subtle  as 
POU4F3 is unlikely to be required for Nr2f2 expression.  
4.7.1  NR2F2 expression in the embryonic rat inner ear 
POU4F3  is  known  to  be  expressed  in  the  inner  ear  at  E18.5  in  the  rat  with  stronger 
expression  in  the  base  than  in  the  apex  (Erkman  et  al.  1996).  Therefore,  this  age  was 
chosen for the investigation of embryonic NR2F2 expression as it provides a gradient of 
POU4F3 expression to which NR2F2 expression could be compared. 
 
Cryosections  were  prepared  from  E18  rat  cochleas  and  immunofluorescence 
immunohistochemistry was carried out with the antibody described (see section 4.6). Figure 
4.4 shows that NR2F2 expression was seen in many cell types in the developing cochlea. 
Though it was diffusely expressed, strong expression was seen in the cells of the cochlear 
duct. However, this expression was not uniform  throughout the turns of the developing 
cochlea.  In  the  apical  and  middle  turns,  expression  is  seen  in  the  supero medial  wall, 
greater epithelial ridge (GER) and lesser epithelial ridge (LER). The supero medial wall 
gives rise to the cells of Reissner’s membrane whereas the GER and LER both contribute to 
hair cell development and other cell types of the sensory epithelium (see section 1.3.1). In 
contrast to widespread NR2F2 expression in the apical and middle turns, basal expression 
was primarily restricted to the LER.  
 
This expression pattern is consistent with that of the developing mouse (Tang et al. 2005). 
Expression of NR2F2 in the basal E18 cochlea (Figure 4.4a, j m) is likely to overlap with 
that of POU4F3 (see Figure 1.9a) (Erkman et al. 1996),  supporting the hypothesis  that 
modulation of Nr2f2 expression by POU4F3 in hair cells may occur and be relevant to hair 
cell development. Colocalisation of the two proteins would provide stronger evidence for 
this; however, I was not able to establish this due to the lack of a suitable anti POU4F3 
antibody. Furthermore, apical cochlear duct NR2F2 expression (Figure 4.4a e) and NR2F2 
expression  outside  the  developing  sensory  epithelium  suggests  a  separate  (POU4F3 
independent) role for NR2F2 in the developing rat cochlea.  
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Figure 4.4. NR2F2 expression in the E18 rat cochlea. 
a) NR2F2  labelling  in  E18 rat cochlea is strongest in the  apical cochlear  duct in the  lesser 
epithelial ridge (LER), greater epithelial ridge (GER) and supero-medial wall (S-MW), where 
NR2F2 labelling (green) overlaps with the nuclear marker, DAPI (blue) consistent with nuclear 
expression  (b-e).  Phalloidin,  a  marker  of  filamentous  actin,  is  labelled  in  red.  In  the  middle 
cochlear turn (f-i), NR2F2 labelling is similar to that in the apex whereas in the basal turn (j-m), it 
is restricted to the LER (arrowhead).  
 
4.7.2  NR2F2 expression in the postnatal rat inner ear 
NR2F2 expression was further characterised by looking at its expression in postnatal rat 
inner ears. POU4F3 expression has been reported to be maintained into adulthood in rats 
(Erkman  et  al.  1996)  and,  therefore,  any  regulatory  relationship  between  POU4F3  and 
Nr2f2  may  be  relevant  beyond  the gestational  period.  P0,  P4  and  P8  rat  cochleas  were 
prepared  similarly  to  E18  tissue  and  examined.  The  same  antibody  was  used  to 
immunolabel this tissue as was used for embryonic rat tissue.  
 
This analysis, summarised in Figure 4.5, showed that NR2F2 is expressed postnatally in 
many  cell  types  of  the  postnatal  rat  cochlea  up  to  and  including  P8  (the  latest  age 
examined) with consistent expression in the Hensen cell nuclei. At P0 and P4, NR2F2 is 
expressed in the nuclei of all cells examined including the POU4F3 expressing hair cells 
(Erkman et al. 1996). This is also true of the P8 apical cochlea though, in the basal turn at 
P8, there is a shift from nuclear to cytoplasmic NR2F2 expression in hair cells.  
 
This expression pattern suggests that NR2F2 continues to function in the organ of Corti 
postnatally.  As  it  is  expressed  in  hair  cells,  which  are  known  to  express  POU4F3,  the 
suggested  modulation  of  Nr2f2  expression  by  POU4F3  could  continue  beyond  gestation. 
Also, the cytoplasmic expression of NR2F2 in the basal P8 rat cochlear hair cells (Figure 
4.5) suggests that NR2F2 may be subject to regulation at the protein level in hair cells. 
Cytoplasmic  NR2F2  expression  has  only  been  reported  in  the  rat  pituitary,  though  the 
significance  and  mechanism  of  this  change  in  subcellular  localization  has  not  yet  been  
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investigated (Raccurt et al. 2006). NR2F2 expression would have to be investigated from P8 
to adulthood to identify the duration of its expression in rat hair cells and, therefore, its 
potential regulation by POU4F3. Such experiments would clarify the timing of the nuclear 
to cytoplasmic transition in NR2F2 expression, and whether this transition is dynamic or 
transient.  
 
 
 
Figure 4.5. NR2F2 expression in the postnatal rat cochlea.  
The basal and apical expression profiles of NR2F2 in the organ of Corti were examined at P0, 
P4 and P8 with two cochleas examined at each age. Representative images of this analysis are 
shown. Green, anti-NR2F2 IgG; red, phalloidin. NR2F2 is seen to be expressed in the nuclei of 
both inner and outer hair cells which are identified by Phalloidin labelling of their stereocilia. 
Nuclear NR2F2 expression is seen in all areas examined except for the P8 basal region where 
NR2F2 appears to be expressed in the hair cell cytoplasm (arrowhead). Many cells that line the 
scala media maintain NR2F2 expression, particularly the Hensen cells (HSC). RM, Reissner’s 
membrane; IHC, inner hair cell; OHC, outer hair cell; SC, support cell; BM, basilar membrane.  
 
 
4.7.3  NR2F2 expression in the postnatal mouse inner ear 
The identified postnatal expression of NR2F2 in the rat cochlea, coupled with its known 
postnatal  functions  in  other  organs  (see  section  4.4),  give  NR2F2  the  potential  to  be 
involved in maintenance functions in the postnatal inner ear. However, it has previously 
been reported that NR2F2 expression reduces to undetectable levels in the postnatal mouse 
organ of Corti (Tang et al. 2005). Therefore, NR2F2 expression in the postnatal mouse inner 
ear was examined using the same antibody that was used in the postnatal rat to investigate 
whether the observed difference in NR2F2 expression was due to variation between species, 
different  antibody/protocol  sensitivity  or  dynamic  variation  in  expression.  P0  mouse 
cochleas  were  dissected  and  fixed  as  for  previous  immunofluorescence  experiments. 
HSC  
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However, the organ of Corti and crista ampullaris were immunolabelled as whole mount 
preparations instead of cryosections. In the organ of Corti, NR2F2 expression was found in 
the apex (Figure 4.6) where it was most clearly seen in the Hensen cell nuclei. In contrast 
to  the  organ  of  Corti,  NR2F2  expression  was  seen  in  hair  cells  in  the  P0  mouse  crista 
ampullaris as well as other cells in the ampulla  (Figure 4.7). This is the  first report of 
NR2F2 expression in vestibular hair cells. 
 
 
Figure 4.6. NR2F2 expression in the postnatal mouse cochlear apex. 
i) An optical section of the whole-mount apical P0 mouse organ of Corti at the level of the hair 
cell nuclei. NR2F2 was very weakly expressed in the hair cell nuclei, but clearly expressed in 
the adjacent Hensen cell nuclei in the two animals examined. a) Phalloidin, b) anti-NR2F2 rabbit 
IgG, c) DAPI, d) Merge. ii) Orthogonal view. IHC, inner hair cell; OHC, outer hair cell. Red, 
phalloidin; green, anti-NR2F2 rabbit IgG; blue, DAPI. NB, hair bundles are flattened due to the 
coverslip placed on the tissue. 
i) 
ii)  
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Figure 4.7. NR2F2 expression in the P0 mouse crista. 
Widespread NR2F2 expression is seen in the P0 mouse crista. Notably, it is expressed in the 
sensory hair cells in this sensory epithelium. a) DAPI, b) anti-NR2F2 rabbit IgG, c) Phalloidin, d) 
Merge. 
 
 
These  results  contrast  both  with  those  previously  reported  in  the  mouse  organ  of  Corti 
(Tang  et al.  2005)  and  those  found  in  the postnatal  rat  inner  ear  (see  Figure  4.5).  The 
discernible differences between this study and the previous report of NR2F2 expression in 
the  postnatal  mouse  inner  ear  are  the  mouse  strain  and  the  antibody  used.  Though 
different  mouse  strains  show  variation  in  hearing  maintenance  –  there  is  differing 
susceptibility to ARHL in commonly used mouse strains (Friedman et al. 2007;Spongr et al. 
1997) – there is no reported difference in the rate of organ of Corti development between 
mouse strains. Therefore, the differences between the antibodies used are most likely to 
explain the difference in detection of NR2F2 expression in the postnatal mouse organ of 
Corti. However, NR2F2 expression may be dynamically regulated or variable at this stage 
and more animals (from different litters) would have to be examined to clarify the observed 
NR2F2 expression pattern in the early postnatal mouse inner ear. 
 
The differences between NR2F2 expression in the mouse and rat organ of Corti could be 
due  to  differences  in  antibody  sensitivity,  interspecies  differences  in  organ  of  Corti  
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development or true differences in NR2F2 expression between the two species. Though rat 
and mouse NR2F2 differ by a single residue that is within the region to which the antibody 
was raised, this is unlikely to explain the difference in rat and mouse expression patterns 
(Tang  et al.  2005).  This  is  because  labelling  of  NR2F2  expression  in  the  developing  rat 
cochlea matches that previously reported in the mouse. Furthermore, the antibody used 
recognises a single band of identical molecular weight to that found in UB/OC 2 cells when 
used in western blot analysis of a neuronal cell line which is a hybrid of rat and mouse cells, 
ND7 (data not shown). 
 
Rat and mouse gestation periods vary (approximately 21 days for mice and up to 24 days 
for rats), and the inner ears of mice and rats consequently mature at different rates. The 
difference seen between the mice and rats investigated may therefore be explicable by this 
developmental  difference  and  NR2F2  expression  would  have  to  be  investigated  with 
markers of hair cell development (e.g. prestin) to account for these differences (Bryant et al. 
2005). Also, investigations of rat inner ears at later stages than those reported may help 
explain if the differences seen are due to slower rat development. Such analyses would help 
identify  whether  the  differences  seen  are  due  to  a  true  difference  in  the  expression  of 
NR2F2 in the developmental organ of Corti between mice and rats. 
 
In  summary,  it  appears  that  NR2F2  is  expressed  in  developing  hair  cells  and  that  its 
expression  in  hair  cell  nuclei  falls  as  hair  cells  mature  from  base  to  apex  in  the  late 
embryonic  (mouse)  or  early  postnatal  (rat)  organ  of  Corti.  NR2F2  expression  therefore 
declines despite reported rises and maintenance of POU4F3 expression in hair cells in the 
same period (Hertzano et al. 2007;Ryan 1997). Furthermore, NR2F2 expression in the hair 
cells of the crista ampullaris (which also express POU4F3) appears to be maintained to 
later stages than in cochlear hair cells (Xiang et al. 1998). It is, therefore, possible that 
POU4F3 influences activation of the Nr2f2 promoter in developing hair cells (when their 
expression overlaps), as suggested by the subtractive hybridization screen. POU4F3 may be 
one of a number of transcription factors acting at the Nr2f2 promoter in developing hair 
cells  whose  combined  action  and  interaction  determine  the  rate  of  Nr2f2  transcription. 
Furthermore,  the  embryonic  NR2F2  expression  pattern  seen  combined  with  the  known 
functions  of  NR2F2  (see  section  4.4)  suggest  a  potential  role  for  NR2F2  in  cochlear 
organogenesis. Therefore, Nr2f2 was further pursued as a candidate target of POU4F3 and 
the effect of POU4F3 on the Nr2f2 promoter was investigated in order to identify whether 
POU4F3  has  a  direct  effect  on  Nr2f2  transcription  and  in  order  to  verify that  Nr2f2  is 
upregulated by POU4F3, as suggested by the subtractive hybridization results. 
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4.8  Does  POU4F3  directly  activate  the  Nr2f2 
promoter? 
Several  Nr2f2  regulatory  elements  have  been  identified,  ranging  from  distal  enhancer 
regions  to  proximal  transcription  factor  binding  sites.  Of  these  sites,  a  number  are 
responsive to members of signalling cascades with which NR2F2 has been shown to interact 
i.e.  the  retinoic  acid,  notch  and  hedgehog  pathways  (see  sections  4.4).  The  schematic 
diagram in Figure 4.8 shows the regions and factors that have been shown to affect Nr2f2 
regulation. Of these, four have been shown to interact with the Nr2f2 promoter – Notch 
(Diez et al. 2007), retinoic acid (RA) (Qiu et al. 1996), sonic hedgehog (Shh) (Krishnan et al. 
1997) and the E26 transformation specific family member, Ets 1 (Petit et al. 2004) – though 
the interaction of POU4F3 with this promoter has not previously been assessed.  
 
As the subtractive hybridization screen suggests that Nr2f2 is upregulated by POU4F3, the 
mechanism  of  this  potential  interaction  was  investigated  to  identify  if  POU4F3  might 
produce  an  increase  in  Nr2f2  expression  by  a  direct  or  indirect  mechanism.  A  direct 
interaction would require POU4F3 binding to transcription factor binding sites in the Nr2f2 
promoter  and  mediating  an  increase  in  the  rate  of  Nr2f2  transcription.  An  indirect 
mechanism  would  require  POU4F3  to  regulate  a  different  target  gene  that  would 
subsequently interact directly with the Nr2f2  gene promoter.  
 
 
 
 
 
 
Figure 4.8. Schematic representation of Nr2f2 regulation. 
Schematic of the factors that influence human and mouse Nr2f2 transcription and the sites at 
which they act. RA, retinoic acid; pink box, 571bp liver enhancer region at -66kb to the Nr2f2 
transcriptional start site (TSS); blue  box, Shh response element (TACATAATGCGCCG) at -
1661bp to -1648bp which confers upregulation by Shh on the Nr2f2 promoter; yellow boxes, two 
inverted Ets protein consensus sequences (TTCC) which confer upregulation by Ets-1; purple 
box, Nr2f2 5’ UTR; orange box, Nr2f2 exon 1. Inhibition of the MAP kinase pathway represses 
NR2F2  expression  (and  vice-versa)  whilst  treatment  with  EGF  or  TGFα  increases  NR2F2 
expression, though the sites of these regulatory actions are unknown (not shown) (Baroukh et al. 
2005;Diez et al. 2007;Krishnan et al. 1997;More et al. 2003;Petit et al. 2004;Qiu et al. 1996). 
RA(9cis) upregulatory region 
 
ATG 
 
   66kb        10kb                                             1.5kb                           +1bp        +264bp 
Notch signalling downregulatory region  
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4.8.1  EMSA Oligonucleotide Design 
In order to identify whether POU4F3’s putative activation of the Nr2f2 promoter is direct, 
possible POU4F3 binding sites in this promoter would need to be identified and POU4F3’s 
ability to bind these sites and activate transcription would have to be tested. Bioinformatic 
software  was  therefore  used  to  predict  potential  POU4F3  binding  sites  in  the  Nr2f2 
5’flanking region.  
 
Nr2f2 promoter prediction 
Prior  to  using  software  to  identify  potential  POU4F3  binding  sites,  the  Nr2f2  gene 
promoter  region  first  had  to  be  predicted.  The  Genomatix  Gene2Promoter  software  was 
selected for this purpose as explained in section 3.5.1. This analysis was carried out using 
the mouse database as promoter reporter constructs that I intended to use in subsequent 
experiments were cloned from this species (see section 4.9 for these experiments).  
 
The  software  revealed  six  putative  promoters  for  Nr2f2.  All  six  of  these  promoters 
corresponded to one or more than one transcript whose 5’ region had been fully sequenced 
i.e.  oligo capping  had  been  used  in  order  to  clone  the  5’  end  of  transcript,  thereby 
identifying the transcriptional start site and improving the promoter prediction. I selected 
the  most  appropriate  Nr2f2  promoter  by  identifying  which  Genomatix  transcript  best 
corresponded to the Nr2f2 transcript identified by the BLAST analysis (Figure 4.9a). The 
transcript identified in the BLAST analysis comprised three exons and this gene structure 
is supported by data in the UniProtKB/Swiss Prot or RefSeq databases (Ensembl 2009). 
Figure  4.9b  shows  that  two  promoters  (GXP_158557  and  GXP_158616)  correspond  to  a 
three exon transcript, however, only the transcript corresponding to GXP_158616 has full 5’ 
region sequencing (i.e. its transcriptional start site had been verified experimentally). This 
promoter was therefore selected as the most appropriate promoter for further analysis (see 
section 3.5.1 for more detail on promoter selection criteria).  
 
Prediction of POU4F3 binding sites in the predicted Nr2f2 promoter 
The  selected  predicted  Nr2f2  promoter  was  analysed  using  the  MatInspector  and 
ModelInspector  programs  to  identify  putative  POU4F3  binding  sites  and  modules 
respectively. As the DNA recognition of POU proteins has been shown to be similar (Rhee et 
al. 1998), all predicted binding sites of the ‘Brn’ sub class of POU domain factors in the 
Genomatix  software  were  considered  for  further  analysis  (see  Andersen  et  al.  2001). 
Putative binding sites with the highest stringency predictions, i.e. the greatest similarity to 
known binding sites, were selected for in vitro assay of POU4F3’s ability to bind them by 
electrophoretic mobility shift assay (EMSA).   
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Fourteen POU family transcription factor binding sites were predicted within the Nr2f2 
promoter at the lowest stringency level (Figure 4.9c.0.00). As the stringency is increased, 
only the transcription factor binding sites that more closely matched their corresponding 
matrices  are  displayed.  At  the  highest  level  of  stringency  only  four  POU family 
transcription factor binding sites remain (Figure 4.9c.0.05). The ModelInspector analysis 
revealed  that  the  labelled  V$BRN2  family  site  (i.e.  POU3  /  Brn 2)  is  contained  in  an 
OCT1 SORY module (Figure 4.9c,V$BRN2), thereby showing that its context as well as its 
sequence is likely to be suitable for regulation by a POU family member. This site was 
therefore  prioritised  for  analysis  and  an  oligonucleotide  was  designed  to  investigate 
POU4F3 binding to its sequence by EMSA (Figure 4.9 and Table 4.2, NR2F2BS2). Of the 
remaining sites at this stringency level, the most 3’ was selected for analysis due to its 
proximity  to  the  transcriptional  start  sites  (red  arrows)  and  the  presence  of  lower 
stringency  POU family  binding  sites  in  the  same  region.  The  EMSA  oligonucleotide 
designed to investigate  this  POU6 (BRN 5) site  was named NR2F2BS1 (Figure 4.9 and 
Table  4.2,  NR2F2BS1).  These  putative  binding  sites  were  then  used  to  design 
oligonucleotides for EMSA analysis (Table 4.2). 
 
Table 4.2. Oligonucleotides for Nr2f2 EMSA analysis. 
EMSA oligonucleotides (NR2F2BS1 and NR2F2BS2) were designed and synthesised for EMSA 
analysis  of  POU4F3  binding  to  two  sites  in  the  Nr2f2  promoter  that  had  been  identified  by 
MatInspector and ModelInspector analyses (Figure 4.9). Bases were included both 5’ and 3’ to 
NR2F2BS1 (underlined) in order to ensure that POU4F3 binding would not be affected by the 
ends of the oligonucleotide. NR2F2BS2 was designed to encompass the OCT1 portion of the 
OCT1-SORY promoter module that had been predicted by the MatInspector program. The part 
of the high-stringency POU3 site identified in MatInspector that overlaps this promoter module is 
represented in bold type. The POU4F3 and AP4 consensus sequences used in subsequent 
EMSA analyses are also shown. 
Name  Sequence  Length 
Matrix 
Similarity 
NR2F2BS1  CTTTTTAGCATATTTGATCACTTTGATT  28  0.836 
NR2F2BS2  GGAATTTATTTTAATTGCATCATAACAATGAGGTGA  36  N/A 
POU4F3 consensus 1  CACGCATAATTAATCGC  17  N/A 
AP4 consensus  CTAGCCCAGCTGTGGCAGCCC  21  N/A 
 
 
 
 
Figure 4.9. Identification of putative POU4F3 binding sites in the Nr2f2 promoter. 
(Legend on page 146) 
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4.8.2  In vitro translated POU4F3 is able to bind to two sites in the Nr2f2 
promoter  
In the EMSA, the ability of POU4F3 to bind the two oligonucleotides designed against two 
sites  in  a  predicted  Nr2f2  promoter  was  tested.  As  binding  to  target  gene  promoters 
appears to be a prerequisite step for their activation by POU4F3 (Sud et al. 2005), binding 
of  NR2F2BS1  and  NR2F2BS2  by  POU4F3  would  support  the  hypothesis  that  POU4F3 
directly activates the Nr2f2 promoter. 
 
1ng  of  radiolabelled  NR2F2BS1  (Figure  4.10a)  or  NR2F2BS2  (Figure  4.10b)  was  either 
incubated  alone  or  with  5 l  in  vitro  translated  protein  (POU4F3  or  luciferase)  at  room 
temperature for 30 minutes. The proteins had been in vitro translated using the TNT®T7 
Coupled Reticulocyte Lysate System (Promega). Samples were then electrophoresed on a 
4% non denaturing polyacrylamide gel at 200 volts at 4ºC for two hours. The gel was dried 
and  autoradiographed  at   80ºC  for  varying  exposures  (typically  16 24  hours).  Protein 
binding  is  identifiable  as  shifted  bands  (bandshifts)  in  protein containing  sample  lanes. 
This is due to the protein oligonucleotide complex having higher molecular weight than 
oligonucleotide  alone  and  therefore  having  slowed  migration  through  the  gel  on 
electrophoresis.  
 
Figure 4.10 shows binding of in vitro translated mouse POU4F3 protein to the putative 
Nr2f2  promoter  binding  sites  (NR2F2BS1  and  NR2F2BS2).  Bandshifts  present  in  both 
protein containing  lanes  were  due  to  non specific  oligonucleotide  binding  of  translated 
proteins or proteins present in the reticulocyte lysate. However, for both putative binding 
sites,  a  bandshift  was  identified  in  the  in  vitro  translated  POU4F3  lane  that  was  not 
present  in  the  control  lanes  (arrowheads,  Figure  4.10).  This  demonstrates  that  in  vitro 
translated POU4F3 is able to bind to both of the sites identified from the Nr2f2 promoter. 
Though these results suggest that POU4F3 is capable of binding the oligonucleotides, the 
assay does not show whether the binding is sequence specific and the in vitro translated 
protein  (that  was  produced  using  a  rabbit  reticulocyte  lysate  system)  may  demonstrate 
different  binding  from  POU4F3  translated  in  UB/OC 2  cells  due  to  different  post 
translational  modifications.  Therefore,  the  sequence specificity  of  this  interaction  was 
further investigated using protein that had been extracted from UB/OC 2 cells.  
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Figure 4.10. Binding of in vitro translated POU4F3 to transcription factor binding sites. 
EMSAs were carried out using [γ-32P]ATP labelled DNA oligonucleotides which corresponded 
to  two  predicted  POU-family  binding  sites  in  the  Nr2f2  gene  promoter:  NR2F2BS1  (a)  and 
NR2F2BS2  (b).  The  binding  sites  were  incubated  without  protein,  with  in  vitro  translated 
POU4F3 or with in vitro translated luciferase protein. Arrowheads indicate a POU4F3-specific 
binding pattern. 
a) b)
POU4F3
No protein
Luciferase
POU4F3
No protein
Luciferase 
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4.8.3  POU4F3  protein  from  UB/OC-2  cell  nuclear  protein  extract 
demonstrates sequence-specific binding to NR2F2BS1 & 2 
Nuclear  protein  extract  prepared  from  UB/OC 2  cells  was  used  to  determine  whether 
POU4F3 binding to NR2F2BS1 & 2 is sequence specific. UB/OC 2 cells were chosen as they 
express  POU4F3  but  do  not  express  POU4F1  or  POU4F2  (Rivolta  et  al.  1998a). 
Furthermore,  the  DNA binding  properties  of  POU4F3  extracted  from  these  cells  should 
better reflect its physiological function than in vitro translated POU4F3 as it is more likely 
to have appropriate post translational modifications that may be required for physiological 
DNA binding. As the nuclear protein extract contains proteins other than POU4F3, some of 
which will bind DNA, POU4F3 specific bandshifts must be identified amongst bandshifts 
produced by other proteins. Two methods are commonly used to identify protein specific 
bandshifts:  supershift  analysis  and  competition  analysis.  As  no  suitable  anti POU4F3 
antibody is available for supershift analysis, competition analysis was the most appropriate 
of the available methods for this analysis.  Therefore, a competition analysis was conducted 
in order to identify if any of the bandshifts that  are produced by UB/OC 2 cell nuclear 
extract are due to POU4F3.  
 
In this analysis, an increasing amount of a non radiolabelled oligonucleotide that is known 
to be bound by POU4F3 (cold POU4F3 consensus, Figure 4.11a&b) was added to EMSA 
reactions.  As  the  unlabelled  DNA  will  compete  with  the  radiolabelled  putative  Nr2f2 
promoter  binding  sites  for  POU4F3  binding,  an  excess  of  non radiolabelled  consensus 
oligonucleotide  will  ensure  that  POU4F3  will  not  bind  enough  radiolabelled  DNA  to  be 
visible on autoradiography. Therefore, bandshifts produced by POU4F3 are abolished by 
sufficient  non radiolabelled  consensus  oligonucleotide.  This  also  abolishes  bandshifts 
produced by non sequence specific DNA binding proteins; therefore, a negative control was 
conducted for the competition analysis to identify sequence specificity of POU4F3 binding. 
For this control, a 1000 fold excess of unlabelled consensus oligonucleotide for a different 
transcription factor (AP4) was added to a separate EMSA reaction. Bandshifts caused by 
non specific DNA binding proteins become invisible to autoradiography in this condition as 
an  excess  of  non radiolabelled  AP4  consensus  sequence  displaces  the  radiolabelled 
oligonucleotides from the non specific DNA binding protein. POU4F3, however, does not 
bind  to  the  AP4  consensus  oligonucleotide  (as  shown  by  previous  experiments  in  our 
laboratory), resulting in a persistent bandshift (cold AP4 consensus lane, Figure 4.11).   
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Figure 4.11. Binding of POU4F3 to Nr2f2 promoter binding sites. 
EMSAs were carried out using [γ-32P]ATP labelled NR2F2BS1 and NR2F2BS2. a) NR2F2BS1 
was incubated with or without UB/OC-2 cell nuclear extract and with varying amounts of non-
radiolabelled POU4F3 or AP4 consensus binding site. The same assay was conducted for the 
second  putative  binding  site,  NR2F2BS2  (b).  For  both  oligonucleotides,  POU4F3-specific 
banding  patterns  (i.e.  bandshifts  that  are  competed  for  by  specific  POU4F3  consensus 
sequence but not by non-specific AP4 consensus sequence) were identified (B1 in both cases) 
along with non-specific bands and complexes. B, bandshift; C, complex. 
a)  b) 
C1 
C2 
B1 
C1 
B1 
B2 
B3  
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On  autoradiography,  bandshifts  were  seen  for  NR2F2BS1  with  UB/OC 2  cell  nuclear 
protein extract (Figure 4.11a). The banding pattern shows a slow migrating band (Figure 
4.11a.B1)  and  two  complexes  of  faster  migration  (Figure  4.11a.C1&C2).  On  competition 
with unlabelled POU4F3 consensus oligonucleotide, B1 was abolished by 100 fold excess of 
unlabelled  POU4F3  consensus  sequence  and  a  1000 fold  excess  of  this  oligonucleotide 
attenuated C1 and C2 density (cold POU4F3 consensus, Figure 4.11a). In competition with 
1000 fold unlabelled AP4 consensus sequence (cold AP4 consensus, Figure 4.11a), B1, C1 
and C2 are restored. This pattern shows that the B1 bandshift is specifically produced by 
POU4F3 as it is only eliminated by specific competition. It also shows that C1 and C2 are 
likely  to  be  produced  by  POU4F3  binding,  however  their  competition  by  unlabelled 
POU4F3 consensus oligonucleotide is not as clear as that of B1 (Figure 4.11a).  
 
As with NR2F2BS1, bandshifts were seen for NR2F2BS2 on EMSA analysis with UB/OC2 
cell  nuclear  protein  extract  (Figure  4.11b).  A  slow migrating  band  (Figure  4.11b.B1),  a 
doublet  (Figure  4.11b.B2&B3)  and  a  fast migrating  complex  were  visible  on  the 
autoradiograph (Figure 4.11b.C1). Of these bandshifts, B2 and B3 and were only slightly 
reduced by maximum unlabelled POU4F3 consensus competition (cold POU4F3 consensus, 
Figure  4.11b.B2,B3&C1),  indicating  that  these  bandshifts  are  unlikely  to  be  due  to 
POU4F3. B1, however, was markedly reduced by 500 fold POU4F3 consensus competition, 
abolished by 1000 fold POU4F3 consensus competition and fully restored on 1000 fold AP4 
consensus  competition.  Similarly,  C1  appears  to  be  reduced  by  1000 fold  POU4F3 
consensus competition and restored on 100 fold AP4 consensus competition. This pattern 
indicates that B1 and C1 are produced by POU4F3 (Figure 4.11b). On comparison of Figure 
4.11a and Figure 4.11b, POU4F3 appears to have a higher affinity for NR2F2BS2 than 
NR2F2BS1 as more competition is required to abolish visible binding to this site (1000 fold 
cold  consensus  sequence  for  NR2F2BS2  compared  to  500 fold  for  NR2F2BS1).  This  is 
consistent  with  the  similarity  of  the  binding  sites  to  their  respective  matrices  in  the 
bioinformatic analysis (0.980 matrix similarity for NR2F2BS2 to a POU3 matrix and 0.836 
matrix similarity for NR2F2BS1 to a POU6 matrix, see section 4.8.1). 
 
The above competition assay shows that murine POU4F3 extracted from UB/OC 2 cells is 
able to bind NR2F2BS1 and NR2F2BS2 oligonucleotides in vitro. When considered with the 
binding of in vitro translated POU4F3 to these oligonucleotides (Figure 4.10), this evidence 
suggests that POU4F3 may be able to bind these sites in the context of the full Nr2f2 gene 
promoter in vivo. Given this evidence of a direct interaction between POU4F3 and Nr2f2, 
the transcriptional regulation of the Nr2f2 gene promoter by POU4F3 was investigated to 
identify whether POU4F3 is able to directly upregulate the Nr2f2 gene as the subtractive 
hybridization suggests.  
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4.9  Transcriptional regulation of the Nr2f2 5’ flanking 
region by POU4F3 
The  ability  of  POU4F3  to  activate  the  Nr2f2  promoter  was  investigated  to  verify  the 
upregulation suggested by the subtractive hybridization and, if verified, provide evidence 
for direct interaction between POU4F3 and the Nr2f2 promoter.  
4.9.1  Investigation of Nr2f2 5’ flanking sequence response to POU4F3 
Plasmids containing Nr2f2 5’ flanking sequences upstream of the firefly (photinus pyralis) 
luciferase gene were used in cotransfections with varying amounts of Pou4f3 expression 
construct  (in  the  pSi  expression  vector).  Empty  pSi  vector  was  used  to  keep  the  total 
amount  of  transfected  DNA  constant  and  pRL null,  a  promoter less  luciferase  construct 
which produces sea pansy (renilla reniformis) luciferase, was included in cotransfections to 
correct  for  differing  transfection  efficiencies  between  replicates.  The  Promega  Dual 
Luciferase and DualGlo kits were used to assay firefly and sea pansy luciferase production. 
 
Two Nr2f2 5’ flanking region constructs were obtained from collaborators. A 4kb luciferase 
reporter  construct  containing  the  sequence  from  approximately   180bp  to  the  Nr2f2 
transcriptional start site to approximately  4.2kb was received from Dr M Vasseur Cognet 
and designated NR2F2p4kb (Figure 4.12a). The other construct, designated NR2F2p1.6kb 
(Figure  4.12b),  was  received  from  Dr  S  Tsai  and  contained  1.6kb  of  sequence  from 
approximately  234bp to approximately  1.8kb. These constructs are occasionally referred to 
as promoters for convenience though they have not been shown to act as full length Nr2f2 
promoters. Both constructs were investigated by cotransfections with POU4F3 expression 
constructs in UB/OC 2, ND7 and BHK cells. Calcium phosphate precipitation was used for 
these and subsequent transfections as it provided sufficient luciferase expression for this 
assay  and  was  more  cost effective  than  liposome based  and  related  systems  (e.g. 
Lipofectamine  (Invitrogen)  and  FuGENE  (Roche)).  Though  an  approximately  two fold 
activation was seen in UB/OC 2 cells, the presence and magnitude of this response varied 
between experiments (data not shown). This may have been due to endogenous UB/OC 2 
cell POU4F3 expression which leads to increased baseline promoter construct upregulation 
that  masks  the  effect  of  the  cotransfected  POU4F3  expression  construct.  Alternatively, 
dynamic POU4F3 expression and post translational modification or cofactors that regulate 
the NR2F2p4kb construct in response to different cell states could produce this variability.  
 
Of the three cell types tested, UB/OC 2 cells should, in theory, provide the most appropriate 
transcriptional environment in which to examine POU4F3 regulation of target genes due to 
their  expression  of  hair  cell  markers  (Rivolta  et  al.  1998a).  However,  the  variability  of 
NR2F2p4kb  response  to  POU4F3  seen  in  these  cells  would  make  it  hard  to  obtain 
meaningful results without accounting for this variability, thereby making UB/OC 2 cells 
unsuitable for further study of this relationship.  
4 Characterisation of the interaction of POU4F3 with the Nr2f2 promoter  153 
In both BHK and ND7 cells, both NR2F2p1.6kb and NR2F2p4kb are activated by POU4F3 
(Figure 4.13). In BHK cells (Figure 4.13a), NR2F2p1.6kb showed a greater response than 
NR2F2p4kb: 5.2 fold and 3.2 fold respectively. In ND7 cells, the response was more even, 
with  both  promoters  responding  approximately  equally:  NR2F2p4kb  3.6 fold  and 
NR2F2p1.6kb 3.3 fold. These results support the hypothesis that POU4F3 activates Nr2f2 
and that this activation is produced by a direct mechanism. 
 
The difference in responses between promoters is attributable to their different lengths and, 
therefore, the transcription factor binding sites present i.e. the difference in response seen 
in BHK cells (Figure 4.13a) is likely to be due to negative regulatory elements that are 
present in NR2F2p4kb and not in NR2F2p1.6kb. Differential response between cell types, 
however, is due to the complex integration of the multiple cell specific factors that influence 
POU4F3 transcription, Nr2f2 promoter upregulation and luciferase translation in the assay. 
 
Though NR2F2p1.6kb showed a greater response than NR2F2p4kb in BHK cells, the latter 
promoter  was  selected  for  further  investigation.  This  was  because  NR2F2p1.6kb  only 
included NR2F2BS1 in its sequence whereas NR2F2p4kb contained both NR2F2BS1 and 
NR2F2BS2  (see  Figure  4.12),  thereby  allowing  further  investigation  of  these  sites. 
Subsequent  transfections  used  ND7  cells  as  the  selected  promoter  showed  a  greater 
response  in  these  cells  than  in  BHK  cells  and  as  variability  of  the  response  seen  in  
UB/OC 2 cells could confound future results. 
 
 
Figure 4.12. Schematic of Nr2f2 5’ flanking region reporter constructs. 
Schematics of NR2F2p4kb (a) and NR2F2p1.6kb (b) showing the location of NR2F2BS1 and 
NR2F2BS2. All values are given relative to the Nr2f2 transcriptional start site in the Ensembl 
database (Ensembl 2008b).  
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Figure 4.13. Nr2f2 promoter regulation by POU4F3 in BHK and ND7 cells. 
a) In BHK cells NR2F2p4kb shows an approximately three-fold upregulation when cotransfected 
with a POU4F3 expression construct whereas NR2F2p1.6kb shows an approximately five-fold 
upregulation. b) In ND7 cells, the two promoter constructs show a similar upregulation of greater 
than three-fold. Luc, firefly (photinus pyralis) luciferase cDNA. 
a) 
b)  
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4.9.2  Characterisation of the POU4F3 activation of NR2F2p4kb 
The activation of NR2F2p4kb by POU4F3 was further characterised in order to identify 
whether this response is dose dependant (a characteristic of direct interactions between 
transcription factors and promoters). A control experiment was also carried out to ensure 
that  the  POU4F3  response  seen  was  not  artefactual  and  previous  experiments  in  our 
laboratory showed that the pGl 3 Basic vector into which NR2F2p4kb was cloned does not 
respond to pSi Pou4f3. 
 
ND7 cells were transfected with NR2F2p4kb as in previous experiments (section 4.9.1), 
however, the amount of POU4F3 expression construct was varied (Figure 4.14a). In order to 
verify that any observed upregulation of luciferase production was due to POU4F3 acting 
through its normal regulatory mechanisms and not due to a non specific upregulation of 
NR2F2p4kb  caused  by  increased  protein  production,  a  control  was  performed  using  a 
version  of  the  POU4F3  cDNA  (named  dreidel)  that  contains  a  dinucleotide  TG  deletion 
(Courtesy of Dr Karen Avraham). The deletion is reported at 388del2 (Hertzano et al. 2004),  
though  I  located  it  at  c.390_391delTG  in  the  Ensembl  sequence.  This  mutation  arose 
spontaneously  in  mice  and  renders  the  transcription  factor  non functional,  causing 
deafness (Hertzano et al. 2004). Dreidel cDNA was first cloned from the pHM6 vector in 
which it was received into the pSi vector for comparability with the pSi Pou4f3 construct. 
Subsequently, it was used in transfections as for pSi Pou4f3 (Figure 4.14b).  
 
Figure 4.14a shows that increasing the amount of pSi Pou4f3 that was included in each 
transfection  resulted  in  an  increase  in  the  averaged  adjusted  relative  luciferase  values 
measured, presumably due to the increasing amount of POU4F3 protein acting directly on 
the  Nr2f2  promoter  to  increase  the  rate  of  luciferase  transcription.  In  the  condition 
containing the largest amount of pSi Pou4f3 expression construct (Figure 4.14a 3000ng pSi-
Pou4f3) an upregulation of greater than five fold was seen.  The dreidel protein did not 
produce  such  an  upregulation  (Figure  4.14b)  as  it  was  only  able  to  produce  an 
approximately  1.5 fold  increase  in  measured  relative  luciferase  values  in  the  condition 
containing  the  largest  amount  of  pSi Dreidel  (Figure  4.14b  3000ng  pSi-Dreidel).  These 
results demonstrate that functional POU4F3 is required in these experiments to upregulate 
the Nr2f2 promoter in a dose dependent fashion, presumably via a direct interaction with 
the Nr2f2 promoter, potentially at the binding sites identified in previous EMSA assays 
(section 4.8).   
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Figure 4.14. NR2F2p4kb dose response to cotransfected POU4F3 expression construct.  
ND7 cells were transfected with NR2F2p4kb and increasing amounts of expression construct. 
10ng pRL-null was included in all conditions and the total amount of DNA was regulated with 
pSi  mammalian  expression  vector  (Promega)  (see  Figure  2.4).  a)  Increasing  amounts  of 
POU4F3  correlate  with  a  dose-dependent  increase  in  luciferase  production.  POU4F3 
expression construct that contains the dreidel dinucleotide deletion (b) does not produce such 
an upregulation. SV40e, SV40 enhancer / early promoter; and SV40l, SV40 late poly(A) in the 
pSi mammalian expression vector.  
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4.9.3  Investigation  of  the  transcriptional  effect  of  POU4F3  on  two 
experimentally verified binding sites in the Nr2f2 promoter 
In order to confirm that NR2F2p4kb is directly regulated by POU4F3, the sites at which 
POU4F3 produces its activation would need to be identified. NR2F2BS1&2 were found to 
be  bound  by  POU4F3  by  EMSA  and  were,  therefore,  the  most  likely  sites  of  POU4F3 
regulation of NR2F2p4kb (section 4.8.1). In order to investigate if NR2F2p4kb is regulated 
by POU4F3 at NR2F2BS1&2, I first investigated the potential of POU4F3 to regulate the 
EMSA oligonucleotides in isolation i.e. out of the context of their promoter. Regulation of 
these isolated binding sites by POU4F3 would support the hypothesis that they are the 
sites of POU4F3 regulation in NR2F2p4kb. 
 
NR2F2BS1  and  NR2F2BS2  were  cloned  upstream  of  a  minimal  TATA  promoter  in  the 
pGL4.23 vector 5’ to the sequence for the synthetic photinus pyralis luciferase gene, luc2. 
This luciferase coding sequence has been codon optimised for mammalian expression and, 
as for the rest of the plasmid, consensus mammalian transcription factor binding sites had 
been  removed  where  possible  in  order  to  reduce  background  regulation.  The  number  of 
copies of the binding sites that had been inserted into different clones were assessed by 
restriction  endonuclease  digestion  followed  by  size  separation  of  inserts  by  agarose  gel 
electrophoresis. Plasmids that contained different copy numbers were obtained. NR2F2BS1 
clones  that  contained  one,  two,  three  and  five  copies  of  the  EMSA  oligonucleotide  were 
identified. One, two, three and four copy number plasmids were obtained for NR2F2BS2.  
 
Each site was assayed in cotransfections with pSi or pSi Pou4f3 and pRL null in order to 
assess whether NR2F2BS1&2 confer POU4F3 regulation onto the luciferase gene in the 
reporter  constructs  used.  This  would  show  whether  POU4F3  can  upregulate  luciferase 
expression  via  these  sites  (as  expected  based  on  its  action  on  the  Nr2f2  promoter  in 
NR2F2p4kb (section 4.9.2)) and, if no regulation was seen, might suggest that other sites or 
non protein DNA  interactions  might  produce  the  observed  upregulation  of  the  Nr2f2 
promoter.  pSi Dreidel transfections were also carried out for each plasmid that contained 
one copy of the binding site in order to demonstrate whether any identified regulatory effect 
required  functional  POU4F3.  Previous  experiments  in  our  laboratory  had  demonstrated 
that luc2 production from the native pGL 4.23 vector is not influenced by POU4F3, thereby 
ruling out regulation of the base vector.  
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Figure 4.15. Upregulation of pGL4.23-NR2F2BS1 by POU4F3 in ND7 cells. 
Reporter  constructs  were  cloned  that  contained  varying  copy  numbers  of  NR2F2BS1  or 
NR2F2BS2 upstream of a synthetic luciferase coding sequence with a minimal TATA promoter. 
100ng of each reporter construct was cotransfected with 10ng pRL-null and 3 g of a POU4F3 
expression construct in ND7 cells. The plasmid that contained a single copy of the binding site 
(a) was also assayed with dreidel mutant POU4F3 expression construct. All four constructs (a-
d) showed a 1.6- to 1.8-fold upregulation in the presence of POU4F3. The effect was dependent 
on  functional  POU4F3  protein  as  dreidel  mutant  POU4F3  did  not  upregulate  luciferase 
production in pGL4.23-NR2F2BS1-1x. a, pGL4.23-NR2F2BS1-1x; b, pGL4.23-NR2F2BS1-2x; c, 
pGL4.23-NR2F2BS1-3x; d, pGL4.23-NR2F2BS1-5x. 
a)  b) 
c)  d) 
pGL4.23-NR2F2BS1-1x  pGL4.23-NR2F2BS1-2x 
pGL4.23-NR2F2BS1-3x  pGL4.23-NR2F2BS1-5x  
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Figure 4.16. Upregulation of pGL4.23-NR2F2BS2 by POU4F3 in ND7 cells. 
As  for  NR2F2BS1,  100ng  of  plasmid  constructs  containing  a  synthetic  luciferase  coding 
sequence under the transcriptional regulation of a minimal TATA promoter and a varying copy 
number  of  NR2F2BS2  was  cotransfected  with  10ng  pRL-null  and  a  POU4F3  expression 
construct. All four constructs showed a 1.4- to 2-fold upregulation in the presence of POU4F3. 
The plasmid that contained a single copy of the binding site was also assayed with dreidel 
mutant POU4F3 expression construct and this showed that the effect of POU4F3 on this binding 
site was dependent on functional protein as the mutant POU4F3 did not upregulate luciferase 
production in pGL4.23-NR2F2BS2-1x (a). a, pGL4.23-NR2F2BS2-1x; b, pGL4.23-NR2F2BS2-
2x; c, pGL4.23-NR2F2BS2-3x; d, pGL4.23-NR2F2BS2-4x. 
a)  b) 
c)  d) 
pGL4.23-NR2F2BS2-1x  pGL4.23-NR2F2BS2-2x 
pGL4.23-NR2F2BS2-3x  pGL4.23-NR2F2BS2-4x  
4 Characterisation of the interaction of POU4F3 with the Nr2f2 promoter  160 
pGL4.23 NR2F2BS1 1x demonstrated a 1.8 fold upregulation in luc2 luciferase expression 
in the presence of POU4F3 protein (Figure 4.15a). This effect required functional POU4F3 
as dreidel mutant POU4F3 did not demonstrate such an upregulation. Promoter constructs 
that  contained  multiple  copies  of  the  binding  site  showed  an  approximately  1.6 fold 
upregulation in the presence of POU4F3 (Figure 4.15b d).  This demonstrates that POU4F3 
is not only able to bind to NR2F2BS1, but is also able to confer regulation on a heterologous 
promoter once bound to this  site. The effect is not increased by multiple repeats of the 
binding site (Figure 4.15b d), suggesting either: (i) the spacing or orientation of these sites 
does not allow more than one copy of POU4F3 to bind; (ii) once bound, multiple POU4F3 
copies are not all able to access cofactors to influence transcription or; (iii) that the context 
of the binding sites limit the activation that POU4F3 is able to produce e.g. due to a limited 
availability of cofactors. 
 
The NR2F2BS2 containing promoters were also activated by POU4F3 (approximately 1.5  
to 2 fold), though they showed a more varied response. As for pGL4.23 NR2F2BS1 1x, the 
effect  of  POU4F3  on  pGL4.23 NR2F2BS2 1x  was  found  to  require  functional  POU4F3 
protein (Figure 4.16). Though increasing copies of the binding site appear to result in a 
small increase in response for one to three copies, the plasmid that contained four copies of 
the  binding  site  showed  a  reduced  response  (Figure  4.16b d).  This  difference  between 
NR2F2BS1 copy number variants may be due to the orientation of the sites in this plasmid 
or secondary regulatory factors discussed above. Furthermore, the difference in response for 
promoters containing different copy numbers of NR2F2BS2 may be sequence specific or due 
to  the  spacing  between  binding  sites  in  these  different  constructs  (NR2F2BS2  is  longer 
than NR2F2BS1). 
 
As these results show that POU4F3 is capable of binding and upregulating the identified 
binding sites in the Nr2f2 promoter, they suggest that the upregulation of NR2F2p4kb seen 
in  luciferase  assays  (Figure  4.14)  occurs  at  these  two  binding  sites.  These  results  also 
suggest that POU4F3 may be able to upregulate Nr2f2 in genomic DNA at these binding 
sites.  Given  that  these  sites  were  selected  as  the  two  most  likely  sites  to  be  bound  by 
POU4F3 in bioinformatic analysis (section 4.8.1), it is likely that a significant proportion of 
the upregulation of NR2F2p4kb by POU4F3 is due to upregulation at these sites. Though 
the above results demonstrate the ability of POU4F3 to bind to and upregulate the two 
binding sites, they do so in conditions that are quite different to those found in the normal 
cell.  The  cloned  binding  sites  are  removed  from  the  transcriptional  influence  of  other 
binding sites that surround them in the full Nr2f2 promoter and a heterologous promoter 
confers  a  basal  upregulation  of  reporter  gene  expression  that  is  not  present  in  the  full 
promoter. This is also likely to be the reason that the activation of the binding sites in the 
above  experiments  is  not  as  large  as  that  of  NR2F2p4kb  (1.5 fold  compared  to  5 fold). 
Furthermore, experimental factors such as the amount of DNA transfected can affect the  
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assay and confound results e.g. by causing cytotoxicity. I therefore proceeded to identify 
whether the upregulation of NR2F2p4kb by POU4F3 required NR2F2BS1 and NR2F2BS2 
in order to verify the function of these sites in the more physiological context of the Nr2f2 5’ 
flanking region. 
4.10  Site-directed  mutagenesis  of  POU4F3  binding 
sites in the Nr2f2 promoter 
In order to identify the contribution of NR2F2BS1 and NR2F2BS2 to the upregulation of 
NR2F2p4kb, I attempted to mutate these sites in order to abolish POU4F3 binding. The 
purpose of this site directed mutagenesis (SDM) was to demonstrate whether the isolated 
abolition of the two binding sites was sufficient to affect the observed upregulation of the 
Nr2f2 promoter in NR2F2p4kb seen in section 4.9.2, thus clarifying their action in the more 
physiological context of their promoter. The ability of POU4F3 to bind to the mutated sites 
designed  was  first  assessed  by  EMSA  analysis  and  these  mutations  were  subsequently 
introduced  to  the  NR2F2p4kb  plasmid  in  order  to  quantify  their  effect  on  POU4F3 
upregulation of this Nr2f2 promoter construct.  
4.10.1  Design of NR2F2BS1 and NR2F2BS2 mutations to abolish POU4F3 
binding 
The sequences of NR2F2BS1 and NR2F2BS2 were compared to published POU4F3 binding 
sites to predict: (i) where exactly POU4F3 might  bind within these oligonucleotides; (ii) 
which bases are expected to be essential for binding; and (iii) what changes could be made 
to these sites to abolish POU4F3 binding (Figure 4.17). Five studies that report binding 
sites (Gruber et al. 1997;Li et al. 1993;Trieu et al. 1999;Xiang et al. 1995), effects of binding 
site organisation (Gruber et al. 1997;Li et al. 1993;Rhee et al. 1998) and effects of sequence 
variation (Gruber et al. 1997;Trieu et al. 1999;Xiang et al. 1995) on POU4F DNA binding 
were used to identify the regions within NR2F2BS1 and NR2F2BS2 that are likely to be 
required for POU4F3 binding. This information also aided the choice of mutations to apply 
to  NR2F2BS1  and  NR2F2BS2  in  order  to  abolish  POU4F3  binding  (Figure  4.17).  After 
having predicted POU4F3 binding sites within EMSA oligonucleotides based on the original 
Genomatix  analysis  (section  4.8.1)  and  their  sequence  similarity  to  published  POU4F3 
consensus sequences (particularly the CATAATTAAT sequence identified in Gruber et al. 
1997),  reported  effective  mutations  of  POU4F3  binding  sites  were  used  to  aid  in  the 
prediction  of  mutations  of  the  Nr2f2  promoter  binding  sites  that  would  abolish  their 
binding and upregulation by POU4F3 (Xiang et al. 1995). In particular, the CAT sequence 
identified as being important for upregulation by Xiang et al. was targeted and AT was 
replaced  with  CG  to  maximise  any    effect  on  POU4F3  binding  (Xiang  et  al.  1995).  For 
NR2F2BS1 (Figure 4.17a) a two base pair mutation was sufficient however, for NR2F2BS2 
(Figure 4.17b) a three base pair was required to disrupt two neighbouring CAT motifs.  
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Figure 4.17. Design of mutant POU4F3 binding sites. 
The EMSA oligonucleotide sequences are shown with the identified regions of likely POU4F3 
binding  highlighted  in  blue.  These  sites  were  mutated  in  order  to  abolish  POU4F3  binding 
(mutations highlighted in pink). The reverse complement (RC) sequences of  unmutated and 
mutated (mut) NR2F2BS1 (a) and NR2F2BS2 (b) are shown for easy identification of antisense 
putative POU4F3 binding  sites compared to  a POU4F binding site consensus sequence (c) 
(Gruber et al. 1997). 
a) 
                        10        20          
               ....|....|....|....|....|... 
 
NR2F2BS1       CTTTTTAGCATATTTGATCACTTTGATT  
NR2F2BS1RC     AATCAAAGTGATCAAATATGCTAAAAAG  
 
                        10        20          
               ....|....|....|....|....|... 
NR2F2BS1mut    CTTTTTAGCCGATTTGATCACTTTGATT  
NR2F2BS1mutRC  AATCAAAGTGATCAAATCGGCTAAAAAG  
 
 
 
b) 
                        10        20        30           
               ....|....|....|....|....|....|....|. 
NR2F2BS2       GGAATTTATTTTAATTGCATCATAACAATGAGGTGA  
NR2F2BS2RC     TCACCTCATTGTTATGATGCAATTAAAATAAATTCC  
 
                        10        20        30           
               ....|....|....|....|....|....|....|. 
NR2F2BS2mut    GGAATTTATTTTAATTGCAGGGTAACAATGAGGTGA  
NR2F2BS2mutRC  TCACCTCATTGTTACCCTGCAATTAAAATAAATTCC  
 
 
c)  
                             10  
               ....|....| 
POU4F3 consensus 2  CATAATTAAT  
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4.10.2  Effect  of  mutated  EMSA  oligonucleotides  on  in  vitro  translated 
POU4F3 binding 
Prior to assessing the effect of the mutations shown in Figure 4.17 on POU4F3 regulation 
in  luciferase  assays  (in  the  context  of  the  Nr2f2  promoter),  the  mutant  sequences  were 
synthesised and the oligonucleotides were used in EMSA analysis with in vitro translated 
POU4F3 in order to assess the effect of the mutations on POU4F3 binding. The analysis 
was carried out as described in section 4.8.2, except that the protein was translated using a 
new  wheat  germ  quick coupled  transcription/translation  system  rather  than  rabbit 
reticulocyte lysate, and in vitro translated Barhl1 transcription factor was used instead of 
luciferase protein to test non specific binding background. 
 
Figure  4.18a&b  shows  that  the  two  base pair  mutation  of  NR2F2BS1  resulted  in  a 
substantial decrease in POU4F3 binding (indicated by opaque arrowheads). Unexpectedly, 
the mutation also resulted in an increase in Barhl1 binding to the sequence. Barhl1 and 
POU4F3 binding sites have since been observed to overlap at some loci in our laboratory (by 
VG). Mutation of NR2F2BS2 (Figure 4.18c&d) resulted in a reduction in the amount of 
oligonucleotide  bound  by  POU4F3  (Figure  4.18,  hollow  arrowhead).  In  contrast  to 
NR2F2BS1,  the  Barhl1  binding  pattern  was  similar  for  both  the  wild  type  and  mutant 
oligonucleotide. 
 
These results demonstrate that the mutations designed for the two POU4F3 binding sites 
in the Nr2f2 promoter reduce POU4F3 binding to these sites. In the context of a promoter, 
this  reduction  in  POU4F3  binding  should  result  in  a  reduction  of  POU4F3 mediated 
upregulation of these promoters if these sites are required for POU4F3 regulation. In order 
to  verify  that  these  binding  sites  are  necessary  for  POU4F3  regulation  of  Nr2f2,  I 
attempted  to  reproduce  the  above  mutations  in  the  NR2F2p4kb  reporter  construct.  A 
reduction  in  upregulation  of  this  promoter  due  to  these  mutations  would  demonstrate 
whether  the  changes  in  POU4F3  binding  shown  in  Figure  4.18  have  an  effect  on 
transcriptional activation in the context of the NR2F2p4kb promoter and how much the two 
binding sites contribute to the upregulation of the Nr2f2 promoter seen in Figure 4.14.  
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Figure 4.18. Effect of binding site mutation on transcription factor binding. 
a)  NR2F2BS1  is  bound  by  POU4F3  but  not  by  Barhl1.  b)  The  mutated  base-pairs  in 
NR2F2BS1mut  strongly  reduce  POU4F3  binding  (filled  arrowheads)  and  facilitate  Barhl1 
binding. In contrast, both wild type (c) and mutant (d) NR2F2BS2 are bound by Barhl1, but 
POU4F3 binding is reduced by mutation of NR2F2BS2 (hollow arrowheads). 
a)
No protein
POU4F3
Barhl1
No protein
POU4F3
Barhl1 b)
No protein
POU4F3
Barhl1 c)
No protein
POU4F3
Barhl1 d)
    NR2F2BS1                 NR2F2BS1mut                  NR2F2BS2                 NR2F2BS2mut  
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4.10.3  Site-directed mutagenesis using the QuikChangeII XL kit 
In order to introduce the desired mutations into the POU4F3 binding sites in NR2F2p4kb, 
site directed mutagenesis (SDM) was attempted for both binding sites using the Stratagene 
QuikChangeII XL kit. This kit offers rapid SDM by hybridization of mutant primer to the 
target site, polymerisation of the remaining plasmid sequence and subsequent digestion of 
parent DNA to yield mutant plasmid alone. The QuikChange XL kit was selected as it is 
designed to work for large and difficult plasmids (>8kb) and NR2F2p4kb is approximately 
9kb long. Primers were designed using the QuikChange primer design program (Stratagene 
2006) and subsequently manufactured and purified commercially.  
 
Though  multiple  attempts  were  made  using  this  technique,  and  the  troubleshooting 
optimisations  suggested  in  the  manufacturer’s  manual  were  implemented,  this  strategy 
was  unsuccessful.  The  Nr2f2  promoter  contains  GC rich  regions  that  are  likely  to  have 
interfered with polymerase activity even though the QuikSolution™ reagent contained in 
the kit was used in an attempt to overcome this problem. I therefore used an overlapping 
PCR method in order to produce the required mutations in NR2F2p4kb. 
4.10.4  SDM of NR2F2p4kb by overlapping PCR for NR2F2BS2 
NR2F2BS2  lies  in  a  less  GC  rich  and  repetitive  region  of  the  Nr2f2  promoter  than 
NR2F2BS1  and  therefore  presented  less  challenges  in  its  mutagenesis.  This  site  was 
mutated by an overlapping PCR strategy that is summarised in Figure 4.19 (initial SDM 
PCR conducted by SD). Briefly, NR2F2p4kb was used as template DNA in two initial PCR 
reactions. In the first reaction, (5’ reaction) MVCER5’ and NR2F2BS2RC or its equivalent 
SDM  primer  were  used  to  amplify  a  region  from   621  to  the  most  3’  nucleotide  of 
NR2F2BS2 to produce fragment a. The second reaction (3’ reaction) used NR2F2BS2 and 
MVCER3’ and amplified up to +182bp from the most 3’ nucleotide of NR2F2BS2 to produce 
fragment b (Figure 4.19). The DNA amplified in these two reactions was then used as the 
template  for  the  ‘overlap  extension’  reaction.  In  the  initial  cycles  of  this  PCR,  the  two 
fragments  are  denatured  and  annealed  to  each  other  in  their  overlapping  regions.  The 
sense strand of fragment a binds to the antisense strand of fragment b and the overlapping 
region primes polymerisation of missing 5’ to 3’ sequence at both ends of parent fragments. 
The  primers  included  in  the  reaction  (MVCER5’  and  3’)  are  then  able  to  prime 
polymerisation  of  this  long  fragment  in  subsequent  cycles.  The  long  fragment  of  the 
reactions that initially used the EMSA oligonucleotides as primers was then cloned in to 
the pDrive cloning vector by TA cloning and the insert was verified by sequencing. The 
flanking primers used (MVCER5’ and 3’) had been designed to overlap EcoRI restriction 
endonuclease recognition elements that were used to subclone the digested mutant PCR 
fragment of approximately 790bp back into NR2F2p4kb. The orientation of the fragment 
was checked by restriction digest and verified by sequencing yielding NR2F2p4kb BS2mut.  
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Figure 4.19. Site-directed mutagenesis (SDM) of NR2F2p4kb by overlapping PCR. 
a) structure of the NR2F2p4kb promoter construct; b) NR2F2BS2 mutagenesis PCR; c) full-
length insert generation by overlapping PCR; d) ligation of full-length insert into the pDrive PCR 
cloning vector by TA ligation; e) restriction digestion of template and full-length insert; f) ligation 
of full-length insert into NR2F2p4kb.  
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4.10.5  SDM of NR2F2p4kb by overlapping PCR for NR2F2BS1 
Having mutated one of the two sites in the Nr2f2 promoter that bioinformatic prediction 
and  our  experiments  suggest  are  responsible  for  the  upregulation  of  NR2F2p4kb  by 
POU4F3, I attempted to produce a construct in which both POU4F3 binding sites were 
mutated in order to determine the combined effect of these sites on POU4F3 regulation.  
 
 
Figure 4.20. Screening of SDM colonies for incorporation of mutation. 
a) the orientation of inserts that had been subcloned into the pDrive vector were screened for 
incorporation of  insert and orientation by restriction  endonuclease digestion  and subsequent 
electrophoresis. An example of the pattern seen on gel visualisation under UV light is shown. 
Correctly incorporated and oriented inserts were identified by the presence of a predicted band 
of 683bp in the absence of any other bands smaller than 1.6Kb (i.e. lanes 2, 5, 6 & 10). b) 
Miniprep DNA from pDrive clones that had incorporated the insert in the correct orientation were 
subsequently screened to identify if the desired mutation (NR2F2BS1mut) had been produced 
by  DNA  hybridization  with  radiolabelled  EMSA  oligonucleotides.  Colonies  which  had 
incorporated the mutation are identifiable by stronger hybridization with radiolabelled NM1 than 
with radiolabelled N1. A negative control (NR2F2p4kbBS2mut) that was known to contain wild 
type NR2F2BS1 was included as a negative control (box 12). All clones screened contained the 
desired mutation apart from 10 (which contained wild type NR2F2BS1) and 11 (which contains 
an unknown sequence or was of low concentration). NB, box 2 has been edited for presentation 
purposes  as  this  clone  was  spotted  out  of  sequence  at  the  bottom  of  the  NM1  membrane 
(cropped). c) inserts that had been directly subcloned into NR2F2p4kb-BS2 mut were screened 
for incorporation of the desired mutation in the same way as those cloned into pDrive prior to 
checking of insert orientation. Box 22 contains the negative control DNA (NR2F2p4kb-BS2mut). 
Boxes 1-10, 12 and 15-20 are consistent with mutated clones whilst the clone in box 14 appears 
unmutated and the remaining boxes appear to contain an unknown sequence or an inadequate 
amount of DNA. 
a)
b)
c)
0.5Kb  
1.0Kb   
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The  strategy  used  to  mutate  NR2F2BS2  was  also  used  for  NR2F2BS1  with  some 
modification in order to produce a version of NR2F2p4kb in which both NR2F2BS1 and 
NR2F2BS2 were mutated (named NR2F2p4kb BS1&2mut). Once the full length mutated 
PCR fragment had been made (i.e. Figure 4.19c), an aliquot of the purified fragment was 
digested  and  ligated  directly  into  the  NR2F2p4kb BS2mut  construct  using  the  ApaI 
restriction  endonuclease  as  well  as  cloning  the  remainder  of  the  undigested  purified 
fragment into the pDrive vector by TA cloning. pDrive colonies were screened by Miniprep 
(Qiagen)  and  restriction  endonuclease  digestion  in  to  identify  whether  the  full length 
mutant  PCR  fragment  had  been  incorporated  and  to  determine  its  orientation  (Figure 
4.20a). pDrive colonies that had been shown to contain the desired insert in the correct 
orientation were then screened by DNA hybridization to determine whether the mutation 
had been incorporated or whether the colonies had arisen from wild type NR2F2p4kb i.e. 
due to incomplete digestion or phosphorylation of this plasmid during earlier cloning stages 
(Figure 4.20b). Colonies yielded by direct ligation of the full length mutated fragment into 
NR2F2p4kb BS2mut  were  also  screened,  though  their  orientation  was  not  determined 
(Figure 4.20c). Having identified colonies that had incorporated the mutation, these clones 
were sent for sequencing in order to verify that NR2F2BS1 had been mutated and, in the 
case of colonies that had been directly ligated into NR2F2p4kb BS2mut, that the insert was 
in the correct orientation. 
4.10.6  Correction of unintended mutations in NR2F2p4kbmut 
On sequencing, unintended mutations were noticed to have arisen in the mutated clones, 
presumably due to PCR errors (different mutations were identified between colonies). A 
strategy  was  therefore  designed  to  correct  unwanted  mutations.  The  BclI  restriction 
endonuclease was used to excise a region from a clone with a mutation 5’ to NR2F2BS1 and 
replace it with the equivalent region in another clone that did not contain the 5’ mutation 
but  did  have  a  mutation  within  the  excised  region.  Orientation  of  this  fragment  was 
checked by restriction endonuclease digestion and the correction was verified by sequencing 
of this plasmid (NR2F2p4kb BS1&2mut). This plasmid had a c to t missense mutation  
288bp from the intended mutagenesis site that could not be repaired, however, a c to t 
missense mutation at +74bp and a three base pair deletion starting at +301 to the intended 
mutation were repaired. The remaining mutation is unlikely to have an effect on POU4F3 
specific  interactions  with  this  promoter  due  to  its  distance  from  POU4F3  binding  sites. 
However, as the remaining mutation might interfere with the binding of other transcription 
factors  to  the  Nr2f2  promoter  sequence,  basal  expression  of  this  promoter  construct 
(NR2F2p4kb BS1&2mut) was not compared to the wild type construct (NR2F2p4kb) as any 
difference in luciferase production could not be assigned to POU4F3 alone.   
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4.10.7  Luciferase  assay  shows  reduced  response  of  NR2F2p4kb-
BS1&2mut to POU4F3 compared to wild type NR2F2p4kb 
NR2F2p4kb BS1&2mut  was  used  in  cotransfection  assays  and  compared  to  NR2F2p4kb 
which  was  assayed  as  previously  described  (see  section  4.9.2)  in  order  to  assess  the 
contribution of the two binding sites to the upregulation of the Nr2f2 promoter by POU4F3. 
However, a lower total amount of DNA (1210ng instead of 3110ng) was used in order to 
reduce the possibility of cytotoxicity from the transfection confounding the results. If the 
upregulation is produced by the action of POU4F3 at the identified sites, the mutations 
should  reduce  POU4F3  binding  and  therefore  reduce,  or  abolish  the  upregulation  of 
luciferase  protein  production  in  response  to  increasing  amounts  of  POU4F3  seen  with 
NR2F2p4kb (Figure 4.14).   
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Figure 4.21 shows that the mutation of the two POU4F3 binding sites (NR2F2BS1 and 
NR2F2BS2) reduces the upregulatory effect of POU4F3 on NR2F2p4kb. In this experiment, 
wild  type  NR2F2p4kb  demonstrated  a  two fold  upregulation  in  response  to  1000ng  of 
cotransfected pSi Pou4f3 and the mutated promoter (NR2F2p4kb BS1&2mut) shows a 1.3 
fold upregulation. The response of the wild type promoter (NR2F2p4kb) to POU4F3 in this 
experiment is lower than the previously identified five fold upregulation (see Figure 4.14), 
though this is likely to be due to less POU4F3 expression construct being cotransfected in 
this experiment to avoid cytotoxicity. Furthermore, the response of NR2F2p4kb to POU4F3 
in ND7 cells may vary between passages. This evidence provides further proof that the two 
POU family binding sites identified and investigated in the Nr2f2 promoter are essential 
for the observed upregulation of this promoter by POU4F3 in this context i.e. NR2F2BS1 
and NR2F2BS2 must be intact in order for POU4F3 to be able to upregulate the Nr2f2 
promoter in ND7 cells.  
 
The  data  in  this  chapter  demonstrate  that  NR2F2BS1&2  are  bound  by  POU4F3  in 
NR2F2p4kb  and,  therefore,  are  likely  to  be  bound  in  the  Nr2f2  promoter;  POU4F3  is 
capable  of  binding  these  sites  in  EMSA  assay  and  a  reduction  in  POU4F3  binding  to 
mutant binding sites in EMSA assay is reflected in the reduced response of the mutated 
Nr2f2 5’ flanking region (NRF2p4kb BS1&2mut). These results confirm and extend those of 
the subtractive hybridization which produced Nr2f2 as a putative target of POU4F3 as it is 
also likely that upregulation of Nr2f2 by POU4F3 is via a direct mechanism with POU4F3 
binding the Nr2f2 promoter at the sites identified (NR2F2BS1 and NR2F2BS2). 
4.10.8  Conservation of POU4F3 binding sites in the Nr2f2 promoter 
As  with  coding  sequence,  regulatory  elements  are  conserved  through  evolution  if  their 
sequence is required for the production of a given phenotype and depending on redundancy 
i.e. whether a base pair can be exchanged or deleted without affecting protein binding and 
upregulation at a cis regulatory element. I therefore investigated the conservation of the 
identified  POU4F3  cis regulatory  elements  in  order  to  estimate  the  importance  of  the 
interaction that had been identified in the mouse. 
 
The chromosomal locations of the verified mouse cis regulatory elements NR2F2BS1 and 
NR2F2BS2 were identified and compared with the equivalent regions of the human and rat 
genomes using precomputed genomic alignments from the Vista project (Loots et al. 2004). 
Once obtained, the sites’ conservation was quantified using the BioEdit software package 
which calculated the percentage sequence similarity between these species.  
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Nr2f2 promoter POU4F3 binding site 1 
 
 
Figure 4.22. Alignment of mouse NR2F2BS1 with equivalent human and rat sequences. 
Both the human and rat sequences had 100% sequence similarity to the mouse sequence, 
showing a strong conservation of this site. This figure is modified from the precomputed Vista 
genomic alignment (Loots et al. 2004). + and - indicate sense or antisense strand respectively 
for each species. 
 
 
NR2F2BS1 showed 100% conservation between the three species investigated (Figure 4.23). 
This  indicates  that  this  POU4F3  binding  site,  along  with  its  flanking  sequence  is  well 
conserved  and  is  therefore  likely  to  play  an  important  role  in  the  regulation  of  Nr2f2 
expression. 
 
Nr2f2 promoter POU4F3 binding site 2 
 
 
Figure 4.23. Alignment of mouse NR2F2BS2 with equivalent human and rat sequences. 
Though  this  sequence  was  less  well-conserved  than  NR2F2BS1,  the  region  previously 
predicted to be the POU4F3 binding site (Figure 4.17), which is shaded in red,  has only a single 
mismatch between mouse and rat sequences (91.7% sequence similarity), showing that this 
binding  site  is  well-conserved.  Figure  modified  from  precomputed  Vista  genomic  alignment 
(Loots et al. 2004).  + and - indicate sense or antisense strand respectively for each species.  
 
 
NR2F2BS2  was  less  well conserved  than  NR2F2BS1.  Across  the  whole  sequence,  the 
sequence similarity between species was as follows: mouse:human = 80.5%, mouse:rat = 
97.2% and human:rat = 77.7% (Hall 2007). However, in the region that had previously been 
predicted  to  be  the  POU4F3  binding  site  (Figure  4.17b),  the  conservation  was  high: 
mouse:human  =  100%,  mouse/human:rat  =  91.7%.  Given  the  small  sample  size,  it  is 
difficult to compare the conservation of this site to its surrounding sequence, however, it is 
possible to say that this site, as for NR2F2BS1, is well conserved. This high level of binding 
site conservation again indicates that the POU4F3 Nr2f2 interaction that takes place at 
NR2F2BS2 is likely to take place in vivo. 
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4.11  Discussion of Nr2f2 activation by POU4F3 
NR2F2  was  identified  as  a  putative  target  of  the  POU4F3  transcription  factor  by  a 
subtractive hybridization screen in UB/OC 2 cells. It was selected for further investigation 
based on its known functions: NR2F2 is known to be required for organogenesis in a range 
of organs where it has been shown to interact with a number of signalling networks that 
are known to be involved in inner ear development (sections 4.4 and 4.8). Furthermore, it is 
expressed  in  the  inner  ear  where  it  has  been  suggested  to  play  a  role  in  inner  ear 
development (section 4.5.2) and many reagents were available for its investigation. 
 
NR2F2 expression in the inner ear was investigated to identify whether it is expressed in 
hair cells that express POU4F3. The results of these expression studies showed that NR2F2 
is widely expressed in the apex of the E18 rat cochlear duct with its expression becoming 
increasingly restricted to the lesser epithelial ridge towards the base of the cochlear duct 
(see Figure 4.4). Its expression in the E18 rat inner ear is, therefore, likely to overlap with 
that of POU4F3 in hair cells (Erkman et al. 1996) and is similar to the pattern seen in the 
developing  mouse  inner  ear  at  E15.5  (Tang  et  al.  2005;Xiang  et  al.  1998). 
Immunofluorescence experiments also showed, for the first time, that NR2F2 is expressed 
in the cochlear hair cells of the postnatal rat inner ear (see Figure 4.5) and the hair cells of 
the crista in the postnatal mouse inner ear; NR2F2 was only detected in the Hensen cells of 
the apical organ of Corti in postnatal mice (see Figure 4.6 and Figure 4.7). Furthermore, 
cytoplasmic NR2F2 expression was detected in basal P8 rat cochlear hair cells (similar to 
that seen in the rat pituitary gland (Raccurt et al. 2006)), suggesting that the function of 
NR2F2 in hair cells may be controlled by modulation of its subcellular localization. This 
expression  pattern  supports  the  possibility  of  a  physiologically  relevant  regulatory 
relationship between POU4F3 and Nr2f2 in hair cells. Therefore, the putative activation of 
the  Nr2f2  5’  flanking  region  by  POU4F3  was  investigated  to  verify  activation  and,  if 
activation was confirmed, to identify the mechanism of regulation. 
 
Two well conserved POU4F3 binding sites were identified in the Nr2f2 5’ flanking region by 
bioinformatic analysis and POU4F3 binding to these sites was verified by EMSA (sections 
4.8 and 4.10.8). Having verified that POU4F3 is able to bind to these sites, POU4F3 was 
shown  to  activate  two  reporter  constructs  containing  differing  lengths  of  the  Nr2f2  5’ 
flanking region by luciferase assay (section 4.9). Furthermore, the POU4F3 binding sites 
that  had  previously  been  identified  in  the  Nr2f2  5’  flanking  region  were  found  to  be 
required for the activation of an Nr2f2 5’ flanking region reporter construct (NR2F2p4kb) 
as mutation of these sites reduced its activation from two fold to 1.3 fold (section 4.10). 
 
Collectively, the data presented provide strong evidence that POU4F3 activates Nr2f2 and 
that this may be relevant to hair cell development, though evidence of this regulation would 
be strengthened by additional experimentation. Firstly, to better characterise the timing  
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and variation of NR2F2 expression, a larger number of animals require investigation and 
investigation of older animals will help explain differences in postnatal NR2F2 expression 
between  mice  and  rats.  Study  of  NR2F2  expression  in  relation  to  markers  of  hair  cell 
development may aid in this comparison and help determine whether the differences seen 
are due to the slower development of the rat or true interspecies differences.  
 
To  better  characterise  the  effect  of  POU4F3  on  NR2F2p4kb,  independent  mutations  of 
NR2F2BS1 and NR2F2BS2 require investigation. Though the reduction in the activation of 
NR2F2pBS1&2mut  compared  to  NR2F2p4kb  shows  the  requirement  of  these  sites  for 
NR2F2p4kb activation, individual mutations of these sites will determine their contribution 
to this activation. Furthermore, the ability of POU4F3 to bind to these sites in genomic 
DNA  could  be  investigated  by  chromatin  immunoprecipitation.  At  a  late  stage  of  this 
investigation, preliminary attempts were made to identify POU4F3 binding to NR2F2BS1 
and NR2F2BS2 by this method using a POU4F3 fusion protein (to overcome the lack of a 
suitable  anti POU4F3  antibody).  Though  this  assay  did  not  identify  NR2F2BS1  or 
NR2F2BS2, the protocol used requires optimization (this was not carried out due to time 
constraints) and the possibility that the fusion protein used interferes with DNA binding by 
POU4F3 needs to be excluded. 
 
Finally,  the  interaction  of  POU4F3  with  the  Nr2f2  promoter  in  hair  cells  requires 
investigation in order to clarify the relevance of this interaction to their development and, if 
NR2F2  expression  in  hair  cells  is  maintained  throughout  life,  survival.  In  order  to 
investigate the effect of POU4F3 expression on Nr2f2 in hair cells, two models could be 
used:  cochlear  cultures  and  Pou4f3  mutant  mice.  Though  we  intended  to  manipulate 
POU4F3 levels in hair cells in culture, we were unable to do so due to extremely low hair 
cell transfection efficiency despite a number of methods being attempted in our laboratory. 
Furthermore,  we  were  unable  to  obtain  Pou4f3  mutant  mouse  inner  ear  tissue  for 
investigation of the effect of Pou4f3 mutation on NR2F2 levels. However, an adenovirus 
based transfection protocol is currently being developed in our laboratory for use in cochlear 
cultures in order to overcome previous transfection problems. 
 
In summary, future work will focus on the in vivo relevance of the regulatory relationship 
identified and clarification of the role of NR2F2 in the developing organ of Corti will aid in 
our understanding of its role in hair cell development and, potentially, maintenance. As 
NR2F2 has been shown to be essential for organogenesis and maintenance of a number of 
organs through signalling networks that are known to be active in the inner ear, future 
work  on  the  role  of  NR2F2  in  the  inner  ear  is  likely  to  focus  on  understanding  how  it 
interacts  with  these  signalling  cascades  in  this  system.  Given  that  its  family  member, 
NR2F1,  has  been  shown  to  be  essential  for  normal  inner  ear  morphogenesis,  NR2F2’s 
potentially important role could be investigated using a conditional inner ear knockout to  
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circumvent  the  problems  of  the  embryonic  lethality  of  the  homozygous  Nr2f2  knockout 
mouse.  Such  investigations  would  shed  much  light  on  the  role  of  this  multi faceted 
transcription factor in the development of hearing and balance.  
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5   
INVESTIGATION OF PUTATIVE LUZP1, 
RBMS1 AND ZRANB2 REGULATION 
BY POU4F3 
Having identified putative POU4F3 target genes from a subtractive hybridization screen in 
UB/OC 2 cells, four candidate genes were prioritised for investigation: Nr2f2 (chapter 4), 
Luzp1, Rbms1 and Zranb2. These genes were selected based on their potential roles in hair 
cell  development,  likelihood  of  regulation  by  POU4F3  (estimated  by  the  presence  of 
predicted POU4F binding sites in their 5’ flanking regions), and availability of reagents (see 
section 3.7). The identification and investigation of Luzp1, Rbms1 and Zranb2 is reported in 
this chapter. 
 
As for Nr2f2, investigation of these genes focused on verification of the ability of POU4F3 to 
bind  sites  in  their  predicted  promoter  regions  and  to  activate  transcription  in  reporter 
constructs  containing  these  regions.  Furthermore,  as  an  antibody  was  available  for 
ZRANB2  which  was  suitable  for  immunohistochemistry,  its  inner  ear  expression  profile 
was characterised to identify whether it is expressed in hair cells and thereby assess the 
likelihood of its being regulated by POU4F3 in vivo.  
5.1  Introduction to Luzp1, Rbms1 and Zranb2 
5.1.1  Luzp1 
The Luzp1 gene is located on mouse chromosome 4 (human chromosome 1) and encodes an 
mRNA with a long (3940bp) 3’ UTR that is suggested to be subject to rapid degeneration 
due to its AU rich content. The protein encoded by Luzp1 (LUZP1, also known as LUZP) 
was predicted to contain three leucine zipper motifs, numerous putative phosphorylation 
sites, eight potential glycosylation sites and three putative nuclear localization signals (Sun 
et al. 1996).  
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Of the predicted protein domains, the three leucine zipper motifs have been the focus of 
speculation over LUZP function. These domains are commonly seen in transcription factors 
where they mediate protein protein interactions. They are often preceded by an adjacent 
basic region that is involved in sequence specific DNA binding. Where this basic region is 
lacking, as is the case for LUZP1, leucine zipper containing proteins can interact with a 
wide variety of proteins of varying function and subcellular localization. Such proteins are 
less likely to be involved in transcriptional regulation. However, the predominantly nuclear 
localization  of  LUZP1  expression  identified  by  immunohistochemistry  in  neural  tissue 
suggests that it may have a transcription factor function despite not containing this basic 
region (Lee et al. 2001;Sun et al. 1996). 
 
Expression of LUZP1 is strongest in the brain with lower expression levels in the kidney 
and lung (Sun et al. 1996). Immunohistochemical analysis of the perirhinal cortex showed 
LUZP1 expression in the nuclei of neurons with weaker expression in dendrites (Sun et al. 
1996).  Its  expression  in  neural  tissue  was  further  investigated  by  Lee  et  al.  who 
demonstrated expression in pyramidal neurons in the cerebral cortex and hippocampus as 
well as neural tissue in teratomas (Lee et al. 2001). Luzp1 knockout mice die perinatally 
due to cardiac and neural tube defects. Some homozygotes display exencephaly and less 
severely  affected  animals  show  hypomorphic  development  of  the  brain  and  adjacent 
structures. These defects are due to neural tube closure defects that have been shown to be 
associated  with  ectopic  sonic  hedgehog  signalling  and  elevated  apoptosis  in  the  dorso 
lateral hindbrain neuroepithelium (Hsu et al. 2008).  
 
Based on these data, a working model of LUZP1 function proposes that it acts as a negative 
transcriptional regulator by binding to transcription factors via its leucine zipper motifs 
(e.g. bHLH transcription factors which have been shown to be inhibited by leucine zipper 
containing  proteins)  and  inhibiting  their  function.  Furthermore,  phosphorylation  of 
predicted sites in LUZP1 may acts as a means of modulating its function (Sun et al. 1996). 
However, the above model is almost entirely based on computational predictions and the 
ability of LUZP1 to dimerise and be phosphorylated has not been tested experimentally. 
The expression and function of LUZP1 in the inner ear has also not been investigated. 
5.1.2  Rbms1 
RBMS1 (also known as MSSP gene 2) is a 16 exon gene with a coding sequence of over 60kb. 
This sequence gives rise to alternative transcripts to produce the proteins MSSP 1, MSSP 2, 
SCR2 and human YC1 (Haigermoser et al. 1996;Kanaoka et al. 1994). MSSP (i.e. either 
MSSP 1 or MSSP 2) and SCR2 expression was found in all tissues examined though short 
MSSP transcripts were found to be abundantly expressed in testis tissue (Fujimoto et al. 
2000).   
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MSSP has been shown to have versatile functions that are, for the most part, relevant to its 
interaction with the proto oncogene c Myc. The first of its functions to be identified were 
those of DNA binding and replication. MSSP was found to bind to both the single  and 
double stranded forms of a putative DNA replication origin / transcriptional enhancer in 
the human c Myc gene (myc21) (Negishi et al. 1994). The DNA binding properties of MSSP 
1  and  MSSP 2  were  shown  to  be  identical  and  mediated  through  two  ribonucleoprotein 
binding  domains  (RNP 1A  and  RNP 1B)  which  are  both  contained  in  all  MSSP  family 
proteins and are required for DNA binding to an MSSP recognition sequence (TCTCTTA). 
Furthermore, these proteins were found to promote DNA replication, resulting in G1 to S 
phase cell cycle progression and this function was shown to require the integrity of almost 
the whole MSSP protein (Takai et al. 1994). The mechanism by which MSSP produces this 
effect has been investigated by GST ‘pull down’ assays and it was found to bind to the N 
terminus of the DNA polymerase alpha catalytic subunit both in vitro and in human cells. 
Furthermore, MSSP was able to stimulate DNA polymerase activity in vitro, suggesting 
that it forms part of the origin of DNA replication complex (tested at the DNA replication 
origin of the c-myc gene) and demonstrating a mechanism through which it can promote G1 
to S phase progression (Niki et al. 2000a). 
 
As  well  as  DNA  replication,  MSSP  has  been  shown  to  play  a  role  in  transcriptional 
regulation. It is able to bind to cMyc protein (which acts as a transcription factor as well as 
performing other functions (for review see Eilers et al. 2008)) in order to affect its DNA 
binding  ability.  cMyc  is  able  to  bind  to  a  DNA  consensus  sequence  (the  E box)  as  a 
heterodimer with a transcription factor called Max. This heterodimerisation takes place at 
the cMyc leucine zipper motif which, unlike in LUZP1, has a basic region on its N proximal 
side. MSSP 2 was shown to be able to bind to this basic region to form a cMyc/Max/MSSP 2 
ternary complex that abrogates the ability of cMyc/Max to bind, and therefore regulate, the 
E box  DNA  sequence  (Niki  et  al.  2000b).  Therefore,  MSSP  may  be  able  to  modulate 
transcriptional regulation at other cMyc target genes such as those that promote cellular 
growth e.g. eIF 2α (Rosenwald 1993). Furthermore, MSSP has been shown to be able to 
regulate  transcription  directly  e.g.  there  is  strong  evidence  that  it  is  able  to  directly 
transrepress the chicken alpha smooth actin gene at a site (TATCTTA) in the 5’ flanking 
region of this gene (Kimura et al. 1998). 
 
The  final  experimentally  verified  functions  of  Rbms1  gene  products  are  induction  of 
apoptosis and cell transformation (i.e. induction of neoplasia). Overexpression of MSSP 1 or 
MSSP 2  in  HeLa  cells  was  shown  to  result  in  apoptosis  in  a  dose dependent  manner 
through a Fas dependent mechanism (Iida et al. 1997;Nomura et al. 2005) and MSSP was 
shown  to  promote  cell  transformation  by  ras/myc  in  a  manner  dependent  on  its  RNP 
domains which have been shown to be necessary for all of its functions (Niki et al. 2000b).  
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Unlike Luzp1 and Zranb2, the regulation of RBMS1 has been investigated in some detail 
by  investigation  of  transcriptional  activity  at  its  5’  flanking  region.  Haigermoser  et  al. 
investigated the basal regulation of RBMS1 5’ flanking region constructs of differing length. 
A region from –1709 to +61 (relative to the identified transcriptional start site) was shown 
to be basally expressed in HeLa cells by luciferase assay. Deletion of the 5’ sequence of this 
construct  to  as  far  as   1283  resulted  in  an  approximately  two fold  increase  in  the 
transcription  of  the  sequence  and  further  deletions  resulted  in  a  reduction  in 
transcriptional activation to levels near or below that of the longest sequence tested. This 
analysis  identified  that  the  region  from   1709  to   1283  is  likely  to  contain  negative 
regulatory elements with positive regulatory elements present from  1283 to  196 and a 
region  from   488  to   196  being  responsible  for  an  approximately  four fold  reduction  in 
luciferase  production  when  deleted  (Haigermoser  et  al.  1996).  This  GC  rich  region  was 
thought to be regulated by SP1 or AP2 due to consensus sequences for these binding sites 
being  present  in  this  region  from  which  the   474  to   440  fragment  was  shown  to  be 
protected from DNAseI by two proteins – one of 38kDa one of 62kDa – that are activated in 
the G1 stage of the cell cycle. However, neither SP1 nor AP2 was able to bind this region in 
a DNA binding assay, and neither of the proteins that bind this region have been identified 
(Fujimoto et al. 1998;Haigermoser et al. 1996). 
 
The apparently wide reaching functions of Rbms1 are reflected by homozygous knockout 
mice that demonstrate an approximately 50% embryonic lethality rate, though surviving 
animals do not display any overt phenotype. This may be due to a similar protein, SCR3 – 
an MSSP family protein that is produced by a distinct gene – compensating for the lack of 
Rbms1 gene products. On closer examination, homozygous knockout mice were shown to 
have  retarded  testicular,  uterine  and  ovarian  development,  with  adult  females  showing 
disrupted serum progesterone levels in pregnancy (Fujimoto et al. 2001). As for Luzp1 and 
Zranb2, the function, expression and regulation of Rbms1 and its products has not been 
studied  in  the  inner  ear  and  the  inner  ears  of  Rbms1  knockout  mice  have  not  been 
investigated. However, given the versatility of its function and potential relevance to inner 
ear development, the actions of MSSP 1, MSSP 2 and Scr2 in the inner ear could be of 
particular interest. 
5.1.3  Zranb2 
Zranb2 (formerly known as  Zis and  Znf265) is  the most recently discovered of the four 
genes prioritised in this investigation and encodes ZRANB2, which has been shown to be 
able to induce alternate splicing of RNA transcripts (Adams et al. 2001;Karginova et al. 
1997).  ZRANB2  is  an  extremely  well  conserved  protein  with  human  and  rat  ZRANB2 
having  identical  protein  sequences  and  the  mouse  protein  differing  by  a  single  residue 
(Karginova et al. 1997). There are two splice variants of human and mouse ZRANB2 which  
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differ by ten amino acids with ZRANB2 1 (the longer form that contains exon 11 instead of 
exon 10) appearing to be more predominantly expressed than ZRANB2 2 (the shorter form 
that contains exons one to ten) (Li et al. 2008;Mangs et al. 2006;Nakano et al. 1998).  
 
The expression of Zranb2 mRNA has been widely investigated by Northern blot analysis 
which has shown it to be expressed in the brain, heart, liver, kidney, lung, testis, skin, 
placenta, muscle and pancreas (Adams et al. 2000;Karginova et al. 1997;Nakano et al. 1998). 
Its expression appears consistently lower in the lung and liver than in other tissues and the 
level  of  expression  and  detectable  transcripts  in  all  organs  appears  to  vary  between 
organisms and ages tested (Adams et al. 2000;Karginova et al. 1997;Nakano et al. 1998). 
Generally, its expression is stronger and more consistent between organs in foetal tissues, 
becoming reduced and more specific in adult tissues (Adams et al. 2000;Karginova et al. 
1997;Nakano  et  al.  1998).  This  pattern  of  expression  suggests  that  ZRANB2  is  widely 
required for development, progressing to more restricted functions in adult tissues (Adams 
et  al.  2000;Karginova  et  al.  1997;Nakano  et  al.  1998).  The  subcellular  localization  of 
ZRANB2  has  been  investigated  in  cell  lines  by  western  blot  and  immunofluorescence, 
showing expression throughout the nucleus or slightly more restricted to nuclear speckles 
(structures that contain pre mRNA) (Adams et al. 2001;Mangs et al. 2006). 
 
The  ZRANB2  protein  is  composed  (from  N terminal  to  C terminal)  of  two  zinc  fingers 
followed by a predicted nuclear localization signal and an Argine/Serine rich (RS) domain. 
The zinc finger motifs are separated by a 24 residue flexible linker (characteristic of an 
RNA recognition motif) and have been classified as Ran binding domains based on their 
homology to this motif (reviewed in Mangs et al. 2008). Though the nuclear localization 
signal was predicted to lie between the zinc finger and RS region, deletion assays with 
EGFP  fusion  proteins  revealed  that  this  region  is  not  required  or  sufficient  for  nuclear 
ZRANB2  expression  in  transfected  cultured  cells  and  that  it  is  the  RS  domain  that  is 
responsible  for  nuclear  localization  in  this  system.  However,  the  exact  location  of  the 
nuclear localization signal within the RS region of ZRANB2 remains unknown (Adams et al. 
2001). 
 
The zinc fingers of ZRANB2 underlie its ability to induce alternative splicing (Adams et al. 
2001). ZRANB2 is thought to be active at the early spliceosome where it binds to single 
stranded RNA containing AGGUAA repeats with micromolar affinity. Through this binding, 
it is thought to influence splice site selection as it may be able to contact both splice donor 
and splice acceptor sites to influence splicing (Loughlin et al. 2009). Supporting evidence for 
the  role  of  Zranb2  in  alternative  splicing  is  provided  by  its  ability  to  interact  with  the 
spliceosomal constituents SFRS17A, U1 70K and U2AF35 in yeast two hybrid assays and its 
colocalisation with these proteins in the nucleus (Adams et al. 2001;Mangs et al. 2006). 
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More  recently,  ZRANB2  has  been  suggested  to  play  a  role  in  immune  responses  as  its 
expression changes in response to Ureaplasma Urealyticum infection in Sertoli cells (both 
in cultured cells and in vivo) (Li et al. 2009) and viral infection (Finsterbusch et al. 2009) 
though the mechanisms of these observations have not been characterised. The regulation 
of Zranb2 has also not been characterised (Mangs et al. 2008). Though its function and 
expression are poorly understood, characterisation of the potential role of ZRANB2 in the 
inner ear through its involvement in alternative splicing may aid in the understanding of 
alternative splicing in hair cells, which is also poorly understood.  
5 Investigation of putative Luzp1, Rbms1 and Zranb2 regulation by POU4F3  182 
5.2  Identification  of  Luzp1,  Rbms1  and  Zranb2  as 
potential POU4F3 targets 
In  the  subtractive  hybridization  screen,  Luzp1,  Rbms1  and  Zranb2  were  identified  as 
putatively  upregulated  POU4F3  targets  from  three  clones  (D3,  FB5  and  FA8).  As 
previously  described  (sections  3.3.1),  these  clones  were  sequenced  and  adaptor 
oligonucleotides from the subtractive hybridization screen were identified and deleted from 
the  resulting  sequencing  files  (Figure  5.1a,  Figure  5.2a  and  Figure  5.3a).  The  trimmed 
sequences were submitted to the Ensembl BLASTN software to identify alignments to the 
Ensembl mouse cDNA library (Figure 5.1b, Figure 5.2 b and Figure 5.3 b) with the most 
significant match from the BLAST analysis being investigated as the corresponding gene 
for  each  clone.  Furthermore,  for  prioritised  genes,  all  matches  of  a  given  clone  to  its 
corresponding  gene  were  aligned  with  the  corresponding  gene  sequence  as  the  BLAST 
software does not return matches that are likely to have arisen due to chance e.g. due to 
single base pair repeats (Figure 5.1c, Figure 5.2c and Figure 5.3c).   
5.2.1  Clone D3 of the subtractive hybridization screen matches Luzp1 
On  BLAST  analysis,  the  trimmed  727bp  sequence  of  clone  D3  of  the  subtractive 
hybridization screen (Figure 5.1a) most significantly matched a 727bp region of the Luzp1 
3’UTR with 99.7% sequence identity (Figure 5.1b). The next match was of 23bp with 95.7% 
sequence identity to another gene and was therefore likely to have arisen by chance. The 
best match was confirmed by alignment of the trimmed sequence with the Ensembl Luzp1 
sequence which revealed a full alignment apart from a 1bp mismatch and a 1bp insertion 
(Figure 5.1c). Luzp1 was therefore selected as the corresponding gene for clone D3. 
5.2.2  Clone FB5 of the subtractive hybridization matches Rbms1 
Similarly,  the  trimmed  286bp  sequence  of  clone  FB5  (Figure  5.2a)  was  found  to  most 
significantly  match  a  region  in  the  Rbms1  gene  of  132bp  with  100%  sequence  identity 
(Figure 5.2b). All other matches were also to Rbms1. Alignment of the trimmed clone FB5 
sequence with the Ensembl Rbms1 sequence showed a full length match between clone FB5 
and Rbms1 of 99.7% sequence identity i.e. a 286bp match with a 1bp mismatch (Figure 
5.2c). Furthermore, the position of this alignment to Rbms1 (Figure 5.2b) suggested that 
clone FB5 corresponded to the shortest Rbms1 transcript in the Ensembl library. 
5.2.3  Clone FA8 of the subtractive hybridization matches Zranb2 
Finally, clone FA8 fully matched 108bp of the Zranb2 3’ UTR (Figure 5.3b), the next best 
match being 19bp long (100% sequence identity) and therefore likely to be due to chance. 
Alignment of the trimmed clone sequence (Figure 5.3a) with Zranb2 revealed that all 548bp 
of this sequence fully matched the corresponding region in the Zranb2 3’ UTR (Figure 5.3c). 
Zranb2  was  therefore  selected  as  the  corresponding  gene  for  clone  FA8. 
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Figure 5.1. Clone D3 of the subtractive hybridization screen matches Luzp1. 
a) adaptor sequences from the subtractive hybridization screen (red type) and non-specified 
bases (N) were deleted from the clone D3 sequence. (b) the full length of the trimmed clone 
matched a region in the Luzp1 3’ UTR with 99.7% sequence identity. This alignment is shown at 
the nucleotide level in (c). c.a, Ensembl sequence; c.b, trimmed clone D3.  
TCGAGCGGCCGCCCGGGCAGGTACCAATTGGCAGCCCTGAGAGTTAAAAGGAAACAGGCCCC
CTGTGGTGGTCCACTGAAGAGTATAGGAAATTAAGTCTGTGGCTCTTCTCTGCTGATAAAAAC
AGAGGGGCACCAAGCCCTGCCTCAAAATATCTCGTCAATAATTTTTGTCTTTGGGTGTTGAGC
CCTGGATTCTTCTGGTGCTGTAGCTCCTGGTGCCAAAGTCTGGATCTTTCCACATTTTAGCAGC
ACCAACACCTGCTGCTATTTGAAATGTTCTGTGGAAAAGGGACAGCTGTGGGATGCCATTTTG
AAAATCTGAGTGCAATAGCATTTGATTGTAACAATTATTTCAGGATATTTTGTTTCTTTAGTCT
GCACACTTTGTAGTCCTGCCATAAAGTAGATTTTATTTTTAAATACCTTCAGCATTGCAAATGT
TTATACCAAGCAAATGGAGGCTAGAGGGTTCAAGTCCCCTTGGGCCTCATATGGATGGCTAGA
CTGACTCTGATTTCAAGGTCGAAAGACATATCACTTCTGAAAACACCAAGATGTAACCTTTGG
GCCCAAGCCAGAAGCTGCAGGAAGCCTCCACATAGAAGGGAGACTGGTATTCAAACCATTGT
CTAATCAAGCCAAATATTCCCCACTAAAAGACCCACTTTCCTGACAGTGCTTCTCTAAAGTTTG
GGTAGGTGGCTAAATTGAGCCAGCAGGTCAGGAGTCTATGAGAGTTCTGAGTNCCTCGGCCG
CGAGCACGCT 
a) 
b) 
c) 
a)  
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Figure 5.2. Clone FB5 of the subtractive hybridization screen matches Rbms1. 
a) Full sequencing of clone FB5 was verified by identification of adaptor sequences and non-
specified bases (red type) from the subtractive hybridization screen. These were deleted from 
the sequence prior to BLAST analysis, leaving insert sequence alone (black type). b) Ensembl 
‘ContigView’ of the match of the trimmed insert sequence to the Rbms1 gene. Red boxes on the 
‘Blast hits’ row represent matches to the Rbms1 transcripts below. c) the trimmed clone FB5 
sequence (c.b) matches the Ensembl Rbms1 sequence (c.a) with a one base-pair mismatch.
NNNNNNNNNNANGCTGCAGACGCGTTACGTATCGGATCCAGAATTCGTGATT
AGCGTGGTCGCGGCCGAGGTACTTGTTTGGGTTCTGTCTCTTTTTCTGTCCTCC
ATCCGCAAACTTGCACAGTAAAGGTTCTGTAGGAGCAGAAACTCCTGGTGGG
GTCTTGATGAATTTTCCATTAAAATGACCAATTACAGCTTCGCATTTTTCCGTT
GATTCCATCCTGGCAAAGCCAACACCACGGCTGGCACCACTGGAATCACGTA
GGACCCTTGTAGAAATAACTTGTCCAAAGGGTTTGAGCATATTTTCAAGTTCC
TGCTCATCCATGGACAGCGGCAGGTTAGAAATGTACCTGCCCGGGCGGCCGC
TCGAAATCTGA 
a) 
b) 
c) 
a)  
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Figure 5.3. Clone FA8 of the subtractive hybridization screen matches Zranb2. 
a) Adapter oligonucleotide sequences and non-specified bases (red type) were trimmed from 
the clone FA8 sequence prior to BLAST analysis. This analysis (b) revealed that part of the 
clone FA8 sequence (red) matched Zranb2 known protein coding sequence (maroon). c) shows 
the  alignment  of  the  trimmed  FD8  sequence  (c.a)  with  the  matching  region  in  the  Ensembl 
Zranb2 sequence (c.b). 
NNNNNNNANNNNNANGCNGCAGACGCGTTACGTATCGGATCCAGAATTCGT
GATTAGCGTGGTCGCGGCCGAGGTACGATACTTTGTTTTCATCTTTAGATCAG
TTGAGAAGAGAAACACTCACTTTAAAATAAAAACATTTTGTTTGATCTGTCTA
CTAAACATCTTAGAAGGCTTTACTTATTTAAACTGCAGCAGACAAATACTAA
AGGAGAAACAGGAAAAATAATTCCCTCACAAGGAGCCCCAGCACAACTGTT
GTCCCTTATATACTTACCTTGCTTTTGCTGCTGAAGAGACTGTTAAAGAGAAA
CCTTTTAACTTTTAAACCAGAGAACAAAATGGATCTCAAGTGACCAGATTTTA
ATTTGAGAAATAAAACTCCAAAAGCATTTTAAGCCATATGGTTTTCTTTTTCA
GATGTGGAGAAAAATGATTTTGCTTAAATTGTGCAGAAATAAGAATTCTTCT
GTTACTTAGGTATCTGCAATGTTCAAAATCAGACATCACAAGGCAAATGTTC
ACTTAAATTCATGTCCCTGTCAGCCTGCCACTGAGAAACAGGTTTCAAAAGCT
TTCTTCAATTTGCTCATTAACTATGATTTAGCCTTTTTTAAAAATCCACCTGCC
CGGGCGGCCGCTCGAATCTG 
a) 
b) 
c) 
a)  
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5.3  Initial prioritisation of Luzp1, Rbms1 and Zranb2 
for investigation 
As  previously  described  (section  3.8),  Luzp1,  Rbms1  and  Zranb2  were  prioritised  for 
investigation over other putative POU4F3 target genes in part due to their known function 
and  availability  of  reagents  for  their  study.  The  investigation  of  the  known  function  of 
candidate genes was based on the GO units identified for these genes (see section 3.3.2) 
that  were  judged  with  additional  information  on  their  supporting  evidence  from  the 
literature.  The  availability  of  reagents  was  also  investigated  in  the  literature  and  in 
company catalogues. These analyses are reported here in detail.  
5.3.1  Selection of Luzp1 for investigation 
Unlike Nr2f2, Luzp1 was (and remains) an uncharacterised gene with only three GO units 
reported through the Ensembl genome browser (Table 5.1). The lack of GO units reflected 
the lack of published data for Luzp1 at the time of the analysis (2006) with only two papers 
reporting the predominantly nuclear expression of LUZP1 in neural tissue (some expression 
was seen in dendritic profiles) (Lee et al. 2001;Sun et al. 1996). Of the GO units identified, 
GO:0005634 refers to the nuclear LUZP1 expression pattern that is found in neurons and 
neural  tissue  in  teratomas  (Lee  et  al.  2001;Sun  et  al.  1996).  The  two  other  GO  units 
(GO:0003674 and GO:0008150) refer to the predicted leucine zipper motifs in LUZP1 that 
may mediate protein protein interactions and allow it to act as a transcription factor (Sun 
et al. 1996).  
 
Though the expression pattern of LUZP1 in the inner ear has not been investigated and its 
expression in the inner ear was not identified in  the online databases investigated (see 
section 3.6), the predominantly nuclear expression of this protein coupled with its predicted 
transcription  factor  function  suggest  that  it  may  play  an  interesting  role  in  hair  cell 
development and maintenance if expressed in these cells (Lee et al. 2001;Sun et al. 1996). 
Furthermore, the presence of two binding sites in the Luzp1 5’ flanking region with high 
similarity to known POU family binding sites (see sections 3.5 and 5.5.1), supported the 
possibility that Luzp1 is a directly regulated POU4F3 target. Therefore, despite not being 
able to obtain an anti LUZP1 antibody at the time of these analyses, Luzp1 was selected for 
further investigation due to its potentially interesting role in the inner ear. 
  
Table 5.1. Luzp1 GO units.  
ND, no biological data available, IDA, inferred from direct assay. 
GO ID  GO Term  Evidence Code 
GO:0003674  Molecular function  ND 
GO:0005634  Nucleus  IDA 
GO:0008150  Biological process  ND  
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5.3.2  Selection of Rbms1 for investigation 
NB  For clarity, Rbms1 gene products are collectively referred to as RBMS1 
though, in the literature, different isoforms are often referred to as MSSP 
(for MSSP-1 and/or MSSP-2) and Scr2. 
 
In  contrast  to  Luzp1,  RBMS1  has  experimentally  verified  DNA  binding  ability  and  is 
known to play a role in DNA replication (Negishi et al. 1994). The GO units identified for 
this  gene  reflected  this  as  well  as  proposed,  unproven  roles  in  RNA  processing  and 
translation  (Table  5.2).  However,  they  fail  to  identify  the  ability  of  RBMS1  to  act  as  a 
transcription factor (e.g. Kimura et al. 1998). These results demonstrate that, though this 
method  provides  a  useful  means  by  which  to  rapidly  assess  gene  function,  a  literature 
search is required for more sensitive and specific identification of target gene functions.  
 
As for Luzp1, the inner ear expression pattern for RBMS1 is unknown, though it has been 
found to be expressed in all organs examined by Northern blot (Fujimoto et al. 2000). Given 
that  the  processes  in  which  RBMS1  has  been  implicated  are  relevant  to  hair  cell 
development and maintenance, and as reagents were available for its study (an antibody, 
expression  construct  and  5’  flanking  region  luciferase  reporter  construct),  Rbms1  was 
selected for further investigation. 
 
Table 5.2. Rbms1 GO units. 
IEA, inferred from electronic annotation; TAS, traceable author statement; NAS, Non-traceable 
author statement; ND, no biological data available. 
GO ID  GO Term  Evidence Code 
GO:0000166  Nucleotide binding  IEA 
GO:0003690  Double stranded DNA binding  TAS 
GO:0003697  Single stranded DNA binding  TAS 
GO:0003723  RNA binding  NAS 
GO:0005634  Nucleus  IEA 
GO:0006260  DNA replication  TAS 
GO:0006396  RNA processing  TAS 
GO:0006445  Regulation of translation  TAS 
GO:0008372  Cellular component unknown  ND 
5.3.3  Selection of Zranb2 for investigation 
As for other candidate genes, Zranb2 GO units were obtained, examined and compared to 
those of other candidate genes in order to decide whether to pursue its putative regulation 
by POU4F3 in hair cells. Zranb2 had six identified GO units, four of which were supported 
by author statements and two of which were predicted based on a zinc finger domain in its 
sequence (Table 5.3). It was thought to be capable of binding DNA or RNA with the two zinc 
fingers in this domain (Karginova et al. 1997), though subsequent analysis of this region in 
ZRANB2 showed it to be an RNA binding protein (Plambeck et al. 2003).  
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Though this candidate gene was not as thoroughly characterised as others, its ability to 
influence splicing made it an interesting candidate for further investigation (Morris et al. 
2001),  i.e.  if  ZRANB2  is  expressed  in  hair  cells,  it  might  contribute  to  the  hair  cell 
phenotype through this process. Furthermore, it was possible to obtain a sample of an anti 
ZRANB2 antibody from a company, making it possible to rapidly assess its expression in 
the inner ear if found to be suitable for immunohistochemistry (as for LUZP1 and RBMS1, 
the  inner  ear  expression  pattern  of  ZRANB2  was  unknown).  Therefore,  Zranb2  was 
selected for further investigation. 
 
Table 5.3. Zranb2 GO units. 
TAS, traceable author statement; IEA, inferred from electronic annotation. 
 
5.4  Investigation of the inner ear expression patterns 
of selected genes 
Following candidate gene prioritisation, I aimed to identify whether the selected genes are 
expressed  in  the  POU4F3 expressing  hair  cells  of  the  inner  ear.  Such  coexpression  of 
POU4F3 with candidate genes would aid in the decision to continue the investigation of 
these genes as it would support the putative upregulatory relationships between POU4F3 
and these genes suggested by the subtractive hybridization screen. Two methods, RNA in 
situ hybridization and immunohistochemistry, are best suited to the assessment of target 
gene expression in situ. If a suitable antibody is available for the target gene of interest, 
immunohistochemistry is the most rapid and robust of these methods. Therefore, I searched 
the  literature  and  antibody  company  catalogues  to  identify  suitable  reagents  for  the 
intended analysis. 
 
Antibodies  were  found  to  be  available  for  LUZP1,  RBMS1  and  ZRANB2.  Therefore,  I 
attempted to obtain gifts or samples of these antibodies with which to investigate the inner 
ear expression patterns of these proteins. By this method, I was able to obtain an anti 
RBMS1 antibody from a collaborator (Dr H Ariga) which has been shown to recognise two 
Rbms1 alternative transcripts (MSSP 1 and MSSP 2). An anti ZRANB2 antibody sample 
was also obtained from a company (Abnova 2008a). I was, however, unable to obtain an 
anti LUZP1 antibody at this stage. 
GO ID  GO Term  Evidence Code 
GO:0003700  Transcription factor activity  TAS 
GO:0003723  RNA binding  TAS 
GO:0005634  Nucleus  TAS 
GO:0008270  Zinc ion binding  IEA 
GO:0008380  RNA splicing  TAS 
GO:0046872  Metal ion binding  IEA  
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5.4.1  Western  immunoblot  to  investigate  RBMS1  and  ZRANB2 
expression in UB/OC-1 and UB/OC-2 cells 
Prior to use in immunohistochemistry, the anti RBMS1 and anti ZRANB2 antibodies were 
used in western immunoblots. Though both of these antibodies had previously been shown 
to be suitable for use in western immunoblotting (see Abnova 2008a for anti ZRANB2;Takai 
et al. 1994 for anti RBMS1) this analysis was conducted to verify the specificity of these 
antibodies and to identify which RBMS1 and ZRANB2 isoforms might be expressed in the 
cells  investigated.  UB/OC 2  cells  were  selected  for  this  analysis  as  they  were  shown  to 
express Rbms1 and Zranb2 mRNAs and were therefore likely to express the corresponding 
proteins (Figure 3.1). As for a similar investigation of the anti NR2F2 antibody (section 
4.6.1), UB/OC 1 cell protein extract was included for comparison. UB/OC 1 and UB/OC 2 
whole cell protein extract was electrophoresed with a molecular weight marker on a 10% 
polyacrylamide gel and electroblotted onto a PVDF membrane for immunodetection. The 
transfer  of  sufficient  protein  to  the  membrane  for  immunodetection  was  confirmed  by 
Ponceau S staining.  
 
Figure 5.4 shows the results of immunoblots with the anti RBMS1 (Figure 5.4a) and anti 
ZRANB2 (Figure 5.4b) antibodies. For anti RBMS1, a single band of approximately 45kDa 
was  identified  which  was  consistent  with  its  previously  reported  molecular  weight  of 
approximately 50kDa (Figure 5.4a) (Kimura et al. 1998). This demonstrated the specificity 
of the anti RBMS1 antibody, though it was not possible to identify to which RBMS1 isoform 
this band might correspond based on the available literature. Having verified its specificity, 
this antibody was used in immunohistochemical investigations of the inner ear expression 
pattern of RBMS1. 
 
In the anti ZRANB2 immunoblot (Figure 5.4b), three bands were identifiable in the UB/OC 
1 cell lane and two bands were seen in the UB/OC 2 cell lane. The most dense of these 
bands is approximately 55kDa and matches the previously reported size of human ZRANB2 
identified by polyclonal rabbit antibodies (Adams et al. 2001;Li et al. 2008), though this is 
heavier than the predicted 38kDa of both the predicted protein size and the recombinant 
protein against which it was raised  (Abnova 2008a). Two less dense bands were also seen 
in UB/OC 1 whole cell protein extract. One was lighter and one was heavier than the most 
dense (55kDa) band. Only the 55kDa band and the lighter band were identified in UB/OC 2 
cell protein extract, though both of these bands were less dense in these cells. The latter 
difference may have been due to unevenness of protein loading onto the SDS PAGE gel or 
uneven transfer to the PVDF membrane as Ponceau staining of the membrane revealed 
that the protein concentration in the UB/OC 2 cell lane was slightly less dense than that in 
the UB/OC 1 cell lane (data not shown). However, as the assessment of relative levels of 
protein expression between cell types was not the focus of this experiment, the equality of 
protein concentration between cell types was not compared by equalising the membrane  
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with  an  antibody  to  a  housekeeping  gene.  This  pattern  raises  the  possibility  that  the 
expression  of  different  Zranb2  isoforms  may  be  influenced  by  differential  POU4F3 
expression between these two cell types, though the western blot would have to be repeated 
with confirmation of equal protein loading in order to confirm that the difference seen was 
not due to a lack of sufficient protein for detection in the UB/OC 2 lane.  
 
Two transcripts of Zranb2 are known to exist in humans and mice and many alternative 
transcripts have been identified by Northern blot (Adams et al. 2001;Li et al. 2008;Mangs et 
al. 2008;Nakano et al. 1998). Furthermore, the characterisation of regulation and potential 
autoregulation of Zranb2 is poor (Mangs et al. 2008). Therefore, these bands were assumed 
to have arisen due to alternate transcripts of Zranb2 though it is possible that the antibody 
used displays some non specific binding or that different ZRANB2 isoforms exist due to 
post translational modification. Given its affinity to a band of equivalent molecular weight 
to a known ZRANB2 isoform (55kDa), the antibody was judged to be sufficiently specific for 
immunohistochemical investigation of the ZRANB2 expression.  
 
 
Figure 5.4. RBMS1 and ZRANB2 expression in UB/OC-1 and UB/OC-2 cells. 
a) immunoblot analysis of UB/OC-1 and UB/OC-2 whole cell protein extract was carried out with 
an anti-RBMS1 antibody. This analysis revealed a single band of approximately 45kDa in both 
UB/OC-1 and UB/OC-2 protein extract lanes. b) the same analysis was carried out with an anti-
ZRANB2  antibody.  This  identified  a  band  of  approximately  55kDa  for  both  UB/OC-1  and 
UB/OC-2 cells. A heavier, less dense band of approximately 60kDa was also identified in these 
two cell types though a lighter band of approximately 46kDa was only identified in UB/OC-1 cell 
protein extract. 
OC-1 OC-2  
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5.4.2  Investigation of RBMS1 expression in the inner ear 
Having confirmed the sensitivity of the anti RBMS1 antibody by western blot, this antibody 
was used with cryosections of early postnatal rat cochleas, as for NR2F2 (see section 4.7), to 
characterise RBMS1 expression in this tissue. Several antibody dilutions were attempted 
and  an  alternative  detection  method  was  used  to  enhance  any  signal  (ABCelite  with 
DAB/Nickel enhancement (Vector)). However, no specific signal was identified. Therefore, 
immunofluorescence  experiments  were  attempted  in  UB/OC 2  cells  in  which  RBMS1 
expression had been confirmed by western blot. Again, no specific signal was detected (data 
not  shown)  and  the  antibody  was  therefore  determined  not  to  be  suitable  for  use  in 
immunohistochemistry. 
5.4.3  Investigation of ZRANB2 expression in the inner ear 
The  mouse  monoclonal  anti ZRANB2  antibody  was  also  used  in  immunofluorescence 
experiments with cryosections of rat inner ears at P0, P4 and P8 to identify any ZRANB2 
expression in this tissue and, particularly in hair cells. ZRANB2 expression was detected at 
P0 (Figure 5.5), though it was not detected at P4 or P8 (data not shown). At P0, all labelling 
appeared predominantly nuclear with stronger expression noted in cells of the cochlear duct 
compared to surrounding cells. Its subcellular localization in hair cells was also nuclear 
(arrows  Figure  5.5)  with  no  base to apex  gradient  of  expression  noted  within  sections. 
Furthermore, no difference in signal intensity was noted between hair cells and other cells 
of the cochlear duct (Figure 5.5). These results represent the first description of the cellular 
and  subcellular  localization  of  ZRANB2  in  the  inner  ear  and  require  verification  by 
replication, though they support the hypothesis that POU4F3 may regulate Zranb2 in hair 
cells.  Given  that  no  ZRANB2  expression  was  identified  by  P4  in  the  rat  cochlea,  the 
apparently  rapid  downregulation  of  its  expression  could  be  further  investigated  by 
examining  the  inner  ears  of  rats  at  intervening  ages  to  determine  the  pattern  of  this 
downregulation. 
5.4.4  Immunohistochemistry as a means of investigating the expression 
patterns of candidate genes 
The results of attempts to characterise the expression of candidate POU4F3 target genes 
presented in this section illustrate the strengths and weaknesses of the strategy used. The 
dependence  of  this  strategy  on  the  availability  of  a  suitable  antibody  for 
immunohistochemical investigation of candidate gene expression resulted in it not being 
possible  to  investigate  LUZP1  and  RBMS1  expression  in  the  inner  ear.  However,  the 
specificity  of  the  anti RBMS1  antibody  seen  in  western  blot  suggested  that  it  could  be 
valuable  for  future  investigations  e.g.  supershift  or  chromatin  immunoprecipitation 
(Nomura et al. 2005). In contrast, this strategy was suitable for investigation of ZRANB2 
expression  (as  it  had  been  for  NR2F2).  Furthermore,  the  cost  and  duration  of  this 
investigation was much lower and shorter than that of alternative strategies.  
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5.5  Design of oligonucleotides for EMSA analysis of 
Luzp1, Rbms1 and Zranb2 
Having selected candidate genes for investigation and attempted to characterise their inner 
ear expression patterns, the putative activation of all three remaining candidate genes by 
POU4F3  was  investigated.  As  previously  described  in  section  1.5.5,  it  is  thought  that 
POU4F3 is only able to transactivate target gene promoters once bound to DNA (Sud et al. 
2005) i.e. POU4F3 binding to target gene promoters is likely to be required if these genes 
are POU4F3 targets. Therefore, the identification of POU4F3 binding sites in target gene 
promoters would support the possibility that these genes are direct POU4F3 targets.  
 
As for Nr2f2 (section 4.8.1), remaining candidate gene promoters were predicted using the 
Genomatix Gene2Promoter software (see section  3.5.1)  and binding  sites  were predicted 
within these regions using the Genomatix MatInspector and ModelInspector programs (see 
section 3.5.2). Oligonucleotides were designed against these putative binding sites and used 
in EMSA analyses to determine whether POU4F3 is able to bind these regions in candidate 
gene 5’ flanking regions. 
5.5.1  Luzp1 promoter prediction, binding site identification and EMSA 
oligonucleotide design 
In the original BLAST analysis that identified Luzp1 as the corresponding gene for clone 
D3 of the subtractive hybridization screen (section 5.2.1), the clone sequence matched that 
of the Luzp 3’ UTR (Figure 5.1b). On subsequent analysis of the Luzp1 locus in the Ensembl 
genome  browser,  only  two  of  the  annotated  Luzp1  transcripts  contained  the  3’  UTR  to 
which  the  original  BLAST  match  for  LUZP1  was  found  (Figure  5.6a).  Of  these  two 
transcripts, one was a Havana protein coding transcript and one was an Ensembl protein 
coding  transcript  (Figure  5.6a).  As  Havana  protein  coding  transcripts  are  manually 
annotated and therefore based on greater evidence than automatically annotated Ensembl 
protein  coding  transcripts,  the  Havana  protein  coding  transcript  was  selected  as  the 
transcript that most likely corresponded to that identified by the subtractive hybridization 
screen (Figure 5.6a, arrowhead) (Ensembl 2009). 
 
This  transcript  comprised  four  exons,  and  two  promoters  corresponding  to  four exon 
transcripts  were  identified  by  the  Gene2Promoter  promoter  prediction  program  (Figure 
5.6a,  GXP_287887  and  GXP_287889).  Only  one  of  these  transcripts  had  confirmed  5’ 
sequencing and was, therefore, selected as the best matching promoter for MatInspector 
and ModelInspector analysis (Figure 5.6b, GXP_287887 (arrowhead)).  
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The selected promoter was submitted for both MatInspector and ModelInspector analysis. 
Though an OCT1 PBXC module was identified by the ModelInspector program (data not 
shown),  this  was  more  distal  to  the  TSS  than  two  predicted  high  stringency  POU4F3 
binding sites (V$3.02 in Figure 5.6c). These two sites were selected for EMSA analysis and 
another  site  was  not  selected  for  analysis  because  of  its  lower  matrix  similarity  to  its 
corresponding POU binding site. 
 
LUZP1BS1 was designed against a region that, on the sense strand, contained a predicted 
Brn 4  (POU3F)  binding  site  of  0.942  matrix  similarity  and,  on  the  antisense  strand, 
contained a POU4F3 binding site of 0.940 matrix similarity. To this sequence, additional 
bases were included in the 5’ region so that the end of the oligonucleotide did not interfere 
with POU4F3 binding and to the 3’ region to include POUHD binding motifs (TAAT) and to 
ensure that this end of the oligonucleotide did not interfere with POU4F3 binding either 
(Table 5.4). 
 
LUZP1BS2 was designed against a predicted POU4 (Brn 3) binding site of 0.940 matrix 
similarity. This was the second highest stringency match identified and was more proximal 
to the TSS than LUZP1BS1. As for LUZP1BS1, additional sequence was included both 5’ 
and 3’ to the predicted binding site in order to avoid interference with POU4F3 binding in 
EMSA analysis (Table 5.4). 
 
Table 5.4. Luzp1 EMSA oligonucleotides. 
Two EMSA oligonucleotides were designed using the MatInspector software to identify putative 
POU4F3  binding  sites  in  a  predicted  Luzp1  promoter  region  (GXP_287887).  Bases  were 
included  both  3’  and  5’  to  the  sites  identified  (underlined)  to  ensure  that  the  ends  of  the 
oligonucleotides would not interfere with POU4F3 binding. 
Name  Sequence 
LUZP1BS1   GGATTATCACATTTAATTAATCAACTAATTAACTAATTAAC 
LUZP1BS1RC  GTTAATTAGTTAATTAGTTGATTAATTAAATGTGATAATCC 
LUZP1BS2  ATTTTTATTTATTAATTTTTTCATGTGGATG 
LUZP1BS2RC  CATCCACATGAAAAAATTAATAAATAAAAAT 
5.5.2  Rbms1 promoter prediction, binding site identification and EMSA 
oligonucleotide design 
Though putative mouse Rbms1 5’ flanking region POU4F3 binding sites were originally 
predicted  by  the  same  method  used  for  Nr2f2  (section  4.8.1),  Luzp1  (section  5.5.1)  and 
Zranb2  (section  5.5.3),  this  analysis  was  repeated  for  the  human  RBMS1  gene  as  the 
luciferase reporter constructs obtained and cloned for this gene contained segments of the 
human RBMS1 5’ flanking region (see section 5.7.1). 
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In the original Rbms1 (mouse) promoter prediction, the Genomatix promoter GXP_149594 
(Figure 5.7a) was found to best match a 14 exon Rbms1 transcript in the Ensembl database. 
Comparative  genomic  analysis  between  the  transcripts  corresponding  to  this  promoter 
(Figure 5.7a, green  boxes) and human transcripts in  the Genomatix transcript database 
revealed that the human transcripts (Figure 5.7a, salmon boxes) that most closely matched 
the GXP_149594 transcripts corresponded to the human promoter GXP_286780. 
 
This  promoter  was  subjected  to  MatInspector  and  ModelInspector  analysis  in  order  to 
identify putative POU4F3 binding sites and modules. As for Luzp1, suitable modules were 
identified in the RBMS1 5’ flanking region by the ModelInspector software, though these 
were  further  5’  than  predicted  (MatInspector)  POU  binding  sites  and  were  therefore 
thought to not be contained in an available RBMS1 5’ flanking region reporter construct. 
Though  many  MatInspector  predicted  POU  binding  sites  were  later  shown  to  not  be 
contained in this reporter construct either, they were thought to be included at the time of 
this analysis. Therefore, EMSA probes were designed against the binding sites identified by 
the MatInspector software.  
 
RBMS1BS1 was designed against a cluster of POU factor binding sites which contained a 
V$BRN5.03 binding site of 0.791 matrix similarity (Brn 5 (POU6) binding sites have been 
shown to be similar to POU4F binding sites (Rhee et al. 1998)) and two V$BRNF binding 
sites of 0.898 and 0.910 matrix similarity (Figure 5.7b). As before, additional bases were 
included both 5’ and 3’ to these predicted binding sites in EMSA oligonucleotides to prevent 
the ends of the oligonucleotide from interfering with POU4F3 binding (Table 5.5). 
 
RBMS1BS2  was  designed  against  a  cluster  of  predicted  POU4F  binding  sites  which 
contained  a  high  stringency  (0.909  matrix  similarity)  predicted  POU4F3  binding  site 
(Figure 5.7b) and a lower stringency (0.793) POU4F binding site, plus additional flanking 
bases (Table 5.5). As a third cluster of POU family binding sites of comparable stringency to 
the two described was identified in GXP_286780, a third EMSA probe (RBMS1BS3) was 
designed for RBMS1. This probe encompassed a V$BRN5.04 binding site of 0.907 matrix 
similarity (i.e. of higher stringency than the V$BRN5 binding site in RBMS1BS1) (Figure 
5.7b)  as  well  as  two  POU4F3  binding  sites  of  high  stringency  (0.923  and  0.927)  plus 
flanking bases (Table 5.5).  
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Table 5.5. RBMS1 EMSA oligonucleotides. 
Three  EMSA  oligonucleotides  were  designed  using  the  MatInspector  software  to  identify 
putative POU4F3 binding sites in a predicted RBMS1 promoter region (GXP_286780). As for 
other  EMSA  oligonucleotides,  bases  were  included  both  3’  and  5’  to  the  sites  identified 
(underlined) to ensure that the ends of the oligonucleotides would not interfere with POU4F3 
binding. 
Name  Sequence 
RBMS1BS1   TTATCATATAAAAATAATAACTGTTTAACAAAATAATGCATTCCAG 
RBMS1BS1RC  CTGGAATGCATTATTTTGTTAAACAGTTATTATTTTTATATGATAA 
RBMS1BS2  CGGGGACCAATTAATTCCATTAAATTATATCTAGTTA 
RBMS1BS2RC  TAACTAGATATAATTTAATGGAATTAATTGGTCCCCG 
RBMS1BS3  TTGTGAAAAAAAATTACTGGGCGGTGGGAAGTGAACGATTAATCAGATTTCCTCT 
RBMS1BS3RC  AGAGGAAATCTGATTAATCGTTCACTTCCCACCGCCCAGTAATTTTTTTTCACAA 
5.5.3  Zranb2 promoter prediction, binding site identification and EMSA 
oligonucleotide design 
The mechanism of the putative upregulation of Zranb2 by POU4F3 was first investigated, 
as for other candidate genes, by the identification of putative POU4F3 binding sites in its 
promoter. On searching the Gene2Promoter software for predicted Zranb2 promoters, five 
options  were  returned.  Of  these,  three  were  eliminated  as  they  were  solely  based  on 
computational  prediction  (Figure  5.8a)  and  two  promoters  remained  in  the  analysis: 
GXP_132934 and GXP_430971. The supporting evidence for the former was a single one 
exon transcript of gold standard (i.e. this transcript had verified full 5’ sequencing, showing 
that  its  transcriptional  start  site  had  been  identified),  whereas  the  latter  had  14  gold 
standard  transcripts of ten exons i.e. the same exon number as the Ensembl transcript 
identified by the BLAST analysis (Figure 5.3a and Figure 5.8b). Therefore, GXP_430971 
was selected for further analysis.  
 
The MatInspector and ModelInspector programs were used to analyse the Zranb2 promoter 
in order to identify putative POU4F3 transcription factor binding sites. The ModelInspector 
analysis yielded an OCT1 PIT1 module, a HOXF HOXF OCT1 module and a PIT1 GATA 
module  within  the  region  examined.  Of  these,  the  OCT1 PIT1  module  was  selected  for 
further  investigation  as,  unlike  the  other  modules  identified,  both  of  the  transcription 
factors  that  relate  to  this  module  are  POU  domain  transcription  factors.  Therefore,  an 
EMSA  oligonucleotide,  ZRANB2BS1  (Table  5.6),  was  designed  to  a  region  within  this 
module that had a POU4F (Brn 3) binding site on the sense strand and a POU6 (Brn 5) 
binding site on the opposite strand (Figure 5.8c). Furthermore, the POU4F binding site had 
the second highest matrix similarity of the sites identified by the MatInspector software for 
this promoter.  
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Of  the  three  remaining  putative  binding  sites  at  the  highest  level  of  stringency, 
ZRANB2BS2 was designed against the middle site (Table 5.6). This site was selected as it 
had a higher matrix similarity to its corresponding (POU6/Brn 5) sequence than the most 3’ 
site (0.818 compared to 0.807) and was closer to the Zranb2 transcriptional start site than 
the  most  5’  site,  though  it  had  slightly  lower  matrix  similarity  to  its  corresponding 
transcription factor’s DNA sequence matrix (0.818 compared to 0.832) (Figure 5.8c). 
 
As for other EMSA oligonucleotides, additional sequence was included at both ends of both 
Zranb2  EMSA  oligonucleotides  to  ensure  that  the  ends  of  the  oligonucleotide  did  not 
interfere with POU4F3 binding. Furthermore, the 3’ region of both oligonucleotides was 
extended to encompass a additional homeodomain binding motifs (TAAT) (Table 5.6). 
 
 
 
Figure 5.8. Prediction of potential POU4F3 binding sites in the Zranb2 promoter. 
(Legend on page 200) 
a)  
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Table 5.6. Zranb2 EMSA oligonucleotides. 
Zranb2  EMSA  oligonucleotides  designed  against  the  Genomatix  predicted  promoter 
GXP_430971. Additional bases included at both ends are underlined.  
Name  Sequence 
ZRANB2BS1   TCATAGTTTTATACATTATGGTTTTAATTTTAC 
ZRANB2BS1RC  GTAAAATTAAAACCATAATGTATAAAACTATGA 
ZRANB2BS2  TAGTAACAGCACAATTAATAATAATTGAATTAA 
ZRANB2BS2RC  TTAATTCAATTATTATTAATTGTGCTGTTACTA 
5.6  EMSA  analysis  of  POU4F3  binding  sites  in 
candidate gene 5’ flanking regions 
Having designed EMSA oligonucleotides to predicted POU4F3 binding sites in the Luzp1, 
Rbms1 and Zranb2 5’ flanking regions, these oligonucleotides were used in EMSA analysis 
to identify whether in vitro translated POU4F3 and POU4F3 from UB/OC 2 cell nuclear 
protein extract is able to bind to them. 
5.6.1  In vitro translated POU4F3 is able to bind sites in the Luzp1 and 
Zranb2 promoter 
The ability of POU4F3 to bind LUZP1BS1, LUZP1BS2, ZRANB2BS1 and ZRANB2BS2 was 
tested by EMSA analysis with in vitro translated protein. As for Nr2f2 (section 4.8.2), the 
radiolabelled EMSA oligonucleotides were incubated either alone, with in vitro translated 
POU4F3  or  with  in  vitro  translated  luciferase  protein  that  had  been  produced  using  a 
rabbit  reticulocyte  lysate  in  vitro  transcription  /  translation  system.  Samples  were 
electrophoresed on a 4% polyacrylamide gel that was then dried and autoradiographed. If 
the oligonucleotide is bound by the in vitro translated POU4F3, then a bandshift is seen in 
the in vitro translated POU4F3 lane that is of higher molecular weight than bands seen in 
the lane containing probe alone. If this bandshift is not due to non specific binding by other 
proteins in the in vitro translation mixture, it should not be present in the lane containing 
in vitro translated luciferase protein.  
 
On EMSA analysis (see Figure 5.9), LUZP1BS1 (Figure 5.9a), LUZP1BS2 (Figure 5.9b), 
ZRANB2BS1 (Figure 5.9c) and ZRANB2BS2 (Figure 5.9d) all show bandshifts produced by 
in vitro translated POU4F3.  These bandshifts are shown to be due to POU4F3 by their 
absence or marked reduction in in vitro translated luciferase protein containing lanes and 
lanes that do not contain in vitro translated protein (Figure 5.9, arrowheads). These results 
show that in vitro translated POU4F3 is able to bind to the four EMSA oligonucleotides 
tested in this analysis, though they do not show whether this binding is sequence specific. 
Therefore, the sequence specificity of these interactions was tested by competition with a 
POU4F3 consensus sequence (see section 5.6.3). As for Nr2f2 binding sites previously tested, 
this  analysis  was  carried  out  with  UB/OC 2  cell  nuclear  protein  extract  as  POU4F3  in 
UB/OC 2 cells is more likely to have the post translational modifications required for native 
DNA binding that in vitro translated protein may lack (see section 4.8.3).  
5
 
I
n
v
e
s
t
i
g
a
t
i
o
n
 
o
f
 
p
u
t
a
t
i
v
e
 
L
u
z
p
1
,
 
R
b
m
s
1
 
a
n
d
 
Z
r
a
n
b
2
 
r
e
g
u
l
a
t
i
o
n
 
b
y
 
P
O
U
4
F
3
 
2
0
2
 
 
F
i
g
u
r
e
 
5
.
9
.
 
B
i
n
d
i
n
g
 
o
f
 
i
n
 
v
i
t
r
o
 
t
r
a
n
s
l
a
t
e
d
 
P
O
U
4
F
3
 
t
o
 
p
r
e
d
i
c
t
e
d
 
b
i
n
d
i
n
g
 
s
i
t
e
s
.
 
 
T
h
e
 
a
b
i
l
i
t
y
 
o
f
 
i
n
 
v
i
t
r
o
 
t
r
a
n
s
l
a
t
e
d
 
P
O
U
4
F
3
 
t
o
 
b
i
n
d
 
t
o
 
p
r
e
d
i
c
t
e
d
 
b
i
n
d
i
n
g
 
s
i
t
e
s
 
i
n
 
t
h
e
 
L
u
z
p
1
 
a
n
d
 
Z
r
a
n
b
2
 
g
e
n
e
 
5
’
 
f
l
a
n
k
i
n
g
 
r
e
g
i
o
n
s
 
w
a
s
 
t
e
s
t
e
d
 
b
y
 
E
M
S
A
 
a
n
a
l
y
s
i
s
.
 
O
l
i
g
o
n
u
c
l
e
o
t
i
d
e
s
 
t
h
a
t
 
h
a
d
 
b
e
e
n
 
d
e
s
i
g
n
e
d
 
a
g
a
i
n
s
t
 
p
r
e
d
i
c
t
e
d
 
P
O
U
4
F
3
 
b
i
n
d
i
n
g
 
s
i
t
e
s
 
w
e
r
e
 
r
a
d
i
o
l
a
b
e
l
l
e
d
 
w
i
t
h
 
[
γ
-
3
2
P
]
A
T
P
 
a
n
d
 
i
n
c
u
b
a
t
e
d
 
w
i
t
h
 
i
n
 
v
i
t
r
o
 
t
r
a
n
s
l
a
t
e
d
 
P
O
U
4
F
3
 
o
r
 
l
u
c
i
f
e
r
a
s
e
 
p
r
o
t
e
i
n
.
 
L
U
Z
P
1
B
S
1
 
(
a
)
,
 
L
U
Z
P
1
B
S
2
 
(
b
)
,
 
Z
R
A
N
B
2
B
S
1
 
(
c
)
 
a
n
d
 
Z
R
A
N
B
2
B
S
2
 
(
d
)
 
a
l
l
 
s
h
o
w
 
i
n
 
v
i
t
r
o
 
t
r
a
n
s
l
a
t
e
d
 
P
O
U
4
F
3
-
s
p
e
c
i
f
i
c
 
b
a
n
d
s
h
i
f
t
s
 
(
a
r
r
o
w
h
e
a
d
s
)
,
 
i
.
e
.
 
b
a
n
d
s
 
t
h
a
t
 
a
r
e
 
p
r
e
s
e
n
t
 
i
n
 
P
O
U
4
F
3
-
c
o
n
t
a
i
n
i
n
g
 
l
a
n
e
s
 
a
n
d
 
a
b
s
e
n
t
 
o
r
 
m
a
r
k
e
d
l
y
 
a
t
t
e
n
u
a
t
e
d
 
i
n
 
i
n
 
v
i
t
r
o
 
t
r
a
n
s
l
a
t
e
d
 
l
u
c
i
f
e
r
a
s
e
 
p
r
o
t
e
i
n
 
c
o
n
t
a
i
n
i
n
g
 
l
a
n
e
s
.
 
T
h
i
s
 
i
n
d
i
c
a
t
e
s
 
t
h
a
t
 
i
n
 
v
i
t
r
o
 
t
r
a
n
s
l
a
t
e
d
 
P
O
U
4
F
3
 
i
s
 
a
b
l
e
 
t
o
 
b
i
n
d
 
t
o
 
a
l
l
 
f
o
u
r
 
o
f
 
t
h
e
 
o
l
i
g
o
n
u
c
l
e
o
t
i
d
e
s
 
t
e
s
t
e
d
.
 
N
B
,
 
t
h
e
 
a
u
t
o
r
a
d
i
o
g
r
a
p
h
 
i
m
a
g
e
s
 
p
r
e
s
e
n
t
e
d
 
i
n
 
t
h
i
s
 
f
i
g
u
r
e
 
a
r
e
 
c
r
o
p
p
e
d
 
f
o
r
 
p
r
e
s
e
n
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
.
a
)
b
)
P
O
U
4
F
3
N
o
 
p
r
o
t
e
i
n
L
u
c
i
f
e
r
a
s
e
P
O
U
4
F
3
N
o
 
p
r
o
t
e
i
n
L
u
c
i
f
e
r
a
s
e
c
)
P
O
U
4
F
3
N
o
 
p
r
o
t
e
i
n
L
u
c
i
f
e
r
a
s
e
d
)
P
O
U
4
F
3
N
o
 
p
r
o
t
e
i
n
L
u
c
i
f
e
r
a
s
e
 
 
 
 
L
U
Z
P
1
B
S
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L
U
Z
P
1
B
S
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Z
R
A
N
B
2
B
S
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Z
R
A
N
B
2
B
S
2
  
5 Investigation of putative Luzp1, Rbms1 and Zranb2 regulation by POU4F3  203 
 
 
Figure 5.10. Binding of in vitro translated POU4F3 to RBMS1BS1-3. 
EMSA  analysis  of  in  vitro  translated  POU4F3  binding  to  oligonucleotides  designed  against 
predicted binding sites in the RBMS1 5’ flanking region. This analysis revealed POU4F3-specific 
bandshifts  for  RBMS1BS1  (a,  arrowheads).  However,  a  streaky  appearance  was  noted  in 
protein-containing lanes in the analysis of RBMS1BS2 (b) and RBMS1BS3 (c), most likely due 
to protein-DNA complex degradation. During attempts to improve the resolution of bands for 
RBMS1BS2 and RBMS1BS3, POU4F3 binding to these oligonucleotides was identified by an 
alternative method and this method was, therefore, not pursued further.  
  
a)
No protein
POU4F3
Barhl1
No protein
POU4F3
Barhl1 b)
No protein
POU4F3
Barhl1 c)
    RBMS1BS1                       RBMS1BS2                       RBMS1BS3    
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5.6.2  EMSA analysis of in vitro translated POU4F3 binding to predicted 
binding sites in the RBMS1 promoter 
The  ability  of  in  vitro  translated  POU4F3  to  bind  RBMS1  EMSA  oligonucleotides  was 
investigated  in  the  same  way  as  for  other  candidate  genes.  Though  POU4F3 specific 
binding to RBMS1BS1 was seen (Figure 5.10a), autoradiographs for RBMS1BS2 (Figure 
5.10b) and RBMS1BS3 (Figure 5.10c) appeared streaky in protein containing lanes. This 
appearance  can  be  caused  by  protein DNA  complex  dissociation  or  inappropriate  salt 
concentrations (Hellman et al. 2007). It was not thought to be due to the in vitro translated 
Barhl1 or POU4F3 used, as these proteins were able to bind to RBMS1BS1 (Figure 5.10a).  
 
Another  abnormality  noted  in  these  experiments  was  the  appearance  of  RBMS1BS3  on 
autoradiography in the absence of protein (Figure 5.10c). This oligonucleotide appears have 
migrated much slower than RBMS1BS1 or RBMS1BS2 through the polyacrylamide gel in 
similar conditions, though this difference may have been due to its greater length (55bp) 
compared to RBMS1BS1 (46bp) and RBMS1BS2 (37bp) or concatamerisation of the probe. 
As attempts were being made to optimise EMSA conditions to improve the resolution of 
bandshifts  and  thereby  determine  whether  POU4F3  is  able  to  bind  to  RBMS1BS2  and 
RBMS1BS3, POU4F3 binding to these oligonucleotides was identified using UB/OC 2 cell 
nuclear protein extract (see section 5.6.3). Given that the question posed in the in vitro 
translate experiment had been answered by this alternative method, it was not pursued 
further.  The  limitations  of  not  having  identified  POU4F3  binding  to  RBMS1BS1  and 
RBMS1BS2 by this method are discussed below. 
5.6.3  POU4F3 extracted from UB/OC-2 cell nuclei is able to bind to all 
oligonucleotides tested 
The EMSAs conducted with in vitro translated proteins demonstrated that POU4F3 is able 
to bind to LUZP1BS1 & 2, RBMSBS1 and ZRANB2BS1 & 2. However, they do not show 
whether this binding is sequence specific i.e. that POU4F3 is binding to these binding sites 
because of their sequence and not through an abnormal protein DNA interaction produced 
by  the  conditions  of  the  assay  despite  these  conditions  being  kept  as  physiological  as 
possible.  Therefore,  to  verify  that  the  binding  seen  is  sequence specific,  a  competition 
gradient experiment was carried out (as for NR2F2BS1 & 2; reported in section 4.8.3). 
 
In  this  experiment  an  increasing  amount  of  non radiolabelled  POU4F3  consensus 
oligonucleotide was added to EMSA reactions. An oligonucleotide that is known to be bound 
by POU4F3 (POU4F3 consensus) was used for LUZP1BS1 & 2 and ZRANB2BS1 & 2 with 
an oligonucleotide called ‘Prox6 consensus’ – a new POU4F3 consensus sequence designed 
by  SD  –  used  for  RBMS1BS1 3.  In  separate  EMSA  reactions,  a  non radiolabelled  non 
POU4F3 binding sequence (‘AP4 consensus’ for LUZP1BS1&2 and ZRANB2BS1&2; ‘Prox6 
mutant’  for  RBMS1BS1 2)  was  included  (see  Table  5.7).  Sequence specific  binding  was  
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identifiable on autoradiographs as a bandshift that that was attenuated or abolished by 
sufficient POU4F3 consensus sequence competition but not as strongly attenuated by an 
equivalent amount of non specific competitor. Though the non specific competitor should 
not  attenuate  POU4F3  bandshifts  as  much  as  specific  competition,  any  competing 
oligonucleotide  can  reduce  specific  binding  when  present  at  great  excess,  causing  some 
attenuation of these bandshifts (Hellman et al. 2007). The competitor oligonucleotides also 
serve to identify which of the bandshifts produced by the UB/OC 2 cell nuclear extract is 
due  to  POU4F3  and  (within  experiments)  demonstrates  the  relative  POU4F3 binding 
affinity of test oligonucleotides. 
 
Autoradiographs of experiments with LUZP1BS1 & 2 (Figure 5.11), RBMS1BS1 3 (Figure 
5.12)  and  ZRANB2BS1  &  2  (Figure  5.13)  revealed  POU4F3  sequence specific  banding 
patterns for all oligonucleotides tested (arrowheads in Figure 5.11, Figure 5.12 and Figure 
5.13).  For  LUZP1BS1  (Figure  5.11a),  three  such  bandshifts  were  seen  with  the  highest 
affinity bandshift being greatly attenuated by 1000x POU4F3 consensus competition and 
restored  by  AP4  consensus  competition.  Similar  bandshifts  were  seen  for  LUZP1BS2 
(Figure 5.11b), with four POU4F3 specific bandshifts seen, the highest affinity of which was 
abolished by 1000x POU4F3 consensus competition. In contrast, only one POU4F3 specific 
bandshift  was  identified  for  RBMS1BS1  (Figure  5.12a),  RBMS1BS2  (Figure  5.12b), 
RBMS1BS3 (Figure 5.12c), ZRANB2BS1 (Figure 5.13a) and ZRANB2BS2 (Figure 5.13b). 
For the RBMS1 5’ flanking region binding sites, RBMS1BS2 and RBMS1BS3 appeared to 
be of approximately equal affinity, requiring 1000x Prox 6 consensus competition to greatly 
attenuate the POU4F3 specific bandshift; RBMS1BS1 required only 500x Prox 6 consensus 
competition to abolish its equivalent bandshift suggesting a lower POU4F3 binding affinity 
for this site. Of the Zranb2 5’ flanking region binding sites, ZRANB2BS1 appeared to have 
slightly higher affinity for POU4F3 than ZRANB2BS2, requiring 500x POU4F3 consensus 
competition instead of 100x POU4F3 consensus competition to abolish its POU4F3 specific 
bandshift.  Therefore, the relative  affinity of the  binding sites  tested correlates with  the 
Genomatix predictions of their matrix similarity to known binding sites (see section 5.5). 
 
These bandshifts can be attributed to POU4F3 as it is expressed in UB/OC 2 cells (where 
POU4F1  and  POU4F2  are  not  expressed);  all  oligonucleotides  except  RBMS1BS2  and 
RBMS1BS3  were  shown  to  be  bound  by  in  vitro  translated  POU4F3;  and  POU4F3 
sequence specific  bandshift  patterns  were  seen  for  all  oligonucleotides  tested.  Further 
evidence of these bands being produced by POU4F3 would be provided by a ‘supershift’ 
analysis,  though  no  suitable  antibody  exists  for  this  analysis.  For  RBMS1BS2  and 
RBMS1BS3, greater evidence of POU4F3 binding could be obtained by optimisation of the 
EMSA with in vitro translated POU4F3 to reduce the streakiness seen in previous attempts 
of this assay as, in the absence of a supershift analysis, this would support the evidence 
that the POU4F3 sequence specific bands identified in Figure 5.12b and c are produced by 
POU4F3.  
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The evidence provided by the EMSA analyses described above shows that POU4F3 is able 
to bind sites in the Luzp1, RBMS1 and Zranb2 5’ flanking regions. As POU4F3 sequence 
specific  binding  was  seen  at  all  the  binding  sites  identified  by  analysis  of  predicted 
candidate gene promoters (nine binding sites in total), the strategy used to identify these 
sites appears highly sensitive (see section 5.5). If POU4F3 is able to bind these sites in vivo, 
and if candidate gene upregulation is verified, it may be able to transactivate the candidate 
genes identified by the subtractive hybridization at the sites identified. Such binding could 
be  investigated  by  chromatin  immunoprecipitation  experiments.  However,  despite 
preliminary attempts to investigate the binding of a POU4F3 fusion protein to these sites 
by this method (in cell lines) at a very late stage of this investigation, such binding was not 
seen. Furthermore, the practical limitations of antibody and tissue availability made the 
investigation of native POU4F3 binding to these sites in hair cells impractical at this stage 
(see Chapter 6). 
  
Table 5.7. Consensus sequence oligonucleotides for competition assays. 
POU4F3 consensus 1 and AP4 are reproduced from Table 4.2 for ease of reference. Prox 6 
consensus and Prox 6 mutant oligonucleotides were designed by SD. Mutant bases in Prox 6 
mutant are underlined. 
Name  Sequence 
POU4F3 consensus 1  CACGCATAATTAATCGC 
AP4 consensus  CTAGCCCAGCTGTGGCAGCCC 
Prox 6 consensus  TCGATCTCCTGCATAATTAATTACGCCG 
Prox 6 mutant  TCGATCTCCTGCATAAGCAAGCACGCCG 
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Figure 5.11. Binding of UB/OC-2 cell nuclear protein extract to LUZP1BS1 & 2. 
EMSAs were performed using [γ-32P]ATP labelled DNA oligonucleotides which corresponded 
to two predicted high-stringency POU binding sites in the Luzp1 gene promoter (LUZP1BS1 and 
LUZP1BS2).  Oligonucleotides  were  incubated  with  non-radiolabelled  POU4F3  or  AP4 
consensus binding site to determine bandshifts due to sequence-specific POU4F3 binding. This 
analysis revealed POU4F3-specific banding patterns for both LUZP1BS1 (a, arrowheads) and 
LUZP1BS2 (b, arrowheads), indicating that POU4F3 from UB/OC-2 cell nuclear extract is able 
to bind both oligonucleotides. 
a)  b)  
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Figure 5.13. Binding of UB/OC-2 cell nuclear protein extract to ZRANB2BS1 & 2. 
a)  radiolabelled  binding  site  one  (ZRANB2BS1)  was  incubated  with  /  without  UB/OC-2  cell 
nuclear  extract  and  with  varying  amounts  of  non-radiolabelled  POU4F3  or  AP4  consensus 
binding  site.  The  same  assay  was  conducted  using  ZRANB2BS2  (b).    Both  experiments 
demonstrate a banding pattern that is likely to be due to POU4F3 contained in the UB/OC-2 cell 
nuclear protein extract used (arrowheads). 
a)  b)  
5 Investigation of putative Luzp1, Rbms1 and Zranb2 regulation by POU4F3  210 
5.7  Activation of candidate gene 5’ flanking regions 
by POU4F3 
 
The  results  of  the  subtractive  hybridization  suggest  that  all  three  of  the  remaining 
prioritised candidate genes (Luzp1, Rbms1 and Zranb2) are activated by POU4F3 (Table 
3.1). In order to verify and characterise this regulation, the ability of POU4F3 to activate 
the  5’  flanking  regions  of  candidate  genes  (which  are  likely  to  form  part  of  the  gene 
promoter)  was  tested  by  luciferase  reporter  gene  assays.  In  order  to  carry  out  these 
experiments,  plasmid  constructs  containing  the  5’  flanking  region  of  a  candidate  gene 
upstream of luciferase cDNA were obtained from collaborators or cloned. Such constructs 
are occasionally referred to as promoter constructs for convenience though the ability of the 
candidate  gene  5’  flanking  regions  used  to  act  as  full  length  promoters  has  not  been 
demonstrated. These constructs were cotransfected with a POU4F3 expression construct in 
ND7 cells and their response was assessed by luminometry. ND7 cells were selected for 
these  assays  as  they  had  been  shown  to  be  suitable  for  this  application  in  previous 
experiments with Nr2f2 promoter reporter constructs.  
5.7.1  Cloning of candidate gene 5’flanking region reporter constructs 
 
Luzp1 
As no luciferase reporter promoter construct existed for Luzp1, a construct containing 2.8kb 
of  the  Luzp1  5’  flanking  region  was  cloned  and  named  LUZP1p2.8kb.  Primers  were 
designed to amplify the 2.8kb sequence from mouse genomic DNA and this was cloned into 
the pDrive cloning vector prior to subcloning into the pGL4.10 luciferase reporter construct 
(which  contains  a  luciferase  gene  that  is  codon  optimised  for  expression  in  mammalian 
cells) and sequencing to verify insert orientation. The sequence cloned encompassed both 
LUZP1BS1 and LUZP1BS2. 
 
RBMS1 
A vector containing 1.3kb of the RBMS1 5’ flanking region was kindly provided by Dr H 
Ariga (RBMS1p1.3kb). In this reporter construct, the RBMS1 5’ flanking region had been 
cloned into the promoterless pGV B luciferase reporter vector (Haigermoser et al. 1996). 
The regulation of this vector by POU4F3 had not been assessed. Therefore, an empty pGV 
B vector (i.e. pGV B without the RBMS1 5’ flanking region) was created by excision of the 
RBMS1 5’ flanking region to assess regulation of the vector by POU4F3 in luciferase assay. 
 
Notably,  RBMS1p1.3kb  only  contains  RBMS1BS3  and  does  not  contain  RBMS1BS1  or 
RBMS1BS2  which  lie  upstream  of  this  RBMS1  5’  flanking  sequence.  Therefore,  to 
encompass these binding sites, an RBMS1 5’ flanking region reporter construct was cloned  
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in  our  laboratory  (by  SD)  by  excising  5.1kb  of  the  RBMS1  5’  flanking  sequence  from  a 
plasmid  containing  21kb  of  the  RBMS1  5’  flanking  sequence  in  the  pUC19  vector  (also 
kindly provided by Dr H Ariga) and inserting the 5.1kb sequence into the pGL4.10 vector.  
 
Zranb2 
As for Luzp1, no luciferase reporter constructs existed for the Zranb2 promoter.  Therefore, 
a  3.2kb  region  of  the  Zranb2  5’  flanking  region  that  includes  ZRANB2BS1  &  2  was 
amplified  from  mouse  genomic  DNA  and  cloned  into  the  pDrive  cloning  vector  prior  to 
subcloning into the pGL4.10 vector. As the GC content of the region immediately 5’ to the 
Zranb2 transcriptional start site (TSS) was too high for suitable primer design and, given 
that designing a primer 5’ to this region might exclude the core promoter from the cloned 
sequence, I designed the 3’ PCR primer to a region immediately downstream of the TSS. As 
the cloned promoter would contain the Zranb2 TSS, the primer was designed to be in frame 
with the luc2 TSS in the pGL 4.10 vector to avoid interference with luciferase transcription. 
The  fragment  amplified  with  these  primers  was  ligated  into  pDrive  and  the  KpnI XbaI 
fragment  of  this  construct  was  subsequently  inserted  into  the  KpnI NheI  site  of 
pGL4.10[luc2]. Correct insertion of the amplified sequence was verified by sequencing. This 
reporter construct was named ZRANB2p3.2kb. 
5.7.2  Regulation of LUZP1p2.8kb by POU4F3 
The  ability  of  POU4F3  to  regulate  a  Luzp1  promoter  construct  (LUZP1p2.8kb)  was 
investigated by luciferase assay. LUZP1p2.8kb was cotransfected with increasing amounts 
of a POU4F3 expression construct (pSi Pou4f3) and pRL null for normalization of luciferase 
values to transfection efficiency. The total amount of DNA transfected was maintained at a 
constant level with empty pSi vector. An identical assay was carried out with the dreidel 
expression construct (pSi Dreidel) in place of pSi Pou4f3 to ensure that any response seen 
was due to the specific action of POU4F3. The empty pGL4.10 vector has previously been 
show to show modest (1.4 fold) regulation by POU4F3 in ND7 cells in experiments in our 
laboratory (by JK). 
 
The results of this experiment show that the LUZP1p2.8kb responds to 1 g of cotransfected 
pSi Pou4f3 with a two fold upregulation (Figure 5.14). This response is likely to be due to 
specific  regulation  by  POU4F3  as  the  response  of  the  promoter  construct  to  the  same 
amount of pSi Dreidel revealed a smaller (1.4 fold) upregulation. However, the difference in 
regulation  by  POU4F3  and  dreidel  mutant  protein  is  modest.  The  results  presented  in 
Figure 5.14 represent the results of two separate experiments with each condition assayed 
in  triplicate  i.e.  six  samples  per  data  point.  In  order  to  verify  the  small  difference  in 
regulation  between  POU4F3  and  dreidel  mutant  POU4F3,  a  greater  number  of  repeats 
would  be  required  to  ensure  that  the  difference  seen  is  not  due  to  chance  and  thereby 
provide  stronger  evidence  that  the  LUZP1p2.8kb  regulation  seen  is  POU4F3 specific.  
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5.7.3  Regulation of RBMS1p1.3kb and RBMS1p5.1kb by POU4F3 
The  ability  of  POU4F3  to  regulate  the  RBMS1p1.3kb  promoter  construct  was  tested 
similarly to LUZP1p2.8kb (section 5.7.2) though assays were repeated a different number of 
times. Furthermore, due to problems with low transfection efficiency, the amount of pRL 
null  included  in  experiments  where  RBMS1p1.3kb  and  pSi Dreidel  or  pGV B  and  pSi 
Pou4f3 were cotransfected was increased to 50ng to ensure sufficient sea pansy luciferase 
production for detection on luminometry. 
 
These  experiments  showed  that  RBMS1p1.3kb  is  activated  by  increasing  amounts  of 
POU4F3.  At  the  largest  amount  of  pSi Pou4f3  (1 g)  RBMS1p1.3kb  is  activated  2.7 fold 
compared to transfections with an equivalent amount of empty pSi vector.  This effect was 
shown  to  be  POU4F3 specific  and  not  caused  by  regulation  of  the  pGV B  plasmid  into 
which  the  1.3kb  Rbms1  promoter  is  cloned  as  control  experiments  demonstrated  that 
RBMS1p1.3kb activity is repressed by 1 g pSi Dreidel and pGV B is repressed by 1 g pSi 
Pou4f3 (Figure 5.15). 
 
Given  that  POU4F3  has  been  shown  to  bind  the  RBMS1BS3  binding  site  contained  in 
RBMS1p1.3kb by EMSA analysis (Figure 5.12c), it is likely that the upregulation of this 
reporter construct by POU4F3 is produced at this site. As well as RBMS1BS3, two other 
sites (RBMS1BS1 and RBMSBS2) were shown to be bound by POU4F3 in EMSA analysis. 
A construct containing a longer fragment (5.1kb) of the RBMS1 5’ flanking sequence that 
encompassed these sites as well as RBMS1BS1 was cloned in order to identify whether 
their inclusion affected RBMS1 5’ flanking region activation by POU4F3 (see section 5.7.1). 
 
The activation of 200ng RBMS1p5.1kb cotransfected with 0ng or 1 g pSi Pou4f3 and 50ng 
pRL null was compared to RBMS1p5.1kb cotransfected with 0ng or 1 g pSi Dreidel and 
10ng pRL null. Figure 5.16 shows that RBMS1p5.1kb is upregulated 2.6 fold by 1 g pSi 
Pou4f3 – an activation which is similar to that of RBMS1p1.3kb when cotransfected with 
equivalent amounts of pSi Pou4f3. As for RBMS1p1.3kb, this response was shown to be 
POU4F3 specific  as  pSi Dreidel  is  unable  to  activate  RBMS1p5.1kb.  Furthermore,  the 
response seen is not due to regulation of the pGL4.10 vector which only shows a 1.4 fold 
response to POU4F3 in these conditions as determined by JK in our laboratory.  
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Figure 5.16. Regulation of RBMS1p5.1kb by POU4F3. 
200ng  RBMS1p5.1kb  was  cotransfected  with  either  pSi-Pou4f3  and  50ng  pRL-null  or  pSi-
Dreidel with 10ng pRL-null in ND7 cells. The total amount of DNA transfected was kept constant 
using the empty pSi expression vector. RBMS1p5.1kb showed a 2.6-fold response to 1 g pSi-
Pou4f3 and this response was shown to be POU4F3-specific as dreidel mutant POU4F3 did not 
activate RBMS1p5.1kb. SV40e, SV40 enhancer / early promoter; SV40l, SV40 late poly(A). 
 
 
Taken  together,  the  POU4F3 specific  activation  of  two  different  RBMS1  promoter 
constructs  in  two  different  reporter  vectors  (pGV B  for  RBMS1p1.3kb  and  pGL4.10  for 
RBMS1p5.1kb)  clearly  demonstrates  the  ability  of  POU4F3  to  activate  the  RBMS1  5’ 
flanking  region  in  vitro.  Furthermore,  these  results  and  EMSA  data  that  demonstrate 
POU4F3 binding to three sites in the RBMS1 5’ flanking region strongly suggest that this 
activation  is  produced  by  a  direct  mechanism  i.e.  that  POU4F3  binds  to  the  RBMS1  5’ 
flanking region to produce this activation in this cellular context. 
 
Though  it  is  tempting  to  speculate  that  RBMS1BS1  and  RBMS1BS2  are  unlikely  to 
influence POU4F3 regulation of the RBMS1 promoter because RBMS1p5.1kb does not show 
a larger response than the construct that only contains RBMS1BS3 (RBMS1p1.3kb), this is 
not  necessarily  the  case  as  RBMS1p5.1kb  may  contain  binding  sites  for  transcription 
factors that mediate repression of RBMS1. Furthermore, it is known to contain the  1283 to 
 1709  region  (which  contains  RBMSBS1  and  RBMS1BS2)  that  reduces  basal  RBMS1  5’ 
flanking region activation in HeLa cells (Haigermoser et al. 1996). Therefore, the preferred 
method  for  assessment  of  the  putative  contribution  of  each  binding  to  site  to  POU4F3 
activation of RBMS1 promoter reporter constructs remains site directed mutagenesis.  
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5.7.4  Assessment of ZRANB2p3.2kb regulation by POU4F3 
A luciferase assay was carried out with the ZRANB2p3.2kb luciferase reporter construct as 
for RBMS1p5.1kb. As before, the reporter construct was cotransfected with pRL null (to 
control for variation in transfection efficiency and cell number) and either pSi Pou4f3 or 
pSi Dreidel.  The  results  of  this  assay  (Figure  5.17)  show  that  ZRANB2p3.2kb  is 
upregulated 1.6 fold by 1 g pSi Pou4f3 and 2.1 fold by 1 g pSi Dreidel. This shows that the 
Zranb2 5’ flanking region cloned is not specifically activated by POU3F3. 
 
The unusually large response of ZRANB2p3.2kb to dreidel mutant POU4F3 and high levels 
of  basal  luciferase  production  seen  with  this  construct  suggest  that  any  protein specific 
activation may be masked in the conditions used to investigate its regulation. Due to the 
inclusion of the Zranb2 transcriptional start site in ZRANB2p3.2kb, basal regulation of this 
promoter in ND7 cells, which have been shown to express ZRANB2 (data not shown), may 
be  sufficient  to  mask  any  POU4F3 specific  effect.  This  hypothesis  could  be  tested  by 
subcloning a promoter construct that does not include the Zranb2 transcriptional start site 
or  by  assaying  ZRANB2p3.2kb  activation  in  cells  that  do  not  constitutively  express 
ZRANB2  to  reduce  the  suggested  background  regulation,  though  the  transcriptional 
environment  in  such  cells  may  not  be  suitable  for  the  assessment  of  POU4F3  function. 
However, based on current evidence (Figure 5.17), ZRANB2p3.2kb does not appear to be 
activated by POU4F3 and, therefore, Zranb2 is unlikely to be a true target of POU4F3. 
 
 
Figure 5.17. ZRANB2p3.2kb is not regulated by POU4F3. 
Cotransfections were carried out for ZRANB2p3.2kb as for other promoter constructs tested. In 
this experiment 200ng of the reporter construct was cotransfected with differing amounts of pSi-
Pou4f3  (with  50ng  pRL-null)  or  pSi-Dreidel  (with  10ng  pRL-null)  in  ND7  cells.  Though  the 
promoter demonstrated a 1.6-fold increase in luciferase production in the presence of 1000ng 
pSi-Pou4f3, a 2.1-fold response was seen with an equivalent amount of pSi-Dreidel. Therefore, 
ZRANB2p3.2 does not appear to be specifically activated by POU4F3. SV40e, SV40 enhancer / 
early promoter; SV40l, SV40 late poly(A).  
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5.8  Summary  and  discussion  of  candidate  gene 
activation by POU4F3  
Luzp1, Rbms1 and Zranb2 were suggested to be POU4F3 target genes by a subtractive 
hybridization  screen  in  UB/OC 2  cells.  These  genes  were  prioritised  for  further 
investigation on the basis of their potential roles in hair cell development and survival; the 
availability of reagents for their study; and the identification of putative POU4F3 binding 
sites in their predicted promoter regions. 
 
I first attempted to determine the inner ear expression patterns of these candidate genes by 
immunohistochemistry.  As  Zranb2  was  the  only  candidate  gene  (apart  from  Nr2f2)  for 
which I was able to obtain an antibody that was suitable for immunohistochemistry, its 
inner  ear  expression  pattern  was  characterised.  This  revealed  widespread  ZRANB2 
expression in the P0 cochlea that declined to undetectable levels by P4. It was noted to be 
expressed  in  hair  cells  at  P0,  suggesting  that  it  is  coexpressed  with  POU4F3,  which  is 
known  to  be  expressed  in  hair  cells  at  this  stage.  This  coexpression  supported  the 
possibility that POU4F3 might regulate Zranb2 in hair cells. Given that it was not possible 
to obtain suitable antibodies to investigate LUZP1 and RBMS1 expression in the inner ear, 
RNA in situ hybridization could be used in future work to investigate their expression. 
 
Following the investigation of candidate gene inner ear expression, putative regulation of 
target  genes  by  POU4F3  was  investigated  at  the  transcriptional  level.  Bioinformatic 
software was used to identify POU4F3 binding sites in predicted target gene promoters and 
putative POU4F3 binding sites were identified in these regions. The identification of high 
stringency predicted POU4F3 binding sites aided in the selection of these candidate genes 
for further investigation and oligonucleotides designed against predicted binding sites were 
used  in  a  protein DNA  binding  assay  (EMSA)  to  determine  whether  POU4F3  can  bind 
oligonucleotides that correspond to these sites in candidate gene promoters. 
 
This analysis revealed that POU4F3 is able to bind to two sites in the Luzp1 5’ flanking 
region, three sites in the RBMS1 5’ flanking region and two sites in the Zranb2 5’ flanking 
region. These binding sites therefore represent potential locations for POU4F3 regulation of 
candidate  target  genes.  Having  demonstrated  that  POU4F3  is  able  to  bind  sites  in 
candidate gene 5’ flanking regions, its ability to activate candidate gene 5’ flanking region 
luciferase reporter constructs that contain these binding sites was assessed. 
 
Candidate  gene  5’  flanking  regions  were  cloned  for  Luzp1,  Rbms1  and  Zranb2  and  a 
luciferase  reporter  construct  was  obtained  for  Rbms1.  The  Luzp1  promoter  construct 
(LUZP1p2.8kb) and two RBMS1 promoter constructs (RBMS1p1.3kb and RBMS1p5.1kb) 
were shown to be activated by POU4F3, supporting the hypothesis that POU4F3 is able to  
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regulate the 5’ flanking regions of these genes in the context of genomic DNA. However, 
POU4F3 was shown not to be able to specifically upregulate the Zranb2 promoter construct 
ZRANB2p3.2kb.  
 
Based on the above evidence, Luzp1 is suggested to be modestly regulated by POU4F3. 
Therefore, the upregulation of LUZP1p2.8kb should be confirmed by repetition of luciferase 
assays  (section  Figure  5.14)  and  putative  sites  at  which  POU4F3  might  produce 
upregulation of this reporter construct (i.e. LUZP1BS1 and LUZP1BS2) should by mutated 
(as  for  NR2F2BS1  and  NR2F2BS2)  in  order  to  identify  whether  these  are  the  sites  of 
activation  and,  therefore,  whether  POU4F3  is  likely  to  directly  activate  LUZP1p2.8kb. 
Results from these experiments will, furthermore, provide stronger evidence that POU4F3 
might upregulate Luzp1 in vivo. In order to investigate the relevance of any interaction in 
the inner ear, LUZP1 expression requires investigation. Since the conclusion of the studies 
reported in this chapter, an anti LUZP1 antibody has been obtained and is currently being 
used to attempt to identify whether LUZP1 is expressed in the inner ear. 
 
Unlike  Luzp1,  the  evidence  for  POU4F3  upregulation  of  the  Rbms1  5’  flanking  region 
reporter constructs, RBMS1p1.3kb and RBMS1p5.1kb is strong. Therefore, RBMS1BS1 3 
should be mutated in these constructs to identify which, if any, of these is responsible for 
the activations seen at these promoters. As for LUZP1, the expression pattern of RBMS1 in 
the inner ear remains to be characterised and would require an antibody that is suitable for 
immunohistochemistry to be obtained or RNA in situ hybridizations to be conducted. Such 
experiments  would  identify  whether  Rbms1  is  expressed  in  hair  cells  and,  therefore, 
whether Rbms1 activation by POU4F3 is likely to be relevant to hair cell development and 
maintenance. Alternatively, reverse transcriptase PCR strategies or investigation of Rbms1 
knockout mouse inner ears may identify whether it plays a role in hair cell development or 
survival. 
 
ZRANB2 has been shown to be expressed in the inner ear and two sites in its promoter 
have  been  shown  to  be  bound  by  POU43  by  EMSA  analysis.  However,  the  ability  of 
POU4F3  to  activate  the  Zranb2  5’  flanking  region  has  not  been  characterised  as  the 
reporter construct cloned (ZRANB2p3.2kb) displays strong basal regulation in ND7 cells 
that  may  mask  any  transcriptional  effect  of  POU4F3.  Therefore,  a  Zranb2  promoter 
construct should be cloned that omits the transcriptional start site to attempt to abolish 
this basal regulation. Alternatively the response of ZRANB2p3.2kb to POU4F3 could be 
assayed in a cell type that does not exhibit high basal regulation of this construct. However, 
given that POU4F3 has been shown to activate some target gene promoters in a cell specific 
manner, attempts should be made to ensure that the transcriptional environment in the 
cell type chosen is likely to reflect that of neuronal or sensory epithelial cells. 
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The  varying  levels  of  evidence  for  the  expression  and  POU4F3  regulation  of  candidate 
genes reported above demonstrates the difficulty of investigating a large number of genes 
following  a  screen  such as  a  subtractive  hybridization  (discussed  further  in  Chapter  6). 
However, they also demonstrate the value of obtaining clear evidence of candidate gene 
expression  and  regulation  in  order  to  prioritise  these  genes  for  further  investigation, 
thereby allowing more effective allocation of limited resources.  Therefore, based on the 
current evidence available for Luzp1, Rbms1 and Zranb2, the interaction between POU4F3 
and Rbms1 appears to be the best candidate for further investigation. This is because, the 
RBMS1  5’  flanking  region  reporter  constructs  tested  demonstrate  the  most  robust 
activation  in  response  to  POU4F3  and  RBMS1  is  known  to  be  involved  in  many  roles 
relevant to hair cell maintenance and survival (see section 5.1.2). However, a priority in 
such an investigation would be to identify whether RBMS1 is expressed in hair cells in 
order to determine whether the regulatory relationship seen in ND7 cells and the known 
functions of RBMS1 are relevant to the development and maintenance of these cells.  
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6   
GENERAL DISCUSSION 
The investigation reported in this thesis represents an attempt to better understand the 
mechanism by which POU4F3 mediates hair cell differentiation and survival. We aimed to 
clarify  why  hair  cells  fail  to  terminally  differentiate  and  survive  in  homozygous  Pou4f3 
knockout mice and how the human deafness caused by POU4F3 mutation (DFNA15) occurs 
(Collin  et  al.  2008;Vahava  et  al.  1998;Xiang  et  al.  1998).  As  POU4F3  is  a  transcription 
factor with no other identified function, these phenotypes are almost certainly caused by 
dysregulation of POU4F3 target genes.  
 
At  the  time  that  this  investigation  was  commenced  in  our  laboratory,  subtractive 
hybridization was selected to identify POU4F3 target genes, as it was the most appropriate 
strategy available. The selection of this strategy, as well as other methodologies applied in 
this  investigation,  reflects  ongoing  difficulties  in  the  analysis  of  inner  ear  biology.  In 
particular,  the  investigation  of  hair  cells  presents  unique  challenges  as  these  cells  are 
relatively  inaccessible,  making  it  difficult  to  obtain  sufficient  material  for  molecular 
analysis. Furthermore, these cells are mitotically quiescent and must therefore be isolated 
from  primary  tissue  prior  to  investigation.  Finally,  it  is  difficult  to  use  standard 
methodologies and reagents to investigate gene regulation in these cells, requiring time 
consuming  and  potentially  costly  methods  to  be  used  for  their  investigation  e.g.  viral 
transfection. 
 
As  previously  discussed  (section  3.3),  the  subtractive  hybridization  itself  presented  the 
challenge of managing, prioritising and investigating a large number of candidate genes. In 
contrast  to  a  similar  experiment  conducted  in  our  laboratory  for  another  inner  ear 
transcription  factor  that  only  revealed  four  differentially  expressed  clones  (unpublished 
data, VG), the present study yielded a large number of differentially expressed clones. This 
is likely to not only reflect differences in the methodology used (i.e. the stringency by which 
differentially expressed transcripts were identified) but also the nature of POU4F3 function 
i.e. POU4F3 is likely to produce its effects by the subtle modulation of a large number of 
genes which, in turn, mediate hair cell survival and maintenance by a summative action 
rather than it simply activating the expression of known hair cell structural components to  
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produce  the  hair  cell  phenotype.  The  results  of  this  subtractive  hybridization  therefore 
represented  a  difficult  middle ground  whereby  the  potentially  differentially  expressed 
genes  identified  are  too  numerous  to  all  be  investigated  but  too  few  to  submit  to 
bioinformatic  software,  developed  for  microarray  studies,  that  might  be  able  to  provide 
information on the systems level effect of POU4F3 e.g. by extracting common pathways 
that candidate target genes are involved in by literature mining (Munir et al. 2004). 
 
The  method  by  which  target  genes  were  prioritised  for  investigation  was,  therefore,  a 
difficult and sometimes subjective process, with ongoing experiments revealing potentially 
interesting results for genes that were not originally prioritised for investigation by this 
method. Thus, the outcomes seen identify the strengths and weaknesses of the strategy 
employed. For example, the identification of genes with available (and obtainable) reagents 
allowed for the rapid verification and characterisation of NR2F2 and ZRANB2 expression in 
the early postnatal inner ear. However, the lack of available reagents for other candidate 
genes led to their investigation not being pursued despite subsequent work demonstrating 
potentially interesting roles for these genes e.g. recent work with RCN1 has shown that it 
is expressed in hair cells in the P1 mouse inner ear (unpublished data). 
 
The  case  of  Rcn1  and  other  genes  investigated  herein  also  illustrate  a  general  problem 
reaffirmed  by  the  present  study:  that  many  of  the  large  online  databases  of  gene 
information, expression etc. are still incomplete and sometimes misleading. For example, 
clones that were originally not found to significantly match genomic DNA in the mouse 
genome  (through  BLAST  analysis)  can  now  be  seen  to  match  genes  in  this  database. 
Therefore,  such  resources  cannot  be  used  as  a  reliable  replacement  for  appropriately 
reported information in the scientific literature, though they may eventually incorporate 
this information. 
 
Turning  now  to  the  evidence  identified  for  candidate  gene  expression  in  the  ear  and 
potential  regulation  by  POU4F3.  Immunohistochemistry  proved  to  be  a  rapid  and  cost 
efficient method by which to investigate candidate gene expression in the inner ear. In this 
study, it was effective for characterising NR2F2  expression (section 4.7) and identifying 
ZRANB2 expression (section 5.4.3).  
 
Future work for NR2F2 will focus on verifying and explaining differences in its expression 
in the mouse and rat inner ears; characterising the suggested nuclear to cytoplasmic shift 
in its expression seen in the basal P8 rat cochlea; and verifying that POU4F3 is able to 
regulate its expression in this system (see below). Future work for ZRANB2 will focus on 
verifying and characterising its apparently rapid downregulation between P0 and P4 rat 
inner ears. It would also be interesting to examine its expression in development i.e. around 
the time of onset of POU4F3 expression, in order to see what relationship the expression  
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patterns of the two genes bear (if any). Furthermore, the investigation of the potential for 
ZRANB2 to induce alternative splicing in the inner ear could be of particular interest.  
 
As previously mentioned, LUZP1 expression is currently being investigated in the inner ear 
and investigation of Rbms1 expression is dependant on obtaining a suitable antibody for 
immunohistochemistry or pursuing RNA in situ hybridization (which has been attempted 
without success) to characterise its expression. Though RNA in situ hybridization may be 
required for future work, its use at earlier stages of the investigation would have been less 
efficient than immunohistochemistry which was shown to be an efficient means of assessing 
candidate gene expression in the inner ear in this study. For all of the genes that were 
found  to  be  expressed  in  the  inner  ear,  greater  information  on  the  potential  effect  of 
POU4F3 on their regulation could be provided by quantification of their level of expression 
(e.g. by quantitative PCR), though the technical impediments to this may be substantial, 
depending on their expression pattern.  
 
In terms of the investigation of transcriptional regulation reported here, the strategy used 
(identification of POU4F3 binding to sites in target gene 5’ flanking regions and luciferase 
assay  of  target  gene  reporter  promoter  constructs)  appeared  to  be  highly sensitive.  The 
binding  sites  predicted  by  the  Genomatix  programs  used  (MatInspector  and 
ModelInspector) were all shown to be bound by POU4F3 which, in comparison to previous 
experiments in our laboratory, is a substantial improvement compared to older versions of 
this software. Therefore, the existing positional weight matrix and contextual information 
for  POU factor  binding  contained  in  the  Genomatix  database  appears  to  be  extremely 
accurate though, as the TransFac database is no longer being maintained, it is a shame 
that no freely available resource for the collation of transcriptional regulatory information 
now exists. This deficit hindered attempts to investigate the basic mechanisms by which 
POU4F3 binds and activates target gene promoters. 
 
Luciferase assays of reporter constructs with the luciferase gene under the regulation of 
candidate  gene  5’  flanking  regions  demonstrated  that  POU4F3  is  able  to  activate  these 
regions for Nr2f2, Luzp1 (pending verification) and RBMS1 with further work required to 
identify  whether  it  is  able  to  activate  the  Zranb2  5’  flanking  region.  Furthermore, 
activation of the Nr2f2 5’ flanking region tested was shown to occur at identified binding 
sites by site directed mutagenesis, though the individual contribution of each of these sites 
remains  to  be  determined.  Future  experiments  will  focus  on  determining  whether  the 
binding  sites  identified  in  the  Luzp1  and  RBMS1  5’  flanking  regions  are  the  loci  for 
regulation  of  their  reporter  constructs.  This  can  be  investigated  by  site directed 
mutagenesis, as for Nr2f2. Furthermore, demonstration of the ability of POU4F3 to bind 
these sites in a more physiological context than that of the EMSA analysis will provide 
evidence as to whether these sites are likely to be bound by POU4F3 in vivo. At a very late  
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stage of this work preliminary attempts were made to investigate POU4F3 binding to these 
sites by chromatin immunoprecipitation using a fusion protein to overcome the lack of a 
suitable anti POU4F3 antibody. However, none of the binding sites were identified by this 
method. Furthermore, this protocol requires further optimisation and the possibility that 
the fusion protein affects POU4F3 binding ability has not been excluded. 
 
Taken  together,  the  results  of  the  DNA binding  and  promoter  regulation  experiments 
conducted (EMSAs and luciferase assays respectively) verify and extend the results of the 
subtractive hybridization. These results support the hypothesis that the candidate genes 
investigated (Nr2f2, Luzp1, Rbms1 and Zranb2) may be targets of POU4F3 regulation in 
hair  cells  (though  the  ability  of  POU4F3  to  regulate  the  Zranb2  and  Luzp1  5’  flanking 
regions particularly requires further investigation). 
 
In order to investigate candidate gene responses to POU4F3 in hair cells, we intended to 
manipulate  Pou4f3  expression  in  these  cells  in  cochlear  cultures  and  assay  target  gene 
response (to the single cell level) using a cell collection and quantitative (real time) reverse 
transcriptase  PCR  strategy  devised  in  our  laboratory  (unpublished  data).  As  previously 
discussed,  inner  ear  biology  is  difficult  to  investigate  by  such  methods  as  the  required 
tissue  is  difficult  to  obtain  and  manipulate;  hence  the  use  of  UB/OC 2  cells  to  identify 
POU4F3 target genes by subtractive hybridization. Accordingly, despite many transfection 
methods being attempted (e.g. cationic agents, electroporation and gene gun), it was not 
possible to transfect hair cells in cochlear cultures and, thereby, investigate the response 
and  function  of  POU4F3  target  genes  in  this  system.  Current  attempts  to  manipulate 
target gene expression in these cells using viral vectors appear more promising and may 
therefore aid in the elucidation of the physiological regulation of POU4F3 target genes. 
 
An alternative method to examine candidate gene regulation in response to POU4F3 would 
be to examine the inner ears of Pou4f3 mutant mice. However, the abnormalities seen in 
these  mutants  (i.e.  disruption  of  the  elaborate  mosaic  structure  of  the  organ  of  Corti, 
impaired  nascent  hair  cell  terminal  differentiation  and  degeneration  of  hair  cells  by 
apoptosis)  may  mask  the  effect  of  POU4F3  on  their  regulation  (Erkman  et  al. 
1996;Hertzano et al. 2004;Xiang et al. 1998;Xiang et al. 1997). Furthermore, the expression 
patterns of investigated genes show that they are not only expressed in hair cells in the 
inner ear, demonstrating that POU4F3 is unlikely to be required for their expression and 
might  therefore  play  a  subtle  role  in  their  regulation.  Therefore,  the  controlled 
manipulation of Pou4f3 expression in cochlear cultures appears to be a more sensitive and 
versatile means of investigating the proposed regulation of target genes in hair cells and, 
potentially, elucidating their function in hair cells. 
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The clones investigated in this study represent approximately half of those obtained from 
the subtractive hybridization screen. The remainder of these clones were investigated by 
ET  and  a  discussion  of  the  understanding  of  POU4F3  function  gained  from  this 
investigation is, therefore, not complete without the inclusion of these genes. Though some 
of the candidate genes identified share common functions (e.g. transcription factor activity), 
the putative  POU4F3 target genes identified by the subtractive hybridization appear to 
have varied function, ranging from transcription factors to ion channels. As some of these 
putative  POU4F3  targets  are  extremely  undercharacterised  and  others  have  not  been 
characterised  in  the  inner  ear,  it  has  been  difficult  to  relate  the  regulation  of  verified 
POU4F3 target genes to the production of the hair cell phenotype and any such relation 
remains  speculative.  However,  recent  investigations  by  ET  suggest  that  at  least  three 
POU4F3  target  genes  identified  by  the  subtractive  hybridization  may  be  involved  in 
cellular  responses  to  stressful  stimuli  (e.g.  heat  shock  or,  aminoglycoside  antibiotics) 
(unpublished  data),  thus  illustrating  how  POU4F3  may  mediate  hair  cell  responses  to 
stress and suggesting roles for these factors in ensuring hair cell survival in development. 
 
One notable observation of the subtractive hybridization was that it did not identify known 
direct targets of POU4F3 (Bdnf and Ntf3) and transcription factors that have been strongly 
associated  with  POU4F3  expression  and  shown  to  be  involved  in  hair  cell  development 
(Gfi1 and Lhx3). Though POU4F3 regulation in hair cells has only been investigated for 
Bdnf,  its  regulation  of  Bdnf  and  Ntf3  was  identified  in  UB/OC 2  cells  and  they  would, 
therefore, be expected to have been identified by the subtractive hybridization. 
 
There are three likely explanations for this. Firstly, the subtractive hybridization strategy 
used  is  biased  towards  identifying  the  most  differentially  regulated  transcripts  between 
populations tested. Though the genes linked (Bdnf and Ntf3) or associated (Gfi1 and Lhx3) 
with POU4F3 regulation may have been differentially expressed in UB/OC 2 cells in which 
POU4F3  expression  had  been  manipulated,  they  would  not  necessarily  have  been  more 
differentially expressed than candidate genes identified. In fact, clones that appeared less 
differentially  regulated  than  those  sequenced  following  the  qualitative  virtual  Northern 
blot analysis of the subtractive hybridization screen may have corresponded to these genes.  
 
The second explanation is that the above candidate genes were identified to be putative 
POU4F3  target  genes  by  different  methods.  Bdnf  and  Ntf3  were  identified  as  POU4F3 
target genes by CAT assay and DNAse I footprinting of their 5’ flanking regions (Clough et 
al.  2004)  and  Gfi1  and  Lhx3  were  identified  by  cDNA  microarray  that  compared  whole 
homozygous  dreidel  Pou4f3  mutant  mouse  inner  ears  to  those  of    wild  type  animals 
(Hertzano  et  al.  2004;Hertzano  et  al.  2007).  These  differences  in  methodology  may  be 
sufficient  to  explain  the  differences  seen  between  these  quite  different  experiments, 
especially where the effects seen might be transient (Fortunel et al. 2003).  
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The third explanation for this observation centres on the transcriptional environment in 
UB/OC 2 cells. It would not be possible to carry out a subtractive hybridization in hair cells, 
and the transcriptional effects of POU4F3 have been shown to be cell type specific (Smith et 
al. 1998;Sud et al. 2005). Therefore, these cells were selected for the present study as they 
were the best available model of the hair cell transcriptional environment that could be 
manipulated as required and would provide sufficient material for analysis. However, there 
are clear differences between UB/OC 2 cells and hair cells, i.e. though they express hair cell 
marker genes, they do not resemble hair cells morphologically and they are not mitotically 
quiescent in their undifferentiated state (Rivolta et al. 1998a). Therefore, the difference in 
the transcriptional environment between hair cells and UB/OC 2 cells may explain why 
previously described  likely POU4F3 target genes were not identified by the method used in 
this study. 
6.1  Conclusions 
Transcriptional regulation in hair cells of the inner ear is poorly understood and this deficit 
is an impediment to the creation of therapies for hearing loss e.g. gene or stem cell therapy. 
Therefore, in this project I to aimed identify POU4F3 target genes to aid in the explanation 
of the mechanism by which this transcription factor appears to produce and maintain hair 
cells and, therefore, hearing. 
 
14 candidate POU4F3 target genes were identified from 21 clones of transcripts that were 
shown to be differentially regulated by POU4F3 in a subtractive hybridization screen in 
UB/OC 2 cells. Seven putative POU4F3 target genes were initially investigated based on 
their potential role in hair cell development and survival and, of these, four were selected 
for  detailed  analysis  based  on  their  known  expression,  potential  function,  potential  for 
POU4F3 regulation (as determined by the presence of predicted POU4F3 binding sites in 
their 5’ flanking regions) and availability of reagents for their investigation. 
 
Nr2f2 was shown to be a likely direct target of POU4F3; two 5’ flanking region reporter 
constructs  for  Rbms1  were  shown  to  be  regulated  by  POU4F3  with  potential  sites  of 
regulation identified; and POU4F3 was shown to be able to bind to two sites in the Zranb2 
and Luzp1  5’ flanking regions with a likely activation of the Luzp1 5’ flanking region that 
requires verification. This represents a substantial contribution to the understanding of the 
network that POU4F3 regulates. Furthermore, the identification and characterisation of 
NR2F2 and ZRANB2 expression in the hair cells of the inner ear supports the possibility 
that POU4F3 is able to regulate Nr2f2 and Zranb2 expression in these cells and that these 
factors, in turn, might play a role in generating and maintaining the hair cell phenotype. 
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It  is  hoped  that  this  contribution  to  the  understanding  of  transcriptional  regulation  by 
POU4F3 might aid in future work to elucidate its function in hair cell development and 
maintenance, thereby contributing to the development of new therapies for the increasing 
number of people affected by hearing loss.  
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